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Abstract 
A Systems Approach to Understanding Mechanisms of Drug Induced 
Mitochondrial Toxicity 
 
Ashley J Broom, Imperial College London, Department of Medicine 
 
Mitochondria are important to the pharmaceutical industry. Mitochondrial perturbation is central 
to the aetiology of many poorly treated human diseases (e.g. neurodegenerative diseases, diabetes 
and cancer) and hence mitochondria are increasingly becoming therapeutic targets. However, 
drug-induced mitochondrial toxicity (DIMT) has also gained recognition as a significant cause of 
safety related attrition (including multiple post-market withdrawals). The present work ultimately 
aimed to discern the mechanisms downstream of DIMT in vitro and in vivo with two tool 
compounds which act via inhibition of the mitochondrial electron transport chain (ETC) 
(GSK932121A) or via uncoupling of mitochondrial oxidative phosphorylation (GSK2617971A).  
 
The first objective was to compare mitochondrial functional responses between in vitro (treatment 
of mitochondria isolated from control animals or in vitro cell lines) and in vivo scenarios using 
oxygen consumption rate (OCR) and calcium retention capacity (CRC) assays. The direction of 
change in these assays was often different between the in vitro and in vivo situation. Whilst 
seemingly contradictory, these differences reflect an adapted state in vivo which results from the 
initial insult in combination with compensatory changes made by the tissue to maintain energy 
production. In contrast, only the initial, unconfounded, response to treatment is observable in 
vitro. Integration of both is key to the future risk assessment of mitochondrially-active drug 
candidates.  
 
The second objective was to use a systems approach to build candidate adverse outcome 
pathways (AOP)/modes of action (MOA) for both tool compounds. AOP/MOAs were constructed 
based on key events observed in vivo. With both compounds, effect on body temperature, 
increased lactate/pyruvate ratio, gene expression changes indicative of a fasted state (induction of 
gluconeogenic genes) and mitochondrial ultrastructure effects were key events observed in the 
adverse outcome. Future work using additional compounds with mitochondrial activities would 
help validate the proposed AOP/MOAs. 
 
The third objective was to highlight markers of underlying mitochondrial perturbation with utility 
for future pre-clinical monitoring in the absence of overt DIMT. A number of mitochondrial 
functional changes (e.g. effect on CRC) were observed prior to the onset of overt toxicity in vivo, 
with both compounds and these endpoints have potential use in tailored future studies with 
mitochondrially-active drug candidates. 
 
These findings add to the knowledgebase on DIMT, particularly with regard to the candidate 
AOP/MOAs which have been postulated. This will facilitate the selection of more sensitive and 
functional endpoints for use in future toxicology studies with drugs where mitochondrial 
impairment is suspected.  
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1.1. The Importance of Drug-Induced Mitochondrial Toxicity 
“Failures to predict adverse drug reactions have immense financial implications, result in adverse human 
suffering and erode in trust of regulatory and pharmaceutical processes” [1]. 
 
The importance of drug-induced mitochondrial toxicity (DIMT) was realised when a number of 
nucleoside reverse transcriptase inhibitors (NRTIs, used for the treatment of HIV) were withdrawn from 
the market, due in part to deleterious effects on mitochondrial function [2]. Since then, a number of drugs 
have been reported to affect mitochondrial function with consequent adverse clinical reactions, 
necessitating Food and Drug Administration (FDA) black box warnings and drug withdrawals.  An 
example is the first-in-class 2,4-thiazolidinedione anti-diabetic drug troglitazone, which had to be 
withdrawn from the market in 2000 due to delayed onset idiosyncratic hepatotoxicity which was later 
linked to adverse effects on mitochondrial function [3]. 
 
Mitochondria are important to the pharmaceutical industry. Mitochondrial toxicity is increasingly 
implicated in the aetiology of adverse drug reactions. Drugs from diverse chemical and therapeutic 
classes are known to undermine mitochondrial function and despite multiple clinical examples of 
mitochondrial toxicity, there remains no regulatory requirement to discharge the risk of mitochondrial 
effects as part of the pre-first time in human (FTIH) toxicology package [4]. This is not necessarily 
surprising as any regulatory requirement to discharge mitochondrial liability would represent a dynamic 
shift in drug safety assessment away from where the International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is at present (i.e. 
assessing and identifying apical endpoints) and towards identifying key molecular events. Efforts have 
been made in industry in terms of in vitro preclinical screening for mitochondrial activity but there have 
been few rigorous efforts to correlate in vitro findings with in vivo functional endpoints or with 
conventional measures of toxicity. Improved in vivo assessment of mitochondrial function could facilitate 
the development of safer medicines but methods are currently underdeveloped and invalidated for 
practical application in preclinical studies [5]. The overall goal remains to identify and manage 
mitochondrial toxicity from the earliest possible point in drug development and support the safe 
progression of molecules, which may interact with mitochondria, to the market.  
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Despite the potentially potent effect of drugs which cause DIMT, mitochondria are increasingly seen as 
attractive targets for pharmacological intervention (i.e. therapeutic targeting of sub-optimal mitochondria) 
due to their central role in the mechanism of many common human diseases; e.g. as treatments for 
metabolic disorders (e.g. diabetes), neurodegenerative disorders, COPD and cancer. Given the diversity of 
metabolic pathways potentially affected by altering mitochondrial function, development of 
mitochondrial-targeting medicines clearly requires judicious safety assessment and risk management [5, 
6]. Methods to assess drug-induced modulation of mitochondrial processes in vivo require particular 
attention. It is however important to acknowledge that, whilst a change in direction of a mitochondrial 
endpoint may be desirable (e.g. inhibition of the mitochondrial permeability transition pore, mPTP), a 
change in the other direction (i.e. potentiation of the mPTP) might be undesirable. The availability of 
quantitative measures of this activity are particularly useful in both situations.  
 
This thesis focusses on the assessment of DIMT and correlates results obtained from in vivo studies to 
those obtained from in vitro studies. In vivo studies were performed using a systems toxicology approach 
in order to identify biochemical mechanisms downstream of DIMT and to generate adverse outcome 
pathways (AOP).  
 
1.2. Introduction to Mitochondria 
Mitochondria, from the Greek mito (thread) and chondros (grains) are energy producing organelles that 
exist in the cytoplasm of eukaryotic cells. Mitochondria perform a variety of important functions 
including adenosine triphosphate (ATP) synthesis, calcium signalling/homeostasis, fatty acid (FA) 
metabolism, apoptosis initiation, regulation of cellular proliferation and biosynthesis of heme, pyrimidine 
and steroid structures [7].  
 
Mitochondria were discovered in the late 19th century by Robert Alttman. They were originally called 
“bio-blasts” and described as "elementary organisms" living inside cells and carrying out vital functions 
[8]. Upon visualisation by electron microscopy in 1952, they were described as a collection of cytosolic 
free-floating individual vesicles forming thread-like structures inside cells [9, 10]. Just a year later in 
1953, the oxidation capacity of mitochondria was revealed by discovering that specific staining of 
mitochondria by Janus Green B was due to the capacity of cytochrome oxidase to reoxidise the dye [11]. 
The following two decades saw a spate of discoveries relating to the role of mitochondria in cellular 
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respiration and oxidative phosphorylation (OXPHOS). Key discoveries included demonstration of the 
membranous localisation of the respiratory chain [12], demonstration of energy coupling between 
electron transport and ATP synthesis [13] and reconstitution of OXPHOS and related reactions [14].  
 
Mitochondria are now widely acknowledged to be dynamic, pleomorphic structures constantly 
undergoing fission and fusion, with these processes tightly regulated by cellular stimuli and bioenergetic 
need [15]. Fission and fusion events allow the exchange of organelle content such as proteins, solutes, 
lipids and deoxyribonucleic acid (DNA) [16]. A wide body of evidence now suggests that impairment of 
the mitochondrial capacity is implicated in a number of human diseases and neuropathies [17].  
 
The numbers of mitochondria in a cell vary widely depending on the cell type, owing to the differing 
degrees of reliance on cell sustainability and metabolic load [18]. Within a cell, the distribution of 
mitochondria is unequal, depending on the cellular energetic or metabolic demands; for example, in 
cardiac cells, mitochondria are localised to the contractile apparatus, whilst in a sperm cell they are 
wrapped tightly around the motile flagellum [19].  
 
1.3. Mitochondrial Structure and Genome 
Mitochondria are highly compartmentalised organelles with two membranes, an outer mitochondrial 
membrane (OMM) rich in cholesterol / porin molecules and an inner mitochondrial membrane (IMM) 
rich in cardiolipin. These membranes functionally separate two distinct regions, the intermembrane space 
(IMS) and the water-containing matrix (shown in Fig.1.1). Mitochondria can only be visualised in detail 
using an electron microscope and are usually roughly ovoid but they may assume a filamentous shape or a 
vesicular form. 
 
The OMM comprises two lipid bilayer membranes and contains many aqueous pores permeable to all 
ions and molecules up to 14 kDa [20]. This makes the IMS chemically equivalent to the cytosol with 
respect to the small molecules it contains. In contrast to the OMM, the IMM is impermeable to ions and 
polar molecules but contains many protein transporters spanning the membrane. Furthermore, the IMM is 
virtually devoid of cholesterol and is rich in cardiolipin (which binds the proteins of the ETC) [21]. The 
content of the matrix is dependent upon the availability of the transport proteins in the IMM to facilitate 
the import/export of molecules such as ATP/ADP which are transported via the adenosine nucleoside 
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translocator (ANT). The impermeability of the IMM allows an electrochemical gradient to be maintained 
and this gradient provides the proton motive force for ATP generation. Maintaining the integrity of the 
IMM is critical for mitochondrial function. The IMM is the most common target for mitochondrial 
toxicants. Many xenobiotics damage mitochondria either by increasing the permeability of the IMM or by 
inhibiting transport proteins within it. Furthermore, many drugs have a very high affinity for cardiolipin 
and thereby preferentially bind to the IMM and affect important organelle processes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1.1: Structure of a eukaryotic mitochondrion: Electron microscopy image of a mitochondrion. Arrows show the key 
structural regions of the mitochondria, the outer mitochondrial membrane (OMM), the inner mitochondrial 
membrane (IMM), the intermembrane space (IMS), the matrix and the cristae. Image taken from 
[http://imgbuddy.com/mitochondria-microscope.asp] – Accessed 09 June 2015. 
 
The IMM is invaginated forming structures known as cristae which greatly increase its total surface area 
for maximal ATP production. These cristae contain clusters of five protein complexes (complex I, II, III, 
IV and V) which are involved in a process known as oxidative phosphorylation (OXPHOS) where 
electron transport is tightly coupled to ATP synthesis [22]. 
 
OMM 
IMS 
Cristae 
Matrix 
IMM 
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The mitochondrial matrix contains the vast majority of mitochondrial proteins, including those involved 
in fatty acid (FA) β-oxidation, haem/steroid synthesis and the tricarboxylic acid (TCA) cycle. The 
mitochondrial matrix also contains several copies of mitochondrial DNA (mtDNA) with the number of 
copies varying according to cell-type [6]. 
 
Mitochondria are the only organelles outside the nucleus that contain their own genome. A single DNA 
polymerase (polymerase-gamma, pol-γ) with base excision repair activity ensures the replication of 
mtDNA. Although pol-γ is a nuclear derived protein, its only known function is the replication of mtDNA 
and therefore any mutation or inhibition of this enzyme will manifest only in effects on mtDNA. The 
mtDNA shows substantial similarity to bacterial genomes (e.g. circular, unenclosed and lacking histones) 
leading to the theory that mitochondria were originally free-living aerobic bacteria that were then 
engulfed by eukaryotic cells more than a billion years ago [23]. The bacterial origin of mitochondria has 
implications for the drug discovery process as drugs designed to impair bacterial protein synthesis may 
have the potential to cause an adverse effect in the host’s mitochondrial ribosomes [24]. Mammalian 
mitochondrial ribosomes (55S) differ from bacterial (70S) and cytoplasmic ribosomes (80S) in terms of 
weight and molecular structure. Mitochondrial ribosomes are encoded in nuclear genes and imported into 
mitochondria where they assemble with mitochondrially transcribed rRNAs into ribosomes responsible 
for the translation of the 13 mitochondrial mRNAs encoding essential OXPHOS proteins [25].   
 
mtDNA is maternally inherited and is present as several copies within the mitochondrial matrix. The 
mitochondrial genome consists of a small circular chromosome and each copy of mtDNA encodes 13 
proteins, as well as 22 tRNA’s and 2 rRNA’s [26].  Whilst the proteins encoded by mtDNA are essential 
for OXPHOS, the majority of mitochondrial proteins are encoded by the nuclear genome and transported 
into the organelle by the means of protein localisation signalling and transporter molecules [27].  
 
Mutations in mtDNA can cause serious disorders (mitochondrial-diseases) such as neuropathy, ataxia and 
retinitis pigmentosa (NARP), Leber hereditary optic neuropathy (LHON) and myoclonic epilepsy with 
ragged red fibres (MERRF) [28]. Not all mitochondrial diseases are due to mutations in mtDNA with 
some arising as a result of mutation in the nuclear genome. Moreover, polymorphic variations can give 
rise to a situation known as heteroplasmy, where each cell can have copies of both mutated mtDNA and 
wild-type DNA [29]. Unlike nuclear DNA, mtDNA is not protected by histone proteins and is located in 
close proximity to sites where reactive oxygen species (ROS) are routinely generated. This increases the 
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susceptibility of mtDNA to ROS-related oxidative damage. Also, some DNA repair processes are less 
efficient for mtDNA compared with nuclear DNA and as such the mutation rate is estimated to be at least 
10-20 times higher [30]. 
 
1.4. Mitochondrial Function 
1.4.1. MITOCHONDRIA: ENERGY PRODUCTION 
Mitochondrial energy production is achieved by electron transfer in the respiratory chain, using a process 
known as OXPHOS. Approximately 95% of ATP is generated during aerobic (i.e. consuming oxygen) 
respiration by mitochondria. Mitochondria are also the site for other metabolic pathways, most notably 
the β-oxidation of FA’s and the TCA cycle.  
 
Glucose is broken down in the cytosol during glycolysis (shown in Fig.4.3 in chapter 4), yielding a net 
gain of 2ATP molecules, 2 nicotinamide adenine dinucleotide (NADH) molecules and pyruvate. Under 
aerobic conditions, pyruvate is transferred to the mitochondrial matrix where it is converted to acetyl 
coenzyme A (acetyl CoA) by pyruvate dehydrogenase [31].  In the mitochondrial matrix the TCA cycle 
occurs whereby a series of enzyme-mediated chemical reactions occur with the objective of oxidising 
acetyl CoA to produce molecules capable of supplying electrons to the mitochondrial respiratory chain or 
replenishing molecular intermediates for other pathways. In brief, the output of the TCA cycle is the 
formation of 2CO2, 3NADH, 1GTP and 1FADH2. Additionally succinate formed in the cycle can be 
oxidised by complex II of the mitochondrial respiratory chain (see Fig.1.2). 
 
An alternative way of generating energy via OXPHOS is by using lipids which are stored in the form of 
FA’s in triglycerides. FA’s are degraded via catabolism in the mitochondrial matrix via a process known 
as β-oxidation. The process involves the extraction of several units of acetyl CoA by oxidation. The 
triglycerides are hydrolysed by lipases resulting in glycerol and FA. Glycerol can follow the glycolytic 
pathway while FA’s are processed via β-oxidation, wherein dehydration, hydration and oxidation occur to 
convert FA’s into several products used in mitochondrial metabolism including succinyl-CoA, which 
enters the TCA cycle.  
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In addition, the mitochondrion is the site at which the terminal steps of amino acid catabolism occur 
resulting in the production of acetyl CoA. Acetyl-CoA is therefore a convergence point for many 
catabolic pathways and enters the TCA cycle where energy rich electrons, abstracted from the oxidation 
of substrates, are used to reduce nicotinamide adenine dinucleotide (NAD
+
 to NADH) and flavin adenine 
dinucleotide (FAD
+
 to FADH2). These high energy electrons (reducing equivalents) are then transferred 
to the IMM where they enter the electron transport chain (ETC)[32]. 
 
NADH is oxidised by complex I (NADH:ubiquinone reductase) and the released energy is used to reduce  
ubiquinone and produce an electrochemical proton gradient. The majority of substrates produced via the 
TCA cycle (i.e. resulting from dietary fats, glucose and amino acids) are oxidised by this route meaning 
that this is the main entry point for channelling electrons into the ETC. Meanwhile the reduced form of 
FAD (FADH2), a prosthetic group within complex II (succinate dehydrogenase), also donates electrons to 
ubiquinone [33]. This means that the second entry point of the respiratory chain is complex II-III 
(cytochrome bc1 complex) wherein complex III oxidises the reduced ubiquinol, promotes the generation 
of an electrochemical proton gradient by pumping protons across the IMM and reducing the water soluble 
carrier protein cytochrome c. Cytochrome c is attached to the cytosolic side of the IMM and serves as an 
electron carrier between complex III and IV. Complex IV (cytochrome oxidase) directly reduces 
molecular oxygen to water and further contributes protons to the electrochemical proton gradient.  
 
As described above the transfer of electrons down an energy gradient is concomitant with the process of 
proton pumping from the matrix to the IMS by complexes I, III and IV resulting in the generation of an 
electrochemical (proton-motive) gradient i.e. the mitochondrial membrane potential (∆Ψ) [34] . The 
energy contained in the electrochemical gradient is utilised by complex V (ATP synthase) to make ATP 
from adenosine diphosphate (ADP) and inorganic phosphate. The overall rate of electron transport in the 
respiratory chain of mitochondria is regulated by the amplitude of the electrochemical potential (known as 
respiratory control). This is beneficial as under physiological conditions the decrease in proton gradient is 
due to the metabolic demand of the mitochondrion, and as a result an immediate stimulation of oxygen 
consumption (increased ETC activity) is observable. This means that the rate of respiration is therefore 
intrinsically coupled to the rate of metabolism. An overview of the ETC and OXPHOS system is shown 
in Fig.1.2 below. 
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FIGURE 1.2: The mitochondrial respiratory chain: High-energy electrons derived from reduced substrates are transferred 
through several multi-protein complexes to molecular oxygen. This provides the energy to move protons across 
the inner mitochondrial membrane with ATP synthase utilising this energy to generate ATP. [H+- protons, Q- 
ubiquinone]. Image not scaled. 
 
Mitochondria are unique among cellular organelles, in that they can build up a ΔΨ of -180 to -220 mV. 
On particular occasions (e.g. when the IMM becomes permeable or in the presence of a proton/ion-
ophore) the ΔΨ can be completely dissipated resulting in ATP depletion and an increase level of 
mitochondrial oxygen consumption (i.e. increased ETC output). A futile proton cycle then ensues, as 
protons bypass the F0F1 subunit of ATP synthase causing production heat [35]. This process is known as 
mitochondrial uncoupling and can be protein dependent (e.g. in the presence of an uncoupling protein or 
UCP) or protein independent (requiring the presence of an ionophore or cationic lipid). ATP synthesis is 
therefore tightly coupled to electron transport with ATP synthase capable of converting energy from the 
electrochemical gradient into chemical bond energy in either direction [36]. 
 
Mitochondria are able to respond to a certain level of direct or indirect stress by utilisation of an innate 
respiratory reserve capacity. Reserve capacity is used to describe the amount of extra ATP that can be 
produced via OXPHOS at times of sudden increases in energy demand [37]. There are likely to be 
differing sensitivities to drug treatment in individuals based on age/genetics/co-medication etc. that alters 
the reserve mitochondrial capacity. Furthermore, the reserve capacity can often mask potential 
drug/mitochondrial interactions until the cell has a requirement to utilise that reserve capacity (e.g. under 
10 
 
conditions of stress) [38]. Effects may therefore not be seen until much later after exposure, a 
phenomenon recognised with cardiotoxicity. The mechanisms, by which the mitochondrial reserve 
capacities become compromised, are not well elucidated or understood [39].   
 
1.4.2. MITOCHONDRIA: ROS 
The normal process of electron transport is associated with some low level leakage of electrons which are 
directly donated to molecular oxygen. This results in the formation of reactive oxygen species such as 
superoxide which can react with, and damage, phospholipids, proteins and mtDNA [40]. Although the 
superoxide anion has limited chemical reactivity, it can be converted into more highly reactive species for 
example hydrogen peroxide (H202) and more particularly the hydroxide radical via Fenton chemistry [41]. 
Approximately 2-4% of the total oxygen consumed by mitochondria is not totally reduced to water and 
results in the formation of ROS. Under normal physiological conditions cells are able to counteract the 
harmful effects of ROS by several anti-oxidant defence systems including mitochondrial superoxide 
dismutase, glutathione peroxidase, peroxiredoxin (which utilises thioredoxin to counteract the effect of 
hydrogen peroxide) glutathione reductase, α-tocopherol and cytochrome c [42]. Furthermore, the 
methionine residues of mitochondrial proteins are able to prevent the oxidation of protein cysteine 
residues, inducing the formation of methionine sulphoxide and thus maintain protein functionality [43]. 
However when production of ROS exceeds the capacity of the anti-oxidant defence systems, oxidative 
stress ensues.  
 
The main sources of ROS are complex I (primary source due to having the most reducing capacity) with 
complex III, monoamine oxidase and complex IV also contributing to burden. Mitochondrial proteins 
which are localised around the ETC (located primarily in the matrix or acting as IMM transporters) are 
constantly in danger of being impaired by oxidative stress [44]. Furthermore, impairment of complex I 
and complex III by oxidative stress can result in increased ROS generation from these sites and then a 
vicious cycle ensues [45]. In addition, chemical inhibition of the respiratory chain at multiple sites further 
increases the production of superoxide anions and as such drug-induced ROS generation may be a key 
player in the AOP of mitochondrial targeting compounds [46]. 
 
Loss of regulation of cellular calcium concentrations can also increase the production of superoxide 
anions by the mitochondrial respiratory chain. Calcium is able to bind to the phospholipid/cardiolipin rich 
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IMM which induces both a conformational and functional alteration in membrane function in turn 
facilitating electron leak from the respiratory chain [47].  
 
1.4.3. MITOCHONDRIA: CELL DEATH 
Mitochondria have been demonstrated to play a crucial role in the cell death pathways, apoptosis and 
necrosis. 
 
Necrosis describes the processes whereby cells suffer damage that results in increased cellular volume, 
aggregation of chromatin, disorganisation of the cytoplasmic contents, loss of plasma membrane integrity 
and loss of cellular functionality. During the progression of necrosis, most of the cell contents are 
released, causing damage to neighbouring cells, an increase in localised inflammation and irreversible 
damage to the surrounding tissue. Necrosis was always believed to be caused by passive disturbance; 
however, recent studies have suggested it can be regulated although in both scenarios, mitochondria have 
been heavily implicated in the control of necrosis. Cell death by necrosis can occur due to activation of 
the mitochondrial permeability transition (MPT) which comprises collapse of the proton motive force, a 
decrease in ATP production and an increase in ATP hydrolysis via  F0F1-ATP synthase running in reverse 
(i.e. hydrolysing ATP in order to maintain the ΔΨ, resulting in ATP depletion) [48]. Furthermore, it has 
been described that cell swelling during necrosis, due to alterations in the cytoskeleton and inhibition of 
the Na
+
/K
+
 pump) is caused by impaired cellular respiration and loss of ΔΨ [49]. 
 
Apoptosis, a form of programmed cell death, is a process by which cells are eliminated from the body 
during embryonic development, tissue homeostasis, normal cell turnover and following cell injury. In 
brief, apoptosis can result from two independent routes (intrinsic and extrinsic).  During the extrinsic 
pathway, apoptosis is triggered by ligand-induced activation of death receptors at the cell surface, such as 
TNFR, CD95/Fas and TRAIL-R1/R2. The intrinsic apoptotic pathway heavily involves the mitochondria, 
either as initiators or propagators of the apoptotic signal. 
 
An early event during intrinsic apoptosis is the release of cytochrome c from the IMM of the 
mitochondria into the cytosol. Cytochrome c then binds apoptotic protease activating factor (Apaf-1) and 
procaspase-9 promoting the formation of the heptameric apoptosome and the resultant activation of a 
group of cysteine proteases called “caspases”[50]. Caspases are categorised into initiators (caspase-2,-8,-
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9, 10), effectors (caspase-3,-6,-7) and inflammatory (caspase-1,-4,-5) and they function to coordinate 
programmed cell death via chromatin condensation, DNA fragmentation and membrane blebbing [51].  
 
Furthermore under certain apoptotic conditions (e.g. mitochondrial swelling) mitochondria release 
proteins such as cytochrome c (release mentioned above), Smac/DIABLO and the apoptosis inducing 
factor (AIF). AIF is then targeted to the nucleus where it binds to DNA, stimulating chromatin 
condensation and DNA breakdown [52]. Protein release from the mitochondria is a complex process and 
includes the oligomerisation on the OMM of the pro-apoptotic proteins Bax and Bak (pro-apoptotic Bcl2 
proteins), which form a cytochrome c permeable channel. It is also now known the MPT pore (mPTP) can 
regulate calcium induced apoptosis and as such, the alteration in the calcium signal reaching mitochondria 
and/or the combined impact of apoptotic agents or pathological conditions (i.e. oxidative stress) can 
induce a profound alteration of mitochondrial structure, function and downstream cell death. This is 
highlighted by the work of Zamzami and colleagues who demonstrated that mitochondrial fragmentation 
during apoptosis was closely related to the collapse in ΔΨ, with this collapse being considered the point 
of no return in the apoptosis cascade [53].  
 
1.5. Mechanisms of DIMT 
Drugs can interfere with mitochondrial function in many different ways. Given the structural and 
functional complexities of mitochondria it is unsurprising that many of these interactions can lead to 
DIMT. The mechanisms involved are reviewed below (Fig.1.3). 
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FIGURE 1.3: Graphical representation of mitochondria as a mediator of drug-induced toxicity: Mechanisms include not only direct inhibition or uncoupling of ETC and 
OXPHOS but also inhibition of transport or oxidation of substrates, of the mPTP as well as molecular targets of mitochondrial biogenesis (i.e. inhibition of 
mtDNA replication, transcription and translation, and import or post-translational processing of proteins). The result is either inhibition/uncoupling of the 
respiratory chain directly, an indirect failure to generate and assemble functional substrate for the ETC or induction of cell death pathways. All of which lead to 
ATP depletion and cellular bioenergetic deficit. Image taken and adapted from [27]. 
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1.5.1. DIRECT INHIBITORS OF OXPHOS: 
Drugs that interfere with OXPHOS include both inhibitors of the distinct complexes of the ETC and 
uncoupling agents. Acute poisoning of the respiratory chain classically presents signs and symptoms such 
as muscle weakness, fatigue, hypotension, confusion and nausea. The inhibition of the ETC and 
consequential inability to utilise oxygen at cytochrome oxidase causes cytotoxic hypoxia despite normal 
or above average blood oxygen. In contrast, uncouplers of OXPHOS from ETC function (caused by 
dissipation of the electrochemical proton gradient) induce disproportionate oxygen consumption. 
Uncouplers also cause ATP depletion and metabolic acidosis, but classically, little or no effect on blood 
oxygen is observed; The free energy of substrate oxidation is liberated as heat resulting in fever [20].  
 
Complex I is the most susceptible of the ETC complexes to drug-induced malfunction. More than 60 
different types of natural and synthetic compounds can perturb mitochondrial complex I activity including 
pesticides, neurotoxins, and antibiotics. It has been suggested, following rigorous structure activity 
relationship (SAR) studies that, generally compounds with complex I inhibitory activity have modular 
similarity to ubiquinone [54, 55]. Inhibitors of complex I can be broadly classified into one of three 
categories, namely, compounds that inhibit at the level of the NADH-flavin interface (such as rhein), 
complex I and III non-specific quinolone antagonists (such as myxothiazol) and finally, specific and 
potent inhibitors of complex I such as rotenone. 
 
Complex II (succinate dehydrogenase) is less commonly studied in terms of its role in 
pharmacotoxicology. This is unexpected considering that recent research has revealed a role for complex 
II in many roles independent to cell metabolism, such as succinate signalling, ischaemic preconditioning, 
ROS generation and ageing [56]. Complex II is experimentally inhibited using malonate or 3-
nitroproprionic acid, but is also inhibited by a number of foloruoquinilones, fungicides, diazoxide and 
chloramphenicol (although many are not specific to complex II). Other compounds which affect 
mitochondrial complex II include the anticancer-drug etoposide, arsenic trioxide, cisplatin and menadione 
[57].  
 
Complex III is the second membrane spanning protein complex of the ETC. The sensitivity of various 
species to complex III inhibition varies significantly and as such, complex III inhibitors have been 
explored for use as anti-malarials, fungicides and anti-cancer drugs. Importantly the inhibition of complex 
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III of the mitochondrial chain (leading to ATP-depletion) is not the only harmful effect of these 
molecules. The generation of ROS following chemical inhibition of complex III likely contributes to the 
subsequent cellular and tissue toxicity. Inhibitors of complex III are generally categorised according to 
the site of action and these are outlined below. 
 
 Group I – Quinol antagonists encompassing a β-methoxyacrylate group that block the process of 
ubiquinol oxidation (e.g. myxothiazol, strobilurines and oudemasins). 
 Group II – Contain a 6-hydroxyquinone fragment and block electron transfer to cytochrome c1 and 
thus inhibit the reduction of cytochrome b1 (e.g. undecylhydroxydioxobenzothiazole, UHDBT). 
 Group III – Impede electron transfer from heme to a quinone or semiquinone molecule at the Qi site 
of complex III (e.g. antimycin A and funiculosin). 
 
Inhibitors of the Qi site of complex III such as antimycin are specific for the cytochrome-bc1 complex 
whereas naturally occurring Qo site inhibitors are less specific and possess a ubiquinone-like structure 
which often causes co-inhibition of complex I (albeit with significantly lower potency than the inhibitory 
effect they exert on complex III). Zinc ions are also acknowledged to inhibit the mitochondrial respiratory 
chain via complex III. Zinc binds reversibly and with high affinity to the Qo site of the cytochrome-bc1 
complex and is able to inhibit oxygen consumption with high potency. Other mono- and di-valent metal 
cations, such as, Hg
2+
, Ag
+
, Cu
2+
 and Cd
2+
 have been shown to inhibit mitochondrial complex III although 
with lower efficiency [20].  
 
Complex IV is a heme/copper terminal oxidase that exploits cytochrome c as an electron donor. Complex 
IV inhibitors have also been categorised into four distinct groups: (A) heme-binding inhibitors that are 
non-competitive with both oxygen and cytochrome c (e.g. azide, cyanide and sulphide), (B) inhibitors 
competitive with oxygen (e.g. carbon monoxide and nitric oxide) that are reversible, (C) inhibitors which 
are competitive with cytochrome c (e.g. polycations) and (D) non-competitive inhibitors which do not 
affect the heme-groups (e.g. phosphate ions and alkaline pH) [20].  
 
Complex V (ATP-synthase) uses the electrochemical proton gradient to synthesise ATP from ADP and 
inorganic phosphate. The enzyme is able to operate in either direction, for example under some conditions 
it can work as an ATPase to hydrolyse ATP and generate the proton gradient. ATP synthase is well 
conserved evolutionarily and as such many of its known inhibitors are of natural origin (mostly fungal). 
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Many antibiotics/mycotoxins were isolated because of their selective and potent toxicity against other 
fungi (e.g. aurovertins A, leucionstatins A+B and the classical inhibitors of mitochondrial ATP-synthase, 
oligomycin A-D). Injection of the ATP-synthase inhibitor oligomycin into rats causes inhibition of 
oxygen consumption, and severe lactic acidosis with little to no change in arterial blood oxygen levels. 
These mycotoxins all bind to either the F1 or the F0 subunit of the enzyme to block proton conduction. 
The acute 50% lethal dose (LD50) values from both IP and subcutaneous injection are in the region of 1-
10mg/kg in rats and mice [58, 59]. Other compounds and classes of compounds have shown acute 
inhibitory activity against mitochondrial ATP-synthase, though with less potency than the mycotoxins 
described above. These include, local anaesthetics [60], paraquat [61], the β-adrenergic receptor 
antagonist propranolol [62] and organotin composites [63].  
 
Examples of drugs that inhibit the mitochondrial respiratory chain (either via direct ETC complex 
inhibition or mitochondrial uncoupling) are shown in Fig.1.4 below. 
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FIGURE 1.4: Schematic representation of drugs which have been implicated in inhibition of OXPHOS either via direct 
inhibition of respiratory chain complexes I-IV or via chemical uncoupling.  Image taken and modified from 
[http://watcut.uwaterloo.ca/webnotes/Metabolism/rchainOverview.html] – Accessed 29th May 2015. 
 
Uncoupling of OXPHOS is considered to be a common characteristic of anti-inflammatory agents with 
an ionisable group such as the non-steroidal anti-inflammatory drugs (NSAIDs) diclofenac, aspirin, 
nimesulide and indomethancin. All of these drugs, despite being taken routinely across the world, exert an 
uncoupling effect at concentrations corresponding to their pharmacological doses [64, 65]. In their review 
written in 2000, Wallace & Starkov suggest that the term uncoupling should encompass any energy-
dissipating process which competes for energy with routine mitochondrial functions, and thus induces a 
metabolically futile wasting of energy. They explain that this description encompasses any drug-induced 
enhancement of any energy-consuming mitochondrial function (such as ion, metabolite or protein 
transport) as well as the classic idea of uncouplers (the dissipation of the proton gradient and impact on 
ATP production) [20]. Typically uncouplers of OXPHOS provoke a loss of mitochondrial ΔΨ, a 
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reduction in mitochondrial ATP production, increased levels of substrate oxidation and increased heat 
production. Uncouplers can be broadly categorised into the following: 
 
 Lipophilic weak acids – The majority of compounds processing protonophoric activity are lipophilic 
weak acids with an acid-dissociable group and strong electron withdrawing moieties. Examples of 
uncouplers in this group include carbonyl cyanide phenylhydrazones and salicylanilides. Compounds 
such as carbonyl cyanide p-triflouromethoxy-phenyl-hydrazone (FCCP) and cyanide meta-
chlorophenylhydrazone (CCCP) are possibly the most frequently used uncouplers in the laboratory. In 
mice, FCCP and CCP induce rapid rigor mortis and death after IP injection with LD50 values of 32 
and 40µmol/kg respectively. 
 
 Substituted phenols – The best represented and most studied class of uncouplers are the substituted 
phenols, including the highly toxic 2,4-dinitrophenol (2,4-DNP). Used in the 1930’s as a weight loss 
drug, numerous 2,4-DNP-associated side effects were recognised and it was eventually withdrawn 
from the market [5]. Although not licensed as a drug, 2,4-DNP is still occasionally used as a fat 
burning agent to this day, and numerous fatalities per year are still attributed to dinitrophenol 
poisoning [66], with signs and symptoms including hyperthermia, malaise, dyspnea, respiratory 
failure and ultimately death. Its potency is highlighted by an LD50 of just 141µmol/kg in mice [67]. 
SAR studies have confirmed that substituted phenols uncouple via the protonophoric mode of action 
(MOA), and revealed important correlations between the uncoupling activity and physicochemical 
properties such as hydrophobicity, acidity and lipid membrane stability [68].  
 
 Salicylanilide (2-hydroxy-N-phenylbenamide) derivatives – The salicylanilides have been widely used 
as anticestodal, antinematodal and antihelminithic drugs despite being protonophoric uncouplers of 
mitochondrial OXPHOS. The mechanism of uncoupling is similar to that of other A
-
 protonophores. 
SAR relationships with 28 salicylanilide derivatives revealed that both hydrophobicity and electron-
withdrawing potential were required for uncoupling to take place [67]. 
 
 Free fatty acids (FFAs, both endogenous and exogenous) – FFAs have long been known to be 
efficient uncouplers of mitochondrial OXHOS. Studies have shown that the adenine nucleotide 
translocator (ANT) is involved in the uncoupling action of FFAs. Many pathologies are associated 
with the accumulation of free long-chain FA’s in affected tissues and the effect of this accumulation 
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on mitochondrial function can be devastating, rapidly increasing local temperature generation and 
oxygen consumption at the expense of substrates for oxidation.  
 
 Ionophores – Ionophores are compounds of various chemical structures that are capable of 
transporting small ions across a lipid membrane. Ionophores have been reviewed in [69, 70] and 
generally are sub-categorised based on their physicochemical properties or their mechanism of ion 
transport. Channel-type ionophores (e.g. gramicidin A, D and S) are generally short amphiphilic 
peptides that form channels in lipid membranes. These channels can be selective toward small ions 
such as protons or K
+
 depending on the peptide, the membrane structure and conditions. The resulting 
increase in permeability toward protons and K
+
 effectively collapses the ΔΨ in mitochondria, due 
either to proton cycling or electrophoretic K
+
 transport. Carrier type ionophores (e.g. valinomycin and 
nigericin) are able to form neutral or charged lipid soluble complexes with an ion to facilitate its 
electrophoretic transport or electroneutral exchange with protons across the IMM. Furthermore, 
calcimycin can form a lipid-soluble complex with Me
2+
 to transport divalent cations across lipid 
membranes by means of electroneural Me
2+/
2H
+
 exchange. Dissipation of the calcium gradient 
establishes a futile energy-dissipating cyclic flux of calcium.  
 
 Cationic uncouplers (e.g. the cyanine dye triS-C4(5)) – This category of OXPHOS uncouplers 
comprises compounds that uncouple mitochondria by increasing membrane permeability to ions [71]. 
The mechanism of toxicity requires the presence of inorganic phosphate and it is likely that the Pi-
dependent compounds affect the physical integrity of the mitochondrial membranes.  
 
 Alternate electron acceptors – These compounds greatly diminish the efficiency of energy conversion 
by disrupting the prescribed pathway of electrons down the ETC and as a result increase the oxidation 
of substrates and divert excess energy to wasteful heat production. Terminal electron acceptors (those 
which are capable of being reduced by an electron carrier of the ETC) intercept electrons from the 
ETC and participate in futile redox cycling, whereby the compound is reduced at the expense of 
energy derived from substrates. Alternate electron acceptors (or electron-shunts), such as adriamycin, 
paraquat and a number of naphthoquinones, accept electrons and then feed them back to the 
respiratory chain at higher redox potential. This allows electrons to bypass a portion of the ETC 
excluding it from energy generation. Typically the secondary electron acceptor that completes the 
redox cycle is a terminal complex of the ETC and not molecular oxygen. A classic example of an 
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alternate electron acceptor is the antineoplastic agent doxorubicin (adriamycin). With a redox 
potential of -320mV doxorubicin is a good alternate electron acceptor from mitochondrial complex I, 
which then forms the reduced semiquinone free radical intermediate. The oxidation of mitochondrial 
glutathione, induction of the mPTP and the oxidation of cardiac mtDNA highlight the importance of 
mitochondrial redox cycling as a critical pathway in the mechanism of doxorubicin induced 
cardiotoxicity. Furthermore, naphthoquinones represent another important class of alternate electron 
acceptors that redox cycle on the mitochondrial respiratory chain. This area of research has been 
extensively studied in the laboratories of Tim Gant with SAR studies indicating that a univalent redox 
potential of approximately -180mV being the primary determinant of whether naphthoquinones are 
good redox cyclers [72]. Furthermore, the rates of free radical generation correlate with the degree of 
mitochondrial toxicity and the extent of cytotoxicity [73]. Despite the detrimental toxicity associated 
with alternate electron acceptors, electron shunts have been used therapeutically to bypass respiratory 
chain dysfunction (i.e. shunting electrons from complex I to complex IV). A key example of this is 
the use of menadione to treat mitochondrial encephelomyopathies, which are frequently characterised 
by cytochrome bc-1 deficiency. Menadione enables electrons to bypass the dysfunctional portion of 
the chain and significantly improves the bioenergetic deficiency caused by these disorders leading to 
significant improvement in neurological and muscular performance [74].  
 
1.5.2. INHIBITORS OF MITOCHONDRIAL SUBSTRATE OXIDATION: 
 Compounds causing inhibition of substrate oxidation are, for the most part, structural mimics of the 
natural substrate and thus act via competitive inhibition of the respective reaction [75]. Inhibition of 
substrate oxidation interferes with the generation and delivery of reducing equivalents to the respiratory 
chain. As a result, inhibitors of mitochondrial substrate utilisation ultimately cause metabolic deficit 
similar to that of direct ETC inhibitors and therefore tissues with high metabolic rates are most sensitive 
to inhibitors of substrate oxidation.  An example includes the inhibition of FA oxidation by valproic acid 
and salicylic acid [76]. Likewise, fluoroacetate and fluoroacetamide represent structural analogues which 
condense with oxaloacetate to form fluorocitrate, a potent inhibitor of the TCA cycle enzyme aconitase 
[77].  It is important to acknowledge that inhibitors of mitochondrial substrate oxidation include inhibitors 
of both enzymes within the metabolic pathways and transport proteins required for substrate delivery to 
the mitochondrial matrix [78]. For example, etomoxir (a potent inhibitor of carnitine palmitoyl-transferase 
1) was withdrawn from late stage clinical trials due to cardiac toxicity and heart failure [79, 80]. 
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1.5.3. ROS GENERATION: 
In the IMM, ROS, particularly superoxide radicals, can be generated by complex I, iron sulphur protein, 
complex II, complex III, cytochrome oxidase and monoamine oxidase. As described in the previous 
section, generation of ROS such as superoxide, H2O2 and hydroxyl radicals (that escape the antioxidant 
defence mechanisms of the cell) act via the peroxidation of phospholipids in the biological membranes 
and cause oxidative damage to DNA and proteins, as a result, spreading damage beyond the confounds of 
the organelle. The damaging action of ROS in the central nervous system has been implicated in 
Alzheimer’s and Parkinson’s diseases [81]. A plethora of drugs can induce mitochondrial toxicity via 
direct ROS production (by interfering with complex I/III etc.) or indirectly via inducing mPTP induction, 
disrupting the respiratory chain, uncoupling OXPHOS, damaging mtDNA and subsequent protein 
synthesis or by impeding/depleting the cellular antioxidant pool [82]. Likewise many drugs have been 
developed as antioxidants (e.g. coenzyme Q10). Deliberately targeted to mitochondria, these molecules 
have been applied therapeutically in different congenital OXPHOS disorders. 
 
1.5.4. INDUCING MITOCHONDRIAL PERMEABILITY TRANSITION:  
The mitochondrial permeability transition pore (mPTP) resides in the IMM which (under normal 
physiological conditions) is impermeable to all, but a few, selected metabolites and ions. Under 
conditions of stress mitochondria can undergo permeability transition (i.e. pore opening) which in general 
terms encompasses a sudden, non-selective increase in IMM permeability to all solute of a molecular 
mass less than 1500 KDa (see Fig.1.5 below). Upon opening of the mPTP, low molecular weight 
substrates and water can freely penetrate the mitochondrial matrix resulting in mitochondrial swelling, 
loss of ΔΨ, outer membrane rupture and the release of cytochrome c into the cytosol (leading to the 
initiation of cell-death pathways). It is this triggering of cell death which underlies the toxicity of t-butyl-
hydroperoxide, valproic acid and the hepatotoxicity of diclofenac. Further examples of xenobiotics or 
endogenous factors which can induce permeability transition include the steroid hormone 
dehydroepiandrosterone, naproxen, salicylic acid and the neurotoxin MPP
+
 [53]. Importantly, modulation 
of the mPTP tends to occur via binding to a particular component of the pore such as ionidamine binding 
to the adenine nucleotide transloacse (ANT) [6]. 
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FIGURE 1.5:  Putative mPTP proteins in the OMM and IMM in normal physiological and pathophysiological conditions. 
[CK – creatine kinase, HK - hexokinase, Bcl-2 – BAX – BCL2-associated X protein, PBR - peripheral 
benzodiazepine receptor (since renamed Translocator Protein), AIF – apoptosis inducing factor, BAK – BCL2 
antagonist/killer, Cyclo D – cyclophillin D]. Image drawn based on figure published in [83]. Image not scaled. 
 
ANT is one of the principle components of the mPTP. Further examples of drugs which inhibit this 
protein include agaric acid and atractyloside and these agents lead to substrate depletion, decreased ATP 
output and generation of ROS. Importantly, other drugs such as cyclosporine and Ro 68-3400 have the 
opposite effect by inhibiting the mPTP. As well as its use as an immunosuppressant, cyclosporine has 
become a pivotal tool compound for experimental studies into the function and control of the mPTP [84]. 
Furthermore therapeutic groups are investigating the utility of inhibiting the mPTP for the treatment of 
neurodegenerative disorders [85] and ischemia reperfusion injury [86] / myocardial preconditioning [87].  
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1.5.5. OXIDATION AND MUTATIONS OF MTDNA, OR INHIBITION OF MTDNA SYNTHESIS:  
The disruption of nuclear genes important for mitochondrial homeostasis can lead to autosomal inherited 
disease. Over 110 specific mutations of mtDNA have been described [88]. Further, inhibition of mtDNA 
synthesis and/or DNA oxidation is a key characteristic of the toxicity of many antiretroviral drugs.  
 
The thymine analogues zidovudine and stavudine, the adenosine analogue didanosine, the cytosine 
analogues zalcitabine and lamivudine and the guanine analogue abcavir are nucleoside reverse 
transcriptase inhibitors (NRTI) used to prevent the replication of the human immunodeficiency virus 
(HIV). These analogues are recognised by the host DNA polymerases before binding and preventing 
elongation of the replicating strand (resulting in truncated and unstable replicons). Toxicity is associated 
with the fact that mitochondria contain just a single DNA polymerase (Pol-γ) which has a high affinity 
nature for these nucleoside analogues [89]. The resulting truncated and unstable mtDNA is responsible 
for mtDNA depletion observed post-NRTI therapy and this not only leads to a decrease in mitochondrial 
abundance but mitochondria which do survive lack many of the mtDNA-encoded protein subunits 
essential to the ETC complexes [90].  
 
A small number of acquired immunodeficiency disorder (AIDS) patients have suffered adverse outcomes 
as a result of mitochondrial toxicity, caused by long term anti-retroviral therapy that includes 
hyperlactaemia, sensory neuropathy and liver steatosis. In rare cases, NRTI-induced lactic acidosis, liver 
failure or pancreatitis has been fatal.  Furthermore, mtDNA depletion has been demonstrated in the liver 
of HIV patients with both stavudine and zalcitabin NRTI’s inducing time/concentration-dependent 
mtDNA depletion [91]. 
 
Crucially, if a large proportion of the mtDNA present is mutated the mitochondria will become 
dysfunctional, although retain the ability to replicate via biogenesis. This results in the spreading of the 
mutation and may be behind the persistent and cumulative nature of mitochondrial toxicity [92]. As 
mammalian cells contain between 2000-5000 copies of the mitochondrial genome, toxicity from mtDNA 
damage or depletion only becomes apparent gradually with chronic treatment. As a result of the problems 
with the HIV drugs however, the FDA now require all antiviral submissions in this therapeutic class to 
include assessment of the effect on mtDNA [93].  
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ROS generated during OXPHOS has been shown to induce oxidative DNA damage including single- and 
double-strand breaks, abasic sites and base damages. Due to the close proximity of mtDNA to the 
respiratory chain, mtDNA has demonstrated a higher susceptibility (than nuclear DNA) to damage such 
as 8-oxoguanine [94]. 
 
In addition to effects directly to mtDNA, another well-established mode of toxicity is via drug-
interference with mitochondrial protein synthesis (i.e. the translation of mtRNA). Mitochondria contain 
their own enzymatic machinery required to translate protein from mtDNA encoded RNA molecules with 
the ribosomal proteins distinctly different to those in the cytosol which decode the nuclear genome. 
Inhibition of protein synthesis is believed to result from binding to mitochondrial ribosomes with higher 
affinity than ribosome-RNA binding. Examples include linezolid [95], chloramphenicol [96] and some of 
the tetracycline antibacterial medicines [97].  
 
1.5.6. MULTIPLE MECHANISMS 
A major problem relating to the assessment of DIMT is the fact that many drugs likely induce 
mitochondrial dysfunction via a number of different mechanisms. A classic example is the anti-epilepsy 
medication valproic acid that inhibits mitochondrial FA β-oxidation (by both sequestering coenzyme A 
and inactivating β-oxidation enzymes via electrophilic metabolites) and induces mitochondrial 
permeability transition [98, 99]. A second example is the anti-anginal drug, amiodarone which has been 
shown to inhibit mitochondrial complexes I, IV and V, uncouple OXPHOS and inhibit FA oxidation 
[100]. Furthermore both the anti-psychotic drug chlorpromazine, and the anti-cancer drug flutamide, both 
uncouple OXPHOS and inhibit mitochondrial ETC complex I. It is therefore clear that to identify and 
assess DIMT pre-clinically, a battery of endpoints should be analysed which encompasses the array of 
potential mechanisms of mitochondrial toxicity. Furthermore, a wide dose range should always be 
assessed.  
 
1.6. Methods of Detecting DIMT 
No single assay can identify all mechanisms of DIMT. A range of assays, spanning multiple 
mitochondrial endpoints, is therefore required. It is important that attempts to assess DIMT are 
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multifaceted in scope and take into account the distinct mechanisms by which drugs can interfere with the 
coordinated regulation of intermediary metabolism and energy production by the cell [101]. 
 
Model systems for studying mitochondrial toxicity include whole cells maintained in culture, isolated 
mitochondria, tissue sections (for histopathological markers) and sub-mitochondrial particles. The system 
used is largely dependent upon the assay being performed however is of pivotal importance when relating 
findings to potential events in vivo. It is essential to understand the limitations of the systems being used 
and take due consideration of these limitations when interpreting the findings. For example, whilst used 
widely in the study of mitochondrial function/dysfunction the following limitations are associated with 
the use of isolated mitochondrial fractions: 
 
 Reports in the literature suggest that only around 30% of the total mitochondrial pool can be 
isolated by differential centrifugation [102]. 
 Compromised structural integrity following manual homogenisation of tissue and presence of 
cellular debris in the mitochondrial fraction. 
 Disintegration of mitochondrial-cytoskeletal networks and heterogeneous branching of organelles 
[21]. 
 Ex vivo dosing of mitochondria with compounds, provokes an exaggerated response as the drug is 
not subjected to metabolism and does not have to penetrate the cell thus having unrestricted 
access to the mitochondria. 
 It was recently discovered that many subunits of the OXPHOS system are phosphoproteins. 
Furthermore it was suggested that these and other mitochondrial phosphoproteins could be the 
substrates of protein kinase A and protein kinase C amongst others [103]. If a compound has an 
effect on a kinase which regulates the activity of the OXPHOS complexes, this effect may not be 
observed in isolated mitochondria if the affected kinase is not of mitochondrial localisation.  
 
Furthermore it is important to determine the quality of mitochondrial preparations being used. This can be 
achieved by determination of the respiratory control ratio (RCR), calculated as the rate of respiration in 
the presence of ADP divided by the rate obtained after the expenditure of ADP. Typical RCR values can 
range from 3-12.5 depending upon the age of the donor, species, substrate choice and organ [104] (see 
appendix 2). 
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Many of the in vitro experiments described below (table 1.1), such as the oxygen consumption and ATP 
assays, are performed in immortalised cell lines, grown in glucose-containing medium. For ease of 
culturing, it is routine practice to use immortalised cells lines for pre-clinical screening activities however 
these have a preference for synthesising ATP via glycolysis when grown in glucose-conditioned media 
[105]. This phenomenon is named the Crabtree effect and, due to reduced reliance on OXPHOS for 
energy production, makes identification of mitochondrial toxicants challenging [106]. In order to 
overcome this, cells can be grown in a medium containing galactose as opposed to glucose which forces 
the cells to rely on mitochondria for their ATP synthesis and are therefore more susceptible to DIMT with 
compounds which either inhibit the ETC or uncouple mitochondrial OXPHOS [107].   
 
High throughput methods (e.g. oxygen sensitive probes) have been developed with the ultimate objective 
of allowing company and research laboratories to perform large-scale screening of compounds which 
interfere with mitochondrial processes (Table 1.1 below describes assays regularly used in the detection 
of mitochondrial dysfunction in the drug-safety arena). This table is by no means exhaustive as 
mitochondria affect such a wide variety of cellular events. For example analysis of proteins involved in 
cell signalling pathways may provide information about mitochondrial function but is not a regularly used 
assay. 
 
In vitro techniques using cell culture or isolated mitochondria are commonly used to evaluate the effects 
of drugs on mitochondria. These methods will remain crucial for target elucidation, for example, 
distinguishing effects on the ETC (oxidation) from effects on phosphorylation efficiency (uncoupling) 
[108]. It seems unlikely however, that in vitro assessment can adequately define the relevance of 
mitochondrial dysfunction in vivo, especially with enough confidence to adequately monitor safety or 
assess risk. Furthermore, traditional drug safety methodologies may be insufficient. Standard endpoints 
used for safety testing in preclinical and clinical development, such as clinical signs, histopathology, 
haematology and clinical chemistry are very important for detecting compounds with unintended effects, 
but they are relatively imprecise and insensitive for detecting alterations in mitochondrial function. For 
drugs that have some level of in vitro mitochondrial activity, it is anticipated that safety studies may need 
to be augmented with more specialised or targeted evaluations 
 
Specific in vivo endpoints are likely required in the future in order to improve understanding of DIMT in 
vivo. This may include the analysis of isolated mitochondrial fractions from treated animals [109], 
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specialist imaging techniques such as positron emission tomography (PET) [110] or enhanced nuclear 
magnetic resonance (NMR) techniques, such as magnetic resonance spectroscopy (MRS) [111]. The ideal 
assessments for use in drug development would be non-invasive and demonstrate a good degree of target 
organ specificity, predictivity and clinical translatability [5]. At present however, these assessments are 
only implemented when mitochondrial toxicity is a limiting factor in the development of a candidate drug 
and are not routine. Further work is therefore required in order to validate and develop such endpoints and 
to understand their capability and limitations.  
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Assay or Endpoint Model System(s) Technology / Methodology Comments 
 
Morphological analysis Fixed tissue/isolated 
mitochondrial pellet 
/protein isolate. 
Electron microscopy Glutaraldehyde fixation and subsequent steps to sectioning and uranyl acetate/lead-citrate staining. 
Western blot Separation of protein via SDS-PAGE and transfer to nitrocellulose membrane. Probing with 
antibodies against various mitochondrial structural/bioenergetic proteins followed by secondary 
antibody detection and chemoluminescent visualisation. 
Respiration (oxygen 
consumption) 
Cells or isolated 
mitochondria 
Clarke type electrode Polarographic procedure using mitochondria suspended in sucrose EDTA/EGTA solution with 
substrates and specific ETC inhibitors at 25-30°C (stirring). ADP/0 ratio can be calculated (mol ADP 
phosphorylated per mol oxygen atom consumed) 
Oxygen sensitive probes (Luxcel / 
Seahorse Biosciences) 
O2 quenchable fluorophores measure oxygen consumption in a multi-well microplate.  
Seahorse technology produces a transient micro-chamber within which oxygen is measured 
following sequential injections of mitochondrial compounds. BOFA analysis (Basal, ADP, 
Oligomycin, FCCP, Antimycin A) facilitates calculation of multiple respiratory parameters such as 
RCR, respiratory reserve capacity, proton leak, non-mitochondrial respiration, basal respiration and 
respiration at an uncoupled state. 
Calcium retention 
capacity (CRC) 
Isolated 
mitochondria 
Calcium green 5-N, Arsenazo III 
specific ion electrode/ fluorescent 
spectrophotometer. 
Changes in absorbance spectrum at wavelength pair 675-685nm (ASZ III) or calcium Green 
fluorescence (505nm/531nm) denote calcium fluxes following substrate stimulation.  
Mitochondrial  ΔΨ Cells or isolated 
mitochondria 
JC-1, TMRM, TMRE, NAO, RH-
123. Fluorescent spectrometric 
reader. 
Fluorescent markers which accumulate in the matrix and are released when the ΔΨ is decreased.  A 
number of fluorescent dyes are commercially available (e.g. JC-1, TMRM etc.) 
mPTP/mitochondrial 
Swelling 
Isolated 
mitochondria 
Spectrophotometer (JC-1 / 
TMRM) +KH2P04 to induce 
swelling 
Swelling is recorded spectrophotometrically at 540nm using succinate energised mitochondria.  
ATP levels Cells and fresh 
frozen tissue 
High energy phosphate analysis 
(AMP, ADP + ATP) 
Determination of high energy phosphate content in immediately snap frozen tissue / cells (scraped 
into perchloric acid) by HPLC.  
ATP quantification, cell ATP 
luminescent titre. 
Inorganic phosphate determination / Firefly luciferin/luciferase system. Determination of ATP using 
cell-based luminescence system. Measurement of "glow-type" luminescent signal. 
ROS Cells in culture, 
isolated 
mitochondria, 
frozen tissue. 
DCFDA luminol probe Hydrolysed from CM-H2-DCFDA inside cell and reacts with ROS to form fluorescent DCF (503-
529nm).  
GSSH/GSSG ratio. Determination 
of antioxidant status. 
Determination of glutathione in its reduced (GSH) and oxidised state (GSSG) can be analysed by 
mass spectrometry or via absorbance in many different biological samples (cells, mitochondria, 
blood) 
Superoxide dismutase assay 
(SOD) 
Catalyses conversion of superoxide radicals to hydrogen peroxide via redox cycling. Analysis of 
SOD activity using a 96 well colorimetric assay. 
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TABLE 1.1: Examples of assays used in the pharmaceutical industry for the analysis of DIMT.
Flow cytometry techniques. 
Multiple tags (Thiolite Green/ 
Cell Tracker Orange, Mitosox 
Red, Rhodamine 123, CM-
H2DCFDA, H2DCFDA, Xfect) 
Thiolite Green / Cell Tracker Orange – GSH + ROS = GSSG. Thiolite Green is a sensor for 
measuring thiol compounds. (GSH depletion) 
MitoSox Red – Oxidation of MitoSox Red reagent by superoxide produces red fluorescence. 
Rhodamine 123 – binds to mitochondrial membranes and inhibits transport processes such as the 
ETC. Fluorescence proportional to the dissipation of mitochondrial ΔΨ. 
CM-H2DCFDA / H2DCFDA – ROS generation. DCFH-DA hydrolysed by esterases to DCFH, 
DCFH + ROS->DCF (fluorescent product measured). 
Xfect protein transfectant -  DNA damage (γ H2AX, DNA double strand break response biomarker)  
Gene Expression – RT-PCR 
(Taqman/Cybr green analysis) 
Panel of oxidative stress biomarkers on a low density gene-array or TaqMan gene card. RNA-cDNA 
from cells or tissues.  
 
 
Gene 
expression/mtDNA 
content and deletion 
Fresh frozen tissue RT-PCR, Microarray technology RNA isolation from snap frozen tissue or cells. Reverse transcription of RNA to cDNA prior to 
analysis of mitochondrial gene expression using real time quencher/fluorescent TaqMan technology.  
Alternatively to measure mtDNA depletion determine the copy number of a mitochondrial gene (e.g. 
cytochrome c oxidase) relative to a nuclear-DNA housekeeper (e.g. β-actin) 
Mitochondrial complex 
activity (I-V) 
Isolated 
mitochondria 
Mitochondria energised with 
appropriate substrates and product 
dependent changes in absorbance 
are monitored. 
Complex I activity measured as a rotenone-sensitive decrease in NADH concentration at 340nm 
Complex II-III activity is measured by a succinate-dependent antimycin-A sensitive reduction of 
cytochrome c at 550 nm 
The rate at which cytochrome c is oxidised, represents the Vmax of the reaction performed by 
complex IV. 
Citrate synthase activity Cells / snap frozen 
tissue.  
Spectrophotometry. Citrate synthase is involved in the TCA cycle and widely used as a measure of mitochondrial mass. 
Citrate synthase drives the reaction of acetyl CoA and oxaloacetate to form CoA.  The production of 
CoA was monitored by the reaction with DTNB and the increase in absorbance at 412nm.  The Vmax 
rates, when linear are normalized to the protein concentration of samples. 
Lactate/Pyruvate Assay Cells (E.g. HepG2) Mass spectrometry [NADH]/[NAD+] is in equilibrium with [lactate]/[pyruvate] in the cytoplasm and extracellular space. 
Methods are available to measure [NAD+] accurately; however quantifying NADH accurately is a 
challenge.  Quantifying [pyruvate] and [lactate] in culture media is a surrogate for measurement of 
[NAD+] and [NADH].  Measurement of lactate:pyruvate also provides a measure of cellular 
glycolytic activity.  
Blood (serum) Clinical pathology analyser 
Intracellular 
triglyceride 
accumulation/ 
Cells Colorimetric assay – biochemical 
analyser. 
A change in the intracellular triglyceride content of cells provides an indication of potential changes 
in the mitochondrial bioenergetic function or βoxidation. Triglyceride reagent (Randox) determines 
intracellular triglyceride levels through a colorimetric method based on enzymatic degradation of 
triglycerides.  
Metabolites Cells, tissue, blood, 
biological fluids etc. 
NMR, mass spectrometry Global metabolomics has allowed for a systems level analysis of mitochondrial toxicity. Permits the 
identification of a chemical fingerprint allowing the identification of metabolic toxicological 
pathways or to identify biomarkers of mitochondrial dysfunction.  
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1.7. Challenges and Complexities 
Despite the wide range of assays regularly being used to detect mitochondrial perturbation in vitro, many 
challenges remain. 
 
1. Lack of robust in vivo methods for detecting DIMT – As described above, reliance upon traditional 
drug development methods may be insufficient in detecting mitochondrial perturbation in vivo. It is 
important to distinguish between the detection of an adverse effect due to mitochondrial toxicity 
(apical effect) and effects on mitochondria that will lead to toxicity (i.e. an AOP). Current methods 
were designed preferentially to identify and assess apical endpoints (e.g. increased blood lactate 
concentration due to DIMT) whereas the move is now to develop an AOP strategy (i.e. identification 
of reduction in respiratory reserve capacity which may cause toxicity due to mitochondrial 
dysfunction, i.e. an upstream event in AOP). This move will enhance the predictive ability of drug 
safety scientists in R&D.  
 
Meanwhile however, standard endpoints used for safety testing (e.g. clinical signs, histopathology, 
haematology, serum biochemistry etc.) are relatively imprecise and insensitive for detecting 
alterations in mitochondrial function. For drugs that perturb mitochondrial function, development 
studies may need to be supplemented with more specialised or targeted evaluations; however, these 
novel approaches are under-developed and un-validated for use in preclinical toxicology studies. 
Furthermore there have been no rigorous efforts to correlate in vitro and in vivo functional endpoints 
with conventional measures of efficacy and toxicity. As a result, drug safety scientists are currently 
unable to answer difficult questions from drug discovery groups such as; 
- Which changes or what magnitude of mitochondrial perturbation in vitro is required to cause 
adverse in-life toxicity and thus prompt potential candidate-termination? 
- By how much do I need to reduce the in vitro effects on mitochondria to justify replacing the 
lead molecule with a new candidate? 
- Which endpoints from the in vitro or in vivo battery of assays are most relevant to assess the 
safety of drug candidates? 
Ultimately, the complexity of DIMT in vivo makes performing risk assessments a major challenge. 
Progress is required to enable the design of more efficient pre-clinical studies with more sensitive and 
specific measures of mitochondrial function, especially when in vitro activity has been noted. 
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2. Lack of suitable animal models to detect mitochondrial dysfunction: Routine pathology and 
clinical chemistry performed post drug administration in rodent models have so far proved relatively 
insensitive to DIMT. Mitochondrial capacity decreases with age or lack of exercise, suggesting that 
aged, sedentary rodents may be more appropriate and representative models for studying DIMT rather 
than young, active animals. Research has demonstrated that rodents which were selected to be low 
capacity runners, had reduced mitochondrial content, reduced oxidative capacity and were more 
prone to hepatic injury than their control counterparts [112]. Although various mouse models are 
available which exhibit impaired mitochondrial function, few have been used in the pharmaceutical 
industry for toxicology studies. One exception that has seen modest use however is the phenotypically 
normal superoxide dismutase 2 (Sod2
+/-
)
 
mouse. Heterozygous for the mitochondrial antioxidant 
manganese Sod2, this model shows increased levels of oxidative stress. An example of its utility was 
demonstrated when Sod2
+/-
 mice showed signs of hepatotoxicity post-treatment with troglitazone with 
no marked changes observed in the wild-type group [113]. The effect of oxidative stress has also been 
explored in a study of mutant Drosophila melanogaster with reduced Sod2 expression, where the 
authors describe reduced mitochondrial aconitase activity and shorter life spans than wild type flies 
[114]. Toxicological investigations in Drosophila are rarely used however, in drug development due 
to translatability issues. Other mouse models which have been shown to have impaired mitochondrial 
function include, the mtDNA deletion mito-mouse [115], the ANT
-/-
 mouse [116], the mutant pol-γ 
mouse [117] and the Tim23
+/-
 mouse which lacks a translocase for the IMM [118]. These models 
remain largely untested and un-validated for use as tools in the assessment of DIMT. 
 
3. Persistence of mitochondrial aberration: While many assays exist to characterise the effect of a 
drug on mitochondrial function they do not address why the effect is latent (e.g. the delayed-onset 
liver and heart toxicity after treatment with troglitazone). As mitochondria undergo continuous 
replacement through division the most rational hypothesis for persistent perturbation is via 
compound-associated/ROS-dependent damage to the mtDNA which is then passed onto daughter 
mitochondria during replication. Whilst next generation sequencing approaches have vastly improved 
our understanding of mitochondrial diseases few data have been generated on drug-mtDNA 
interaction and DNA damage accumulation. 
 
4. Lack of in silico methods to predict DIMT: In silico methods to predict DIMT are still in their 
infancy, largely due to the large number of mechanisms by which a compound could impair 
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mitochondrial function. However some progress around classification of compounds based on 
physicochemical properties is emerging. For example, studies have identified that many 
protonophoric uncouplers contain characteristic acidic dissociable groups, electron withdrawing 
moieties and large hydrophobic groups (e.g. 2,4-DNP, FCCP, benzimidazoles and even some non-
steroidal anti-inflammatory drugs (NSAID)) [119].  Furthermore, Zhang et al in 2009 discussed the 
potential to predict DIMT in silico and whilst promising prediction accuracies (~77% ) were reported, 
the compound test set used was relatively small and to date no comprehensive analysis downstream of 
a high throughput screen has been published [120]. Further work is clearly required in order to 
identify whether compounds which target mitochondria or impart a particular effect on mitochondrial 
function, share a common set of physicochemical properties. 
 
5. Lack of validated biomarkers for identifying DIMT in patients and/or preclinical species:  In 
2006, the FDA along with other organisations set up a biomarkers consortium to search-for and 
validate new pathological markers (critical path initiative). To date there are no validated biomarkers 
of DIMT and in fact, the CPI has resulted in very few validated/qualified biomarkers of any type. 
Recent attempts have however included the use of mtDNA encoded proteins in peripheral fat and 
peripheral blood mononuclear cells (PBMC’s) from HIV-positive individuals on anti-retroviral 
therapy [121] and the use of blood transcriptomic markers (genes involved in OXPHOS) of drug 
induced liver injury [122]. Furthermore, circulating acylcarnitine metabolites have been suggested as 
good biomarkers of hepatotoxicity related to mitochondrial dysfunction in vivo [123]. Blood lactate 
has also been suggested as a good circulating biomarker of mitochondrial dysfunction however its 
presence in the systemic circulation is likely a secondary adaptation to perturbed energy production, 
takes time to manifest and is largely unspecific (i.e. can be due to generalised liver injury, steatosis, 
diabetes etc.). All of these candidates have shown proof-of-concept; however, they require stringent 
validation prior to use in preclinical safety-studies.  
 
6. Conclusively attributing mitochondrial dysfunction to particular drugs:  Demonstrating that 
in vitro observations predict in vivo outcomes pre-clinically and then conclusively predict clinical 
outcomes in humans (taking into account cross-species concordance) is inherently challenging. 
Hallmarks of mitochondrial toxicity are not easily translatable into the patient population. 
Additionally the hypothesised biomarkers of mitochondrial dysfunction are relatively non-specific, 
i.e. there is no certainty that observations are attributable to an adverse drug reaction as opposed to 
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other influences (e.g. the condition itself, inflammation, poor tissue perfusion etc). Despite this 
caveat, easily translatable endpoints between pre-clinical and clinical studies should be sought. For 
example, whilst isolated mitochondria are still a valuable tool in the understanding of particular 
mechanisms of DIMT perhaps the routine use of isolated tissue mitochondria to assess preclinical 
toxicity is not be a progressive approach (i.e. due to the inherent lack of tissue availability in human 
trials)? It is however important to acknowledge that the era of searching for single protein biomarkers 
which are specific, translatable and measurable may potentially be over or at least in decline. It is 
likely that a tailored selection of specific investigations is required. Alternatively, there is great 
interest in certain types of novel biomarkers such as miRNA species and these will continue to be 
evaluated.  
 
1.8. The use of a Systems Approach 
Where limited understanding exists in terms of the mechanisms downstream of a toxicological event a 
principle method of investigating the response is the use of a systems approach. Whilst the job of a 
toxicologist is to understand and ultimately predict the adverse effect of chemicals in a biological system, 
this task is incredibly complicated due to the inherent complexity of biological systems. Furthermore, 
observational toxicology has certain limitations such as the difficulty in developing effective in vitro 
assays, in developing informative biomarkers and the problems involved in designing out structural 
liabilities based on SAR. The true value of a systems approach is therefore the ability to build an 
AOP/MOA which focuses on the identification of the key events, their quantitative inter-relationships and 
human relevance.  
 
The field of systems toxicology (i.e. a systems approach) is relatively new, with the term coined for the 
first time in 2003 [124]. The definition of what encompasses systems toxicology does however vary 
greatly in the literature. The concept of a “systems approach” is still often confused with the field of 
systems biology, where computational and mathematical modelling is a central aspect. A systems 
approach is more reliant on the integration of data from multiple disciplines/endpoints (including both 
targeted and non-targeted investigations) to improve mechanistic understanding, search for biomarkers 
and identify the most sensitive endpoints for different types of toxicological event. In contrast, systems 
biology/toxicology relies on the modelling of global ‘omics’ data and using mathematical algorithms to 
drive predictions. The use of both approaches have been integral to the shift in emphasis in both drug-
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safety science and in biomedical research away from investigating single cells in isolation and towards 
studying the true complexity of biological systems [125].  
 
A systems approach encompasses the integration of classical toxicology (e.g. pathology, clinical 
chemistry etc.) with both novel methods of evaluation and the quantitative analysis of molecular changes 
occurring across multiple layers of biological organisation. Tailored approaches therefore need to be 
combined with global analyses in order to gain an understanding of both the local effects of xenobiotics 
on hypothesised outcomes and the emergent/systems level effects [126].  
 
The selected endpoints for analysis should be dictated by the aims of the experiment or as a result of any 
known understanding of the molecule’s AOP, and as a result, be tailor-made to the specific adverse 
reaction observed. Whether the effect is observed within a single cell, organ, or at the level of the whole 
organism dictates the depth of the system and thus the approach to be taken (i.e. this drives how complex 
or niche the system needs to be). In toxicology, the effect being studied is often at the organism level (i.e. 
an adverse in life effect) and although targeted evaluations remain pivotal to improve mechanistic 
understanding at a particular target site/organ, these need to be anchored to the adverse effect. 
Alternatively, the toxicological event may be a histopathological lesion in a single tissue and therefore the 
system reduces considerably in size, although one must be cautious that this is not an over-simplification 
(inter-organ/tissue effects may be important). Either way, due to the extent of biochemical cellular 
responses following drug-induced perturbation of cellular processes, a systems approach will likely 
always entail the use of global methods. As a result and key to identifying the fundamental mechanisms 
of dysfunction is careful analysis of these data using interaction networking and biological theme 
analyses. 
 
1.9. Tool Compounds Studied 
Two molecules (no longer in active development within GlaxoSmithKline) were chosen to study 
mechanisms of DIMT, based on their potent and selective effect on mitochondrial function. Furthermore, 
the mechanisms by which they affect mitochondrial function (respiratory chain inhibition and uncoupling) 
are commonly observed in preclinical assessment of drugs for mitochondrial activity. These compounds 
are introduced in section 1.9.1 and 1.9.2 below. 
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1.9.1. GSK932121A (COMPLEX III INHIBITOR) 
GSK932121A (shown in Fig.1.6 below) is a 4(1H)-pyridone molecule that was in development as an anti-
malarial medicine. In FTIH trials, GSK932121A was well tolerated however adverse toxicity was 
observed in pre-clinical studies with a pro-drug of GSK932121A, designed to increase oral 
bioavailability. This toxicity profile was later observed using GSK932121A itself when dosed IP (to 
provide similar systemic exposure levels to those achieved with pro-drug). These data resulted in 
GSK932121A’s termination from development due to a potentially narrow therapeutic index [127].  
 
 
 
 
 
 
 
 
FIGURE 1.6: Chemical structure of GSK932121A (mw: 425.786). This pyridone molecule was designed for the treatment of 
the Plasmodium falciparum malaria infection.  
 
Mitochondria are seen as an attractive target for anti-infective medicines. Due to the integral function 
mitochondria play in cellular biochemistry a sound therapeutic approach is to induce mitochondrial 
dysfunction in the infectious species (e.g. parasite), whilst avoiding crossover to the mammalian target. 
This approach has shown proof of principle by the atovaquone/proguanil (GlaxoSmithKline’s Malarone) 
combination therapy, used today as a treatment of multi-drug-resistant malaria. The drug works via 
inhibition of the Qo site of the cytochrome bc1 complex thus inhibiting mitochondrial electron transport. 
As the ETC is located in the plasma membrane in prokaryotes as opposed to within the mitochondria in 
eukaryotes it is hypothesised that drugs will effect mitochondrial processes with much higher potency in 
prokaryotic systems and thus provide a wide therapeutic window. 
 
Similar to atovaquone, GSK932121A is a selective inhibitor of the mitochondrial ETC. As described by 
Bueno and colleagues in 2012, GSK932121A inhibits the plasmodial cytochrome bc1 complex in the low 
nanomolar range (IC50= 0.007µM). GSK932121A is significantly more potent against the P.falciparum 
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target compared to mammalian cytochrome bc1 isolated from either human HEK293 cells (IC50= 0.4µM, 
57x less potent) or rat H9C2 cells (IC50= 0.6µM, 86x less potent). In whole cells the trend continued, 
wherein, cytotoxicity was observed at significantly higher doses in mammalian derived HepG2 cells 
(IC50=10µM) and H9C2 cells (IC50=14µM) compared to plasmodium derived cultures (3D7A and 
FCR3A) which both showed an IC50 for cytotoxicity of 0.006µM. This represents between a 1600-2400x 
higher potency against plasmodium cells compared to mammalian cells, suggesting a potentially wide 
therapeutic margin, based on in vitro data.  
 
FTIH study with GSK932121A:  There was no evidence of dose-limiting toxicity in oral pre-clinical 
studies and therefore GSK932121A was progressed to a FTIH study. The purpose of the FTIH study was 
to evaluate the safety and tolerability of the parent drug GSK932121A in comparison with placebo and to 
investigate the pharmacokinetics of the compound in man. Eight healthy adult male subjects received 
single doses of GSK932121A parent (3mg, n=4 or 30mg, n=4) with four separate subjects receiving 
placebo alone. GSK932121A was well tolerated.  
 
The pro-drug approach: Improved bioavailability causes an adverse toxicological profile: Despite 
excellent solubility, GSK932121A demonstrated non-linear pharmacokinetics in preclinical species with 
decreased oral bioavailability at high doses of the solid dosage form. In attempts to improve the oral 
bioavailability of GSK932121A a pro-drug approach was investigated. A water soluble phosphate ester 
pro-moiety was attached to the C6-CH2-OH hydroxyl as shown in Fig.1.7 below. Water soluble phosphate 
esters increase solubility and stability and undergo rapid bio-conversion (by endogenous membrane 
bound alkaline phosphatases) causing the release of high concentrations of the parent drug. Early 
indications in rats showed an approximately 10-fold greater oral bioavailability of the pro-drug at high 
dose compared with the parent alone. Due to this outstanding physiochemical and pharmacokinetic 
profile, the pro-drug of GSK932121A was progressed into full pre-clinical testing as a backup for the 
parent GSK932121A candidate. 
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FIGURE 1.7: Schematic of the approach taken to manufacture a GSK932121A pro-drug. (A) A water soluble phosphate 
ester was added to the C6-CH2OH group of GSK932121A in order to improve both stability and solubility for 
the purposes of increasing oral bioavailability.  (B) The resulting pro-drug showed increased bioavailability and 
improved PK profile but the increased systemic exposure levels resulted in acute toxicity consistent with 
mitochondrial impairment, which led to GSK932121A’s termination due to a potentially narrow therapeutic 
index. Diagram adapted from [127]. 
 
During these pre-clinical studies unexpected, acute toxicity was observed in rats after oral administration 
of the pro-drug. The toxicity was characterized by hypothermia, cardiovascular abnormalities and at high-
doses, sudden death. Upon further investigation, the severe, acute toxicity exhibited by the pro-drug could 
be replicated by the parent compound alone following IP administration, which induced similar exposure 
levels to those achieved with the pro-drug given orally. One hypothesis was that the toxicity observed in 
rats was due to inhibition of the mammalian bc1 mitochondrial complex by GSK932121A. FTIH studies 
with GSK932121A were put on hold and the compound later terminated despite its good tolerability 
profile at the two dose levels tested.  A package of investigative work was initiated to explore the acute 
toxicity caused by GSK932121A within which the present work (chapters 3-5) forms an integral first 
stage. 
 
1.9.2. GSK2617971A (OXPHOS UNCOUPLER) 
Unlike GSK932121A (described above), GSK2617971A was withdrawn from active development early, 
during the preclinical stage. GSK2617971A is a pyrazole compound which was designed as a selective 
androgen receptor modulator (SARM) for the treatment of cachexia (muscle wastage). GSK2617971A 
A B 
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(Fig.1.8) has shown potent uncoupling activity in vitro and is acutely toxic in vivo in rats, when dosed at 
60mg/kg–100mg/kg. GSK2617971A was terminated early in development following observations of 
toxicity in oral dose range finding (DRF) tolerability studies. 
 
 
 
FIGURE 1.8: Chemical structure of GSK2617971A (mw: 371.118). This pyrazole molecule was designed as a selective 
androgen receptor modulator (SARM) intended for the treatment of cachexia. 
 
Since GSK2617971A’s termination from development, it has been used as a tool molecule for the study 
of DIMT. As compounds with some degree of OXPHOS uncoupling activity are regularly identified in 
preclinical screening, it was imperative to gain further understanding of its mechanism of toxicity in vivo, 
in order to better inform discovery groups of the potential safety liability of this class of mitochondrial 
toxicant (chapter 6).  Furthermore, adverse effects caused by uncoupling of OXPHOS have been observed 
in the clinical situation following administration of medicines such as doxorubicin and therefore 
improved mechanistic understanding of this class of mitochondrial toxicant is translatable to effects 
observed in patients.   
 
1.10. Thesis Rationale and Aims 
Mitochondria are increasingly seen as attractive targets for pharmacological intervention due to their 
central role in the mechanism of many common human disorders (e.g. as treatments for metabolic 
disorders, neurodegenerative diseases and cancer). On the flipside, DIMT is gaining recognition in the 
pharmaceutical industry as a major cause of safety related attrition and a number of high profile drug 
withdrawals have been linked to deleterious effects on mitochondrial function (e.g. troglitazone, 
nefazodone and cervistatin). The potent effects of many of these compounds underscore the potential 
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risks associated with drugs causing mitochondrial toxicity. Improved methods to assess mitochondrial 
function would therefore aid both risk assessment of mitochondrially acting compounds but also assess 
the impact of drugs deliberately targeted to mitochondria for therapeutic purposes with the direction of 
change in a number of mitochondrial assays potentially being pivotal to assessing either pharmacological 
potential (e.g. inhibition of the mPTP to prevent aberrant cell death) or toxicity (e.g. potentiation of the 
mPTP).  
 
The inherently complex nature of mitochondrial pathophysiology (notably the array of different 
mechanisms by which a compound can effect mitochondrial function) means there is currently a lack of 
understanding on how best to foresee, understand or accurately assess the risk of compounds which effect 
mitochondrial function. The major challenge is in relation to understanding DIMT in vivo and whilst the 
past decade has witnessed advances in the development and integration of in vitro assays to aid pre-
clinical screening of mitochondrial agents, efforts to correlate the resultant data with in vivo outcomes are 
limited [1]. What is clear is that improved knowledge of the downstream toxicities associated with 
mitochondrial dysfunction would better enable toxicologists to provide informed advice to discovery 
groups, that are facing the prospect of potentially developing a drug which has some level of 
mitochondrial activity in vitro or de-selecting a molecule based on adverse mitochondrial effects. 
Furthermore, to date, few comprehensive AOP’s exist where the molecular initiating event (MIE) is a 
drug-interaction with a major mitochondrial process. The benefits of AOP’s to drug safety assessment 
scientists includes (but is not limited to), the ability to predict potential toxicological effects of other 
candidates showing similar in vitro activity, the ability to monitor the progress of an adverse drug 
reaction, the potential to identify early biomarkers and the ability to design more intelligent investigative 
safety studies which are tailored for mitochondrially-active therapeutics in development (i.e. both those 
targeted to mitochondria or those which may produce toxicity by affecting mitochondria).  
 
The overall aim of this project was to use a systems approach to better understand mechanisms of 
mitochondrial toxicity both in vitro and in vivo. The overall hypothesis being that mitochondrial toxicity 
leads to a specific and quantifiable AOP that can be used in drug development to better understand and 
assess the risk caused by DIMT in the pre-clinical setting. Two GlaxoSmithKline compounds with known 
mitochondrial activity (GSK932121A and GSK2617971A) were used in order to develop AOPs for 
toxicity due to drug-induced respiratory chain inhibition and OXPHOS uncoupling respectively. These 
compounds, which are no longer in active development, were chosen as a), the drugs are potent and 
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selective mitochondrial toxicants and b) respiratory chain inhibition and OXPHOS uncoupling are 
frequently observed molecular initiating events in the preclinical analysis of  drugs for mitochondrial 
activity. The overall aim of the thesis was broken down into a series of objectives. 
 
1. To test the hypothesis that in vitro assessment of mitochondrial function (i.e. in vitro cell lines or in 
vitro testing of drugs on naïve isolated mitochondria) provides information on key events relevant to 
the in vivo effects and therefore is useful in detecting mitochondrial toxicity for preclinical hazard 
identification. The rationale was to show that in vitro testing is a suitable means of assessing key 
events for DIMT.  
 
2. To assess the utility of using a systems toxicology approach in order to understand the underlying 
AOPs downstream of mitochondrial perturbation in vivo. Systems toxicology encompasses the 
integration of classical toxicology (e.g. pathology, clinical chemistry etc.) with, a) novel methods of 
evaluation, in this case functional mitochondrial changes and b) with the quantitative analysis of large 
networks of molecular changes occurring across multiple layers of biological organisation (in this 
case transcriptomic and metabolomic assessments). It was hypothesised that this systems approach 
would enable the development of AOP’s for two mechanisms of DIMT (respiratory chain inhibition 
and OXPHOS uncoupling).  
 
3. To identify markers of DIMT at sub-toxic doses (or prior to the onset of overt toxicity) based on the 
AOPs developed and to help in AOP development. The literature describes a number of examples 
whereby a drug is withdrawn from the market due to toxicity which was not evident throughout pre-
clinical and clinical trials (e.g. troglitazone). It has been hypothesised that this is due to underlying 
damage to mitochondria which was not detected at the preclinical stage as mitochondrial functional 
changes have historically not been assessed. Mitochondria are able to respond to a certain level of 
direct or indirect stress (due to a reserve capacity) and this mitochondrial-resilience prevents the 
immediate onset of toxicity early in drug development. Markers of mitochondrial perturbation 
occurring at sub-toxic doses would be of immense value to monitoring the potential long term safety 
of molecules with some degree of mitochondrial activity in vitro but which are generally well 
tolerated. Furthermore, markers of mitochondrial effects at sub-toxic dose-levels helps in the 
development of AOP’s (as described in objective 2) by enabling primary effects to be distinguished 
from consequential effects.  
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2.0. MATERIALS AND METHODS  
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2.1. Animals 
All in vivo studies in rats were ethically reviewed and carried out in accordance with the Animals 
(Scientific Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Animals. All 
regulated procedures (i.e. dosing, implanting of microchip, and taking blood samples) were performed by 
personal license holders in GlaxoSmithKline’s Safety Assessment and Laboratory Animal Sciences 
departments. 
 
2.1.1. GSK932121A STUDIES – GLAXOSMITHKLINE, WARE, HERTFORDSHIRE UK 
Female Crl:CD(SD) rats were obtained from Charles River Laboratories UK (Margate, Kent) and were 
housed under controlled environmental conditions (19-23°C, 55% ± 10% relative humidity, 12h dark-
light cycles), with free access to both water and 5LF2 EURodent Diet (Purina Mills International, St 
Louis, MO, USA). All animals were implanted with an intrascapular Plexx microchip (Plexx B.V., Elst, 
The Netherlands) on arrival for the purposes of identification and body temperature measurement. 
Animals were acclimatised for at least 12 days prior to dose administration, and were 10 to 14 weeks old 
on the day of dosing (~270-350g). 
 
2.1.2. GSK2617971A STUDY – GLAXOSMITHKLINE, UPPER MERION, PENNSYLVANIA, USA 
Male Crl:Wi (Han) rats were obtained from Charles River Laboratories (Charles River Laboratories Inc., 
Stone Ridge, NY, USA) and were housed under controlled environmental conditions (64-79°F, 30-70% 
humidity and 12h dark-light cycles). Rats were offered 5002 Certified Rodent Diet (PMI Nutrition 
International, Richmond, IN, USA) and filtered tap water ad libitum. All animals were implanted with an 
intrascapular Plexx microchip (Plexx B.V., Elst, The Netherlands) on arrival for the purposes of 
identification and body temperature measurement.  Animals were acclimatised for one week and were 10-
12 weeks old on the day of dosing (~200-350g). 
 
43 
 
2.2. In Life Clinical Observations 
In all studies that included the dosing of rodents with test substances, strict in-life monitoring was 
performed to both ensure animal wellbeing (by reducing suffering) and closely monitor the effect of drug 
treatment. Animals were checked for adverse effects immediately post-dose and then at approximate 15 
minute intervals (in line with body temperature measurement). Animals were checked in accordance with 
GlaxoSmithKline Safety Assessment’s project license and adverse effects were recorded directly onto 
Provantis V9.0 data management system (Instem, Staffordshire UK). A scoring metric of slight, moderate 
and severe was recorded alongside notification of the adverse event. Animals were killed immediately for 
ethical reasons if any adverse event was graded severe. Grading of the severity of clinical signs was 
performed by experienced animal technicians alongside the facilities named animal care and welfare 
officer (NACWO), with the in-house veterinary surgeon on standby.  
 
2.3. Preparation of Dosing Solutions 
All doses and concentrations are expressed in terms of the parent compound. 
2.3.1. GSK932121A STUDIES – GLAXOSMITHKLINE, WARE, HERTFORDSHIRE UK 
A nanomilled, spray-dried formulation of GSK932121A (49.5% w/w), containing mannitol (44.5% w/w), 
hydroxypropylmethylcellulose Pharmacoat 603 (5% w/w) and sodium lauryl sulphate (1% w/w) was 
suspended in sterile water for IP administration. A dose of either 12.5mg/kg or 50mg/kg was selected 
based on data generated in previous GSK932121A single-dose tolerability studies. A single dose of either 
12mg/kg GSK932121A, 50mg/kg GSK932121A or vehicle (described above, minus test article) was 
administered IP to female rats at a dose volume of 10 mL/kg.   
 
2.3.2. GSK2617971A STUDY – GLAXOSMITHKLINE, UPPER MERION, PA, USA 
Animals were separated into three groups (vehicle control (VC), low dose and high dose). Groups 
comprised n=6 with the exception of the low dose which had n=2 due to extenuating study circumstances. 
GSK2617971A was suspended in 30% koliphor/70% water vehicle. Vehicle control (VC) animals 
received koliphor/water alone. Doses of 30mg/kg and 60mg/kg were selected for this study based on 
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findings from earlier studies in rats that demonstrated that both doses provoked adverse signs with the 
30mg/kg dose being well tolerated up to 24 hours. A dose of 100mg/kg has been shown to be lethal by 8 
hours. A single dose of 30 mg/kg, 60mg/kg or VC was administered by gavage via the oral route to male 
rats at a dose volume of 10mL/kg. 
 
2.3.3. FORMULATION OF COMPOUNDS FOR IN VITRO EXPERIMENTS 
All compounds were formulated in dimethyl sulfoxide (DMSO) either within advised solubility ranges (as 
obtained from MSDS data sheets) or at a standard top concentration of 10mM. DMSO was used at a final 
concentration of 0.1% for cell culture experiments (to prevent cytotoxicity) or 0.5% for experiments using 
isolated mitochondria (shown to have no direct effect on mitochondrial function). Stocks in DMSO were 
stored at room temperature and out of direct sunlight for up to one year.  
 
2.4. Measurement of Blood Gasses and Bicarbonate 
Blood gas analysis was performed by Dr Jeffrey Ambroso (GlaxoSmithKline, Safety Assessment, RTP, 
NC, USA). For blood gas analysis (pO2, pCO2 and HCO3) separate groups of animals underwent surgery 
to place vascular access ports at the site of blood collection. The jugular artery was isolated, cannulated 
(catheter entered approximately 2 cm into the jugular artery) and the catheter secured in place with 
ligatures of non-absorbable suture material (Ti-cron, Medline Industries Inc., IL, USA). A 2ml saline 
flush was given at the jugular surgical site prior to wound closure using absorbable suture material (PDS, 
Ethicon Ltd, NJ, USA). After surgery a one week recovery period was permitted prior to administration 
of test substance or VC as previously described (section 2.3.1 and 2.3.2). Whole blood samples (0.3mL 
volume) were collected via vascular access ports into heparinized syringes. Blood was sampled at 5 to 6 
hours post dose (dependent on the observed clinical signs). All blood samples were analysed using a 
Roche OPTI CCA Blood Gas Analyser (Opti Medical System Inc., GA, USA), according to 
manufacturer’s recommendations, within 2 hours of collection for pCO2, pO2 and HCO3. Data are 
expressed as a percentage of baseline (pre-dose) measurement values. 
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2.5. Blood Sampling 
Blood samples were taken in all of the in vivo studies for analysis of multiple parameters. Details of the 
blood sampling methodologies are described in table 2.1 below.  
 
In vivo study and 
chapter 
Site and details of 
blood collection 
Volume of  blood 
collected (mL) 
Anti-coagulant and storage Endpoint 
 
 
All studies (chapters 
3, 4, 5 and 6)  
Puncture of 
abdominal aorta 
under isoflurane 
anaesthesia.  
0.3 EDTA microtainer, centrifuged to 
prepare plasma (see section 2.5.1 
below) and frozen on solid carbon 
dioxide. Samples were stored at -
20°C prior to analysis 
 
Toxicokinetics 
All studies (chapters 
3, 4, 5 and 6) 
Puncture of 
abdominal aorta 
under isoflurane 
anaesthesia. 
0.1 0.1mL of blood added directly to 
0.4mL of 0.4M perchloric acid and 
vortexed to ensure thorough mixing 
of blood/acid. Samples frozen on 
solid carbon dioxide and then stored 
at -80°C prior to analysis. 
 
Lactate/ 
Pyruvate  
GSK932121A 
metabolomics study 
Jugular venepunture 
for in-life samples 
and puncture of 
abdominal aorta 
under isoflurane 
anaesthesia for 
terminal samples. 
0.4 EDTA microtainer, centrifuged to 
prepare plasma (see section 2.5.1 
below) and flash frozen in liquid 
nitrogen. Samples stored at -80°C 
prior to analysis.  
Global 
Metabolomics 
Profiling 
TABLE 2.1: Overview of blood sampling methodologies. Detail of blood sampling methodologies, employed on all in vivo 
studies described herein including the site of collection, the volume collected, the nature of the anti-coagulant, 
the storage conditions of the blood and the endpoint for which the blood was used for.  
 
2.5.1. PREPARATION OF PLASMA FROM WHOLE BLOOD SAMPLES 
Plasma forms the liquid component of whole blood and makes up ~55% of total blood volume [128]. 
Within a whole blood suspension, the plasma compartment normally contains the blood cells and is 
regularly used for biochemical analyses. Plasma was prepared from whole blood samples using the 
method described below. 
 
Whole blood (typically between 0.2mL and 0.4mL) was collected into ethylenediaminetetraacetic acid 
[EDTA] microtainers (#365974, Becton Dickinson and Co, New Jersey, USA) and stored on ice until the 
end of autopsy procedure. All blood samples were then centrifuged for 3 minutes at 6000g following 
which the plasma supernatant compartment was removed and placed into pre-labelled polypropylene 
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tubes using a graduated pipette. Plasma samples were then immediately frozen on solid carbon dioxide 
and stored at -20°C prior to analysis. 
 
2.6. Measurement of GSK932121A and GSK261971A Concentration in 
Plasma 
GSK932121A and GSK2617971A levels were assessed in rat plasma (EDTA anticoagulant) by LC-
MS/MS following protein precipitation. Levels of both drugs were quantified against a standard curve and 
normalised to a GSK932121/GSK2617971 [
13
C6] internal standard. The lower limit of quantification 
(LLQ) was 10ng/mL using a 25µL aliquot of rat plasma. Briefly, protein was precipitated by adding 25µL 
of rat plasma to 200µL acetonitrile (plus internal standard working solution) with subsequent vortex 
mixing. Samples were then centrifuged for 10 minutes at 3000g and the supernatant transferred to a fresh 
Eppendorf tube. A sample volume of 2µl was then injected onto a Waters Aquity UPLC (Waters, Elstree, 
Hertfordshire, UK) connected to a SCIEX API4000 mass spectrometer (SCIEX, MA, USA) running in 
positive-ion mode employing the Turbo-Ionspray source. A 50 x 2.1mm BEH C18 1.7µm, (Waters) 
column was maintained at 50°C (solvent A: HPLC grade water 0.1% v/v formic acid, solvent B: 
Acetonitrile) with a flow rate of 0.8mL/min. A gradient from 10% to 80% solvent B was employed over 
1.30min followed by a re-equilibration time of 0.7mins yielding a total run time of 2 minutes.  
 
2.7. Body Temperature Measurements 
All animals were implanted with a Plexx (Plexx B.V., Elst, The Netherlands) microchip for the purposes 
of identification and body temperature measurement.  IPTT-300 programmable temperature transponders 
(#11059, Plexx) were implanted subcutaneously and without anaesthetic. Body temperature or ID 
readings were taken using a DAS-7007 S IPT/IPTT straight reader (#11087, Plexx) and DAS Host 
Software (#11064, Plexx) was used to link animal ID with temperature readings. Data were recorded 
telemetrically. 
47 
 
2.8. Isolated Mitochondrial Methods 
2.8.1. ISOLATION OF MITOCHONDRIA  
Mitochondria were isolated from selected rat tissues as described below.   
 
Liver and Kidney Mitochondria: Mitochondria were prepared using the Qproteome Mitochondria 
Isolation kit (Qiagen, Limburg, Netherlands) according to the manufacturer’s instructions. Briefly, 1.3g of 
liver or 1 whole kidney was homogenised in ice cold lysis buffer using a Qiagen Tissue Ruptor. The 
homogenate was incubated on an end-over-end shaker for 10 minutes at 4°C prior to centrifugation at 
1300g for 13 minutes. The resulting pellet was resuspended in disruption buffer firstly by gentle pipetting 
and secondly using a Dounce homogenizer (4 strokes at 200rpm). The resulting lysate was centrifuged at 
1000g for 13 minutes with the resulting supernatant washed and pelleted twice at 6000g for 13 minutes. 
The crude mitochondrial pellet was finally resuspended in Incubation Buffer B (130mM sucrose, 50mM 
KCl, 2.5mM KH2P04 and 5mM N-2.Hydroxyethylpiperazine-N’-2-Ethanesulfonic Acid [HEPES], pH7.4 
with KOH). 
 
Skeletal Muscle Mitochondria: Mitochondria were prepared as described in [129] with minor 
modifications. Briefly, the gastrocnemius muscle block was removed from one hind limb of the animal. 
Visible tendons and ligaments were removed before the tissue was minced finely using dissection 
scissors. The tissue was washed using phosphate buffered saline (PBS) supplemented with 10mM 
ethylenediaminetetraacetic acid [EDTA], before suspending in PBS+10mM EDTA +0.05% trypsin for 30 
minutes. The tissue was pelleted at 200g for 5 minutes to remove trypsin from solution and resuspended 
in Isolation Buffer 1 (67mM sucrose, 50mM Tris/HCl, 50mM KCl, 10mM EDTA, and 0.2% w/v FA-free 
BSA, pH 7.4). The tissue was homogenised using a Dounce homogeniser powered by an overhead motor 
(7 strokes at 1200rpm) before first filtering through a wide pored mesh (200μm) to remove connective 
tissue and secondly centrifuging at 900g for 10 minutes. The resulting supernatant was centrifuged at 
8500g for 10 minutes and the pellet resuspended in Isolation Buffer 2 (250mM sucrose, 5mM ethylene 
glycol-bis (2-aminoethylether)-N,N,N’,N-tetraacetic acid [EGTA], and 10mM Tris/HCl; pH 7.4). A final 
centrifugation at 8500g for 10 minutes produced the mitochondrial-enriched pellet which was 
resuspended in 0.25ml of Incubation Buffer B. 
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Brain Mitochondria: Mitochondria were prepared as described in [130] with minor modifications. 
Briefly, the whole brain was excised fresh, weighed and homogenised directly in a Dounce homogenizer 
powered by an overhead motor (9 strokes at 300rpm) in isolation medium (IM) (225mM sucrose, 74mM 
mannitol, 1mM EGTA and 5mM HEPES, pH7.4 with KOH). The homogenate was split into two and 
centrifuged twice (separately) at 1,300g for 3 min before re-centrifuging the pooled supernatants at 
21,000g for 12 minutes.  The resulting pellet was resuspended in 15% Percoll (GE Healthcare, UK)  
diluted in IM and layered slowly above a pre-prepared secondary gradient of 40% and 24% Percoll. The 
Percoll density gradients were centrifuged for 8 minutes at 30,750g with no braking to prevent disruption 
of the Percoll bandings. All material banding at the interface of the 24% and 40% gradient was removed 
and re-centrifuged in IM (minus EGTA) at 55,000g. Mitochondria were located at the bottom of the 
centrifuge tube as a liquid mass with approximately 1mL of mitochondria removed for downstream 
processing.  
 
Heart Mitochondria: Mitochondria were prepared as described in [131].  Briefly, the heart was excised 
fresh and weighed before being finely minced using dissection scissors to ~1mm
3
 sections. Aortic tissue, 
fat and clotted blood were removed from the suspension and the tissue rinsed thoroughly in ice cold 
Washing Medium (0.3M Sucrose, 10mM HEPES, 0.2mM EDTA, pH 7.2 with KOH) to remove 
remaining blood. The tissue was then washed a further three times in washing medium on a filter before 
being placed into 2.5mg/mL trypsin (Sigma #T8003) solution for 6 minutes prior to homogenisation using 
a Dounce homogeniser powered by an overhead motor (6 strokes at 400rpm). The homogenate was then 
left for a further 6 minutes in trypsin before undergoing a second homogenisation (4 strokes at 400rpm). 
The trypsin was then deactivated using trypsin inhibitor from soy bean (Sigma #T9128). The suspension 
was filtered through a nylon filter (25µm pore size) to remove remaining connective tissue. The filtrate 
was then centrifuged first at 600g for 15 minutes and second the supernatant was centrifuged at 8500g for 
15 minutes. The pellet was then washed three times with 1mL washing buffer before resuspension and re-
centrifugation at 8500g for 15 minutes. The resulting pellet was then resuspended in 20mL of isolation 
medium (0.3M sucrose, 10mM HEPES, 0.2mM EDTA + 1mg/ml fatty acid free BSA, pH 7.2. with KOH) 
and centrifuged at 9000g for 15 minutes. The final crude mitochondrial pellet was suspended in 0.5mL of 
Incubation Buffer B and stored on ice for immediate use. 
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2.8.2. ASSESSMENT OF PROTEIN CONCENTRATION 
Protein content was measured using a bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, IL, 
USA) according to manufacturer’s recommendations. Briefly, a 1:20 dilution of mitochondrial isolate was 
prepared in CHAPS hydrate. The protein suspension was vortexed before centrifuging at 12000g for 2 
minutes. A volume of 25µL of sample or bovine serum albumin (BSA) standard (0µg/mL - 2000µg/mL) 
was pipetted into a clear bottomed 96 well plate in triplicate. 200µL of working reagent was added to 
each well and the plate was incubated for 15 minutes at 37°C prior to reading. Absorbance was measured 
at 562nm on a FlexStation3 microplate reader (Molecular Devices, Sunnyvale, CA, USA).  A standard 
curve was prepared and used to determine the protein concentration of each unknown sample.  
 
2.8.3. ASSESSMENT OF MITOCHONDRIAL BIOENERGETICS USING THE SEAHORSE XF24 
ANALYSER 
To assess bioenergetic parameters, i.e. ETC function and OXPHOS coupling, in isolated mitochondria, 
the Seahorse XF24 Extracellular Flux Analyser (Seahorse Biosciences, Billerica, MA) was utilised. The 
XF24 Seahorse platform utilises a disposable sensor cartridge that has 24 fluorescent sensors which 
measure the oxygen concentration in the well containing isolated mitochondria in a 24 well plate. The 
sensor cartridge also contains 24 pH probes for measurement of glycolytic function (extracellular 
acidification rate, ECAR), however as mitochondria in isolation do not contain a cytoplasmic 
compartment (and as such the capacity for glycolysis), ECAR measurements were only made in whole 
cells in culture. Oxygen consumption rate (OCR) is measured in a transient 2-7µL “micro-chamber” 
formed immediately above the mitochondrial layer enabling small changes in oxygen to be detected.  The 
fluorescence sensors are connected to a fibre-optic wave guide that delivers light which excites the 
oxygen sensors at 530nm. The resulting florescence signal is emitted at 650nm and is detected by photo-
sensitive detectors in the XF24 instrument [132]. Within the disposable sensor cartridge are four drug-
injection ports which enable the user to inject substrates, inhibitors etc. throughout the course of the 
experiment and visualise, in real-time, the effect on cellular bioenergetics (Fig.2.1). With isolated 
mitochondria the principle assay used is a basal, oligomycin, FCCP, antimycin A (BOFA) assay which 
enables the user to determine drug-related effects on a number of respiratory parameters such as ATP-
linked OCR, maximal uncoupled respiration and proton leak. 
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FIGURE 2.1: The Seahorse Bioscience BOFA assay: The Seahorse Bioscience BOFA assay analyses the effect of drug 
treatment on ETC function. (A) Mitochondria are seeded into a 24 well plate and centrifuged to ensure 
adherence. The mitochondrial monolayer is energised with substrate (and exposed to drug if performing an in 
vitro treatment of control mitochondria). The plate is then inserted into the XF24 analyser and subjected to 
pneumatic and sequential injections of tool-compounds from the assay ports A-D (previously loaded into the 
XF assay cartridge at optimised concentrations) which modulate ETC function. (B) The effect of drug treatment 
can be determined on a number of respiratory states (black text), or on calculated respiratory parameters (orange 
text), e.g. proton leak, respiratory control ratio (RCR, gold standard measure of mitochondrial health) and 
maximal uncoupled respiration.  
 
A significant proportion of time was devoted to the optimisation of BOFA assay parameters from 
mitochondria isolated from five rodent tissues. OCR was monitored in the 24 well plate format as 
previously described [133]. Briefly, sequential measurements of basal respiration, state 3, state 4 and 
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uncoupled driven respiration were made through real-time additions of reagents through the drug-
injection ports. Accordingly, (concentrations expressed as final concentrations and optimised as 
recommended by manufacturers) ADP (5mM for all mitochondria except for 10mM with heart 
mitochondria), oligomycin (2µM), FCCP (4µM) and antimycin A (4µM) were loaded into the 4 injection 
ports of the XF Assay Cartridge and sequentially injected into each well throughout the assay.   
 
Mitochondria were diluted to a concentration of either 10µg protein/well (liver and skeletal muscle 
mitochondria), 7.5µg protein/well (brain mitochondria) or 2µg protein/well (heart and kidney 
mitochondria), in MAS-1 buffer (220mM mannitol, 70mM sucrose, 10mM KH2PO4, 5mM MgCl2, 2mM 
HEPES, 1mM EGTA and 0.2% BSA in sterile water, pH 7.2 adjusted with KOH) supplemented with 
either 10mM succinate (liver, kidney and skeletal muscle mitochondria) or 10mM malate/glutamate (heart 
and brain mitochondria). Mitochondria were seeded at a volume of 50µL into each well of an XF24 V7 
microplate and centrifuged for 20 minutes at 2000g (4°C). Following centrifugation, 450µL of MAS-1 
buffer, supplemented with 10mM succinate and 2µM rotenone (liver, kidney and skeletal muscle 
mitochondria) or 10mM malate / glutamate (heart and brain mitochondria), were added to each well. The 
mitochondria were viewed briefly under a microscope to ensure consistent seeding/adhesion and then 
placed at 37°C for 8 minutes prior to loading into the XF24 analyser. Following a 12 minute equilibration, 
two baseline measurements were made using a 30 second mix, 4 minute measure cycle. Reagents were 
then sequentially injected into each well with a further 30 second mix, 1 minute wait, 4 minute measure 
cycle between each injection. 
 
The direct effect on OCR of compounds was also examined by treating freshly isolated mitochondria in 
vitro following the above procedure with the following modification. A six point concentration range of 
the drug to be evaluated, or 0.5% DMSO control, was added to the mitochondria following centrifugation 
thereby constituting a 20 minute pre-measurement incubation period at 37°C. 
 
2.8.4. CALCIUM RETENTION CAPACITY ASSAY 
The calcium retention capacity (CRC) assay analyses the effect of drugs on the triggering of the mPTP. 
Mitochondria play a key role in regulating intracellular calcium concentrations during both normal and 
pathological states [134]. However, excess calcium is able to trigger the mPTP, characterised by a non-
selective increase in the permeability of the inner mitochondrial membrane [135, 136]. mPTP activity  is 
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affected by compounds that interfere with mitochondrial function and this can be monitored by 
measurement of CRC in mitochondrial isolates. Mitochondria from all five tissues were optimised for use 
in this assay both in the presence of drug (i.e. for in vitro examination of the direct effect of drugs on 
potentiation of calcium-induced mPTP) and in the absence of drug (i.e. analysis of mitochondria isolated 
from treated and control rats in vivo). The CRC assay is summarised in Fig.2.2 below. 
 
 
 
 
 
 
 
 
 
FIGURE 2.2: Graphical representation of the CRC assay. The CRC assay analyses the effects of drug treatment on the 
triggering of the mPTP. Mitochondria are mixed with a calcium sensitive dye (Arsenazo III, ASZIII) which 
upon the addition of a bolus dose of calcium binds and increases optical density (OD). When mitochondria are 
energised by a substrate (either succinate, in the presence of rotenone to prevent electron backflow or a complex 
I substrate i.e. pyruvate) they begin to uptake calcium (reduction in OD) until reaching permeability transition. 
The pore is then triggered and calcium is re-released.  
 
Incubation Buffer B was used as the main CRC assay buffer for mitochondria isolated from all tissues. 
Buffer B was used both to dilute mitochondria to the appropriate concentration and to prepare the 
Arsenazo III dye mixture (calcium-sensing dye). Buffer B contains 130mM sucrose, 50mM KCl, 2.5mM 
KH2P04 and 5mM HEPES, pH7.4 with KOH. 
 
The CRC of freshly isolated mitochondria was determined as previously described [137] with minor 
modifications. Briefly, mitochondria were suspended at 0.2mg/ml (liver, heart, skeletal muscle and brain 
mitochondria) or 0.6mg/ml (kidney mitochondria) in Incubation Buffer B, supplemented either with 
MITOCHONDRIA + 
ASZIII 
+Ca
2+
 
+ SUBSTRATE 
(i.e. succinate) 
CRC = ΔOD  
Compounds that decrease CRC are likely to 
cause mitochondrial dysfunction (e.g. Ca2+ 
uptake inhibitors, uncouplers and ETC 
inhibitors) 
Compounds that increase CRC are likely to 
be direct/selective MPT inhibitors 
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100µM Arsenazo III, 2.5µM rotenone and 1µg/mL oligomycin (liver, kidney and brain mitochondria) or 
in Incubation Buffer B with Arsenzo III alone (heart and skeletal muscle mitochondria) in each well of a 
96 well microplate. Absorbance was measured every 2 seconds at 650nm in a FlexStation3 microplate 
reader (Molecular Devices, Sunnyvale, CA, USA). After approximately 1 minute of reading, calcium was 
added (1µmol/mg mitochondrial protein) shortly followed by the addition of 10mM succinate (liver, 
kidney and skeletal muscle mitochondria), 10mM malate/glutamate (brain mitochondria) or 2mM 
pyruvate (heart mitochondria) as the mitochondrial substrate. The CRC was calculated as the difference in 
optical density (∆OD) between the point at which mitochondria were energised and undergoing MPT 
(highlighted in Fig.2.2 above). 
 
The direct effect on CRC of compounds was also examined by treating freshly isolated mitochondria 
from a control rat in vitro following the above procedure with the following modification. Drugs were 
added over a concentration range, alongside a 0.5% DMSO VC and 1µM cyclosporine A (mPTP 
inhibitor) to the mitochondrial suspension prior to reading. The cyclosporine A control was used to ensure 
drug-induced modulation of CRC was detectable in the system used.  
 
2.8.5. MITOCHONDRIAL MEMBRANE POTENTIAL ASSAY 
Mitochondrial membrane potential (ΔΨ) was analysed in freshly isolated mitochondria using the Sigma 
Aldrich isolated mitochondria staining kit (CS0760) according to manufacturer’s recommendations. The 
kit is based on mitochondrial staining using the 5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazolocarbo-cyanine iodide (JC-1) dye. In normal cells, the JC-1 dye concentrates in the 
mitochondrial matrix where it forms red fluorescent aggregates. Any event that dissipates the ΔΨ 
prevents accumulation of JC-1 dye in the mitochondria. The dye is detected fluorometrically at 490nm 
(excitation) and emission wavelengths of 590nm (JC-1 aggregate) and 532nm (JC-1 monomer) using a 
FlexStation3 microplate reader (Molecular Devices, Sunnyvale, CA, USA).  
 
2.8.6. COMPLEX III ACTIVITY ASSAY 
The effect of GSK932121A on mitochondrial complex III was assessed in bovine heart mitochondria 
using the Mitosciences Complex III Activity Assay Kit (Abcam, Cambridge, UK #ab109905) and 
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following manufacturer’s guidelines. Measurement of the conversion of cytochrome c from its oxidised to 
reduced form was made at 550nm using a Spectramax plus 384 spectrophotometer (Molecular Devices, 
Sunnyvale, CA, USA). Data were expressed in mOD/min. 
 
2.9. Cell Culture Techniques 
2.9.1. HEPG2 CELL CULTURE AND MEDIA COMPOSITION 
The human hepatocellular liver carcinoma cell line (HepG2) was originally purchased from BIOCAT and 
originated from a 15 year old adolescent Caucasian male. Cells were adapted to long term culture in 
modified DMEM medium as described below. Cells were cultured in galactose-conditioned modified 
DMEM according to table 2.2 below. 
 
Constituent Cat Number Final Concentration 
DMEM (with glutamine, without 
pyruvate and glucose) 
Invitrogen #11966 N/A 
Heat Inactivated FBS, EU Approved 
Origin: South America 
Invitrogen #10500-064 10% 
Galactose*  Sigma #G075 10mM 
HEPES  Invitrogen #15630 5mM 
Glutamax Invitrogen #35050 2mM 
Sodium Pyruvate Sigma #S8636 100µM 
Gentamicin Gibco #15750-045 5µg/mL 
TABLE 2.2: Media constituents for HepG2 cell culture - * A stock of 0.5M galactose was prepared in DMEM media, passed 
through a sterile filter and aliquots frozen at -20°C for up to 6 months.    
 
Cell culture work was performed in a class II microbiological safety cabinet using sterile plastic ware. 
Cells were maintained/incubated at 37°C within a humidified atmosphere with 95% air and 5% CO2 
 
Cell Revival: Upon resuscitation, one vial of cells (frozen at 1x10
6
 cells/mL) was flash thawed in a water 
bath at 37°C (for approximately 2 minutes or until no ice crystals were visible) before cells were 
transferred into a T80cm
2
 flask containing 25mL of pre-warmed culture media and placed into an 
incubator to adhere for 24 hours. The following day the media was changed to remove residual DMSO 
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(used as a cryoprotectant to prevent cell ablation) from the freezing medium. Subsequently the media was 
changed every 3 days and cells were passaged once per week according to the method outlined below. 
 
Cell Passaging: To passage cells, medium was removed and cells were washed with 20mL of PBS (at 
room temperature). Three-mL of 0.05% Trypsin-EDTA (Life Technologies #25300062) was added to the 
cells and the flask returned to the incubator for 5 minutes. The flask was then gently tapped to detach 
remaining cells before 10mL of culture medium was added to the flask to deactivate the trypsin. Cells 
were centrifuged at room temperature for 5 minutes at 1200 rpm and the supernatant was discarded. The 
pellet of cells was resuspended in 10mL of fresh complete media and passed through an 18G blunt-ended 
needle 5 times to disperse aggregated cells and generate a single celled population.  Cells were counted 
using a haemocytometer (a 1:5 dilution of cells in culture media was routinely used to reduce the number 
of cells and improve counting efficiency) and seeded as described below. Cells were routinely maintained 
in T175cm
2
 flasks with morphology and growth rate regularly assessed by light microscopy. The seeding 
densities used throughout this thesis were optimised stringently using cell-density titrations. Table 2.3 
below details the seeding densities used both in routine cell maintenance (i.e. in T80 and T175 flasks) and 
in both 96 and 12 well plates. 
 
Flask / Plate Well size Supplier Seeding 
Density 
Time until 70-80% 
Confluent 
 
T80cm2 Flask 80cm2 Nunc (Thermo Scientific # 178905) 1x106 7 Days 
T175cm2 Flask 175cm2 Nunc (Thermo Scientific # 178883) 3x106 6-7 Days 
96 Well Plate 0.32cm2 Corning  (Sigma # CLS3596) / 
Seahorse Bioscience # 101085-004 
2x104 24 hours 
12 Well Plate 3.8cm2 Corning  (Sigma # CLS3513) 2.5x105 48 hours 
TABLE 2.3: HepG2 cell seeding density and flask/plate details. Seeding densities were optimised throughout the project. Cell 
density titration experiments aimed to identify the best condition for the assay in question in relation to cell 
density and confluency and therefore densities are not reflective of the size of the well/flask.  
 
Cryopreservation of HepG2 Cells for maintaining Stocks: Over time it was important to maintain a 
batch of frozen cells. During a passage cycle and immediately following trypsinisation, cells were 
resuspended in freezing medium containing 90% FBS (Invitrogen #10500-064) and 10% DMSO. Cells  
were then counted and 1mL aliquots (at a density of  1x10
6
 cells/mL) were transferred to labelled 
cryovials (alternatively, 4 x 1ml aliquots from a 175cm
2
 flask or 1 x 1ml aliquot from a 80cm
2
 flask were 
cryopreserved). Vials were then placed in a Mr Frosty (controlled temperature freezing container filled 
with iso-propanol, Sigma Alrdich, #C1562) which was placed at -80°C for 24h. The frozen vials were 
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then transferred to a liquid nitrogen freezer for long-term storage.  When freezing a batch of cells, one 
vial of cells was revived after several days to ensure the freezing process had been successful and the cells 
remained viable.  
 
2.9.2. ASSESSMENT OF CYTOTOXICITY 
The LDH Cytotoxicity Detection Kit (Roche Diagnostics, Basel, Switzerland #11644793001) was used to 
assess LDH leakage into cell culture medium following treatment with compounds and respective DMSO 
controls (as recommended by the manufacturer) on a SpectraMax Plus 384 plate reader (Molecular 
Devices, Sunnyvale, CA, USA). Data were expressed as a percentage of leaked LDH against total LDH 
(leaked values + Cell Lytic lysed samples) with 1% v/v Triton X-100 used as a positive control inducer of 
cytotoxicity.  
 
2.9.3. ANALYSIS OF WHOLE CELL BIOENERGETICS IN HEPG2 CELLS 
Whole cell bioenergetics/cell metabolism was assessed using the Seahorse XFe96 Analyser (Seahorse 
Bioscience, Billerica, USA) essentially as described by [138] and [139] with minor modifications. The 
method described below is similar to that described in section 2.8.3 above although for cell culture 
analysis the XFe96 analyser was utilised as oppose to the XF24. Additionally, with whole cells the 
Seahorse Analyser permits the analysis of both OCR (measure of ETC/OXPHOS) and ECAR (measure of 
glycolysis) providing an indication of the metabolic state of cells in culture. Again, drug injection ports 
allow the effect of compounds/inhibitors/substrates on whole cell bioenergetics to be assessed.  
 
Briefly, HepG2 cells grown in galactose-conditioned DMEM media (as described in section 2.9.1) were 
plated into an XF96 cell culture plate (Seahorse Bioscience # 101085-004) at 2x10
4
 cells per well and 
incubated at 37°C (5% CO2) for 24 hours. Following incubation, cells were removed from the incubator 
and the media was replaced with 175µL of serum-free assay media (table 2.4 below). Assay media was 
prepared fresh on the day of the assay and warmed to 37°C prior to the pH being adjusted to pH 7.4 with 
KOH.  
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Constituent Concentration Supplier #Part Number 
XF Base Media  N/A Seahorse Bioscience # 102353-100 
L-Glutamine 2mM Life Technologies #25030-081 
Sodium Pyruvate  1mM Sigma #P2256 
Glucose 10mM Sigma #G8270 
TABLE 2.4: Serum free Seahorse assay media constituents 
 
Following media replacement, cells were placed into a 37°C incubator (no CO2 supplementation) for one 
hour. During this incubation a dose response of the compound of interest was prepared in serum free 
assay media. Oligomycin, FCCP and antimycin A/rotenone were also prepared at the concentrations 
below (table 2.5) in serum free media, enabling the analysis of multiple bioenergetic parameters. 
Compounds were added into the injection ports at increasing concentrations as additions are sequential 
(therefore to maintain a consistent volume of 25µL in each port, the working concentration of compound 
increased by 1X following each injection). 
 
Compound Concentration in Well Final Concentration Volume in Well Following 
Addition (µL) 
Compound X 
 
8X (dependent on dose 
response) 
Dependent on dose 
response chosen 
200 
Oligomycin 9X (18µM) 2µM 225 
FCCP 10X (2.5µM) 0.25µM 250 
Antimycin A / Rotenone 11X (11µM) 1µM 275 
TABLE 2.5: Concentration of BOFA reagents loaded into the drug injection ports and final concentration in the well. 
Concentrations of oligomycin, FCCP and antimycin A/rotenone were optimised as recommended by the 
manufacturer. 
 
Using a multichannel pipette and the supplied XFe96 cartridge loading guide, 25µL of compound X (port 
A), Oligomycin (port B), FCCP (port C) and antimycin A/rotenone (port D) were loaded into the assay 
cartridge which was then loaded into the XFe96 analyser for calibration.  After the cells had been 
incubated for one hour and the cartridge calibration was complete, the cells were loaded into the XF e96 
analyser to undergo a 12 minute equilibration period. Following equilibration, three 3 minute basal 
measurements were made prior to injection of the compound of interest through port A. The protocol then 
ensued with three 1 minute mix, 3 minute measure, 1 minute mix cycles between each respective 
injection. For whole cells in culture, bioenergetic parameters were calculated as shown in Fig.2.3 below. 
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FIGURE 2.3: Graphical representation of the whole cell OCR assay for determination of bioenergetic parameters. 
Respective bioenergetic parameters were calculated in pmol/min as shown. 
 
2.9.4. IN VITRO COMPOUND WASH OUT EXPERIMENT 
In order to assess the reversibility of drug effects on mitochondrial OCR, the experiment described above 
(section 2.9.3.) was performed with the following modification. Following injection of the compound of 
interest from port A of the XFe96 assay cartridge and subsequent capture of compound related effect on 
basal OCR, the cell plate was removed from the analyser. Cells were immediately washed 3 times with 
fresh XF assay media (37°C, pH7.4) with a final volume of 200µL left in the well. Cells were placed for 
approximately 30 minutes into a 37°C incubator (no CO2 supplementation) whilst the XFe96 analyser was 
re-calibrated. Basal OCR was immediately re-analysed in the XFe96 analyser to assess whether the effect 
of the drug was persistent. Data were expressed as a percentage of the 0.1% DMSO control for both pre 
and post-compound wash out.  
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2.10. Imaging and Histology 
2.10.1. TEM ANALYSIS OF ISOLATED MITOCHONDRIAL PELLETS 
TEM analysis of isolated mitochondria is shown in Appendix 1.1. Isolated mitochondria were 
resuspended at a concentration of 1mg/ml in 4% formaldehyde/1% glutaraldehyde and transferred to 
1.5mL Eppendorf tubes. Mitochondria were centrifuged at 12000 rpm for 5 minutes in a bench-top micro-
centrifuge to form a solid pellet and left at room temperature for 48 hours. Pellets were processed into 
Agar 100 resin (Agar Scientific, Essex, UK). Ultra-thin sections (approximately 90 nm thick) were then 
prepared, stained with uranyl acetate and lead citrate and examined in a Hitachi H7500 transmission 
electron microscope (one grid section per mitochondrial preparation).  An AMT XR41 Digital Camera 
System v 600.202 was used to capture TEM images.  Micrographs were observed for mitochondrial 
ultrastructure as well as the presence of other cellular debris/organelles. No scoring metric was used. Data 
are shown in Appendix I. Electron microscopy analysis was performed by Ian Francis and Paul McGill 
(GlaxoSmithKline, Safety Assessment Histopathology, Ware, UK).  
 
2.10.2. TEM ANALYSIS OF HEPG2 CELLS 
HepG2 cells were fixed in 4% Formaldehyde/1% Glutaraldehyde. Cell culture media (plus compound / 
DMSO) was removed and replaced with 1mL of fixative per well (in a 12 well plate format). Cells were 
then gently scraped and analysed using a bench top light microscope to ensure detachment of cells from 
the cell-culture plate. Fixed cells from 3 replicate wells were subsequently pooled and transferred into a 
15mL falcon tube where a further 3mL of fixative was added. Samples were then centrifuged at 1300g for 
5 minutes to create a loose cell pellet. Following centrifugation, excess fixative was removed and the 
loose cell pellet (~1.5mL) was left at 2-8°C for 48 hours. 
 
Following incubation, HepG2 samples were post-fixed using reduced osmium thiocarbohydrazide 
osmium (R-OTO method), and processed manually into Agar 100 epoxy resin (Agar Scientific, Essex, 
UK) [140]. Ultra-thin sections were taken that were subsequently blinded and 100 cells/experimental 
group were examined for any ultra-structural changes (including an assessment of lipid and glycogen 
content and any mitochondrial changes), using a Hitachi H7500 transmission electron microscope, 
operating at 80kV. 
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2.10.3. TEM ANALYSIS OF LIVER 
Small blocks of the right lateral lobe of the liver were fixed in 4% formaldehyde/1% glutaraldehyde. 
These were post-fixed in 1% aqueous osmium tetroxide and processed into Agar 100 resin (Agar 
Scientific, Essex, UK). One m toluidine blue stained survey sections were prepared and examined by 
LM to locate the areas of interest (such as the periportal region).  Ultra-thin sections (approximately 90nm 
thick) were then prepared, stained with uranyl acetate and lead citrate and examined in a Hitachi H7500 
transmission electron microscope (one grid section per animal).  The AMT XR41 Digital Camera System 
v 600.202 was used to capture TEM digital images. No scoring system or blinding was implemented in 
the analysis of TEM samples.  
 
2.10.4. LIGHT MICROSCOPY OF LIVER 
Formalin fixed samples of liver (≤ 4 mm in thickness) were post-fixed in a final working solution of 2.5% 
potassium dichromate and 1% osmium tetroxide in distilled water for 8 hours at room temperature. The 
osmicated tissue samples were rinsed in running water for 2 hours, processed to paraffin block and 
sectioned at 5 microns. Tissue sections were stained with the routine hematoxylin and eosin (H&E) 
method and evaluated using a routine severity scoring system (mild, moderate and marked). Two sections 
per liver were initially analysed by group and then blind to confirm observations.  
 
2.11. Western Blot 
Western blot data is shown in Appendix 1.2. Mitochondrial protein was loaded onto NuPAGE Bis-Tris 
mini gels (# NP3015, Invitrogen) at 10µg in 1X LDS Sample Buffer and 1X NuPAGE Sample Reducing 
Agent and separated by SDS-PAGE at 200V for 35 minutes. Following electrophoresis, protein was 
transferred to a nitrocellulose membrane using the iBlot Dry Blotting System (#IB1001, Invitrogen). 
Following transfer, the membrane was blocked for 1 hour at room temperature in 5% FA-Free milk and 
1X Tris buffered saline with Tween
 
20 [TBST] (#9997, Cell Signalling Technology, MA, USA). The 
membrane was washed three times in TBST (agitated for 5 minutes between each rinse) prior to a 1 hour 
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incubation at room temperature with the primary antibody cocktail (shown below) at a dilution of 1/230 in 
TBST (as recommended). 
 
 Mitochondrial Membrane Integrity WB Antibody Cocktail (#ab110414, Abcam, Cambridge, UK). 
Contains the five mAbs shown in table 2.6 below targeting each of the primary structural units of the 
mitochondrion 
 
Protein Name 
 
Structural Unit Working 
Concentration 
(µg/ml) 
 
Individual 
Catalogue 
Numbers 
Molecular 
Weight 
(KDa) 
VDAC1/Porin 
 
OMM 
 
2 #ab14734 39 
Cyclophillin D Matrix 
 
2 #ab110324 21 
Ubiquinol-Cytochrome C Reductase 
Core Protein I (Complex III) 
 
IMM 2 #ab110252 49 
ATP5a (Complex Va) 
 
IMM 
 
4 #ab110273 53 
Cytochrome C 
 
IMS 0.1 #ab110325 12 
TABLE 2.6: Details of the five antibodies comprising the mitochondrial membrane integrity western blot antibody 
cocktail (ab220414). 
 
The membrane was then washed as described above, before a further 1 hour incubation in Goat-Anti-
Mouse IgG Horseradish Peroxidase (HRP) linked secondary antibody (#ab6789, Abcam) at a dilution of 
1/50000 in TBST. Following incubation the membrane was again washed as described above before 
visualisation of protein banding using the Supersignal West Dura Chemiluminsecent Kit (Thermo 
Scientific #34076) in a Bio-Rad Versa-Doc Imaging System (Bio-Rad, Hertfordshire, UK) according to 
manufacturer’s recommendations.  
 
2.12. Reduced / Oxidised Glutathione Assay 
Measurement of total glutathione, GSH (reduced), GSSG (oxidised) and GSH: GSSG ratio was made 
using the NWLSS Glutathione Assay Kit (Northwest Life Science Specialties, LLC) according to the 
manufacturer’s protocol. Briefly, 25µL of whole blood was resuspended in 1mL of assay buffer.  Protein 
was pelleted by centrifugation following the addition of 100µL of metaphosphoric acid with collection of 
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the supernatant.  Subsequent to further dilution (1:50-1:100 fold) the supernatant was used to measure 
total glutathione. Following addition of the thiol reagent 5-5’-dithiobis[2-nitrobenzoic acid] (DTNB), 
glutathione reductase and NADPH the plates were read at an absorbance of 405nm at 12 second time 
intervals for 3 minutes (reduced glutathione, GSH) or 15 minutes (oxidised glutathione, GSSG), using a 
Spectramax plus 384 spectrophotometer (Molecular Devices, Sunnyvale, CA, USA). GSSG levels were 
assessed by removing an aliquot of the same supernatant and subsequently depleting the sample of GSH 
via the addition of 10µL of 4N Sodium Hydroxide and 10µl of 500mM vinyl pyridine followed by a 1 
hour incubation. Reduced levels of glutathione were calculated by subtracting the oxidised glutathione 
value from the total glutathione value obtained from the original supernatant. 
 
2.13. Measurement of Lactate / Pyruvate in Plasma 
Blood was collected into perchloric acid as detailed above. Lactate was measured on a Siemens Advia 
1650 clinical chemistry analyser (Siemens Healthcare Diagnostics, Surrey, UK) using a Lactate assay kit 
(Randox Life Sciences, Crumlin, Northern Ireland) according to the manufacturer’s instructions. Pyruvate 
was also measured on this analyser using reagents from Sigma-Aldrich. Pyruvate estimation was made by 
measuring the reduction in absorbance at 340nm due to oxidation of NADH to NAD as previously 
described [141]. Pyruvate concentration was established according to a standard curve of between 0 and 
0.45mmol/L pyruvate. All data were recorded in mmol/L and presented as a ratio between lactate and 
pyruvate. 
 
2.14. Measurement of Lactate in Cell Culture Media 
Lactate was measured in supernatant medium using a colorimetric assay originally described by [142] and 
further used by [143]. The assay is based on the conversion of lactate to pyruvate by lactate 
dehydrogenase (LDH) activity reducing nicotinamide adenine dinucleotide (NAD
+
) to its reduced form 
NADH. In detail, NADH reduces N-methylphenazonium methyl sulphate (PMS) to PMSH which reduces 
p-iodonitrotetrazolium violet (INT) to INTH. Briefly, 20µl of supernatant medium was incubated with 
180µl of assay solution consisting of 86mM triethanolamine HCl, 8.6 M EDTA.Na, 3 mM MgCl2.6H20, 
326nM PMS, 790nM INT, 7% ethanol, 0.4% Triton-X-100, 3.3mM β-NAD and 4U/mL LDH. After 
incubating for 7 minutes in dark conditions, the absorption of the colour product (INTH) was measured at 
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490 nm in a Biotek Synergy HT microtitre plate reader (Biotek,Winooski, VT, USA). A lactate standard 
curve (0-25mM) with a non-linear regression fit was used to determine lactate concentrations from treated 
cells (see Fig.2.4 below). Data were expressed as a percentage of control. 
 
 
FIGURE 2.4: A typical lactate assay standard curve. Data points marked with a light grey line of best fit included LDH to 
initiate the assay whereas data marked with a black line lacked LDH (used as a negative control). 
 
2.15. Total RNA Extraction 
Total RNA extraction from rat liver tissue and HepG2 cell lysates was performed using the Promega SV 
RNA Isolation System (#Z3105, Promega, Madison, WI, USA). HepG2 cell lysate and rat liver tissue 
homogenates were prepared as described in section 2.15.1 and 2.15.2 below.  RNA was then extracted in 
the same way and as described in section 2.15.3. 
 
2.15.1. HEPG2 LYSATE PREPARATION 
Remaining culture media was removed using an aspirator and the cell monolayer was washed with PBS 
(1mL/well in 12 well plate format). PBS was then removed and 175µL of SV Lysis Buffer was added to 
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each well prior to freezing the plate at -80°C. Upon thawing, the bottom of each well was scraped 
thoroughly using a sterile cell culture scraper and triplicate wells were pooled into an RNAse/DNAse free 
1.2mL Eppendorf tube. Genomic DNA (gDNA) was sheared by passing the lysate through a sterile 19G 
blunt-ended needle (#300149, BD Biosciences, San Jose, CA, USA) five times and placed on ice. Lysates 
were immediately processed to RNA extraction. 
 
2.15.2. RAT LIVER TISSUE HOMOGENATE PREPARATION 
Approximately 90mg of snap frozen liver tissue was added to 525µL of SV RNA Lysis buffer in a 
Precellys Homogenisation Vial (#CK28, Precellys, Derbyshire, UK) and homogenised twice using the 
Precellys 24 at 6500rpm for 60 seconds. The homogenates were placed on ice for 5 minutes to allow the 
froth to settle before passing through a 19G blunt-ended needle to sheer gDNA. Tissue homogenates were 
immediately processed to RNA extraction.  
 
2.15.3. TOTAL RNA EXTRACTION 
Total RNA was extracted according to manufacturer’s recommendations (Promega SV RNA Lysis 
System). Briefly, 175µL of hepatocyte lysate or liver homogenate was added to 350µL of SV Dilution 
Buffer and mixed by inversion 3 times. The mixture was heated for 3 minutes at 70°C and centrifuged for 
10 minutes at 14,000g. The supernatant was transferred to a fresh RNase/DNase free 1.2mL Eppendorf 
tube containing 200µL 95% v/v ethanol, loaded onto an SV RNA Isolation spin column assembly and 
centrifuged at 14,000g for 1 minute. Liquid in the collection tube was discarded and 600µL of SV Wash 
solution added to each spin column prior to centrifuging at 14,000g for 1 minute. The collection tubes 
were again emptied and 50μL of SV DNase Incubation Mixture (prepared with 40μL of SV Yellow Core 
Buffer, 5μL 0.09M MnCl2 and 5μL SV DNase I enzyme) was applied to the surface of each column 
membrane and incubated at room temperature for 15 minutes to allow DNA digestion to proceed. 
Following incubation, 200μL of SV DNase Stop Solution was added to each column and the spin column 
assemblies were again centrifuged at 14,000g for 1 minute prior to washing with 600μL SV RNA Wash 
solution and re-centrifuging at 14,000g for 1 minute. The collection tubes were again emptied, and a final 
wash step was performed to remove ethanol carry-over by adding 250μL of SV RNA wash solution to 
each spin column assembly and centrifuging at 14,000g for 2 minutes. The column within each SV RNA 
Isolation Tube Assembly was transferred to a fresh 1.2mL RNase/DNase free Eppendorf tube and 100μL 
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of SV Nuclease Free Water applied to the membrane. Total RNA was then eluted by centrifuging the 
column/tube assemblies at 14,000g for 1 minute. The columns were discarded and eluted total RNA 
stored at -80°C until required. 
 
2.16. RNA Quantification and Assessment of Integrity 
2.16.1. QUANTIFICATION USING THE NANODROP SPECTROPHOTOMETER 
RNA concentration and yield were determined by UV absorbance using the Nanodrop ND-1000 
Spectrophotmeter (Wilmington, DE, USA) according to manufacturer’s recommendations. Briefly, the 
absorbance of each total RNA sample was determined (in 2µL volume) at 260nm (peak nucleic acid 
wavelength) and 280nm (protein wavelength) and normalised against an elution blank negative control. 
The A260:A280 ratio was used to determine the level of protein contamination and a ratio of 1.8-2.2 was 
considered acceptable for downstream analysis. RNA concentration was calculated using the 260nm 
reading and a conversion factor based on the extinction coefficient for RNA (A260 of 1.0 = 40µg/ml for 
RNA). RNA concentration was expressed as ng/µL.  
 
2.16.2.  ASSESSMENT OF RNA INTEGRITY  
Quality assurance of RNA samples was performed using the Agilent 2100 Bioanalyser (Santa Clara, CA, 
USA) and RNA 6000 Nano Chips (#5067-1511, Agilent) according to manufacturer’s recommendations. 
Briefly, 550µL of RNA 6000 Nano Gel Matrix was passed through a spin column at 1500g for 10 minutes 
and 65µL aliquots made. To one 65µL aliquot, 1µL of RNA 600 Nano Dye Concentrate was added and 
thoroughly vortexed before centrifuging at 13,000g for 10 minutes. RNA samples (~4µL) were degraded 
at 70°C for 3 minutes. Gel-dye mix (9μl), Agilent RNA 6000 Nano Marker (5μl), ladder (1μl) and 
denatured samples (1μl) were pipetted into specific marked wells on the chip according to manufacturer’s 
recommendations. Fully prepared chips were vortexed on an IKA vortexer at 2400rpm for 1 minute. The 
chip was run using the Bioanalyser 2100 within 5 minutes. During the analysis, negatively charged RNA 
molecules are separated according to size by migration towards an anode. Fluorescent dye molecules 
make RNA detectable by laser scanning with size and concentration of RNA determined by fluorescence 
detected. The Agilent 2100 software filters the data and presents the results as electropherograms or 
densitometry plots (Fig.2.5). Assessment of RNA integrity is made by evaluation of the 
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separation/definition of the 18S and 28S ribosomal peaks (rRNA). RNA integrity is quantified by an 
automatically generated RNA integrity number (RIN) which is scaled between 1-10 (with 10 being 
considered an RNA sample of exceptional quality). RIN numbers are generated using Agilent (Santa 
Clara, CA, USA) proprietary algorithms which base quantification on the entire electrophoretic trace of 
the RNA samples as opposed to simply the ratio of the ribosomal bands. This includes the presence or 
absence of degradation products. Samples not reaching the required RIN of ≥7.5 were re-processed (as 
per the manufacturer’s guidelines). 
 
 
             
 
 
 
 
 
 
 
 
FIGURE 2.5:  Gel image and electropherogram output from Agilent 2100 Bioanalyser – Assessment of RNA integrity. (A) 
Agarose gel image - Negatively charged RNA molecules are separated according to size using “lab on a chip” 
technology and are resolved on agarose gels. The two bands relate to the 18S and 28S ribosomal subunits. (B) 
Data can also be visualized on electropherograms where an RNA integrity number (RIN) is assigned based on 
the separation and definition of the 18S and 28S peaks. Samples 1-3 correspond to RNA isolated from snap 
frozen control rat liver.  
 
2.17. Transcriptional Profiling using Affymetrix Genechip Microarrays 
2.17.1. GENERATION OF SENSE STRAND CDNA  
Sense strand complementary deoxyribonucleic acid (cDNA) was generated from total RNA using the 
Ambion Whole Transcript (WT) Expression Kit (#4411974, Life Technologies, Paisley, UK) according to 
manufacturer’s recommendations. Briefly, 200ng of RNA was used to generate first-strand cDNA using 
A B 
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primers containing a T7 promoter sequence before the resulting single stranded cDNA was converted to 
double stranded cDNA which acts as a template for transcription. This reaction uses DNA polymerase 
and RNase H to simultaneously degrade the RNA and synthesize first-cycle second-strand cDNA. 
Antisense complementary ribonucleic acid (cRNA) is then synthesised and amplified by in vitro 
transcription (IVT) using an RNA Polymerase which binds to the T7 promoter sequence which was 
previously engineered into the template strand based on the procedure outlined in [144]. cRNA was 
purified by removing enzymes, salts, inorganic phosphates and unincorporated nucleotides by magnetic 
bead capturing (using isopropanol), washing and elution. cRNA yield was then determined using the 
Nanodrop ND-1000 spectrophotometer as described above (2.16.1) before second-cycle sense-strand 
cDNA was prepared by random primer reverse transcription of 10µg cRNA. This process also 
incorporated dUTP at a fixed concentration which is required for DNA fragmentation described below 
(section 2.14.2).  RNase H was then used to degrade the remaining cRNA template before second cycle 
sense-strand cDNA was purified using magnetic bead capturing (using ethanol), washing and elution. 
Purified sense strand cDNA yield was then determined using the Nanodrop ND-1000 spectrophotometer 
as described above (2.16.1). 
 
2.17.2. FRAGMENTATION AND LABELLING OF  CDNA TEMPLATE 
Sense-strand cDNA was fragmented and labelled ready for Affymetrix genechip analysis using the 
Affymetrix WT Terminal Labelling and Hybridization Kit (#901524, Affymetrix, Santa Clara, CA, USA) 
according to manufacturer’s recommendations. Briefly, 5.5µg of sense-strand cDNA generated using the 
Ambion WT Expression Kit (section 2.17.1) was fragmented using uracil DNA glycosylase (UDG) and 
apurinic-apyrimidinic endonuclease 1 (APE 1) enzymes in order to remove dUTP residues from ssDNA 
molecules  and cleave phosphodiester backbones, thus leaving 3’-hydroxyl and 5’-deoxyribose phosphate 
terminus fragments.  The length of the fragmented DNA was assessed using the Agilent 2100 bioanalyser 
(as described in section 2.16.2) with fragments ranging from 20-200 bases. Fragmented single-stranded 
DNA was labelled by terminal deoxynucleotidyl transferase (TdT) with biotin allonamide triphosphate as 
recommended. 
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2.17.3. HYBRIDISATION, WASH AND STAINING OF AFFYMETRIX GENECHIPS 
The following procedure utilises the Affymetrix Hybridisation, Wash and Stain Kit (#900720, 
Affymetrix) according to manufacturer’s recommendations. Briefly, fragmented and labelled DNA (from 
section 2.17.2) was added to a hybridisation cocktail containing, 20X eukaryotic hyb-controls, 2X 
hybridisation mix, control oligonucleotide B2, DMSO and nuclease free water (at concentrations defined 
by Affymetrix). The hybridisation cocktail was heated at 99°C for 5 minutes and then 45°C for a further 5 
minutes in a heat block before centrifuging at 14,000g for 1 minute. Affymetrix Rat Gene 2.0 Sense 
Target (ST) Genechips (Format 100 #902125) were equilibrated to room temperature immediately before 
use and 130µL of hybridisation cocktail was injected into the array though the septa on the reverse of the 
chip. The arrays were then placed in a hybridization oven (with rotating arm) at 45°C (60rpm) for 17 
hours.  
 
Following hybridization, the array was vented and the hybridization cocktail removed. The probe array 
was then refilled with 160µL (for format 100 arrays) of Wash Buffer A. The Affymetrix Fluidics Station 
450 was primed using fluidics script PRIME_450 to expose the lines to all wash buffers and to rinse with 
dH20. Stain cocktail 1 and 2 and array holding buffer were pipetted into 1.5mL eppendorf vials and 
centrifuged at 14,000g for 30 seconds to remove air bubbles before being placed into positions 1-3 on the 
Affymetrix Fluidics Station 450.  Wash buffer A, Wash buffer B and dH20 were placed into reservoirs 
with the respective fluidics lines inserted. Arrays were clamped into place and the fluidics script 
FS450_0002 was run. When the wash/stain protocol was complete, arrays were ejected from the Fluidics 
Station and inspected to ensure no bubbles were present (arrays were re-filled with wash buffer A if 
bubbles required removing).  
 
2.17.4. SCANNING OF GENECHIPS AND STATISTICAL ANALYSIS OF MICROARRAY DATA 
The Affymetrix Genechip Scanner 3000 is controlled by the Affymetrix Genechip Command Console 
(AGCC). The scanner was turned on ~10 minutes prior to scanning to warm the laser. In the AGCC, 
autoloader function was selected. Arrays were firstly wiped clean using a non-abrasive tissue before 
loading onto the scanner carousel (up to 30 at a time). Scanning was started by clicking “start scan” in the 
AGCC. Once scanning was complete the hybridisation/scan image was inspected to ensure no gross scan-
errors could be detected. CEL.files were then transferred from the PC and differential gene expression 
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analysis was performed using Array Studio version 7.0 (www.omicsoft.com). Affymetrix data were 
normalised using the robust multichip average (RMA) method [145] and differentially expressed genes 
were defined as those with greater than 1.5 fold change in expression, at p<0.05. 
 
2.17.5. PATHWAY ANALYSIS 
In order to infer biological meaning from transcriptomic data, biological theme analysis was undertaken. 
This analysis provides a functional view of the classes of genes and pathways significantly presented 
within a data-set. Ingenuity Pathway Analysis (IPA, Ingenuity, Redwood City, CA, USA) was utilised 
which is a proprietary analysis system that must be subscribed to (GlaxoSmithKline, Investigative 
Preclinical Toxicology Access, 2013-2015). IPA segregates gene groups according to a level of 
significance defined by the user. In the present study all network associations were defined by 
experimentally-supported literature evidence. All genes with a fold change of ± 1.5x and p<0.05 were 
submitted for pathway analysis. Alternatively, genes identified as being highly statistically significant 
with regard to separating experimental variables (using a principle component analysis, PCA) were 
inputted to IPA for more refined analyses. IPA generates a list of canonical pathways from the genes 
significantly affected alongside toxicological pathways altered. IPA also contains an interaction 
networking capability which enables visualisation of gene-connections within a given biological response. 
This permits visualisation of particular biochemical networks with the effected genes highlighted. 
Furthermore IPA provides an annotation of each mapped gene which vastly supports inference of 
biological meaning from the computationally generated network without repeated interfacing with the 
literature. 
 
2.17.6. COMPOUND CONNECTIVITY MAPPING 
Connectivity mapping is a process whereby novel pharmacological and toxicological properties can be 
identified in small molecules by comparing their gene expression signatures with others in a database. 
The technique also facilitates the identification of novel tool compounds which may mimic the biological 
action of the user’s compound based on the genes which are differentially altered [146]. Compound 
connectivity mapping was used to compare the gene signatures generated from Affymetrix microarray 
analysis of GSK932121A and GSK2617971A treated animals (the query gene signature) to over 1000 
compounds located in the Broad Institute expanded data set (reference dataset). This reference database 
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contains 6100 reference profiles characterised by different treatment conditions of each compound 
(applied to 5 human cell lines). A pattern matching algorithm/similarity metric was used to quantify the 
closeness of connection between the two biological states as a result of small molecule treatment. The 
query gene signature was composed of a short list of differentially altered genes most relevant and 
important to characterise the biological state arising following compound treatment (selection criteria of 
genes used for connectivity mapping analysis described in section 7.2.5). The sscMap (Java Application) 
was used essentially as described in [147]. Data were expressed as connection scores and p-values (-
Log10p).  
 
2.18. TaqMan RT-PCR Analysis from In vitro Samples 
Real-time quantitative PCR (RT-PCR) is a routinely used technique to measure gene expression. RT-PCR 
is usually performed on a small subset of gene transcripts and is a relatively low cost and sensitive 
profiling technique. In the case of TaqMan RT-PCR, the real time monitoring of PCR amplification of an 
amplicon is monitored by the incorporation of a probe consisting of two fluorophores. When the probe is 
either tethered or untethered to the template DNA and prior to polymerisation, the quencher fluorophore 
(usually long wavelength coloured dye) reduces the fluorescence from the reported fluorophore (usually 
short wavelength coloured dye) via fluorescence resonance energy transfer (FRET). The reporter dye is 
located on the 5’ end of the probe and the quencher at the 3’ end. Once the TaqMan probe has bound to 
its specific target piece of template DNA (and following denaturation at high temperatures), the primers 
anneal to the DNA and Taq polymerase incorporates nucleotides which removes the TaqMan probe from 
the template DNA. This polymerization separates the quencher from the reporter and allows the reporter 
to emit its fluorescence which is then quantified internally. RT-PCR allows the time at which the level of 
fluorescence passes a threshold level (known as the Cycle Threshold or Ct) to be determined. The higher 
the copy number of the target gene, the faster the fluorescence passes the Ct, and thus, by comparing Ct 
values for different reactions, it is possible to determine the relative gene expression between samples
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2.18.1. GENE PANEL 
 
 
TABLE 2.7: Details of the primers and probes used for in vitro RT-PCR experiments.  Table shows the details for the 15 genes selected for RT-PCR analysis (G6pd used as 
the housekeeper/normaliser gene). All genes had a FAM-NFQ reporter/quencher. The context sequence describes the nucleotides to which the assay was targeted. 
Gene 
Symbol 
Gene Name Assay ID Lot Number RefSeq 
Accession No. 
Context Sequence 
Pck1 phosphoenolpyruvate carboxykinase 1 (soluble) Hs01572978_g1 1312055 NM_002591 TGACAACTGCTGGTTGGCTCTCACT 
Chac1 ChaC, cation transport regulator homolog 1 (E. coli) Hs00225520_m1 1294249 NM_001142776 TGAAGATCATGAGGGCTGCACTTGG 
Gapdh glyceraldehyde-3-phosphate dehydrogenase Hs02758991_g1 1317397 NM_001256799 GACTCATGACCACAGTCCATGCCAT 
Ppargc1a peroxisome proliferator-activated receptor gamma, 
coactivator 1 alpha 
Hs01016719_m1 1308701 NM_013261 AAGGCAATTGAAGAGCGCCGTGTGA 
Lpin1 lipin 1 Hs00299515_m1 1169040 NM_001261427 AGAGAAAGTGGTTGACATAGAAATC 
Foxo1 forkhead box O1 Hs01054576_m1 1301006 NM_002015 GGCTGGAAGAATTCAATTCGTCATA 
Hmox1 heme oxygenase (decycling) 1 Hs01110250_m1 1305084 NM_002133 TGCTCAACATCCAGCTCTTTGAGGA 
Pdk4 pyruvate dehydrogenase kinase, isozyme 4 Hs01037712_m1 1316401 NM_002612 TTTAAGAATGCAATGCGGGCAACAG 
Nr4a1 nuclear receptor subfamily 4, group A, member 1 Hs00374226_m1 1259635 NM_001202233 GGCTTCTTCAAGCGCACAGTGCAGA 
G6pd glucose-6-phosphate dehydrogenase Hs00166169_m1 1295896 NM_000402 GGGTGCATCGGGTGACCTGGCCAAG 
Nr4a2 nuclear receptor subfamily 4, group A, member 2 Hs00428691_m1 1290694 NM_006186 CTGGACTATTCCAGGTTCCAGGCGA 
Irs2 insulin receptor substrate 2 Hs00275843_s1 1289193 NM_003749 CACGACGGTCACCCCCGTGTCCCCG 
Nr4a3 nuclear receptor subfamily 4, group A, member 3 Hs00545009_g1 1241861 NM_006981 AAAGAAGTTGTCCGTACAGATAGTC 
Ppara peroxisome proliferator-activated receptor alpha Hs00947536_m1 1302244 NM_001001928 GCTGCAAGGGCTTCTTTCGGCGAAC 
Atf3 activating transcription factor 3 Hs00231069_m1 1310874 NM_001030287 CACAAAAGCCGAGGTAGCCCCTGAA 
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2.18.2. FIRST STRAND CDNA SYNTHESIS 
Total RNA samples were reverse transcribed into first strand cDNA prior to RT-PCR analysis. 1µg of 
total RNA was used to generate cDNA using the BioScript Reverse Transcriptase kit (Bioline #BIO-
27036) according to manufacturer’s recommendations. cDNA synthesis was carried out with (RT+) and 
without (RT
-
) the BioScript reverse transcriptase enzyme, to enable substitution of gene expression data 
caused by amplification of gDNA. Briefly, total RNA was diluted to a concentration of 125ng/µL in 8µL 
of DEPC-treated water (1µg) and combined with 10mM deoxynucleotide triphosphates (DNTP) mix 
(Bioline #BIO-39053) and 40µM Random Hexamers (Bioline #BIO38028) in RNase/DNase free PCR 
strip tubes. The samples were incubated at 70°C for 5 minutes using a DNA Engine Tetrad PCR cycler 
(MJ Research, Massachusetts, USA) and chilled for at least 1 minute on ice. 4µL of RT-Buffer, 1µL of 
RiboSafe RNase Inhibitor (Bioline #BIO65027), 1µL of BioScript Reverse Transcriptase (200u/µL) and 
4µL of DEPC-treated water was then added to each reaction in a master-mix and tubes centrifuged to 
collect the contents at the bottom of the tubes. Samples were then incubated at 25°C for 10 minutes, 42°C 
for 30 minutes and then the reaction was terminated at 85°C for 5 minutes. Following incubation, 
reactions were cooled on ice, immediately diluted 1:15 with DEPC treated water and stored at -20°C until 
required.  
 
2.18.3. TAQMAN RT-PCR 
TaqMan RT-PCR was performed in 384 well plates using the QuantStudio 6 Flex Real-Time PCR System 
(Applied Biosystems, Life Technologies, Paisley, UK). Briefly, 9 µL of 1:15 diluted cDNA was loaded 
into each well of a 384 well plate (n=3 biological replicates with two technical replicates per sample) and 
the plate centrifuged at 300g for 2 minutes to collect the cDNA at the bottom of each well. 10µL of 
TaqMan Universal MasterMix II With UNG (Applied Biosystems, Life Technologies #4440045) and 1µL 
the PCR primers/probes for individual genes (table 2.7) were added to each well ensuring that both the 2X 
MasterMix II and the 20X primers/probes were both at 1X final concentrations in the well (TaqMan 
Universal MasterMix and the PCR primers/probes were combined and added to each well in one step to 
reduce variability due to pipetting error). One gene per plate was analysed (16 genes) with all samples 
included on each plate. Non-template controls (NTC’s) were included (~ 6 wells per gene) where DEPC-
treated water replaced the cDNA template. 
 
Plates were sealed with MicroAmp optical adhesive film covers (Applied Biosystems, Life Technologies 
#4311971) and the contents mixed thoroughly be inverting 3-4 times. Plates were centrifuged at 300g for 
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4 minutes to collect the reaction products at the bottom of each well. Plates were then placed into the 
QuantStudio 6 Flex instrument and run at default running conditions, for 40 cycles, with detection set at 
FAM-NFQ for the detection of amplification fluorescence.   
 
2.18.4. RT-PCR STATISTICAL ANALYSIS 
Cycle threshold (Ct) values were exported from the QuantStudio software as tab-delimited text files and 
data were transferred to Microsoft Excel for downstream analysis. Ct values were converted to copy 
numbers of each gene and the RT
-
 value was substituted from the RT
+
 value to correct for amplification 
of gDNA. Averages of duplicate (technical replicate) wells were calculated and sample copy numbers 
were then normalised by division against the housekeeper gene, glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh). Statistical significance was derived using analysis of variance (ANOVA) (n=3) 
with post-hoc Dunnett’s test in TaqMan toolkit (Microsoft Excel plug-in).  
 
2.19. Global Metabolomics Profiling 
Liver and plasma samples were sent to Metabolon (Metablon Inc, Durham, NC, USA) on dry ice for 
global metabolomics analysis. In brief, samples underwent a methanol extraction to remove the protein 
fraction prior to being placed under a Zymark TurboVap (Biotage AB, Sweden) under nitrogen to remove 
the organic solvent. Samples were then split into equal parts for analysis on the GC/MS, LC/MS/MS, and 
polar LC platforms. For liquid chromatography (LC), the samples were stored under nitrogen overnight.  
For gas chromatography (GC), the samples were dried under vacuum overnight. Bioanalytical methods 
are briefly described below. 
 
Please note: a pooled matrix sample, generated by taking a small volume of each experimental sample, 
was used as a technical replicate throughout the metabolomic analysis. This pooled sample was used to 
distinguish between biological and process derived variability and was randomly included amongst study 
samples.  
 
Ultrahigh Performance Liquid Chromatography/Mass Spectroscopy (UPLC/MS/MS):  The LC/MS 
portion of the platform was based on a Waters ACQUITY ultra-performance liquid chromatography 
(UPLC) and a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a 
heated electrospray ionisation (HESI-II) source and Orbitrap mass analyser operated at 35,000 mass 
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resolution.  The sample extract was reconstituted in acidic or basic LC-compatible solvents, each of 
which contained 8 or more injection standards at fixed concentrations.  One aliquot was analysed using 
acidic positive ion optimised conditions and the other using basic negative ion optimised conditions in 
two independent injections using separate dedicated columns (Waters UPLC BEH C18-2.1x100 mm, 
1.7µm).  Extracts reconstituted in acidic conditions were gradient eluted from a C18 column using water 
and methanol containing 0.1% formic acid. The basic extracts were similarly eluted from C18 using 
methanol and water, however with 6.5mM ammonium bicarbonate. The third aliquot was analysed via 
negative ionization following elution from a HILIC column (Waters UPLC BEH Amide 2.1x150 mm, 1.7 
µm) using a gradient consisting of water and acetonitrile with 10mM ammonium formate. The MS 
analysis alternated between MS and data-dependent MS
2
 scans using dynamic exclusion, and the scan 
range was from 80-1000 m/z. 
 
Gas Chromatography-Mass Spectroscopy (GC-MS):  The samples destined for analysis by GC-MS 
were dried under vacuum for a minimum of 18 h prior to being derivatised under dried nitrogen using 
bistrimethyl-silyltrifluoroacetamide.  Derivatised samples were separated on a 5% diphenyl/95% dimethyl 
polysiloxane fused silica column (20 m x 0.18 mm ID; 0.18µm film thickness) with helium as carrier gas 
and a temperature ramp from 60° to 340°C in a 17.5 min period.  Samples were analysed on a Thermo-
Finnigan Trace DSQ fast-scanning single-quadrupole mass spectrometer using electron impact ionization 
(EI) and operated at unit mass resolving power. 
 
Metabolon proprietary software was used to match ions to an in-house library of standards for metabolite 
identification and for metabolite quantitation by peak area integration. Metabolon maintains a library 
based on authenticated standards that contains the retention time/index (RI), mass to charge ratio (m/z), 
and chromatographic data (including MS/MS spectral data) on all molecules present in the library.  
Biochemical identifications are based on three criteria: retention index within a narrow RI window of the 
proposed identification, accurate mass match to the library ± 0.005 amu, and the MS/MS forward and 
reverse scores between the experimental data and authentic standards.  The MS/MS scores are based on a 
comparison of the ions present in the experimental spectrum to the ions present in the library spectrum. 
Peaks were quantified using area-under-the-curve. For studies spanning multiple days, a data 
normalisation step was performed to correct variation resulting from instrument inter-day tuning 
differences (pooled plasma).  Essentially, each compound was corrected in run-day blocks by registering 
the medians to equal one (1.00) and normalising each data point proportionately. As such all data 
presented herein is expressed as scaled intensity of a median equal to 1.00. 
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3.0. MECHANISMS OF DIMT – GSK932121A INDUCED 
COMPLEX III INHIBITION 
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3.1. Introduction 
As outlined in section 1.9.1, GSK932121A was developed as a 4(1H)-pyridone antimalarial drug and is a 
potent, reversible inhibitor of the mitochondrial respiratory chain complex III in Plasmodium falciparum 
(cytochrome bc1 IC50 = 0.007µM). The molecule inhibits the same target in mammalian species but with 
lower potency (two orders of magnitude less potent on the isolated protein target from rats and three 
orders of magnitude less potent in intact rodent cells). Despite this difference in potency, GSK932121A 
was withdrawn from development following FTIH trials, due to unexpected toxicology findings in rats, 
when dosed via the intraperitoneal (IP) route or orally as a pro-drug to increase exposure. Cross-over 
inhibition of mammalian complex III activity by GSK932121A was considered to be a possibility [127].    
 
A package of investigative work was initiated to follow up on the toxicological findings and the possible 
role of ETC inhibition. The work presented here describes initial aspects of this investigative program 
whereby the conditions known to cause the acute toxicity were recreated in order to study the nature of 
the toxic response. 
 
The analyses presented here provide additional weight of evidence that the main mechanism of toxicity 
with GSK932121A was mitochondrial complex inhibition and provide significant detail regarding the 
profile of downstream effects of such inhibition, including molecular adaptive changes. This 
comprehensive comparison of multiple endpoints also allows for better informed selection of endpoints 
for future mechanistic investigative studies where mitochondrial toxicity or therapeutic mitochondrial 
modulation is suspected and highlights the need to consider both in vitro and in vivo data together when 
interpreting mitochondrial effects. Finally, the data presented is of significant value in developing an AOP 
for mitochondrial ETC inhibition, and a follow-up study with earlier time points and a lower dose is 
presented in chapter 4, to add further detail in this regard.  
 
3.1.1. CHAPTER AIMS 
The present chapter describes the first phase of an investigative program which was initiated to explore 
the acute toxicity caused by GSK932121A, when dosed via the IP route of administration. In order to 
investigate the adverse effects caused by GSK932121A the conditions which caused the aforementioned 
acute toxicity were recreated. As such, the present chapter aimed to,  
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1. Analyse the effects of GSK932121A in vitro by treatment of isolated mitochondria from control 
animals to provide mechanistic detail and to allow comparison with the in vivo data.  
 
2. Profile the acute effects of GSK932121A in vivo, based on the likelihood that the observed 
clinical signs in rat were due to complex III inhibition, via measurement of mitochondrial 
function, liver glutathione levels, hepatic microscopy, blood gasses and lactate/pyruvate ratio 
alongside gene expression profiling. 
 
3.2. Results 
3.2.1. CONFIRMATION OF RESPIRATORY CHAIN INHIBITION  
The inhibitory effect of GSK932121A on the mammalian respiratory chain was assessed in vitro using a 
complex III activity assay (as described in section 2.8.6). GSK932121A was tested using 9 concentrations 
spanning the range 0.01nM to 100µM, to ensure accurate determination of an IC50. GSK932121A caused 
a concentration-dependent reduction in complex III activity with an IC50 of 0.63µM (Fig.3.1). Data shown 
correspond to mean ± SD of measurements obtained with bovine heart mitochondria minus the rates 
obtained without mitochondria (negative control). The potency of GSK932121A on bovine heart 
mitochondria complex III was approximately 4.6x less than that of the gold standard complex III inhibitor 
antimycin A (IC50=136nm as indicated by Cayman Chemicals, data not shown). Furthermore, potency 
was comparable to that obtained by Bueno et al (2012) for cytochrome bc1 inhibition in mammalian 
species (IC50 = 0.4µM with isolated target from HEK293 cells and 0.6µM with the isolated target from 
H9C2 cells) [127]. Further work is required to compare the effect of GSK932121A on mitochondrial 
complex III activity to other classical complex III inhibitors, in order to accurately assess potency. 
Furthermore, the selectivity of GSK932121A for the cytochrome bc1 complex should be assessed by 
measuring its effect on the other respiratory chain complexes in isolation.   
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FIGURE 3.1: Complex III activity assay with GSK932121A. A concentration-dependent reduction in bovine heart 
mitochondrial complex III activity was observed following GSK932121A exposure (IC50: 0.63µM). Data 
shown in mean ± SD of change in OD rate (per minute) representing conversion of cytochrome c from its 
oxidised to its reduced form (n=5).  
 
Following confirmation of GSK932121A’s complex III inhibitory activity, the effect of GSK932121A on 
other mitochondrial processes was assessed in vitro. Mitochondria were isolated from the liver of 3 
control female Crl:CD (SD) rats and exposed to GSK932121A separately in vitro. Female rats were 
chosen for comparability with the sex and species used in the corresponding in vivo study (outlined in 
section 3.2.2 below) and as female rats have been shown to be more sensitive to GSK932121A toxicity 
than males in previous tolerability studies. Following treatment, OCR and CRC were assessed in order to 
better understand the direct effect of GSK932121A on mitochondria. 
 
Exposure of isolated liver mitochondria from untreated rats to GSK932121A resulted in concentration-
dependent decreases in basal respiration (IC50: 9.5µM) and state 3 respiration (IC50: 5.8µM), characteristic 
of a mid-respiratory chain inhibitor (Fig.3.2) Maximal respiratory rate and RCR were markedly reduced 
at 100µM and 10µM, with only minor effects on respiratory chain function observed at lower 
concentrations. It is however important to ackonowledge that maximal respiration is still stimulated by 
FCCP with the 10µM concentration of GSK932121A. This data suggests partial inhibition of the 
respiratory chain which is in contrast to the high level of potency observed in Fig.3.1. (IC50 : 0.63µM). 
Further work is required to better understand the effect of GSK932121A on oxygen consumption ex vivo.  
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FIGURE 3.2: Analysis of liver mitochondrial OCR following in vitro treatment of control liver mitochondria with 
GSK932121A (measured using Seahorse XF24 analyser).  (A) Exposure to 100µM GSK932121A (light 
grey) caused a significant reduction in OCR at all respiratory states (p<0.001) and a reduction in basal, state 3 
and state 3u respiration at 10µM (dark grey) was noted. No other concentration (data not shown) significantly 
affected mitochondrial respiration compared to that with the 0.5% DMSO control (black). (B) GSK932121A 
reduced basal OCR in a concentration-dependent manner [IC50 = 9.5µM], correlation, R
2: 0.8937 (data is mean 
only, n=3). 
 
CRC was calculated as the difference in OD between the point at which mitochondria are energised and 
begin to take up a given bolus of calcium to the point of undergoing MPT. GSK932121A (100µM-1µM) 
in vitro reduced the CRC in liver mitochondria from untreated animals in a concentration-dependent 
manner with an IC50 of 1.36μM (Fig.3.3).  
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FIGURE 3.3: Assessment of the mitochondrial CRC. Freshly isolated liver mitochondria from female control Crl:CD(SD) rats 
were treated in vitro with GSK932121A. A concentration-dependent reduction in CRC was observed at 1µM, 
10µM and 100µM of GSK932121A [IC50 = 1.36µM], correlation, R
2=0.9031. Data shown is mean ± SD (n=3). 
 
3.2.2. ACUTE DOSE IN VIVO STUDY (NON MITOCHONDRIAL ENDPOINTS) 
Female Crl:CD (SD) rats were dosed (via the IP route) with either 50mg/kg GSK932121A (n=12) or 
vehicle alone (n=12) and observed for a period of five hours (as described in section 2.1.1 and 2.3.1). 
Female rats were used because previous tolerability studies using GSK932121A showed slightly more 
marked in-life effects in female rats than in males. A dose of 50mg/kg was selected based on data 
generated in previous GSK932121A single-dose tolerability studies where dose-limiting clinical signs 
were noted in a proportion of the animals at approximately 5.5 hours post-dose. The aim of the 
investigation was to follow-up on the toxicological issue which led to GSK932121A’s termination from 
development and therefore the 50mg/kg dose (which replicated the dose known to cause acute toxicity) 
was selected and a time-point of 5 hours was chosen (i.e. to induce mitochondrial derived toxicity whilst 
minimising in-life effects).  
 
Clinical Signs. 
Significant inter-animal variability was noted in terms of both the severity and speed of onset of clinical 
signs. Moderate clinical signs were observed approximately 3-5 hours post dose and included slight to 
moderate piloerection, hunched posture, slightly irregular or deep abdominal breathing and mildly 
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subdued behaviour. Reduction in body temperature was noted in some animals approximately 1.5h post 
dose, with body temperature continuing to fall by an average of 3.4°C by 5 hours post dose. The reduction 
in body temperature over the course of the study was highly variable but was closely associated with the 
plasma concentration of GSK932121A (R
2 
0.9063) (Fig. 3.4).   
 
 
FIGURE 3.4: Relationship between core body temperature and plasma GSK932121A concentration.  The correlation is 
shown between reduction in core body temperature observed at 3.5-5 hours (dependent on observed clinical 
signs) post treatment with GSK932121A (50 mg/kg) and plasma drug concentration (R2=0.9063, p<0.0001). 
Two animals (circled) showed little reduction in body temperature but also had a very low systemic exposure 
(284-485ng/mL) to GSK932121A. These animals were excluded from all further analyses.  
 
No body temperature reduction was observed in two females throughout the course of the treatment 
period but in these animals the terminal plasma concentrations of GSK932121A were very low 
(284ng/mL and 485ng/mL, respectively, with all other animals having exposures of ~10-35µg/mL). These 
animals were therefore excluded from all further analyses. Reduction in body temperature also correlated 
with adverse clinical signs, those animals with the greatest fall in body temperature showing the most 
severe clinical effects. 
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Arterial Blood Gas (pO2 and pCO2) and Bicarbonate (HCO3) 
GSK932121A at a dose of 50 mg/kg produced a significant increase in pO2 and a significant decrease in 
pCO2 in arterial whole blood at approximately 5-6 hours post-dose (depending on observed clinical 
signs)(Fig.3.5). These findings are suggestive of impaired mitochondrial respiration in GSK932121A 
treated animals consistent with the mechanism of action (ETC inhibition). Bicarbonate (HCO3) was also 
reduced in GSK932121A treated rats compared to VC (Fig.3.5) which suggests that metabolic acidosis is 
occurring following respiratory chain inhibition in vivo. This may be as a result of increased lactate 
production following a metabolic switch to glycolysis which will be presented in the next section. 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.5: Analysis of arterial blood gasses (p02 and pC02) and bicarbonate (HCO3) in whole blood of animals treated 
with GSK932121A (50mg/kg). GSK932121A (50mg/kg – grey bars) caused a significant reduction in arterial 
pCO2 and HC03 at 5 hours post-dose compared with VC (black bars). A significant increase in arterial pO2 was 
also observed in GSK932121A treated animals. Results are mean ± SD (n=6) **p<0.01. 
 
The Metabolic Shift: Light and Electron Microscopy 
Key histological alterations in the liver following exposure to GSK932121A in vivo were identified by 
light microscopy (Fig.3.6 A and B). Hepatocellular changes included an increase in periportal lipid 
(microvesicular steatosis) highlighted by prominent osmium tetroxide staining in the livers of the treated 
group. This is suggestive of a shift in metabolism within the liver towards glycolysis and/or a reduced 
level of mitochondrial β-oxidation. 
 
Electron microscopy was utilised in order to assess the effect of GSK932121A treatment on 
mitochondrial ultrastructure. Mitochondria appeared swollen with a pale matrix with moderate to severe 
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disorganisation of the cristae. Mitochondrial diameter increased from approximately 0.45µm to 0.55µm 
on average and an increase in the number of condensed degenerating mitochondria was observed with 
mitochondria often observed within phagosomes (Fig 3.6 C and D). Further to the increase in lipid 
observed in LM analyses, a reduction in glycogen stores was evident in GSK932121A treated hepatocytes 
(peri-portal region).  This supports LM observations of changes suggestive of increased glycolytic 
activity. 
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FIGURE 3.6: Effect of 50mg/kg GSK932121A on liver LM and TEM compared to VC. Panels A + B (200x magnification) 
show H&E stained liver sections post-fixed in osmium tetroxide. (A) VC rat, note the rare hepatocytes that 
contain a small number of osmium tetroxide-stained lipid droplets (black arrow depicted). (B) Rat treated with 
50 mg/kg GSK932121A; note that the cytoplasmic droplets within hepatocytes are extensively and darkly 
stained with osmium tetroxide which confirms the accumulation of neutral lipid. Panels C+D show electron 
micrographs of rat hepatocytes from the right lateral lobe focussed on the mitochondria at 50,000X 
magnification (Images shown are taken from peri-portal regions of the liver). (C) Mitochondria from VC 
animal, with intact membrane structure and normal histology. Stores of glycogen are depicted by red arrows (D) 
Mitochondria from GSK932121A treated animal which appear swollen with pale matrices and a significant 
increase in the number of condensed degenerative mitochondria were observed (white stars). Glycogen stores 
(highlighted by red arrows in C) were reduced in animals treated with GSK932121A. 
 
To confirm this metabolic shift (reported to be characteristic of mitochondrial dysfunction in vivo) 
circulating lactate and pyruvate were measured in whole blood. Animals given 50mg/kg GSK932121A 
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had higher blood lactate concentrations than controls (3.53-fold, p<0.001) and the lactate:pyruvate ratio 
was also increased by 1.66-fold (p<0.01) (Fig. 3.7). Elevated lactate/pyruvate ratios are indicative of 
deficiencies of the respiratory chain, tricarboxylic cycle or pyruvate metabolism. Change in 
lactate:pyruvate ratio correlated with plasma exposure of GSK932121A as shown in Fig.3.7B (R
2
: 
0.4689, p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.7: Effect of 50mg/kg GSK932121A on whole blood lactate:pyruvate ratio compared with blood taken from VC 
animals. (A) GSK932121A (50mg/kg, n=10) treatment caused a statistically significant increase in blood 
lactate:pyruvate ratio compared to blood taken from VC animals (n=12). ** p<0.01. (B) The correlation is 
shown between plasma GSK932121A concentration and blood lactate:pyruvate ratio (R2: 0.4689, p<0.05) 
 
Ratio of Reduced Glutathione (GSH) to Oxidised Glutathione (GSSG) 
GSK932121A, at a dose of 50mg/kg caused a statistically significant (54.6%) reduction in the 
GSH:GSSG ratio in liver tissue at a terminal 5 hour time-point compared to VC animals (p<0.001) 
(Fig.3.8C). The reduced GSH:GSSG ratio manifests due to a significant reduction in reduced GSH 
compared to VC animals (p<0.05) and a significant increase in oxidised GSSG in the liver of treated 
animals compared to VC (p<0.01) (Fig.3.8 A and B). This data suggests that treatment of rats with 
50mg/kg GSK932121A for 5 hours causes increased levels of oxidative stress and a resulting reduction in 
the glutathione antioxidant system, in the liver compared with time matched VC animals. 
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FIGURE 3.8: Analysis of liver GSH, GSSG and ratio of GSH:GSSG following treatment of rats with 50mg/kg 
GSK932121A compared to vehicle control. GSK932121A (50mg/kg – open bars, n=10) caused a significant 
reduction in GSH (panel A), a significant increase in GSSG (panel B) and a significant reduction in GSH:GSSG 
ratio (panel C) in the liver, compared with vehicle controls (0mg/kg - solid bars, n=12). Results are mean ± sd. 
*p<0.05, **p<0.01, ***p<0.001. 
 
3.2.3. ACUTE DOSE IN VIVO STUDY (MITOCHONDRIAL ENDPOINTS) 
 
Calcium Retention Capacity   
In direct contrast to the effects of GSK932121A in vitro (Fig.3.3), the CRC of liver mitochondria isolated 
from rats treated in vivo with 50mg/kg GSK932121A was increased, (Fig.3.9A, for clarity only means for 
the kinetic data are shown). When calculated as delta-OD, the increase in liver mitochondria CRC 
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following GSK932121A treatment (n=10) was 79% (p<0.01) compared with mitochondria from control 
animals (n=12), (Fig. 3.9B). These data demonstrate a desensitisation to calcium-induced mPTP opening 
following in vivo treatment with GSK932121A. Increase in liver mitochondria CRC showed a mild 
degree of correlation to the plasma concentration of GSK932121A (R
2
: 0.4939, p<0.05). 
 
No effect was observed on CRC in mitochondria isolated from the heart or skeletal muscle of 
GSK932121A treated animals in comparison with VC (p>0.05, data not shown). There was also no 
correlation to plasma exposure levels of GSK932121A in these tissues. It is currently unknown whether 
this was a result of lower plasma exposure levels in these organs and follow-up pharmacokinetic analyses 
in multiple tissues are required.   
 
 
                      
 
 
 
 
 
 
 
FIGURE 3.9: Analysis of liver mitochondrial CRC following treatment of rats with GSK932121A in vivo. (A) 
Mitochondria isolated from rats treated with 50 mg/kg GSK932121A (n=10, grey circles) displayed an 
increased CRC compared to control animals (n=12, black squares) treated with vehicle alone. Data shown in 
this kinetic trace are mean only (B) The increase in GSK932121A-induced CRC is displayed as increase in 
ΔOD (difference in OD between point of succinate substrate addition and mitochondria undergoing 
permeability transition, i.e. lowest OD value before calcium release). Data shown is mean ± SD. ** p<0.01. 
 
Mitochondrial Bioenergetics 
In contrast to the effects seen in vitro, mitochondria isolated from the livers of rats treated in vivo with 
GSK932121A, showed an increase in basal respiration of 30.3% compared to VC (p<0.001) (Fig. 3.10 A 
0 5 0 1 0 0 1 5 0 2 0 0
0 .2
0 .4
0 .6
0 .8
1 .0
1 .2
1 .4
1 .6
T im e  (s )
C
a
lc
iu
m
  
R
e
te
n
ti
o
n
  
C
a
p
a
c
it
y
O
p
ti
c
a
l 
D
e
n
s
it
y
 (
6
5
0
n
m
)
* *
V eh ic le  C on tro l
5 0m g /k g  G S K 9 321 21A
G S K 9 3 2 1 2 1 A  D o s e
C
a
lc
iu
m
 R
e
te
n
ti
o
n
 C
a
p
c
it
y
D
e
lt
a
-O
p
ti
c
a
l 
D
e
n
s
it
y
 (
6
5
0
n
m
)
0 m g /k g  5 0 m g /k g
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
* *
A 
B 
88 
 
and B). A similar degree of increased respiratory demand is maintained throughout state 3 (27.5%, 
p<0.01) and state 4 (28.4%, p<0.001), demonstrating increased background levels of oxygen consumption 
linked to ATP production (Fig. 3.10 A and B). This increase in OCR further coincides with an 11.9% 
(p<0.001) increase in proton leak across the inner mitochondrial membrane.  Whilst increased proton leak 
is suggestive of a decline in efficiency of the OXPHOS machinery, the percentage of total OCR linked to 
ATP synthesis was the same in mitochondria from control and treated after normalisation to basal 
respiration (Fig. 3.10 C). Furthermore the RCR (state 3/state 4 ratio), often used as a gold-standard 
measure of general mitochondrial health, was not significantly altered between mitochondria isolated 
from control (4.25) and GSK932121A treated (4.20) rats (p>0.05 – data not shown). FCCP was used to 
uncouple mitochondria and determine the maximum respiration rate (often termed the maximal uncoupled 
or state 3u respiration). This was reduced by 24.7% in mitochondria isolated from GSK932121A treated 
rats (p<0.001) indicating a diminished maximal capacity for the ETC in the uncoupled state.  This is 
particularly visible in Fig.3.10C where normalisation of data to basal respiration highlights the maximal 
OCR deficit following FCCP-induced uncoupling. Correlation analysis between the various respiratory 
states and the plasma concentration of GSK932121A revealed only marginal correlation to plasma 
exposure levels as shown in the R
2 
values in Fig 3.10B.  
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FIGURE 3.10: Analysis of liver mitochondrial bioenergetics using the Seahorse XF24 analyser following treatment of rats 
with GSK932121A in vivo (A) Representative OCR data for liver mitochondria isolated from animals treated 
with GSK932121A (grey line) or VC (black line). (B) Effect of GSK932121A treatment (grey bars) on basal, 
state 3, state 4o, state 3u respiration and on proton leak, compared with VC (black bars). R2 values correspond 
to the correlation between OCR and the plasma concentration of GSK932121A  (C) Normalisation of OCR data 
to basal respiration, demonstrating the lack of significant change in total ATP linked OCR (shaded box) 
between mitochondria isolated from control (black line) and treated (grey line) animals and the reduction in 
maximal uncoupled respiration. Data shown is mean ± SD (n=12 VC, n=10 GSK932121A treated). Each 
biological replicate is the mean of 5 technical replicate wells / XF24 plate ** p<0.01, *** p<0.001 
 
Overall mitochondria from rats treated in vivo with GSK932121A showed a loss of mitochondrial reserve 
capacity (p<0.001, 74.47% reduction) calculated as the difference between state 3 and state 3u OCR 
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highlighting the potential for bioenergetic insufficiency should the cells require ATP levels beyond that 
which can be manufactured at a basal level. 
 
No significant effect on OCR was observed in mitochondria isolated from the skeletal muscle or heart of 
GSK932121A treated animals compared to VC (p>0.05, data not shown). Isolated mitochondrial data 
presented in section 3.2.3 therefore suggests that the liver might be a key target organ in response to 
GSK932121A toxicity and no effects of GSK932121A was observed in skeletal muscle or heart 
mitochondria (in terms of mitochondrial function). The suggestion that the liver is a key target organ will 
be further explored in chapter 4. 
 
3.2.4. TRANSCRIPTOMICS 
Transcriptomic analysis was performed on liver samples from control and GSK932121A treated rats. The 
entire raw gene-data (discussed herein) has been deposited in NCBI’s Gene Expression Omnibus (GEO) 
and are accessible through GEO Series accession number GSE65374 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65374). Affymetrix data was normalised using 
the robust multichip average (RMA) method [145] and differentially expressed genes were defined as 
those with greater than 1.5 fold change in expression, at p<0.05. These genes were examined using a 
principal component analysis (PCA) and interestingly separation of data-points for treated animals from 
those for VC, correlated well with plasma drug concentration, as shown in Fig.3.11 below. 
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FIGURE 3.11: PCA of Affymetrix transcriptomics data (from liver of GSK932121A and VC animals) highlighting 
relationship between degree of experimental data separation and plasma drug concentration. PCA 
analysis showing the breadth of data separation between VC (blue circles) and GSK932121A treatment (yellow 
circles). Separation of data points in the PCA analysis appeared to correlate with plasma drug exposure levels 
(expressed in µg/ml). 
 
Following PCA analysis, these genes were subjected to IPA analysis (Ingenuity Systems, Redwood City, 
CA). This analysis identified perturbation of pathways associated with the cellular response to glycogen 
depletion, with glucocorticoid receptor signalling the most significantly up-regulated. Other pathways 
identified were immunological (IL10, IL6 and Acute Phase response signalling) and activation of retinoic 
acid receptor responsive genes (data not shown). The ratio of genes involved in each identified pathway 
was low (less than 10%), for example for the glucocorticoid receptor signalling pathway 24/299 genes 
were altered (8.02%). Consideration of these data alongside the observed increase in blood lactate and 
observed depletion of cellular glycogen (TEM micrographs) did however prompt further analysis of genes 
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involved in the cellular response to glycogen depletion. Peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (Ppargc1a) was upregulated 8.2-fold (p<0.001) and Forkhead box protein O1 
(Foxo1) expression increased 1.6-fold. Ppargc1a and Foxo1 interact to coordinate the expression of genes 
involved in gluconeogenesis, such as Pck1/PEPCK (1.9-fold; p<0.001) and Glucose-6-Phosphatase 
(G6pd). Ppargc1a and Foxo1 expression levels both correlated well with GSK932121A plasma 
concentrations (R
2
: 0.6587 and 0.7493 respectively) (Fig. 3.12). Insulin Receptor Substrate 2 (Irs2) and 
Pyruvate Dehydrogenase Kinase 4 (Pdk4) expression levels, which were upregulated 4.8 and 2.2-fold 
respectively, also correlated well with GSK932121A plasma levels (Fig.3.12). 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.12: Correlative analysis of gene copy number for 4 significantly altered genes and GSK932121A plasma 
concentration. Correlation between terminal plasma GSK932121A concentration in treated rats and the copy 
number of 4 hepatic gluconeogenic response genes, Foxo1 (dark grey crosses) (R2:0.7943), Pdk4 (orange 
squares) (R2:0.7389), Ppargc1a (black circles) (R2:0.6587) and Irs2 (light grey triangles) (R2:0.5457). The 
expression of all four genes was significantly increased compared to VC (p<0.001). 
 
3.3. Discussion 
It is important for successful drug development that we improve our understanding of how mitochondrial 
toxicity is manifested in our preclinical test species. To this end, and as part of a mechanistic toxicology 
investigation, the present study profiled the acute toxicity caused by a candidate molecule 
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(GSK932121A), suspected of causing acute toxicity by complex III inhibition in vivo. The work 
highlighted the utility of a multi-system approach for detecting mitochondrial dysfunction in vivo, and 
should aid other investigators in designing studies and selecting endpoints for future studies with 
potentially mitochondrially active molecules. GSK932121A is a potent inhibitor of the mitochondrial 
respiratory chain complex III in the target species, P. falciparum.  It is two orders of magnitude less 
potent on the isolated target from rats, and three orders of magnitude less potent in intact rodent cells 
[127].  At the dose of GSK932121A used in the present study, the plasma concentrations achieved were 
2-6 times above the IC50 in rodent cells and, consistent with this, it was acutely toxic. Blood gas analysis 
in the present study confirmed inhibition of respiratory function highlighted by an increase in the levels of 
arterial O2 and a reduction in arterial CO2. It remains likely that the animals are in a state of “cytotoxic 
hypoxia”, characterised by effective oxygen deprivation (i.e. inability of cells to utilise oxygen as 
opposed to impaired oxygen availability). This has been highlighted as a central cause of toxicity relating 
to other respiratory chain inhibitors such as cyanide [148]. 
 
Body temperature changes have been reported with a range of mitochondrial toxins acting by different 
mechanisms, for example, 2,4-DNP (mitochondrial uncoupling) causes hyperthermia [149] and 3-
nitroproprionic acid (complex II inhibition) causes hypothermia [150]. In the present study, hypothermia 
was an early consequence of treatment of rats with GSK932121A, the magnitude of the response 
correlating well with plasma levels of the drug, suggesting that respiratory chain inhibition was the 
primary cause of the reduced thermal energy generation. Of the gross in-life measures, body temperature 
appeared to be the most sensitive marker of mitochondrial impairment, at least when monitored internally 
(core temperature) and measured regularly (15 minute intervals) via the implanted chips used in this 
study.  The liver is a major thermoregulatory organ in the rat [151] and therefore the reduction in body 
temperature may be directly associated with disruption of mitochondrial function and morphology 
changes noted in this organ. The value of monitoring body temperature demonstrated here, combined with 
the ease of data collection when using implantable chips (which are primarily used for animal 
identification), means that this endpoint would be suitable for consideration in all in vivo studies with 
compounds suspected of having mitochondrial activity. 
 
Lactic acidosis and an increase in hepatic lipid (steatosis) are  common outcomes of mitochondrial 
dysfunction [152], as observed with the early nucleoside reverse transcriptase inhibitors [153]. Both of 
these outcomes were observed in this study. The increase in lactate/pyruvate ratio suggests an increase in 
glycolytic metabolism and this is supported by the TEM evidence of glycogen depletion in the liver of 
treated rats.  Furthermore, the blood gas data was also suggestive of metabolic acidosis, with a reduction 
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in bicarbonate noted. Combined with body temperature, lactate levels are a potentially useful marker of 
DIMT [143] and it has been suggested that a rise in blood lactate concentrations alongside a reduction in 
core body temperature may be indicative of a generalised adverse event [154].  Further studies with 
GSK932121A at sub-toxic doses are on-going and it will be interesting to see if lactate:pyruvate ratio can 
be utilised as a marker of more mild underlying mitochondrial perturbation.   
 
The switch in metabolism towards glycolysis, indicated by ultrastructural changes and blood lactate 
levels, was also reflected in the gene expression findings. Foxo1 was up-regulated following 
GSK932121A treatment and this gene has been shown to play a central role in the response to glycogen 
depletion via activation of gluconeogenesis [155]. Foxo1 interacts with PGC1α to regulate the expression 
of gluconeogenic genes by binding and activating promoter regions, for example, the PGC1α-dependent 
transcription of Pepck [156]. Pepck catalyses the first committed step in gluconeogenesis via conversion 
of oxaloacetate to phosphoenolpyruvate [157].  Foxo1 is also essential to the up-regulation of Pdk4 and 
Irs2 in response to glycogen depletion and fasting and these were up-regulated in the present study [155]. 
This fasted/starvation-like transcriptional response has previously been associated with respiratory chain 
deficiency and mitochondrial myopathy [158]. These gene findings demonstrate a potentially adaptive 
response to reduced liver glycogen by activation of gluconeogenesis via Foxo1 mediated transcription.  
 
With regard to the functional mitochondrial endpoints, specifically OCR and CRC in this study, 
GSK932121A had effects both in vivo and in vitro, however the direction of change was not consistent. It 
is unlikely that this difference is due to a metabolite of GSK932121A since it is known that there is 
limited metabolism of the compound within the timescale applicable here. In vitro, GSK932121A reduced 
basal mitochondrial OCR in HepG2 cells, entirely consistent with its proposed complex III inhibitory 
activity and effects of other known respiratory chain inhibitors (shown in chapter 7) [6, 132]. The same 
effect was observed when isolated liver mitochondria from naïve control rats were directly exposed to 
GSK932121A. In contrast, the opposite was true with liver mitochondria isolated from rats treated with 
GSK932121A in vivo, where basal OCR was seen to be increased. In the same vein, the CRC of isolated 
liver mitochondria from naive control rats was reduced following direct exposure to GSK932121A, again 
consistent with the effects of other known respiratory chain inhibitor compounds, but opposite to the 
effect observed in mitochondria isolated from the livers of rats treated with GSK932121A in vivo.  
 
It is clear then that the in vitro functional data are consistent with GSK932121A’s proposed complex III 
inhibitory mechanism and published data regarding other tool ETC inhibitors. Likewise the body 
temperature findings, LM/TEM, gene expression, blood lactate and gas analyses findings also point 
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convincingly to GSK932121A blocking mitochondrial complex activity as expected. So why are the 
functional measures (OCR and CRC) obtained with the mitochondria isolated from animals treated with 
GSK932121A in vivo seemingly at odds with the overall picture? 
 
In terms of the OCR data, it may be that GSK932121A washes out during isolation of the liver 
mitochondria from treated rats. However, here samples of isolated mitochondria from the in vivo 
experiment were analysed for GSK932121A and appreciable levels were detected (appendix 3). The was 
also a reduction in the maximal OCR following FCCP treatment and a clear effect in the CRC assay 
(discussed below) in the mitochondria isolated from treated animals, arguing against a complete washout 
of compound and reversal of effects during the isolation procedure. An alternate possibility is that the 
increase in OCR reflects a compensatory increase in the overall ETC activity within the isolated 
mitochondrial population as a result of increased proton leak due to ROS-induced mitochondrial damage. 
Consistent with other respiratory chain inhibitors (i.e. antimycin a [159]), there was evidence for an 
increase in oxidative stress in the livers of GSK932121A treated animals (significantly reduced GSH: 
GSSG ratio), but for ROS-induced damage to be a causative factor in the observed OCR increase, this 
would again rely on the de-inhibition of the ETC. A third possibility may be linked to stabilisation of the 
mitochondria and this is discussed below. 
 
Mitochondria play a key role in regulating intracellular calcium concentrations during both normal and 
pathological states [134]. However, excess calcium is able to trigger the mPTP, characterised by a non-
selective increase in the permeability of the inner mitochondrial membrane [135, 136]. mPTP activity  is 
affected by compounds that interfere with mitochondrial function and this can be monitored by 
measurement of CRC in mitochondrial isolates. Exposure in vitro to respiratory chain inhibitors typically 
reduces the CRC of isolated mitochondria [160] and this is exactly what was observed with GSK932121A 
(IC50 of 1.36µM, well below the plasma concentrations of GSK932121A achieved in the in vivo study, 
~30-75µM). In contrast liver mitochondria isolated from GSK932121A treated rats showed a significant 
and unexpected increase in CRC. It has been reported that the mPTP can be desensitised to calcium-
induced opening during times of myocardial infarction due to a reduction in pH [161].  It is possible that 
the lactic-acidosis induced pH reduction, observed in rats treated with GSK932121A, may cause an effect 
on the mPTP in vivo that persists and is maintained throughout the isolation procedure and CRC assay, 
i.e. despite the mitochondria being prepared and the CRC assay being performed in neutral pH buffers. 
Furthermore, the observed desensitisation of mPTP triggering could act to stabilise the mitochondria 
during the stressful isolation process, resulting in a higher proportion of intact (non-permeabilised) 
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mitochondria per mg of measured protein; potentially explaining the increase in basal OCR level 
observed with mitochondria from the treated animals.   
 
Mitochondria are capable of responding to increased energy demand or stress by utilising their spare 
respiratory reserve (i.e. the difference between basal respiration and maximal possible respiration rates) 
[39]. Significant depletion of this reserve capacity has been noted in response to increased ROS, aging, 
following drug exposure [162] and importantly, has been demonstrated to precede cell death [37]. One 
consistent functional effect observed both in vitro and in vivo in this study was an apparent reduction in 
the maximal respiration rate following GSK932121A exposure (i.e. uncoupled OCR following FCCP 
injection).  This raises the question of whether monitoring erosion of maximal respiratory capacity, in the 
absence of overt clinical signs, could be a way to overcome a key limitation of current preclinical safety 
testing with respect to detecting mitochondrial toxicity; namely the use of  healthy young animals with 
inherently high reserve capacity. This current pre-clinical model is at odds with the low underlying 
metabolic reserves of many key patient groups who are often elderly, on co-medications, have co-
morbidities etc. A more detailed analysis of metabolic reserve capacity using doses of GSK932121A 
below that which cause overt clinical signs would help to test this possibility and this is on-going.  
 
3.3.1. SUMMARY 
The conclusions that can be drawn from this initial study with GSK932121A are as follows… 
 
1. The in vitro and in vivo data presented here support the proposition that GSK932121A 
administered at 50mg/kg via the IP route causes acute toxicity in rats due to perturbation of 
mitochondrial function, most likely via inhibition of the ETC.  
 
2. Building understanding around the progression of toxicity from complex III inhibition to adverse 
in vivo outcomes (clinical signs) required consideration of both the in vitro and in vivo data; 
neither on its own would have been sufficient. The in vitro data informed on the likely molecular 
initiating event and initial (non-confounded) respiratory response, whist the in vivo data provided 
a view of the integrated state of the mitochondria in response to the initial insult plus the 
compensatory adaptations made by the tissue and organism. The in vivo experiment also informed 
on the final adverse outcomes and provided a platform to investigate specific molecular and 
morphologic changes in a key tissue, for example, highlighting the role of the metabolic switch 
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gene Foxo1 and the downstream effectors PGC1α, Pepck, Pdk4 and Irs2 in the cellular response 
to glycogen depletion in the liver.  
 
The data presented here provides the ground work for developing AOPs around ETC inhibition and also 
provides a platform for evaluating new methods for monitoring underlying mitochondrial perturbation. 
Further work based on a systems approach is required  in order to further  understand the downstream 
mechanisms and pathways [163], of which the metabolomics based follow-up investigation presented in 
chapter 4 overleaf is part.  
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4.0. A METABOLOMICS APPROACH TO UNDERSTANDING 
MECHANISMS OF DRUG-INUDCED RESPIRATORY 
CHAIN INHIBITION  
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4.1. Introduction 
GSK932121A was a late stage drug, destined for the market as a novel 4(1H)-pyridone anti-malarial 
medicine with huge therapeutic potential, (i.e. due to the prevalence of malaria in the developing world). 
GSK932121A acts via inhibition of mitochondrial electron transport at complex III. The molecule was 
however withdrawn from development following observations of acute toxicity in rats at high plasma 
exposure levels following administration either via the oral route as a pro-drug or via the IP route as the 
parent compound alone.  
 
Work outlined in chapter 3, described stage one of an investigative package which aimed to evaluate the 
acute toxicity caused by compounds, including GSK932121A, with potent respiratory chain inhibitory 
properties. The study revealed that, (in conjunction with the adverse in-life effects), respiratory chain 
inhibition caused a switch in metabolism to glycolysis (leading to metabolic acidosis, hepatic steatosis 
and liver glycogen depletion), rapid onset hypothermia and effects on mitochondrial ultra-structure and 
function (although the direction of change in two commonly used mitochondrial assays was opposite to 
that observed in vitro). Transcriptomics analysis also identified gene changes indicative of a fasted-like 
state. 
 
Although the initial study (described in chapter 3) was necessary to characterise the acute toxicity profile 
of GSK932121A in vivo at a dose associated with the adverse outcome, the high dose single time point 
experimental design made it a challenge to determine the events preceding overt clinical signs i.e. 
difficult to assess primary from adaptive toxicity. It was therefore important to follow up these findings 
with GSK932121A using a sub-toxic dose and earlier time points. Metabolomics was used to seek both 
early and progressive biochemical markers of respiratory chain inhibition.    
 
In order to correlate the early biochemical effects to a functional and well characterised effect, the study 
parameters outlined in chapter 3 were repeated (i.e. an acute IP dose of 50mg/kg GSK9232121A over a 4 
hour time point) with timed bleeds used for metabolite analyses in order to identify early biochemical 
changes. A lower dose group of 12.5mg/kg GSK932121A (a dose which was previously reported to be 
well tolerated) was included in order to identify markers of respiratory-chain inhibition which occur at 
sub-toxic doses of GSK932121A and to facilitate the determination of pathways involved in underlying 
mitochondrial adaptation and perturbation.  Timed bleeds were taken as early as 30 minutes post dose in 
attempts to identify the earliest possible markers of dysfunction.  
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Biochemical metabolites are sensitive indicators of homeostatic changes (whether induced by genetics, 
the environment, drug treatment etc.). This makes them excellent candidates for biomarkers as they can 
be easily measured and, if present in blood, are accessible and translatable to the clinical situation. In 
addition, metabolites play a crucial role in the signalling and regulation of genes and proteins thus making 
them an ideal complement to other ‘omics’ assessments. Finally, because metabolic pathways are 
generally well understood and highly translatable across species, metabolomics data is often highly 
actionable in terms of assessing potential safely liability using a top-down systems biological approach 
[164]. Metabolites were mapped to their biochemical pathways and those that exhibited statistically 
significant, time/dose-dependent; compound-related changes in comparison to the time-matched control 
groups are herein discussed.  
 
4.1.1. CHAPTER AIMS 
The purpose of this study was to… 
 
1. Confirm mitochondrial functional changes observed with GSK932121A in chapter 3 (with a 
50mg/kg dose) and assess the effect of a well tolerated 12.5mg/kg dose on underlying 
mitochondrial function and clinical measures.  
 
2. Evaluate potential plasma and liver biomarkers of mitochondrial toxicity (specifically mid-
respiratory chain inhibition) using a global metabolomics approach and assess the pathways 
implicated in the toxicological response to complex III inhibition via analysis of plasma 
metabolites at progressive time points and liver metabolites at the terminal time point.    
 
4.1.2. STUDY DESIGN 
Crl:CD(SD) rats were exposed to GSK932121A essentially as described for chapter 3.  Six or seven rats 
per group were sampled for plasma prior to compound treatment (pre-dose) and then exposed to either 
12.5mg/kg GSK932121A (n=7), 50mg/kg GSK932121A (n=7) or vehicle alone (n=6). The number of 
animals for each group was based on the known potential for low systemic exposure levels using the IP 
route of administration for this compound and to provide sufficient statistical power for metabolomics 
assessment. Plasma samples were then taken at 0.5, 1, 2 and 4h with time-matched VC samples taken in 
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parallel.  Terminal liver samples were also harvested at the end of each study for a total of 100 plasma 
samples and 20 liver samples for analysis.  
 
Plasma and liver samples were stored at -80°C and sent to Metabolon on dry ice for analysis (as described 
in section 2.19). Liver tissue was also used to isolate fresh mitochondria in order to both confirm 
mitochondrial function changes highlighted in chapter 3 (increase in basal OCR and increase in CRC) and 
investigate whether these changes occur at a sub-toxic dose of GSK932121A. Blood toxicokinetics and 
lactate/pyruvate analysis were also performed.  
 
4.1.3. METABOLOMICS DATA VISUALISATION 
Metabolomics data presented throughout section 4.2 below can be interpreted based on the schematic 
shown in Fig.4.1 below. Plasma metabolite data is depicted using line charts to demonstrate the change in 
scaled ion levels throughout the 4 hour time period (mean ± standard error). Liver metabolite data is 
presented in the same y-axis scale although using a box and whisker plot to show the key statistical 
parameters. All data is presented as a scaled intensity of the total ion counts for each metabolite whereby 
the median ion level for each metabolite is equal to 1.00. Total ion counts were used as opposed to 
absolute quantification to ensure that the relative quantitation of each biochemical is consistently made on 
the parent ion for a specific platform (e.g. LC/neg, LC/pos, etc) and as it is the degree of change that 
determines the outcome, not the absolute level. This method ensures the quantitation of each biochemical 
is made consistently. 
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FIGURE 4.1: Metabolomics data visualisation.  Visualisation of the study data in line or box plot format (A) Plasma data is 
represented by line plots with mean ± standard error plotted. (B) Box plots are used to convey the spread of the 
data with the middle 50% of the data represented by the boxes and the whiskers reporting the range of the data. 
The solid line across the box represents the median value of the data while the + is the mean. All metabolomics 
data are scaled such that the median value measured across all samples was set to 1.0. 
 
4.2. Results and Discussion 
In chapter 3 a single acutely toxic dose of GSK932121A was used in order to relate the observed in-life 
effects to functional effects. Whilst informative, this study design and dose were not designed to 
distinguish primary events from secondary consequences (rather just to characterise the acute toxicity).  
The first task of this follow-up study was to determine whether the key observations which occurred with 
a 50mg/kg (toxic) dose occurred with a 12.5mg/kg (well tolerated) dose to determine more subtle low 
dose effects of complex III inhibition in vivo.  
 
4.2.1. IN LIFE EFFECTS AND COMPARISON OF ENDPOINTS TO CHAPTER 3 STUDY 
The key observations made in chapter 3 with regard to the effect of GSK932121A in vivo were 
hypothermia, increase in both basal respiration and CRC compared to VC animals and an increased blood 
lactate:pyruvate ratio. The same endpoints were assessed in the present study. 
 
Maximum of Distribution 
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-1 Standard Error 
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+1 Standard Error 
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Using the 12.5mg/kg dose led to an expected lower plasma drug concentration than in the 50mg/kg study 
outlined in chapter 3. The average plasma drug concentration was 4.45µg/mL (12.5mg/kg) compared with 
18.3µg/mL at 50mg/kg in chapter 3. However here, the plasma concentration with the 50mg/kg dose was 
markedly different to that in the previous study, with a plasma concentration of only 5.40µg/mL being 
achieved in this follow up investigation. This data is striking as it shows that at 50mg/kg the animals had 
3.4 times less exposure in the present study compared to the study described in chapter 3 (reason behind 
this discrepancy remains unknown). Furthermore the plasma concentration of GSK932121A at 4-hours 
post treatment with 50mg/kg was just 21% greater than that achieved with the 12.5mg/kg dose. The 
difference in the toxicokinetics between the 12.5mg/kg and 50mg/kg group is however greater in liver 
tissue where an average concentration of 3.38µg/mg was observed with 12.5mg/kg GSK932121A 
compared to 7.67µg/mg with 50mg/kg GSK932121A (2.7x difference). Together these data highlights 
that GSK932121A is rapidly deposited in the liver following IP dosing and suggests that animals in the 
present study were exposed to less drug than in the initial study. Despite this lower internal exposure at 
the 50mg/kg dose compared to the previous study described in chapter 3, the remainder of the results 
presented in this chapter are from the new 50mg/kg study and its paired 12.5mg/kg dose.  
 
Consistent with the significant reduction in plasma exposure levels (compared to that described in chapter 
3), no adverse clinical signs were observed at either 12.5mg/kg or 50mg/kg GSK932121A.  Despite this, 
a significant reduction in body temperature was still observed in 50mg/kg animals compared to VC, with 
an average temperature reduction of 2.8°C observed (p<0.01) (Fig.4.2A). No effect on body temperature 
was observed at 12.5mg/kg (p>0.05, n=7). On this occasion reduction in body temperature showed no 
correlation with GSK932121A plasma concentration (R
2
:0.3227, p>0.05) or liver concentration 
(R
2
:0.5833, p>0.05).  In contrast to results in chapter 3, no significant effect of GSK932121A treatment 
was observed on whole blood lactate:pyruvate ratio with either 12.5mg/kg or 50mg/kg groups (Fig.4.2B), 
compared to VC (p>0.05).  
 
A statistically significant increase in liver mitochondria basal OCR was seen in mitochondria isolated 
from both 12.5mg/kg GSK932121A (n=7, p<0.05) and 50mg/kg GSK932121A (n=7, p<0.01) groups 
compared to VC (n=6) (Fig.4.2C). These data supports observations made in previous chapters and 
further confirms the opposite effect of GSK932121A in mitochondria isolated from GSK932121A-treated 
animals compared to in vitro treatment of control (not previously exposed) mitochondria.  Similarly, 
GSK932121A caused a statistically significant and dose dependent increase in CRC in mitochondria 
isolated from the livers of both 12.5mg/kg (p<0.05, n=7) and 50mg/kg (p<0.01, n=7) animals compared 
to VC (n=6) (Fig.4.2D). Again this supports previous observations in terms of the direction of change 
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observed between mitochondria isolated from animals treated with GSK932121A in comparison to in 
vitro treatment of control mitochondria. These data support effects of GSK932121A on mitochondrial 
function at doses which are well tolerated which lends credence to the hypothesis that altered 
mitochondrial function is central to downstream toxicities as opposed to being a consequential effect.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4.2: Effect of 12.5mg/kg and 50mg/kg GSK932121A on body temperature, blood lactate:pyruvate ratio and 
isolated liver mitochondria CRC and OCR. The data above shows the effect of 12.5mg/kg and 50mg/kg 
GSK932121A on the endpoints deemed pertinent from chapter 3. These were re-tested in the present study to 
assess the effect of a well tolerated 12.5mg/kg dose and to analyse the reproducibility of a 50mg/kg dose on 
body temperature (A), blood lactate:pyruvate ratio (B) and isolated liver mitochondria OCR (C) and CRC (D). 
All data shown is mean ± SD (VC, n=6, 12.5/50mg/kg, n=7). p<0.05*, p<0.01** 
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It is important to acknowledge that lactate/pyruvate data generated using clinical chemistry methods 
outlined in section 2.13 (and shown in Fig.4.2B) bared high degrees of similarity to the plasma lactate and 
pyruvate measures made by Metabolon (see Appendix 5). Metabolomic data described below (and shown 
in Appendix 5) showed a spike in plasma lactate both at 0.5 hours and 4 hours post-dose. The 50mg/kg 
dose of GSK932121A showed a significant elevation in lactate at 4 hours with the Metabolon dataset 
however, whereas the data shown in Fig.4.2B shows that the increase was merely trending. 
 
4.2.2. EFFECT OF GSK932121A ON TOTAL METABOLITES IN THE LIVER AND PLASMA 
A high-level statistical summary of the data obtained from the metabolomics analyses is shown in table 
4.1 below. A total of 609 and 658 identifiable/named metabolites were detected in the plasma and liver 
respectively. Metabolomics raw data (for the metabolites described in this chapter), can be found in 
Appendix 4. Within the plasma, there was a dose dependent effect of compound treatment on the 
metabolomic profiles observed in this study when compared to time-matched controls. The low dose of 
GSK932121A (12.5mg/kg) elicited changes beginning at ~2 hours post treatment whilst the high dose of 
GSK932121A (50mg/kg) had clear effects beginning at 1h post-treatment with some indication of 
significantly altered metabolites as early as 0.5h (though the number of changes was limited at this time 
point). 
 
Similar to the plasma, the end of study liver samples also showed a more notable metabolomic impact 
with high dose, at which there was a 294% increase in significantly altered metabolites compared to low 
dose. The number of metabolite changes in the liver at 4 hours post-dose with both low dose and high 
dose of GSK932121A was much lower than the number of significant alterations observed in the plasma 
at the same time point.  It is therefore possible that additional, non-hepatic effects of GSK932121A 
contribute to the plasma metabolomic shift that was observed herein.  This lack of corroboration between 
the plasma and liver metabolome is evident elsewhere in the metabolomics data and therefore assessment 
of other tissues such as muscle, lung, heart and kidney may be warranted. 
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-12.5mg/kg  Significant Effect of 12/5mg/kg GSK932121A on Plasma Metabolites 
Compared to Time Matched VC 
 
Pre Dose 
 
0.5 hours 
 
1 hour 
 
2 hours 
 
4 hours 
 
Significant up | down 51 | 8 30 | 17 4 | 34 55 | 30 54 | 55 
 
Percentage change in significant 
metabolites from pre dose (up 
or down) 
- -20% -36% +44% +85% 
Percentage of total detected 
metabolites changing (up or 
down) 
9.9% 7.7% 6.2% 14% 17.9% 
    
 
 
 
 
 
 
 
 
 
 
 
TABLE 4.1: Statistical summary of a plasma and liver metabolite changes. Data shown represents change in statistically 
significant metabolites in plasma following treatment with 12.5mg/kg GSK932121A  (A) and 50mg/kg 
GSK932121A (B) compared to time-matched VC samples. Effect of both 12.5mg/kg and 50mg/kg doses on 
liver metabolites compared to VC is shown in table C. (green = significant reduction in expression, red = 
significant increase in expression). 
 
4.2.3. METABOLOMICS: COMPLEX III INHIBITION HAS A PROMINENT IMPACT ON PLASMA 
TCA CYCLE INTERMEDIATES 
Mitochondrial ETC function and TCA cycle energetics are intimately linked. Data shown below (Table 
4.2) illustrate the impact that altering mitochondrial function at the level of complex III has on TCA 
-50mg/kg Significant Effect of 50mg/kg GSK932121A on Plasma Metabolites 
Compared to Time Matched VC 
 
Pre Dose 
 
0.5 hours 
 
1 hour 
 
2 hours 
 
4 hours 
 
Significant up | down 47 | 3 41 | 19 37 | 50 81 | 104 128 | 71 
 
Percentage change in 
significant metabolites from 
pre dose (up or down) 
- +20% +74% +270% +298% 
Percentage of total detected 
metabolites changing (up or 
down) 
8.2% 9.9% 14.3% 30.4% 32.7% 
 Effect of GSK932121A on  Liver 
metabolites compared to VC 
 
GSK932121A Dose 12.5mg/kg 50mg/kg 
 
Significant up | down 
 
26 | 8 70 | 64 
Percentage of total detected 
metabolites changing (up or 
down) 
5.2% 20.4% 
A 
B 
C 
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intermediates (TCAi) in the plasma. Acute treatment with 50mg/kg GSK932121A revealed a significant 
increase in all plasma TCAi at 4 hours post dose with the exception of succinate (trending increase but 
p>0.05) compared to VC. No effect on plasma TCAi was observed at 12.5mg/kg (data not shown). The 
absolute levels of these TCAi in the plasma with a 50mg/kg dose were however relatively low, with 
substantial effects noted only at 4 hours (and in conjunction with severe hypothermia). This is suggestive 
that alterations in plasma TCAi may only occur at a late stage in the AOP following GSK932121A 
administration or are secondary adaptive changes. This data suggests a delay in organ specific alterations 
in TCA cycle energetics which requires time to significantly impact the circulating plasma TCAi. 
 
TABLE 4.2: Impact of GSK932121A (50mg/kg) on plasma TCAi. Data shown represents fold change in TCAi compared to 
time matched VC samples. Statistical significance is represented by colour (red = statistically significant 
increase, green = statistically significant reduction).  
 
Evaluation of terminal 4 hour liver TCAi did not reveal any major impact of compound on mitochondrial 
TCA cycle function in the liver (data not shown), in contrast to observations in the plasma.  These data 
indicate that only higher dose/later stage mitochondrial dysfunction causes any change in TCA cycle 
energetics highlighted by plasma biomarkers.  Additionally, the general lack of TCAi change within the 
liver suggested that the 4h plasma change may have originated in a non-hepatic target organ(s). Although 
increases in released TCAi have been previously demonstrated in response to complex III inhibition 
induced by antimycin A [165], the present data reveals this is not an early event and may either be a 
secondary consequence of other tissues or a downstream event in the AOP.  
 
With respect to the overt increase in plasma TCAi, multiple carbon energy sources would be expected to 
become impacted by a loss of TCA cycle efficiency, glycogen metabolism including FA oxidation and 
amino acid catabolism. The next three sections will evaluate the impact of GSK932121A on these energy 
sources, both systemically (plasma) and in the liver.  
 
Metabolite Pre Dose 0.5 Hours 1 Hour 2 Hours 4 Hours 
 
Citrate 1.14 0.94 1.08 1.17 1.39 
 
α-ketoglutarate 1.34 0.62 1.25 1.07 2.47 
 
Succinate 1.77 1.18 0.69 0.71 2.74 
 
Fumarate 1.51 1.22 1.02 1.07 4.35 
 
Malate 1.57 1.22 1.07 1.09 5.06 
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4.2.4. METABOLOMICS: COMPLEX III INHIBITION CAUSES AN INCREASE IN GLYCOGENOLYSIS 
AND GLYCOLYSIS 
Consistent with observations made in chapter 3, metabolomics analysis revealed a prominent metabolic 
switch in energy production, away from mitochondrial OXPHOS and towards glycogenolysis, glycolysis 
and substrate level phosphorylation. When mitochondrial function was altered by GSK932121A, a 
rapidly available alternative energy source would be from glycogen mobilisation and flow into glycolytic 
metabolism at the level of glucose-6-phosphate as shown in Fig.4.3 below.  
 
 
 
 
FIGURE 4.3: Schematic representation of the glycogenolysis, glycolysis and PPP. Biochemicals which showed significant 
changes on treatment with GSK932121A in the present study are presented in red boxes.  
 
A major biochemical outcome of GSK932121A treatment shown in chapter 3 was the significant 
reduction in hepatocellular glycogen. Consistent with this observation a decrease in all liver 
starch/glycogen intermediates was observed in GSK932121A treated animals in the present study. This 
concentration dependent decrease in all liver glycogen was trending a decrease at the 12.5mg/kg dose and 
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reached statistical significance at 50mg/kg (Fig.4.4). Glycogen itself was however unchanged in the liver 
of 12.5mg/kg GSK932121A treated animals. Reduction in glycogen levels therefore manifest only at 
higher doses due to increased reliance on hepatic glycolysis (i.e.  Reduction in glycogen is not a critical 
event following GSK932121A treatment in vivo). 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4.4: GSK932121A causes a dose dependent reduction in liver starch/glycogen intermediates at a 4 hour time 
point. Data shown represents scaled intensity of the total ion counts for each metabolite whereby the median 
ion is equal to 1. A significant reduction in maltohexaose (A), maltotriose (B) and maltose (C) was observed in 
the liver of animals treated with 50mg/kg GSK932121A (n=7, orange) compared to VC (n=6, black). All 
glycogen intermediates were trending a reduction at 12.5mg/kg (n=7). **p<0.01, ***p<0.001. 
 
In line with the hypothesis of compensatory energy sourcing, the dramatic depletion of liver glycogen 
intermediates correlated with a progressive increase in liver glucose-6-phosphate, the input level at which 
increased glycogenolysis would be expected to impact glycolytic metabolism (Fig.4.5A). Additional 
support for increased glycolytic compensation was given by a statistically significant decrease in liver 
glucose levels, an elevation in the glycolysis intermediates 2-phosphoglycerate and phosphoenolpyruvate 
(PEP) and a significant decrease in both pyruvate and lactate with high dose acute exposure (Fig4.5 D and 
E). Importantly, while elevated glycolytic metabolism might be expected to result in elevated lactate 
levels within the liver, it is known that the liver is able to utilise lactate as a non-carbohydrate fuel source 
in order to generate glucose (gluconeogenesis) via the Cori cycle. This theory is supported by gene 
expression changes presented in chapter 3 which highlight up-regulation of genes involved in 
gluconeogenesis, i.e. Pck1, Foxo1 and PGC1α. The significant increase in lactate observed in the blood at 
late time points in chapter 3 (despite trending increase this was not evident in the present study, likely due 
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to lower drug exposure levels) is likely originating from the skeletal muscle although further work is 
required to better understand its origins. Furthermore, the observation that GSK932121A caused a 
significant increase in liver phosphoenolpyruvate (PEP) and a significant reduction in liver pyruvate/ 
lactate (with the 50mg/kg dose) is suggestive that the activity of pyruvate dehydrogenase kinase may be 
inhibited. This would support observations made in chapter 3 which showed an increased level of Pdk4 
gene transcription in liver tissue of rats treated with 50mg/kg GSK932121A compared to VC. Further 
work is required to understand the effect of DIMT on both the activity and expression of the pyruvate 
kinase family of enzymes and the associated upstream substrates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
  
 
 
 
 
FIGURE 4.5: Effect of GSK932121A treatment on key glycolysis metabolites in the liver of GSK932121A and VC treated 
animals.  Data shown represents scaled intensity of the total ion counts for each metabolite whereby the median 
ion is equal to 1. Data represents the differential effect of a 12.5mg/kg (n=7, grey) or 50mg/kg (n=7, orange) 
dose of GSK932121A  on glucose-6-phosphate (A), 2-phosphoglycerate (B), phosphoenolpyruvate (C), 
pyruvate (D), lactate (E) and glucose (F) compared to VC livers (n=6, black). p<0.01**, p<0.001*** 
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It is important to highlight that no biochemical involved in glycogenolysis or the glycolysis pathway was 
affected at the well-tolerated 12.5mg/kg dose. Lactate has long been regarded as a useful biomarker of 
mitochondrial dysfunction however the evidence obtained would suggest that the effect of complex III 
inhibition on circulating lactate is only apparent at high doses and in conjunction with severe clinical 
toxicity. It is currently unknown what level of mitochondrial dysfunction in vivo is required to provoke 
significant effects on circulating lactate. Despite this, the current data improves understanding of the 
effect of drug-induced respiratory chain inhibition on metabolic pathways in the liver. Further work 
exploring glycogen depletion and lactate generation at sub-toxic doses will be presented in chapter 7.  
4.2.5. METABOLOMICS: COMPLEX III INHIBITION HAS AN EFFECT ON MITOCHONDRIAL FA 
OXIDATION 
Elevation of plasma TCAi following high dose compound exposure indicated some level of altered 
energy metabolism, and presuming liver is a major target of compound toxicity, one would anticipate that 
altered hepatic FA -oxidation may be the primary impact in the acute exposure situation. It is important 
to acknowledge that the general pathology relating to the effect of GSK932121A on cellular lipid relates 
to an increase in hepatocellular lipid and as such the metabolomic footprint downstream of GSK932121A 
may be likened to that described in studies following high fat diet feeding, observation of hepatic steatosis 
or insulin resistance (type II diabetes mellitus) [166]. 
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FIGURE 4.6: Schemiatic representation of the carnitine shuttle and ketogenesis. Biochemicals depicted in red were 
differentially affected due to GSK932121A’s impact on FA β-oxdation. 
 
Mitochondrial FA oxidation requires FA-conjugation with carnitine in order to facilitate transport across 
the IMM for FA -oxidation to proceed (Fig.4.6 above). Consistent with increased FA conjugation (i.e. 
attempts to increase mitochondrial substrate for β-oxidation) a significant reduction in plasma carnitine 
(significant at 2h and 4h with low and high doses of GSK932121A) was observed compared to VC 
(Fig.4.7). End of study liver carnitine was not significantly altered compared to control.  
 
 
 
 
 
Ketogenesis 
3-hydroxybutyrate (BHBA) 
Carnitine 
Fatty acylcarnitine 
Fatty acylcarnitine 
Carnitine 
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FIGURE 4.7: Effect of GSK932121A on plasma free carnitine. A significant reduction in free carnitine was observed in the 
plasma of 12.5mg/kg (grey line, n=7) and 50mg/kg (orange line, n=7) treated animals at 2 and 4 hours 
compared to VC animals (black line, n=6). Data shown represents scaled intensity of the total ion counts for 
each metabolite whereby the median ion is equal to 1 with mean ± SE shown. *p<0.05, **p<0.01, ***p<0.001. 
 
Consistent with the metabolic attempts to increase β-oxidation shown by significant reduction in free-
carnitine with escalating time and dose, an increase in a number of ketone bodies was observed. Efficient 
FA -oxidation leads to the formation of acetyl-CoA, which is incorporated into the TCA cycle [167].  If 
this process is perturbed, efficient FA oxidation is diverted into ketogenic FA metabolism, resulting in the 
accumulation of ketone bodies (such as 3-hydroxybutyrate, BHBA) and the accumulation of upstream 
FA-acylcarnitines [168-170].  In the current study, a significant increase in both plasma and liver BHBA 
was observed compared to time matched VC animals (Fig.4.8 A and B). Increased levels of plasma 
BHBA have been previously observed in individuals with diabetes-related fatty liver [171]. This occurred 
alongside a significant increase in plasma long-chain acylcarnitines which lends further credence to the 
hypothesis that mitochondrial FA -oxidation is altered with acute exposure (Fig.4.8 C, D and E). It is 
however important to acknowledge a trending yet appreciable increase in the three fatty acylcarnitines 
shown in Fig.4.8 at the pre-dose stage. Recent research has shown that elevations in the plasma 
concentrations of FA-acylcarnitines reflect mitochondrial dysfunction associated with metabolic disease 
states [168, 169, 172-175]. Furthermore, increased levels of circulating acylcarnitines have also been 
investigated as biomarkers, specifically of mitochondrial dysfunction following drug induced liver injury 
using acetaminophen [123]. Furthermore increased levels of circulating palmitoylcarnitine, 
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stearoylcarnitine and oleylcarnitine were observed in mice with increased levels of hepatic lipid after 
being fed a high fat diet [176]. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4.8: Effect of GSK932121A on plasma and liver BHBA and plasma FA-acylcarnitine levels. A significant increase 
in plasma (A) and liver (B) BHBA was observed in 12.5mg/kg (n=7) and 50mg/kg (n=7) GSK932121A treated 
animals compared to VC animals (n=6). Increases in the FA-acylcarnitines palmitoylcarnitine (C), 
oleoylcarnitine (D) and stearoylcarnitine (E) was observed as early as 0.5 hours post dose with both 12.5mg/kg 
(grey, n=7) and 50mg/kg (orange, n=7) line compared to VC animals (black, n=6). Data shown is mean ± SE. 
p<0.05*, p<0.01**, p<0.001*** 
 
Acylcarnitines are derivatives of long chain FA’s which are essential for the transport of FA into the 
mitochondria [177]. Liver FA-acylcarnitines were not significantly affected by compound under any 
treatment condition (data not shown). This apparent lack of change could reflect a more substantial 
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baseline concentration of FA-acylcarnitines in the liver (as the major lipid metabolising organ) when 
compared to plasma baseline levels. Alternatively, this may reflect a shift from complete FA oxidation 
with TCA cycle incorporation towards increased ketogenesis which would fit with the increase in both 
plasma and liver BHBA. Similar to the discord between plasma and liver TCAi, the general lack of 
consistency between plasma and liver FA-acylcarnitine levels suggests that other, non-hepatic effects of 
the compound may contribute to plasma acylcarnitine accumulation. In any case, circulating 
acylcarnitines may have potential as a biomarker of drug induced respiratory chain dysfunction with 
increased expression levels observed at sub-toxic doses in vivo (12.5mg/kg) and as early as 0.5 hours post 
dose. Overall, these data indicate a significant impact of acute compound exposure on mitochondrial FA 
oxidation efficiency leading to increased ketogenesis.  
 
4.2.6. METABOLOMICS: COMPLEX III INHIBITION HAS AN EFFECT ON AMINO ACID 
CATABOLISM  
There are multiple upstream carbon energy sources that may be altered with a significant perturbation in 
mitochondrial TCA cycle efficiency.  In addition to the predominant lipid source used by the liver, amino 
acid catabolism might also be anticipated to show changes with decreased mitochondrial function 
(Fig.4.9).   
 
 
 
FIGURE 4.9: Schematic representation of α-ketobutyrate and α-hydroxybutyrate involvement in the supply of carbon 
sources to the TCA cycle.  
 
α-hydroxybutyrate (AHB) α-ketobutyrate (AKB) 
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A significant increase in the levels of several plasma and liver amino acids corroborated the hypothesis 
that mitochondrial amino acid catabolism was impacted by GSK932121A.  Of particular interest was the 
notable increase in plasma branched chain amino acids (BCAA), 4 hours post-treatment with 50mg/kg 
GSK932121A (Fig.4.10 A-C). No significant difference in plasma BCAA’s were observed following low 
dose administration of GSK932121A compared to VC. Increases in a number of BCAA were also 
observed in the liver at both 12.5mg/kg and 50mg/kg GSK932121A compared to VC (Fig.4.10D). These 
data suggest that hepatic amino acid catabolism is affected despite absence of clinical signs and these 
increases are only observed in the plasma at higher doses. Perturbations in BCAA metabolism have been 
shown to correlate with metabolic disease and the underlying mitochondrial dysfunction that is manifest 
in such disease states [170, 178-180]. Furthermore, increased levels of glycogenic and ketogenic amino 
acids (valine and leucine respectively) have been observed in states of hepatic insulin resistance due to 
fatty liver which is consistent with the pathological steatosis observed following GSK932121A treatment 
[181]. Similarly to this observation, the exact three amino acids which were increased in the plasma in 
this study (valine, leucine and isoleucine) were also significantly elevated in the plasma of human 
diabetes-induced fatty liver patients suggesting impaired short term metabolic control [171] although the 
exact mechanism for these elevations remains unknown. 
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FIGURE 4.10: Effect of GSK932121A on plasma and liver BCAA’s. To demonstrate the effect of GSK932121A on amino 
acid catabolism the effect of compound treatment on the BCAA’s is displayed. A significant increase in plasma 
valine (A), leucine (B) and isoleucine (C) was observed at 4 hours post dose with 50mg/kg GSK932121A 
(orange line, n=7) compared to VC animals (black line, n=6). (D) A significant increase in liver BCAA’s was 
also observed at both 12.5mg/kg (grey bars, n=7) and 50mg/kg (orange bars, n=7) compared to VC (black bars, 
n=6) 4-hours post dose with GSK932121A. All data displayed is mean ± SE.  p<0.05*, p<0.01**, p<0.001*** 
 
Plasma concentrations of -ketobutyrate (AKB) and its alternative metabolite, α-hydroxybutyrate (AHB) 
showed time and concentration dependent increases with acute exposure to GSK932121A (Fig.4.11). 
Recent publications have shown that elevated AHB serves as a marker of insulin resistance, a condition 
known to involve mitochondrial dysfunction [182-184] and provides one of the most notable markers of 
increased amino acid catabolism in the current model system.  Accumulation of AHB is postulated to 
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occur when levels of AKB exceed the rate of its catabolism to propionyl-CoA which appears to be the 
case in the present study.  
 
 
 
 
  
FIGURE 4.11: Effect of GSK932121A on plasma AKB and its downstream metabolite AHB over a 4 hour time course. 
GSK932121A causes a significant dose and time dependent increase in AHB (A) and AKB (B) with both 
12.5mg/kg (grey line, n=7) and 50mg/kg (orange line, n=7) compared to VC animals (black line, n=6). Data 
shown is mean ± SE of scaled intensity (median = 1) of total metabolite counts. p<0.05*, p<0.01** 
 
Whilst the metabolomics data point towards an insulin-resistance / metabolic syndrome-like phenotype it 
is important to acknowledge that, to date, no reports have appeared in the literature that an increase in 
circulating or hepatic BCAA or in circulating levels of AHB/AKB are markers of DIMT. 
 
4.2.7. METABOLOMICS: INHIBITION OF COMPLEX III CAUSES INCREASED LEVELS OF 
HEPATIC OXIDATIVE STRESS 
In addition to alterations in glycolytic metabolism shown in section 4.2.4, there was a notable shift in 
hepatic intermediates of pentose phosphate pathway (PPP) metabolism that suggest, at least in part, 
elevated glucose-6-phosphate was also being tapped as a source feeding PPP metabolism.  PPP 
metabolism is commonly increased to serve two major purposes: 1) increase nucleotide biosynthesis in 
the context of elevated proliferation, or 2) increase the reducing NADPH equivalents necessary to reduce 
oxidised glutathione (GSSG) to the major tissue antioxidant GSH [167, 185].  Sedoheptulose-7-phosphate 
A B 
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was significantly elevated in the liver of animals with both low and high dose compound in the acute 
setting (Fig.4.12A), consistent with an increase in PPP metabolism.  In the current model of acute 
compound-induced toxicity, this profile likely reflects an increased need to maintain antioxidant GSH 
levels in the liver (versus increased nucleotide biosynthesis). 
 
Cysteine-glutathione disulphide is a reported marker of oxidative stress [186].  Increased liver cysteine-
glutathione disulphide levels observed at both doses of the drug in the present study indicate elevated 
hepatic oxidative stress with GSK932121A exposure (Fig.4.12B).  Importantly, liver GSH levels were not 
significantly diminished with low dose compound exposure, but were significantly decreased with acute 
high dose compound treatment (Fig.4.12D).  These data indicate a compound related increase in oxidative 
stress with both low and high dose treatment, but an inability to maintain antioxidant GSH levels in the 
acute high dose setting vs. low dose treatment.  In line with this observation was a significant increase in 
liver ophthalmate levels with low dose GSK932121A and a trending decrease in liver ophthalmate levels 
with high dose exposure (Fig.4.12C). Ophthalmate is co-ordinately synthesised alongside glutathione 
through the promiscuity of GSH biosynthetic enzymes [167, 185], but is typically a more stable marker of 
GSH biosynthesis than GSH itself (particularly within a changing redox environment). Altered 
ophthalmate levels suggested that GSH biosynthesis was appropriately up-regulated with low dose 
exposure, but appeared compromised at 50mg/kg. This data is consistent with a two-hit paradigm in the 
latter scenario, where altered energy metabolism could be coupled with significant impairment of a 
crucial redox response in the liver of animals treated with high dose GSK932121A, thus contributing to 
the observed toxicity.  
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FIGURE 4.12: Effect of GSK932121A on oxidative stress and anti-oxidant stress response in the liver. GSK932121A had a 
significant effect on the liver oxidative stress markers cysteine glutathione disulphide (A) and sedoheptulose-7-
phosphate (B). (C) A transient increase in opthalmate was observed with 12.5mg/kg GSK932121A (grey, n=7) 
which was significantly reduced at 50mg/kg (orange, n=7). Furthermore, 50mg/kg GSK932121A caused a 
significant reduction in reduced GSH (D) and a significant increase in oxidised GSSG (E) compared to VC 
(black, n=6).  Data represented as scaled intensity whereby the median value is equal to 1.p<0.05*, p<0.01**, 
p<0.001***. 
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4.3. Further Discussion  
4.3.1. METABOLOMICS 
Metabolomics analysis identified biochemical changes occurring as a result of respiratory chain inhibition 
at both early time-points and at a sub-toxic dose of GSK932121A. The analysis demonstrated an increase 
in plasma TCA cycle intermediates, increased levels of hepatic oxidative stress, impaired mitochondrial 
β-oxidation / amino acid catabolism and an increased level of glycogenolysis. This metabolomic profile is 
similar to that observed in metabolic syndrome, fasting, fatty liver and insulin resistance. Furthermore the 
data outlined in this chapter correlates closely with clinical observations in patients with mitochondrial 
diseases caused by mutation to mtDNA [187]. Many of these disorders manifest in respiratory chain 
deficiencies and as such validate the translatability of the present work to patients with impaired 
bioenergetic capacity and mitochondrial myopathies. Particularly acute are increases in acylcarnitines, 
BCAA’s and  ketone bodies and future work will no doubt explore the effect of DIMT on these 
parameters further (i.e. during longer term dosing regimens).  
 
The similarity of the metabolomics signatures in the present study to observations made in other studies 
of mitochondrial dysfunctions opens the possibility of a mechanism-independent metabolite footprint 
from generalized mitochondrial perturbation. This is supported by the authors of a recent review into the 
metabolic and biochemical effects of mitochondrial dysfunction in vivo [188]. 
 
Furthermore, it is important to acknowledge the current study showed a delayed and diminished toxic 
response to GSK932121A when compared to previous studies (outlined in chapter 3), i.e. 50mg/kg dose 
showed no adverse clinical signs and significantly lower plasma exposure levels. This would suggest that 
the response profiles may manifest earlier in a more typical scenario – thus providing the potential for 
markers at 0.5h with acute high dose. Drug-induced observations in the present study are  therefore 
particularly sensitive in detecting underlying mitochondrial dysfunction as clinical signs were absent up 
to the 4  hour time-point.  
 
4.4. Summary 
In this chapter I have detailed the effect of GSK932121A (complex III inhibition) on early biochemical 
changes in plasma and liver. The following conclusions can be drawn for the experimental evidence in 
this chapter… 
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 With the exception of plasma lactate:pyruvate and clinical signs (no effect likely due to lower plasma 
exposure levels of GSK932121A), the key observations made in chapter 3 were reproducible with a 
50mg/kg dose in the present study. Furthermore it has been confirmed that increases in basal OCR 
and increases in CRC occur 4-5 hours following administration with a well tolerated 12.5mg/kg dose 
confirming they are primary effects of drug-induced respiratory chain perturbation and not secondary 
events. This is especially apparent as no significant effect on body temperature was observed with a 
12.5mg/kg dose. 
 Analysis of plasma metabolites at progressive time points and liver metabolites at the terminal time 
point helped to identify key biochemical changes occurring as a result of GSK932121A treatment. 
Most notable was the increase in liver glycogenolysis, FA import and oxidative stress alongside 
impairment of amino acid catabolism and FA β-oxidation. These data suggest altered cell metabolism 
of all available substrates with continued metabolic efforts to feed carbon sources into the TCA cycle 
for generation of reducing equivalents, alongside substantial hepatic ROS production. Globally the 
metabolomics data shows a degree of similarity to the metabolomics signature of metabolic syndrome 
/ hepatic insulin resistance and of human-clinical mitochondrial diseases. This opens up the 
possibility of a generalised metabolomic footprint of mitochondrial dysfunction although this requires 
further investigation.  
 
In future studies it remains important to take tissue samples at early time points in order to identify any 
early biochemical / mitochondrial functional changes occurring at the tissue level. Validation work is also 
required to assess the utility of measuring metabolomic markers (e.g. acylcarnitines or ketone bodies) as 
biomarkers of mitochondrial dysfunction in vivo. 
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5.0. INTEGRATION OF GSK932121A DATA INTO AN 
AOP/MOA  
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5.1. Introduction – AOP/MOA of GSK932121A Toxicity 
The aim of this thesis was to use a systems approach to improve current understanding of the mechanisms 
of DIMT. In essence, I attempted to devise AOP’s in order to detail the key events leading from the 
molecular initiation event (MIE) to clinical toxicity. In any complex biological system there is however 
more than one plausible pathway leading to an adverse outcome, which therefore complicates the task of 
distinguishing key events from casual associated occurrences. This is especially pertinent within an 
acutely stressed system where it is likely multiple biological mechanisms/pathways are involved, with 
many events consequential as opposed to primary/causative. It is this multi-mechanism and multi-system 
response which makes defining causation (according to Bradford Hill considerations) so difficult. For this 
reason a hybrid AOP/MOA approach was taken to detail the integrated learning’s from chapters 3 and 4 
with regard to the acute toxicity caused by respiratory chain inhibitors (using both data from the literature 
and data generated with GSK932121A in rats). Whilst small differences exist between an MOA and an 
AOP (i.e. an AOP goes out to the population level whereas an MOA does not) a hybrid AOP/MOA 
enables the description of both parameters.  
 
When building a hybrid AOP/MOA it was important to distinguish between four categories of event (see 
below, not including the MIE and adverse outcome). This approach takes into account the uncertainties 
surrounding each stage of the toxicological response and enables the AOP/MOA to develop gradually, 
from known key events to events which are merely associated…  
 
 Key events (including the molecular initiating event if known): There should be good evidence that 
these are causally related and necessary for the adverse outcome. A key event is an empirically 
observable step or marker which is a necessary element of the MOA and is critical to the outcome. 
Key events are measurable and reproducible. 
 Possible key events (PKE): Those events which are plausible but for which there is not yet clear 
evidence. 
 Modifying factors: These can affect the progression or magnitude of a key event but are themselves 
not essential for the outcome to occur. 
 Associated events: Processes occurring in parallel with the key events, but not involved in the 
outcome. 
 
There is likely to be little utility in generating single-compound AOP’s unless in-depth investigations are 
required on a single compounds mechanism of action (i.e. if there is a late stage drug development issue). 
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It is therefore important to ensure data generated with GSK932121A is incorporated into a generalised 
AOP for complex III inhibition taking into account data from the literature. Taking this into 
consideration, key events (detailed in section 5.2) and possible key events (detailed in section 5.3) contain 
occurrences which are not necessarily specific to GSK932121A but are characteristic of complex III 
inhibition in general. Associated events (detailed in section 5.4) will then incorporate additional 
observations made specifically with GSK932121A which require further analysis. 
 
I will therefore start by identifying just the key events known to be causal in the toxicological response to 
complex III inhibition (see Fig.5.1. below). The AOP/MOA will then be assembled based on possible key 
events (PKE) and associated events with the uncertainties at each level discussed. 
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5.2. Key Events: Complex III Inhibition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5.1.: Key events in the AOP/MOA for complex III inhibition. Detailed are the key events (labelled 1-4) which are 
observed downstream of the molecular initiating event (MIE) i.e. GSK932121A binding to the Qi site of 
cytochrome bc1 complex, to the adverse outcome (AO) in rats (moribund state/hypothermia). 
 
 
The key events described in the above pathway clearly do not capture the complexity of the full response 
to respiratory chain inhibition in vivo. To be considered key events however, observations must be 
measurable, casually related (to each other and the outcome) and required for progression of the AOP. 
Table 5.1 below, details the experimental evidence or literature support which confirms the occurrence of 
Reduction in OXPHOS-dependent mitochondrial ATP 
production and OCR 
 
Molecular Initiating Event 
Inhibition of Cytochrome bc1 activity – Binding 
to Qi site of complex III 
Metabolic Acidosis 
Increased systemic lactate and 
reduced blood bicarbonate / pH 
Animals Moribund 
Reluctance to move, hypothermia and hunched posture 
Increased hepatic glycolysis 
Increase in non-mitochondrial energy production via 
glycolysis. Reduction in cellular glycogen 
1- MIE 
2 
3 
AO 
4 
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the key events (1-4, as labelled in Fig.5.1 above), and the plausibility for the relationship between the key 
events, including any remaining uncertainty.  
 
 
 
TABLE 5.1: Experimental and literature evidence of key events in the complex III AOP/MOA including the plausibility 
of the relationships between the key events and remaining uncertainties at each stage. Key events are 
labelled 1-4 (and AO) according to the numbering in Fig.5.1 above. 
 
 
 
 
KE Experimental evidence Literature support Key event relationship plausibility and uncertainties 
 
1 - 
MIE 
Covalent binding of 
GSK932121A to the Qi 
binding site of the 
cytochrome Bc1 subunit.  
Proven in X-ray 
crystallography study [189]. 
1-2+3: Literature and data suggests that inhibition of 
cytochrome bc1 activity causes ATP depletion and a 
metabolic switch to glycolysis due to inhibition of 
OXPHOS. 
1-AO: Reduction in ETC activity provokes loss of 
temperature due to decreased metabolic rate.  
Uncertainty – It is uncertain whether GSK932121A causes 
reduction in mitochondrial oxygen consumption and ATP 
production. It is likely this energy deficit promotes the 
relationship to 2 and 4, rather than the MIE itself. 
2 None Primary event following 
respiratory chain perturbation is 
a reduction in mitochondrial 
oxygen consumption and a 
reduction in mitochondrial ATP 
synthesis following antimycin 
A and myxothiazol treatment 
[190]. This effect was also seen 
using rotenone and cyanide 
[191]. 
Difficulty in assessing and quantifying mitochondrial ATP 
in vivo. To date no evidence of ATP depletion observed 
however this may be as yields are supplemented by 
glycolytic substrate level phosphorylation. 
There is however strong evidence in the literature 
supporting its inclusion as a key event and reduction in 
OXPHOS activity (ATP and OCR output) is known to 
cause a switch in metabolism to glycolysis (key event 3). 
3 Reduction in liver 
glycogen (TEM), 
metabolomics evidence 
of glycogenolysis, 
transcriptomic evidence 
of a liver fasted state. 
Much evidence supporting 
switch in energy production 
[192] 
3-4: Uncertainty – Lactate originating from other (non-
hepatic) organs and tissues such as the skeletal muscle? 
Lactate likely being consumed by the liver for 
gluconeogenesis via the Cori cycle? 
 
4 Increase in blood lactate  Clinical evidence of lactic 
acidosis from mitochondrial 
toxicants [193]. 
4-AO:  Lactic acidosis widely acknowledged as a key event 
in the progression of a mitochondrially toxic event and a 
poor prognosis [194]. 
 
AO Severe and rapid onset 
hypothermia observed in 
vivo alongside other 
clinical signs (e.g. 
hunched posture, 
reluctance to move etc). 
Hypothermia noted 
downstream of other 
respiratory chain inhibitors 
such as 3-nitropropionic acid 
[150]. 
4-5: Hypothermia widely acknowledged as a key event in 
the progression of sepsis like toxicity [163, 195]. Reduced 
metabolic rate and temperature related effects on enzymatic 
function. 
Uncertainty - Is this of hepatic origin (liver is a key 
thermoregulatory organ in rat) and is this a local event in 
the short-term?  
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5.3. Possible Key Events: Complex III Inhibition 
 
By adopting a hybrid “weight of evidence” based AOP/MOA approach it prevents the need to try and fit 
all endpoints into a single AOP. This is beneficial as some pathways may be occurring in parallel and are 
responsive as opposed to progressive (and as such do not fit the criteria as key events). These PKEs may 
be important in terms of detection for risk assessment purposes or for understanding the adaptation to 
mitochondrial perturbation but not enough evidence currently exists to definitively relate them to each 
other or the adverse outcome.   
 
It is important to acknowledge that the below possible key events are supported by data in the literature 
using other tool complex III inhibitors (e.g. myxothiazol and antimycin A).  This is especially important 
as within any given in vivo study it is not always possible to measure every step in the progression of a 
toxicological outcome. To date our knowledge is restricted to two studies and therefore gaps in our 
understanding remain. Furthermore, it was intended to generate a hybrid AOP/MOA for complex III 
inhibition and not GSK932121A toxicity which therefore requires additional data from other compounds 
with similar in vitro activities.  
 
Detailed below, in the same AOP as the key events were portrayed, are the observations where 
experimental data or strong biological fundamentals suggest they are possibly important to the 
progression of the AOP but there is not yet sufficient evidence to classify them as key events (Fig.5.2). 
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FIGURE 5.2: PKE’s in the AOP for complex III inhibition. Insufficient evidence currently exists to definitively include the 
PKE’s (black text and lettered a-d) as key events (red text). 
 
The events shown in black in Fig.5.2 above are categorised as PKE’s as not enough sufficient evidence 
currently exists to definitely conclude they are essential to the progression of the AOP/MOA (i.e. unclear 
whether they are casually related or whether they are a requirement in the progress of a toxicological 
response towards an adverse event). These events are however generally considered in the literature 
Molecular Initiating Event 
Inhibition of Cytochrome bc1 activity- Binding to 
Qi site of complex III 
Metabolic Acidosis 
Increased systemic lactate and 
reduced blood bicarbonate / pH 
Animals moribund 
Reluctance to move, hypothermia and hunched posture  
Reduction in OXPHOS-dependent 
mitochondrial ATP production and OCR 
Increased oxidative stress 
(reduced GSH / increased 
GSSG) 
Mitochondrial 
structural damage 
(e.g. swelling) and 
mitochondrial 
degeneration 
(mitophagy) 
Deep abdominal 
breathing 
(shortness of 
breath) 
(d) 
(c) 
(b) 
(a) 
AO 
Increased blood 
O2 / reduction 
in Blood CO2 – 
Inability to use 
available O2 
Increased hepatic glycolysis 
Increase in non-mitochondrial 
energy production via glycolysis 
Reduction in cellular glycogen 
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and/or demonstrated downstream of GSK932121A to be potentially key to the AOP for complex III 
inhibition although further studies are required in order to generate a weight-of-evidence for re-
categorisation as key events. Detailed in table 5.2 below, is both the evidence of their involvement in the 
AOP/MOA for drug-induced respiratory chain inhibition and the remaining uncertainties at each stage.  
 
 
PKE Evidence Uncertainty 
a Blood gas data with 50mg/kg GSK932121A 
demonstrates an increase in plasma 02 and 
reduction in plasma CO2 compared to VC. 
High level of certainty that this observation is due to 
reduction in mitochondrial oxygen consumption. This 
observation is however under-reported in the literature and as 
such further work is required to assess whether this is 
common to other complex III inhibitors.  
 
b Experimental - Principle clinical observation with 
the 50mg/kg dose was deep abdominal breathing / 
respiratory depression at 4-5 hours post-treatment.  
Literature evidence of hypoventilation and 
respiratory depression in vivo with patients 
suffering cyanide poisoning (cyanide is an ETC 
inhibitor – complex iv) [196]. 
Patients with some degree of acidosis (key event 3) usually 
increase breathing rate, however this is a compensatory effect 
of increased blood CO2 which is not observed in the present 
study. 
Breathing rate could be as a result of temperature effects as 
opposed to blood gas findings. 
c Increase in oxidative stress marker cysteine 
glutathione disulphide with low dose of 
GSK932121A. Over time oxidative stress 
overwhelms antioxidant response = Increase in 
GSSG and reduction in reduced GSH. 
Literature evidence of ROS generation following 
respiratory chain inhibition [197]. 
High level of certainty that ROS generation is primary to the 
MIE however uncertain what effect oxidative stress has in 
downstream events i.e. lipid oxidation and DNA damage? 
d Evidence of mitochondrial swelling and 
degeneration at 50mg/kg GSK932121A at a 
terminal time point. Mitochondria were often seen 
engulfed within phagosomes. 
Likely to be due to a combination of factors (i.e. ATP 
depletion, drug binding) and not just caused by ROS. 
Unsure whether key to the adverse outcome or just an 
associated event?  
 
TABLE 5.2: Evidence for, and remaining uncertainty surrounding, PKE’s in the AOP/MOA of complex III inhibition.  
PKE’s are labelled a-d according to the lettering shown in Fig.5.2 above. 
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5.4. Associated Events 
Further to both the key events shown in Fig.5.1 and the PKE’s shown in Fig.5.2 are a number of 
associated events which are likely occurring in parallel to the AOP, however are not likely essential to the 
progression toward the adverse effect. Please note that the associated events described below are more 
specific to the effects observed with GSK932121A and overlays the AOP/MOA developed in sections 5.2 
and 5.3 above.  
 
In the acute toxicological scenario the associated events are generally consequential adaptations, cellular 
responses to the key events or mitochondrial effects where uncertainty remains (i.e. with regard to the 
direction of change). These events may be extremely important in terms of chronic adaption to respiratory 
chain inhibition however are not key to the AOP in an acute scenario. Associated events which have been 
identified and their relationship to the key events and PKE’s are shown in Fig.5.3 and are briefly 
described below. 
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Key events, Possible Key Events and Associated Events 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5.3: Hybrid AOP/MOA including key events, possible key events and associated events in the toxicological 
progression of complex III inhibition related toxicity. Key events (red), PKE’s (black) and associated events 
(blue) are shown in order to detail the observable series of events leading from complex III inhibition to the 
adverse outcome (AO). 
PGC1α-Foxo1 co-ordination 
of gluconeogenesis via 
activation of transcription 
(e.g. Pck1, Irs2, Pdk4) 
Increased FA import (increased 
acylcarnitines / reduction in free 
carnitine) and Impaired β-
oxidation 
Ketogenesis 
Impaired amino acid catabolism 
(increase in BCAA) 
De-sensitization of mPTP 
(delayed triggering) 
Unexpected increase in 
basal OCR in isolated 
mitochondria? 
Continued metabolic activity to 
generate reducing equivalents for 
oxidative metabolism  
Reduction in maximal 
respiration (max 
uncoupled OCR) 
Animals moribund 
Reluctance to move and hunched posture  
Molecular Initiating Event 
Inhibition of Cytochrome bc1 activity – Binding to Qi site of 
complex III 
Increase hepatic glycolysis 
Increase in non-mitochondrial energy 
production via glycolysis  
Reduction in cellular glycogen/glucose 
Metabolic acidosis 
Increased circulating lactate and reduced 
blood bicarbonate / pH 
Reduction in OXPHOS-dependent 
mitochondrial ATP production and OCR 
Increased oxidative stress 
(Reduced GSH / Increased GSSG) 
Mitochondrial structural 
damage (e.g. swelling) 
and mitochondrial 
degeneration 
(mitophagy) 
Immune Response 
Deep abdominal 
breathing (shortness of 
breath) 
Increased blood O2 / 
Reduction in blood CO2 
Inability to use available 02 
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Unexpected increase in basal OCR in isolated mitochondria: An increase in basal OCR was observed 
in isolated mitochondria from GSK932121A treated rats. This is in contrast to data in vitro (both HepG2 
cells and control isolated mitochondria treatment) and the cause remains unknown (hypotheses described 
in section 3.3). Whilst seemingly contradictory, these differences likely reflect an adapted state in vivo 
resulting from the initial insult in combination with compensatory changes made by the tissue to maintain 
energy production. Only the initial, unconfounded, response is observable in vitro. The increase was 
however shown at a 4 hour time point with both 12.5mg/kg and 50mg/kg GSK932121A and as such is a 
dose-dependent and sub-toxic marker of complex III inhibitory toxicity. All in vivo observations however 
suggest that GSK932121A does cause a reduction in mitochondrial OCR/ATP synthesis in vivo (i.e. 
blood gas findings, body temperature reduction etc). Increase in basal OCR in isolated mitochondria can 
therefore only be labelled an associated event as the mechanisms remain unclear and it likely does not 
represent what is occurring in vivo.  
 
PGC1α-Foxo1 co-ordination of gluconeogenesis via activation of transcription (e.g. Pck1, Irs2, 
Pdk4): Increased levels of both PGC1α and Foxo1 alongside their downstream effectors Pck1, Irs2 and 
Pdk4 was observed in the liver of GSK932121A treated rats. These genes function to induce 
gluconeogenesis, the process of generating glucose from non-carbohydrate sources. This process is 
unlikely to be related to the adverse event as it is a consequence of drug-induced glycogenolysis and low 
liver glucose levels. Gluconeogenesis is likely activated to increase levels of substrate and therefore does 
not constitute a toxicologically progressive event.  
 
Desensitisation / delayed triggering of mPTP: A dose dependent effect of GSK932121A was observed 
on the triggering of the mPTP in isolated mitochondria. This has been attributed to the acidification of the 
liver due to increased levels of glycolysis (a result of the metabolic switch to glycolysis). It has been 
widely documented that a pH below 7 can inhibit the action of the mPTP [161]. Inhibiting the mPTP is 
however generally a cyto-protective / anti-apoptotic effect and as such is likely a protective response and 
not key to the progression towards the adverse effect. Furthermore, and similarly to the increase in basal 
OCR described above, this observation was in contrast to in vitro observations and therefore enough 
uncertainty exists to classify this as an associated event. 
 
Reduction in maximal respiration rate (maximal OCR): An effect seen with 50mg/kg GSK932121A 
was a reduction in the ability of the ETC to maximally increase activity (OCR) following dissipation of 
mitochondrial ΔΨ. This data suggests that mitochondria may be unable to increase the activity of the ETC 
should ATP be required beyond that which is produced at a basal level. This may be a key event in the 
134 
 
pathway towards the adverse outcome of GSK932121A-toxicity but to date it is unknown whether it is a 
requirement for the adverse event to take place and how reduced maximal respiration manifests. It also 
remains unclear how the reduction in maximal respiratory rate relates to overall ATP levels and whether 
this is observed in vivo (as opposed to just in isolated mitochondria from treated animals). Its lack of any 
downstream connection justifies its inclusion as an associated event as further data is required. 
 
Continued metabolic activity to generate reducing equivalents for oxidative metabolism (increased 
FA import, impaired β-oxidation, Ketogenesis, impaired amino acid catabolism): Metabolomics data 
presented in chapter 4 has identified that cells and tissues (specifically hepatocytes) continue to drive cell 
metabolism relating to amino acid catabolism and FA oxidation in order to generate reducing equivalents 
for oxidative metabolism (despite acute respiratory failure). This is a cellular response to the reduction in 
mitochondrial ATP production and likely has little impact on the progression of the toxicological 
response towards the adverse outcome. Specific metabolites essential to these processes may however 
prove useful biomarkers of respiratory chain dysfunction (e.g. acylcarnitines, ketone bodies or α-
hydroxybutyrate).  
 
 
This exercise has highlighted that GSK932121A-related reduction in mitochondrial ATP synthesis and 
oxygen consumption is absolutely central to the AOP/MOA. However it remains only a PKE due to the 
present lack of experimental evidence. It is pivotal that future experiments focus on the effect of complex 
III inhibition on ATP levels in vivo. This is not a trivial measurement however and to date investigation 
into the effect of GSK932121A on high energy phosphate levels in vivo has been attempted using both  
magnetic resonance spectroscopy (MRS) and high-performance liquid chromatography (HLPC) with 
limited success. Furthermore, it is important that measurements are specific to mitochondrial ATP as it is 
hypothesised that global high energy phosphates may be unaffected due to glycolytic compensation.  
 
Immune response: Evidence for the activation of the immune system following GSK932121A treatment 
is substantiated by data in the literature which shows that the inflammatory response is involved in the 
toxic response to respiratory chain inhibitors in general. Experimentally, transcriptional up regulation of 
genes involved in the control of inflammation both pro- and anti-inflammatory (IL-10, IL-6, Acute Phase 
Protein Response) was observed in chapter 3.  In addition, the literature reports a link between ROS 
generation and immune response [198] and between immunostimulation and onset of acute toxicity [199]. 
It is however currently unknown whether transcriptional activation of immune response genes is 
representative of increased protein levels (i.e. of cytokines, white blood cells, chemokine’s etc). 
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5.5. Modifying Factors 
It is important to also acknowledge the involvement of modifying factors in the AOP/MOA of 
GSK932121A toxicity. A modifying factor is an event which can affect the magnitude or progression of a 
key event but is not itself essential to the adverse outcome. In the acute scenario differentiating modifying 
factors from other events is extremely challenging as the rapid deterioration in health of the animals gives 
only a narrow window to identify which endpoints constitute key events, associated events, modifying 
factors etc. Furthermore modifying factors could easily be mistaken for key events as inherently, anything 
which affects the magnitude of toxicity is clearly extremely important in terms of a toxicological 
response. The real difficulty is determining whether they are essential to the outcome i.e. does the adverse 
outcome still occur in the absence of the modifying factor? Does the adverse outcome manifest earlier or 
with an increased level of severity when the modifying factor is present?  
 
From close examination of the above AOP/MOA (Fig.5.1-5.3) it could be postulated that the immune 
response for example, may be considered a modifying factor. Despite clear evidence which suggests the 
involvement of immunostimulation in adverse clinical reactions, it is likely that impaired energy 
metabolism would provoke the adverse outcome in the absence of the immune response. Importantly for 
classification as a modifying factor, it is likely that the involvement of the immune response (i.e. pro-
inflammatory response, cytokine storm etc.) may increase the magnitude of the adverse effect but is likely 
not a pre-requisite for the clinical manifestation of GSK932121A toxicity. 
 
Further work clearly needs to focus on how events interact within the AOP to effect either progression or 
magnitude as clearly not enough evidence currently exists in order to unequivocally identify modifying 
factors in the AOP of GSK932121A toxicity.   
 
5.6. AOP/MOA of Respiratory Chain Inhibitors 
When attempting to assemble an AOP/MOA for a novel compound, an informative exercise is to assess 
the similarity of the observations made to other compounds with similar mechanistic activities. The 
difficulty in terms of GSK932121A is the paucity of data in the literature which describe the toxicological 
effects of other respiratory chain inhibitors, at the toxic level, in vivo. Despite being unspecific to the 
cytochrome bc1 complex the toxicological effect of compounds which inhibit the activity of other 
respiratory chain complexes are likely to be similar. It is for this reason that the key comparator discussed 
below is the complex IV inhibitor cyanide. The toxicity of the classical inhibitors used experimentally to 
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study the mitochondrial respiratory chain (i.e. antimycin A and rotenone) has yet to be fully examined in 
vivo. Having said this, numerous  in vitro studies have suggested that treatment with antimycin A causes a 
collapse in ΔΨ, ATP depletion and increase ROS production [200].  One in vivo study which was specific 
for complex III was with myxothiazol, however at the exposures tested the drug was well tolerated in 
mice[201].  
 
Like GSK932121A, the anti-androgen medication and inhibitor of mitochondrial complex I, nilutamide, 
caused an inhibition of FA oxidation, however this was observed in isolated hepatocytes. In the same 
study nilutamide also caused ATP depletion and early onset cytotoxicity which was not observed when 
treated alongside glucose. This data suggests that, like with GSK932121A, the action of glycolysis in 
maintaining ATP levels is a pivotal event downstream of treatment with nilutamide [202]. Furthermore, 
nilutamide toxicity has been attributed to an increase in mitochondrial superoxide production and 
oxidative stress [203]. 
 
Cyanide is an extremely toxic respiratory chain complex IV (cytochrome oxidase) inhibitor found in fire 
and cigarette smoke but has also been used as a suicide/terrorist agent due to its potency. Like 
GSK932121A, the mechanism of cyanide toxicity is based on chemical asphyxiation via effective oxygen 
deprivation (i.e. inability of cells to use oxygen) and loss of cellular ATP [148]. Manifestations of cyanide 
toxicity are similar to those of GSK932121A and include respiratory depression, increased blood 
oxygenation, lactic acidosis and metabolic acidosis characterized by a pH of <7 and a reduction in 
circulating bicarbonate levels [196]. Furthermore metabolomics studies identified an acute effect of 
cyanide on  bile acid metabolism and as such, and considering the potent effect of GSK932121A on liver 
function, this should be explored in future studies with GSK932121A [204]. 
 
From undertaking this review it appears that the toxicological response to GSK932121A is comparable to 
that of other respiratory chain inhibitors (independent of the site of inhibition). Clearly further work is 
however required. Future experiments should aim to assess the toxicity of more respiratory chain 
inhibitors in order to both validate the AOP/MOA and increase the confidence surrounding the 
relationships between key events and the adverse outcome. 
 
5.7. Summary 
In this chapter I have attempted to create a hybrid AOP/MOA for complex III inhibition, which details the 
toxicological series of events occurring between the MIE (drug binding to the Qi site of the cytochrome 
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bc1 complex) and the adverse effect (animals moribund/hypothermia). Key events and PKE’s detailed in 
section 5.2 and 5.3 respectively identified the main mechanism-dependent effects anchoring the MIE to 
the adverse outcome for complex III inhibition. The associated events in section 5.4 adds further 
mechanistic details regarding compensatory/adaptive effects of GSK932121A which requires further 
investigation (including analysis post-treatment with tool respiratory chain inhibitors) in order to 
understand how they fit within the complex III inhibition AOP. In essence, further work is required in 
order to validate the proposed AOP/MOA with other compounds which inhibit the mitochondrial 
respiratory chain. With regard to GSK932121A, it is important to take tissue samples at early time points 
in order to identify any early biochemical / mitochondrial functional changes occurring at the tissue level. 
Validation work is also required to assess the utility of measuring metabolomic markers (e.g. 
acylcarnitines or ketone bodies) as biomarkers of mitochondrial dysfunction in vivo. 
 
Following on from this comprehensive “systems” based analysis of DIMT (related to respiratory chain 
inhibition) it was decided to perform similar systems-based analyses of the toxicological effects of a 
compound with OXPHOS uncoupling activity in vitro and in vivo. This analysis is detailed in chapter 6.  
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6.0. MECHANISM OF DIMT – GSK2617971A INDUCED 
UNCOUPLING OF OXPHOS 
  
139 
 
6.1. Introduction 
Uncouplers of OXPHOS inhibit the coupling between the mitochondrial ETC and ATP synthesis, by 
dissipation of the proton gradient between the IMM and the matrix. Uncouplers (reviewed in section 
1.5.1) cause protons to bypass the F0F1 subunit of ATP-synthase, causing the collapse of mitochondrial 
ΔΨ and the production of heat [205, 206].   
 
Generally, OXPHOS uncouplers collapse both the pH gradient and electrochemical potential across the 
IMM, thereby stimulating substrate oxidation and oxygen consumption [27]. Classically, uncouplers often 
represent weak, hydrophobic, organic acids [207]. Furthermore, NSAIDs often have this biochemical 
characteristic, with many NSAIDs (such as diflunisal, mefenamic acid and flufenamic acid), 
demonstrating uncoupling activity albeit it with low potency (i.e. doses which are unlikely to be clinically 
relevant) [208, 209].  
 
The risks associated with compounds that uncouple mitochondria are significant. 2,4-DNP is a classic 
example. Used in the 1930’s as a weight loss drug, numerous 2,4-DNP associated side effects were 
recognised and it was eventually withdrawn from the market [5]. Although not licensed as a drug, 2,4-
DNP is still misused as a fat burning agent, and numerous fatalities are still attributed to dinitrophenol 
poisoning per year [66]. DNP’s potent effects underscore the potential risks associated with mitochondrial 
uncoupling agents and emphasises the importance of understanding and assessing the risk of DIMT pre-
clinically. 
 
As described in section 1.9.2, GSK2617971A is a pyrazole compound which was designed as a selective 
androgen receptor modulator (SARM) for the treatment of cachexia (muscle wastage). GSK2617971A 
has shown potent uncoupling activity in vitro and is acutely toxic in vivo when dosed at 60mg/kg. 
GSK2617971A was terminated early in development following observations of adverse toxicity in pre-
clinical studies. Since GSK2617971A’s termination from development, it has been used as a tool 
molecule for the study of DIMT. As molecules with some degree of OXPHOS uncoupling activity are 
regularly observed during preclinical assessment of compounds for mitochondrial activity, it was 
considered valuable to gain further understanding of its mechanism of toxicity in vivo, in order to better 
inform discovery groups of the potential safety liability of this class of mitochondrial toxicant.  
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6.1.1. CHAPTER AIMS  
The experimental aims of this chapter were… 
 
1. To assess the toxicological profile of GSK2617971, in order to better understand the downstream 
toxicological consequences of OXPHOS uncoupling in vivo and build an AOP/MOA of OXPHOS 
uncoupling. 
 
2. To further current understanding of how in vivo outcomes relate to data generated using ex vivo / 
in vitro methods with molecules which uncouple mitochondrial respiration. 
 
3. To identify endpoints which most sensitively detect the effect of OXPHOS uncoupling agents for 
future studies involving compounds with this potential mechanism of action. It was especially 
hoped to identify markers of mitochondrial dysfunction at sub-toxic doses of GSK2617971A. 
 
6.2. Results 
6.2.1. CONFIRMATION OF THE UNCOUPLING ACTIVITY OF GSK2617971A 
In order to assess the uncoupling activity of GSK2617971A, isolated liver mitochondria from control rats 
were directly exposed to increasing concentrations of the drug and basal OCR was assessed. The response 
was compared to that with 2,4-DNP (selected as the comparator due to its history of adverse clinical 
toxicity associated with OXPHOS uncoupling) in order to gauge the relative potency of GSK2617971A. 
Uncoupling of OXPHOS generally causes an increase in OCR as the activity of the ETC increases due to 
the drop in charge difference across the IMM, i.e. it attempts to compensate for the collapse in ΔΨ caused 
by the uncoupler.  
 
Isolated liver mitochondria from naïve male Crl:Wi (Han) rats (12-14 weeks of age) were separately 
exposed to increasing concentrations of both GSK2617971A and 2,4-DNP following which, OCR was 
measured using the Seahorse XF24 analyser (Fig.6.1A). The experiment was repeated on three occasions. 
GSK2617971A induced a biphasic and dose-dependent increase in OCR with the peak response occurring 
at 1µM that led to a 1000% increase in OCR compared to DMSO control (although the low dose of 
0.01µM GSK2617971A also induced an average increase in OCR of over 150% compared to the DMSO 
control). The uncoupling effect of GSK2617971A on isolated liver mitochondria was insensitive to 
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oligomycin, indicating compound-induced dissipation of the proton gradient following ATP-synthase 
inhibition (Fig.6.1B). Uncoupling activity is often observed in a biphasic (bell shaped) dose response as at 
high doses uncoupling agents can become toxic to the respiratory chain and ETC activity becomes 
inhibited [210]. There is however contradictory reports in the literature as the inhibition of ETC activity at 
high doses of uncoupler could be due to “non-specific toxicity” caused by binding to the IMM thus 
inhibiting electron flow [295], or due to decreased substrate availability to drive respiration [296]. These 
hypotheses are however in the whole cell scenario and therefore further investigations are required to 
understand the kinetics of this dose-response relationship with uncoupling agents within isolated 
mitochondria. 
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FIGURE 6.1: Comparison of the OXPHOS uncoupling activity of GSK2617971A to 2,4-DNP in control isolated liver 
mitochondria. (A) Freshly isolated liver mitochondria from naive Crl:Wi (Han) rats were exposed to increasing 
concentrations of GSK2617971A (0.001-100µM) or 2,4-DNP (0.1-100µM) and basal OCR was analysed. Data 
was compared to basal OCR readings from a 0.5% DMSO control and is expressed as a percentage of this 
control (mean ± SD, n=3). GSK2617971A (grey bars) induced a biphasic uncoupling of OXPHOS with peak 
uncoupling activity stimulated at 1µM. 2,4-DNP (black bars) caused a significant increase in OCR at 50-100µM 
(concentration of 0.01µM not tested). (B) Representative OCR trace showing the acute uncoupling effect of 
GSK2617971A following ex vivo treatment of control isolated liver mitochondria. GSK2617971A (doses up to 
5µM shown for clarity) caused a dose dependent and biphasic uncoupling effect compared to a 0.1% DMSO 
control (grey line), mean ± SD data is shown (n=3). 
 
Taking into account the concentrations tested, GSK2617971A induced maximal respiration with 
significantly higher potency than 2,4-DNP (over three orders of magnitude). Following these 
observations, GSK2617971A was profiled in the CRC assay to assess direct impact on mPTP function 
and calcium retention. The concentration range of GSK2617971A was modified based on the high 
potency observed in terms of OCR, and a six point dose response (0.02-2µM) was assessed.  
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Calcium Retention Capacity  
GSK2617971A reduced the CRC in liver mitochondria from untreated animals in a concentration 
dependent manner with an IC50 of 0.16μM (Fig.6.2). The reduction in CRC observed was strongly dose-
dependent in the concentration range assessed (R
2
:0.9918). The classical uncoupler 2,4-DNP also reduced 
the CRC of control isolated liver mitochondria although only at doses above 10µM (IC50=46.7µM). In 
terms of the dose required to inhibit CRC to 50% of that achieved by the 0.5% DMSO control, 
GSK2617971A was 292-fold more potent than 2,4-DNP.  
 
 
 
  
 
 
 
 
 
 
 
 
FIGURE 6.2: Assessment of the mitochondrial CRC following in vitro treatment of control liver mitochondria with 
GSK2617971A and 2,4-DNP. Freshly isolated liver mitochondria from male control Crl:Wi (Han) rats were 
treated in vitro with GSK2617971A (0.02-2µM) and 2,4-DNP (0.1-100µM) in order to assess the potency of the 
drugs on succinate-driven CRC (ΔOD upon addition of succinate and undergoing MPT expressed as percentage 
of DMSO control).  [GSK2617971A IC50 =0.16µM, = R
2: 0.9918]. [2,4-DNP IC50=46.7, correlation= R
2: 
0.7012]. Data shown is mean only (n=3). 
 
In summary, GSK2617971A is a potent uncoupler of OXPHOS. A concentration of 1µM causes the 
largest increase in OCR in control isolated liver mitochondria although substantial effects are noted down 
to 0.01µM. GSK2617971A reduces the CRC of control isolated liver mitochondria in vitro down to 
0.05µM (IC50: 0.16µM) in a strongly dose dependent manner. Both observations are evidence of the 
substantial uncoupling capacity of the molecule. The observed responses show that GSK2617971A is 
significantly more potent than the classical uncoupler, 2,4-DNP. 
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Following confirmation of GSK2617971A’s uncoupling activity, GSK2617971A was administered to 
male Crl:Wi (Han) rats in order to assess the effect of OXPHOS uncoupling in vivo. 
 
 
6.2.2. ACUTE DOSE IN VIVO STUDY WITH GSK2617971A – NON MITOCHONDRIAL 
ENDPOINTS 
 
Male Crl:Wi (Han) rats were dosed (via the oral route) with either 30mg/kg GSK2617971A (n=2), 
60mg/kg GSK2617971A (n=6) or vehicle alone (n=8) for a period of four hours (as described in section 
2.1.2 and 2.3.2). Doses of 30mg/kg and 60mg/kg GSK2617971A were selected based on data generated 
in previous GSK2617971A single-dose tolerability studies where dose-limiting clinical signs were noted 
in a proportion of animals dosed with 60mg/kg GSK2617971A at approximately 5 hours post-dose and 
30mg/kg appeared well tolerated. The aim of the investigation was to follow-up on the acute toxicity 
noted with the 60mg/kg dose and investigate any underlying functional effects in the well-tolerated 
30mg/kg animals.  Four hours was selected as the time point in order to induce the desired mitochondrial 
effects whilst minimising in-life effects.  
 
Clinical Signs  
All animals given 60mg/kg GSK2617971A showed clinical signs between 2-4 hours post dose which 
included slight to moderate piloerection, subdued behaviour, salivation and partially closed eyes. 
Although not quantifiable, there appeared to be a strong correlation between the severity of clinical 
observations at the time of necropsy, and the plasma concentration of GSK2617971A. Rapid increase in 
body temperature was noted in all animals treated with 60mg/kg approximately 1.5 hours post dose with 
body temperature continuing to rise by 2.68°C on average by 4 hours post dose. No increase in body 
temperature or clinical signs were observed in the two animals dosed with 30mg/kg GSK2617971A up to 
4 hours. Similar to observations made in chapter 3 (relating to decline in body temperature following 
exposure to GSK932121A), the peak increase in body temperature following GSK2617971A 
administration was closely associated with the terminal plasma concentration of GSK2617971A (R
2 
= 
0.8198) (Fig.6.3) and the two animals at 30mg/kg that did not show an elevated body temperature had 
lower plasma concentrations of GSK2617971A. 
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FIGURE 6.3: Relationship between core body temperature and plasma GSK2617971A concentration.  The relationship is 
shown between increase in core body temperature (expressed as increase in body temperature compared to a 
pre-dose measurement) post treatment with GSK2617971A and plasma drug concentration. Two circled data-
points correspond to animals treated with 30mg/kg dose (n=2) where no significant increase in body 
temperature was observed (<0.5°C increase). 60mg/kg (n=6) corresponds to un-circled data points (one animal 
not displayed due to being found moribund – no sample available for concentration analysis). (R2=0.8198, 
p<0.001) 
 
Lactate: Pyruvate 
A significant increase in lactate:pyruvate ratio was observed in whole blood of animals given 60mg/kg 
GSK2617971A compared to blood from VC animals (p<0.01**) (Fig.6.4). GSK2617971A, dosed at 
60mg/kg, caused a 135.3% increase in lactate:pyruvate ratio which is indicative of increased glycolytic 
metabolism.  No effect on lactate or pyruvate was noted in animals dosed at 30mg/kg GSK2617971A 
which, when taken into consideration with the lack of clinical signs/body temperature change, indicate 
that 30mg/kg was a tolerated dose up to 4 hours in the present study. 
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FIGURE 6.4: Effect of GSK2617971A treatment on blood lactate: pyruvate ratio compared to VC. Treatment of rats with 
60mg/kg GSK2617971A causes an increase in lactate/pyruvate ratio (in whole blood) compared to VC blood 
samples (p<0.01**, n=6, mean ± sd). No effect on lactate: pyruvate ratio was observed in animals treated with 
30mg/kg GSK2617971A (n=2, mean ± range) compared to VC (p>0.05).    
 
Changes to Mitochondrial Ultra-structure in the Kidney (TEM Analysis) 
TEM was employed to assess the effect of OXPHOS uncoupling on mitochondrial ultra-structure and 
general cell architecture. Small block sections of liver (median lobe) and kidney (cortex) tissue were fixed 
in 4% formaldehyde/1% glutaraldehyde, although adverse fixation artefacts prevented the reading of liver 
micrographs.  
 
Treatment related effects were observed in kidney cortex tubular epithelial cells (Fig.6.5). Minimal to 
mild mitochondrial swelling and increased lysosomal activity/residual bodies, many of which contained 
mitochondrial-fragments (suggesting induction of mitophagy) were observed in 60mg/kg GSK2617971A 
treated animals in comparison to VC (arrowed). Furthermore, disorganisation of the congregated 
mitochondrial networks was noted and this is especially visible when comparing Fig.6.5B with Fig.6.5D.  
No ultra-structural effects were observed in animals treated with 30mg/kg GSK2617971A (images not 
shown). 
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FIGURE 6.5: TEM analysis of kidney sections of rats treated with 60mg/kg GSK2617971A and VC. Panels A and B 
(10,000x & 25,000x magnification, respectively) show mitochondria from VC animal, with intact membrane 
structure and normal histology. Note the orderly arrangement of mitochondria within the tubular epithelium. 
Panels C and D (10,000x & 15,000x magnification, respectively) show mitochondria from GSK2617971A 
treated animals (60mg/kg) which appear mildly swollen. Increased lysosomal activity is also observed in these 
treated animals, highlighted by an increase in the number of residual bodies (depicted by red arrows). 
Disorganisation of mitochondrial networks / arrangement is also visible in treated sections.  
 
6.2.3. ACUTE DOSE IN VIVO STUDY WITH GSK2617971A – MITOCHONDRIAL ENDPOINTS 
Following administration of GSK2617971A (30mg/kg and 60mg/kg) or VC to Crl:Wi (Han) rats, 
mitochondrial fractions were isolated from the left lateral liver lobe and left kidney using methods 
described in section 2.8.1. 
 
 
 
 
A B 
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OCR Assessment (Seahorse Bioscience) 
Mitochondria isolated from the liver and kidney of animals given 30mg/kg GSK2617971A showed no 
significant change in OCR compared to VC (data not shown). 
 
In contrast to the increase in OCR observed following treatment of mitochondria isolated from a naive rat 
with GSK2617971A in vitro (Fig.6.1), mitochondria isolated from the kidney of rats treated in vivo with 
GSK2617971A showed a reduction in basal OCR by an average of 27.1% compared to VC (Fig.6.6 A 
and B). A significant reduction in OCR was further observed at state 3 (33.9% reduction), state 4 (25.8% 
reduction) and maximal (state 3u) respiration (38.7% reduction).  
 
No significant effect on OCR was observed in mitochondria isolated from the liver of GSK2617971A 
(60mg/kg) treated rats compared to VC (Fig.6.6 C and D).  
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FIGURE 6.6: Analysis of kidney and liver mitochondrial bioenergetics using the Seahorse XF24 analyser following 
treatment of rats with GSK2617971A in vivo. (A) Representative OCR data for mitochondria isolated from 
the kidney of animals treated with GSK2617971A (grey line) or VC (black line). (B) GSK2617971A treatment 
(grey bars) caused a reduction in  basal, state 3, state 4o and state 3u respiration in the kidney compared with 
VC (black bars). (C) Representative OCR data for mitochondria isolated from the liver of animals treated with 
GSK2617971A (grey line) or VC (black line). (D) GSK2617971A had no effect on OCR at any respiratory state 
in the liver compared to VC (p>0.05). Results shown are mean ± SD (GSK2617971A treated, n=6 and VC, 
n=8). *p<0.05, ** p<0.01, *** p<0.001. 
 
The data shown in Fig.6.6 above was striking as mitochondrial uncouplers typically cause an increase in 
OCR when treated directly (in vitro and ex vivo treatment) whereas mitochondria isolated from 
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GSK2617971A (liver and kidney) showed either no response or a reduction in OCR. One potential 
hypothesis for this is that GSK2617971A may have been washed out of the mitochondrial preparations 
during the isolation procedure and therefore had limited effects in these isolates. For this to be the case 
however, we must assume that the effects of OXPHOS uncoupling on CRC and mitochondrial ΔΨ are 
more persistent and are irreversible (or only very slowly reversible) upon removal of the drug. Though 
further work is required, the data shown in Fig.6.7 confirms that the effect of GSK2617971A on OCR 
(using Seahorse Bioscience technology) in vitro, can be reversed upon removal of the drug (i.e. the drug 
and its effect can be “washed out”). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6.7: Reversibility of the uncoupling effect of GSK2617971A demonstrated in vitro in HepG2 cells. HepG2 cells 
were exposed to increasing doses of GSK2617971A (0.1-10µM) and a biphasic dose response was observed on 
basal OCR with a maximal respiratory rate noted at 1µM. Cells were then removed from the analyser, washed 
with PBS and the medium was replaced with Seahorse XF assay medium minus GSK2617971A. Removal of 
the compound reversed the uncoupling effect previously observed and no effect was observed in comparison 
with the 0.1% DMSO control. Data shown is mean ± SD (n=3). 
 
Mitochondrial Membrane Potential 
In order to further assess the effect of GSK2617971A on the ETC, mitochondrial ΔΨ was assessed using 
JC-1 dye. This dye concentrates and aggregates in the mitochondrial matrix. Any event that dissipates the 
ΔΨ (e.g. membrane damage or uncoupling) causes the dye to disperse out of the mitochondrial matrix and 
form green fluorescent monomers. This change in fluorescence can be detected in a multi-plate format 
fluorometrically.  
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A significant reduction in ΔΨ was observed in mitochondria isolated from the liver and kidney of animals 
treated with both 30mg/kg and 60mg/kg GSK2617971A compared to VC (Fig.6.8). At 60mg/kg (n=6, 
p<0.001) a 17.4% reduction in ΔΨ was observed in liver mitochondria and a 15.5% reduction was 
observed in kidney mitochondria, meanwhile 30mg/kg (n=2) reduced ΔΨ by 30.7% (p<0.01) and 25.5% 
(p<0.001) respectively.  
 
This effect was observed despite the absence of any increase in OCR being observed in the Seahorse 
BOFA assay in these two tissues (Fig.6.6). An increase in OCR would have been expected in any 
mitochondria with a loss of ΔΨ due to increased ETC activity to drive proton motive force. This suggests 
that the JC-1 mitochondrial ΔΨ assay is more sensitive in terms of detecting changes in ΔΨ caused by the 
MOA of an OXPHOS uncoupler, compared to the Seahorse Bioanalyser. 
 
 
 
 
              
 
 
 
 
 
 
FIGURE 6.8: Analysis of mitochondrial ΔΨ (JC-1) in liver and kidney mitochondria from animals treated with 
GSK2617971A compared to VC. A significant reduction in mitochondrial ΔΨ was noted in mitochondria 
isolated from the liver and kidney of both 30mg/kg (n=2, mean ± range, clear bars) and 60mg/kg (n=6, mean ± 
SD, grey bars) GSK2617971A treated animals compared to VC (n=8, mean ± SD, black bars) is plotted. p<0.01 
**, p<0.001 ***   
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Calcium Retention Capacity 
Mitochondria isolated from the liver and kidney of GSK2617971A treated animals had a decreased level 
of CRC compared to VC (Fig.6.9). These data are consistent with findings generated in vitro which show 
that GSK2617971A directly reduced the CRC of naïve mitochondria from control animals (Fig.6.2).  
 
Mitochondria isolated from the kidney of GSK2617971A treated animals showed a significant reduction 
in CRC compared to VC animals. This reduction occurs in a dose dependent manner with 30mg/kg 
provoking a 38% reduction (p<0.001***), whilst 60mg/kg reduced the CRC by 55.2% (p<0.001***) 
(Fig.6.9). The reduction in CRC in the kidney appears to be as a result of earlier potentiation of mPTP 
triggering following calcium pre-loading. 
 
Similarly, mitochondria isolated from the liver of GSK2617971A treated animals (dosed at both 30mg/kg 
and 60mg/kg) also showed a reduced CRC compared to mitochondria isolated from VC animals, reducing 
the CRC by 66.6% and 65.8% respectively (Fig.6.9). The data shows a similar degree of inhibition in 
calcium uptake between 30mg/kg and 60mg/kg despite no evidence of body temperature increase, clinical 
signs, lactate generation or mitochondrial ultra-structure changes in animals given 30mg/kg 
GSK2617971A.  
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FIGURE 6.9: Analysis of mitochondrial CRC in kidney and liver mitochondria isolated from GSK2617971A treated rats 
and VC. Mitochondria isolated from the kidney (A) and liver (B) of rats treated with 30mg/kg GSK2617971A 
(light grey, n=2) and 60mg/kg GSK2617971A (orange, n=6), showed a statistically significant reduction in 
average CRC (calculated as the ΔOD between the point of energising with succinate and mitochondria 
undergoing calcium induced permeability transition) compared to VC (black, n=6). Tables show average 
(±SD/Range) delta OD along with % reduction compared to VC. p<0.001***  
 
 
 
Kidney Mitochondria 
Group Delta 
OD 
(A650) 
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Standard 
Deviation  
(A650) 
% 
Reduction 
Statistical 
Significance 
Control 0.76 0.21 - - 
30mg/kg 0.47 Range: 
0.15 
38.04 *** 
60mg/kg 0.34 0.03 55.21 *** 
Liver Mitochondria 
Group Delta 
OD 
(A650) 
± 
Standard 
Deviation  
(A650) 
% 
Reduction 
Statistical 
Significance 
Control 0.51 0.09 - - 
30mg/kg 0.17 Range: 
0.006 
66.60 *** 
60mg/kg 0.18 0.01 65.77 *** 
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6.2.4. IDENTIFYING MECHANISMS OF TOXICITY FOLLOWING OXPHOS UNCOUPLING IN VIVO 
USING TRANSCRIPTOMICS 
 
Global transcriptomic assessment was performed in the liver of GSK2617971A treated animals. The liver 
was chosen for analysis due to the effects observed in this organ in terms of reduction in CRC and ΔΨ 
and to allow comparative analysis to be undertaken between the gene expression signatures downstream 
of both OXPHOS uncoupling (GSK2617971A – present chapter) and complex III inhibition 
(GSK932121A- chapters 3-5).  The aim of the transcriptomics was to identify downstream pathways or 
cellular functions which are differentially affected by drug-induced OXPHOS uncoupling, compared to 
VC and build these into an AOP. It was also hoped that early marker genes of OXPHOS uncoupling 
activity might be identified. 
 
GSK2617671A dosed at 30mg/kg caused 1250 gene transcripts to be differentially expressed (1.5 fold ±, 
p<0.05) compared with VC of which 452 (36.16%) were protein coding. Despite the onset of severe 
toxicity occurring at a dose of 60mg/kg GSK2617971A, fewer genes were differentially altered compared 
to VC. 60mg/kg GSK2617971A caused the increase or decrease of 1019 gene transcripts (1.5 fold ±, 
p<0.05) with 271 of those transcripts (26.59%) mapped to protein coding genes. Table 6.1 below shows 
the direction of change in expression of protein coding genes across the study.  
 
Direction of Change 30mg/kg GSK2617971A 60mg/kg GSK2617971A 
Increased 169 (37.39%) 175 (64.58%) 
Decreased 283 (62.61%) 96 (35.42%) 
TABLE 6.1: Direction of change in protein coding gene expression in GSK2617971A treated rat livers. 
 
PCA analysis of the data was performed using Qlucore Omics Explorer (OE) 3.0. 64-bit (Qlucore, Lund, 
Sweden). The entire raw data set (following normalisation by the RMA method) was incorporated into 
Qlucore OE and a PCA plot was generated (Fig.6.10A). This was based on data variance observed across 
the entire array and limited separation of the data was visible (i.e. the PCA was unable to identify 
principal components which suitably explain the variation of the raw data). 
 
Qlucore OE facilitates the user to adapt the statistical parameters from a lenient to stringent statistical 
significance, and identify the genes that best separate the experimental variables Qlucore OE is therefore 
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a useful tool both to identify the key components within large gene expression data sets (i.e. the most 
significantly affected genes in terms of separating control vs treatment) and to visualise this effect within 
a dynamic-PCA plot in real time. 
 
A multi-group statistical comparison was employed between both 30mg/kg and 60mg/kg groups versus 
the VC with the aim of separating GSK2617971A treatment (for both dose groups) in terms of the top 30-
40 gene transcripts. The user is then able to view the corresponding effect on the PCA plot (Fig.6.10B). 
Using a variance level of 0.29, p≤0.05 and fold-change of 1.5x reduced the number of significant 
variables to 67 of which 32 were protein coding genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6.10: PCA analysis of global hepatic transcriptional data pre and post statistical refinement. (A)  PCA analysis of 
the full raw data set which shows limited separation between VC (black circles), 30mg/kg GSK2617971A 
(orange circles) or 60mg/kg GSK2617971A (grey circles). (B) Qlucore OE permits the user to adjust the 
statistical stringency of the data-set. Upon refining the data (0.29 variance, p<0.05 and 1.5 fold change in 
expression), only the most statistically significant gene expression changes are included in the PCA analysis 
thus producing a more robust separation of control and treated data. Such analysis reduced the number of 
significantly affected variables to 67, of which 32 were protein coding transcript (used in subsequent pathway 
analysis).  
 
The 32 most statistically important protein-coding genes identified to best separate GSK2617971A 
treatment from control (as determined by PCA analysis) were then selected for IPA analysis with the aim 
of identifying key biological themes characteristic of GSK2617971A toxicity (as pathway analysis is 
unbiased the theme analysis is not simply reflective of OXPHOS uncoupling). It was decided to input 
B A 
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only the top most statistically significant genes into pathway analysis as submission of all genes 
differentially expressed following GSK2617971A produced an unspecific pathway prediction (biased 
towards most studied transcriptional responses e.g. tumourgenesis and neurodegenerative disorders). The 
gene list was filtered by IPA based on known biological function and mapped into interaction networks 
which were ranked quantitatively. These networks indicate functional association between genes which 
were affected by GSK2617971A treatment and other known genes within a biological pathway (Table 6.2 
below). This functional association is ranked by score with the top three biological functions associated 
with each gene network provided. 
 
 
Network 
Rank 
Genes in Network Score Focus Genes Biological Function 
 
1 ADRB, Alp,ATF3, Cyclin A, CYP1A1, ERK1/2, 
estrogen receptor, G0S2, GADD45B, GOT, GOT1, 
Hdac, HSPB1, HSPH1, IGFBP1, IgG, IL1, IRS2, 
JUN, KLF6 LDL, LPIN1, MAP2K1/2, MEF2, mir-
122, MT1E, PDGF BB, PEPCK, PPARGC1A, 
RGS16, RNA polymerase II, SIK1, SLC38A2, 
thyroid hormone receptor, Tnf (family) 
47 16 Cell Death and 
Survival, Lipid 
Metabolism, 
Molecular 
Transport 
2 ACOT13, AIP, CCDC64B, CHAC1, CHP1, CMSS1, 
CTDNEP1, DAG1, ECI2, ETHE1, GCKR, Gstm3, 
HNF4A, MEF2BNB-MEF2B, MID1, MID1IP1, 
MT1E, MT1H, NDUFA1, NDUFB5, NDUFV1, 
NECAP1, NUF2, P4HA1, POR, PPP1R3B, PWP1, 
RAB30, SDS, SLC30A7, SRP19, TMC6, TRIP11, 
TRMT61B, UBC 
15 8 Cell Death and 
Survival, Cellular 
Assembly and 
Organization, 
Cellular 
Compromise 
3 ADRA2A, Akt, BTG2, CDKN2D, Cebpd, Cg, 
CYP17A1, ERK, FSH, GPC1, Histone h4, Igf, 
Insulin, Interferon alpha, Jnk, lipoxin A4, Mapk, 
MT1E, NFkB (complex), P38 MAPK, Pdgf 
(complex), PDK4, PI3K (complex), Pka,Pkc(s), 
PTP4A1, RGS16, S1PR1, SRC (family), TCR, 
TNFAIP2, tyrosine kinase, USP18, vitamin K1 
15 6 Cell Morphology, 
Cellular 
Development, 
Molecular 
Transport 
 
TABLE 6.2: IPA network analysis (biological theme analysis) of top 32 protein coding genes differentially altered in 
response to GSK2617971A (30 and 60mg/kg). Direction of change is indicated by colour (Red= increased, 
Green = decreased). Genes not coloured red or green have known (experimentally proven) interactions with 
other members of the network. Scores are calculated from p-values (-log10p) and equate to the likelihood of the 
focus genes (differentially changing in response to GSK2617971A treatment) being associated by chance. 
Biological function indicates the top three biological themes corresponding to each network.  
 
The top ranked network (due to the high score value, i.e. low likelihood that focus genes changing in 
GSK2617971A treated livers are associated in the network due to chance) relates to cell death and 
survival, lipid metabolism and molecular transport cell functions. Biological functions which were 
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inferred with less confidence by second and third ranked networks also include cell death / survival, effect 
on cell morphology, cellular compromise and cellular development. 
 
Changes in genes such as Atf3, Irs2, Lpin1 and PGC1α (incorporated in the top rank network) were also 
observed following GSK932121A treatment (shown in chapter 3) and this may be suggestive of 
mitochondrial-toxicity signature genes. This concept will be explored further in chapter 7.  
 
The 32 most significant protein coding transcripts which were altered by GSK2617971A treatment were 
subjected to an IPA-Tox analysis (Table 6.3). This analysis compares the user’s gene signatures with 
other sets of genes known to change when perturbed by particular compounds and go on to provoke 
downstream pathology. The IPA-Tox-analysis describes adaptive, defensive, or reparative responses to 
xenobiotic insult and was used to better understand the potential tox specific downstream pathways, as 
suggested by gene expression analyses. Table 6.3 below includes a column which, where applicable, links 
the toxicological pathways generated by IPA (and indicative of the gene signatures differentially altered) 
to relevant observable effects which occurred in the current study and are presented in the current chapter. 
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TABLE 6.3: IPA-Tox analysis of top 32 protein coding genes differentially altered in response to GSK2617971A. Top 20 
toxicity pathways or functions linked to the 32 gene signatures inputted following GSK2617971A treatment (30 
& 60mg/kg). –log(p-value) shows significance that the focus gene is not simply included in the toxicity 
pathway by chance. The ratio refers to the ratio of focus genes compared to total number of genes in the toxicity 
pathway (IPA database). These ratios are low but this is largely due to the fact only 32 transcripts were 
submitted for analysis. Any toxicity pathways arising from IPA-Tox analysis which is supported by other 
observations in this chapter are shown in orange with supporting evidence described.   
Ingenuity Tox Lists -log (p-value) Ratio Focus genes Observable link to current study? 
 
Acute Renal Failure Panel 
(Rat) 5.23E00 6.45E-02 
JUN, ATF3, 
IGFBP1, MT1E 
Evidence of renal toxicity (CRC, 
OCR, TEM,  ΔΨ ) 
Liver Necrosis/Cell Death 3.92E00 1.85E-02 
JUN, GADD45B, 
IGFBP1, MT1E, 
PPARGC1A 
Evidence of hepatic mitochondrial 
toxicity (CRC and  ΔΨ ) 
Nongenotoxic 
Hepatocarcinogenicity 
Biomarker Panel 3.06E00 9.09E-02 BTG2, MT1E No relevant measurement 
Renal Proximal Tubule 
Toxicity Biomarker Panel (Rat) 2.91E00 7.41E-02 IGFBP1, HSPB1 
Evidence of renal toxicity (CRC, 
OCR, TEM,  ΔΨ ) 
Aryl Hydrocarbon Receptor 
Signalling 2.57E00 1.88E-02 
CYP1A1, JUN, 
HSPB1 No relevant measurement 
PXR/RXR Activation 2.31E00 2.99E-02 
IGFBP1, 
PPARGC1A No relevant measurement 
Liver Proliferation 2.14E00 1.39E-02 
JUN ,IGFBP1, 
MT1E No pathology available 
Increases Liver Steatosis 2.1E00 2.74E-02 
LPIN1, 
PPARGC1A No pathology available 
 
p53 Signalling 2.01E00 2.02E-02 JUN, GADD45B No relevant measurement 
 
Hepatic Fibrosis 1.86E00 2.08E-02 mir-122, IGFBP1 No pathology available 
Decreases Permeability 
Transition of Mitochondria and 
Mitochondrial Membrane 1.85E00 1.43E-01 BTG2 
Decrease in CRC noted in vitro and in 
vivo 
Mechanism of Gene Regulation 
by Peroxisome Proliferators via 
PPARα 1.85E00 2.11E-02 JUN, PPARGC1A No relevant measurement 
Genes Downregulated in 
Response to Chronic Renal 
Failure (Rat) 1.75E00 1E-01 CYP1A1 
Evidence of renal toxicity (CRC, 
OCR, TEM,  ΔΨ ) 
FA Metabolism 1.74E00 1.69E-02 CYP1A1, SDS 
Increased levels of lactate (likely 
corresponding effect on lipid 
metabolism) 
Decreases Respiration of 
Mitochondria 1.7E00 9.09E-02 MT1E 
Decrease OCR in kidney 
mitochondria 
 
Increases Renal Proliferation 1.66E00 1.56E-02 JUN, MT1E No relevant measurement 
Cytochrome P450 Panel - 
Substrate is a Xenobiotic 
(Human) 1.56E00 5E-02 CYP1A1 No relevant measurement 
Increases Depolarization of 
Mitochondria and 
Mitochondrial Membrane 1.53E00 5.88E-02 BTG2 
Evidence of depolarization in kidney 
and liver mitochondria (MMP) 
Cardiac Hypertrophy 1.52E00 8.04E-03 
JUN, ATF3, 
PPARGC1A 
No pathology or other relative 
assessments available 
Cardiac Fibrosis 5.43E-01 5.52E-03 ATF3 
No pathology or other relative 
assessments available 
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Of the top 20 pathways generated via IPA-Tox analysis (with the 32 protein coding genes most 
significantly altered by GSK2617971A treatment used as the comparator), 8 of the pathways could be 
supported by other experimental data presented in this chapter (40%). In these cases many of the 
pathways identified by this method were very specific to the experimental data generated (e.g. decreases 
in permeability transition of mitochondria and increased depolarisation of mitochondria). Caution must 
however be advised as many of these Tox-pathway predictions are based on alterations in just a single 
gene. Furthermore, this analysis is not suggesting that gene expression data in one tissue can predict a 
toxic effect in another, just that (as a resource for toxicologists) the IPA-Tox analysis can identify gene-
signatures which are suggestive of certain toxic effects, independent of the tissue or organ. In the present 
studies these suggestions were deemed fairly predictive and were substantiated by functional endpoints.  I 
believe further studies of this kind are required in order to better assess the true utility of the IPA package.  
  
These data do however suggest that if the genes inputted for IPA analysis are first filtered to only the 
most significant (i.e. in terms of separating control versus treatment) then the output from pathway 
analysis appears to be more robust. 
 
6.3. Discussion 
Uncouplers of OXPHOS are a common class of mitochondrial toxicant seen in pre-clinical screening 
[211]. Despite this, few studies have been reported which detail the AOP arising from drug-induced 
OXPHOS uncoupling in vivo. Since they are a common class of mitochondrial toxicant, it is important to 
understand their toxicological effect in vivo, in order to better advise discovery groups of the potential 
risk involved with progressing such molecules and offer strategies to manage their development when 
required. This is especially important considering OXPHOS uncouplers are considered attractive 
therapeutic agents for the treatment of many disorders [212] including  non-alcoholic fatty liver disease 
[213], type 2 diabetes [214], ischemia reperfusion injury [215] and acute neurological injury [216]. 
 
To provide a benchmark for the evaluation of in vitro assays of mitochondrial dysfunction, the present 
study investigated the MOA of the acute toxicity caused by an uncoupler of OXPHOS in rats. To 
facilitate the assembly of an AOP, a single administration (mid and high dose) study which was likely to 
cause an adverse outcome was performed in male Crl:Wi (Han) rats, and a systems approach was used to 
detect downstream consequences.  
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Uncouplers of OXPHOS have been shown to cause hyperthermia in vivo. An example of this is the 
hyperthermic response caused by 2,4-DNP which has been linked to fatal incidences in recent years 
following the use of DNP as a dieting aid [149, 217, 218]. Hyperthermia has also been reported in vivo 
following administration of other known uncouplers such as tolcapone [219]. This is not unexpected 
considering uncoupling of OXPHOS is the fundamental mechanism of non-shivering thermogenesis in 
brown adipose tissue [220]. Uncoupling proteins (UCP’s), specifically UCP1 (or thermogenin), decrease 
the proton gradient generated by the ETC by increasing the permeability of the IMM to protons [221, 
222].  In the present study, hyperthermia was an early consequence of treatment of rats with 
GSK2617971A, the magnitude of the response correlating well with plasma levels of the drug suggesting 
that drug-induced OXPHOS uncoupling is the primary cause of increased thermal energy generation. 
Interestingly however, no effect on body temperature was noted at 30mg/kg GSK2617971A, despite 
abnormalities in mitochondrial function noted at this dose. This observation is suggestive that OXPHOS 
related hyperthermia is downstream in the AOP from mitochondrial effects such as reduction in ΔΨ and 
CRC. It is likely that compensatory mechanisms are able to maintain whole body temperature regulation 
following milder mitochondrial uncoupling and heat generation is confined to the tissue-level during the 
early stages.  
 
As discussed, 30mg/kg GSK2617971A did not affect either body temperature or provoke adverse clinical 
signs up to four hours post dose but did cause a marked and statistically significant reduction in CRC and 
ΔΨ in the liver and the kidney (also observed at 60mg/kg). Firstly, it is important to acknowledge that all 
observations with 30mg/kg require validation because of the low number of experimental repeats (due to 
study circumstances beyond control). Having said this, samples obtained for all endpoints at 60mg/kg 
were taken at a time-point where the animals showed clinical signs but those at 30mg/kg were obtained 
from animals which were to all appearances normal. This highlights that endpoints significantly altered 
with a 30mg/kg dose (i.e. CRC and ΔΨ) are representative of underlying sub-toxic DIMT and that 
endpoints significantly affected by the 60mg/kg dose group may be attenuated with the high level of 
toxicity. Furthermore, this surprising observation suggests that membrane depolarisation and impaired 
CRC does not necessarily cause an adverse clinical reaction and that these events most certainly occur at 
lower toxicity (dose) levels than the observed increases in body temperature and effects on mitochondrial 
ultra-structure. 
 
Induction of MPT has been noted with other compounds with known uncoupling activity such as the 
selective serotonin reuptake inhibitor sertraline [223] and the tyrosine kinase inhibitor regorafenib [224], 
with both groups speculating that MPT induction was a key mechanism of hepatocyte injury. Further 
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work should explore whether reduction in CRC and ΔΨ observed in mitochondria isolated from animals 
treated with 30mg/kg GSK2617971A is recoverable at later time points (i.e. due to turnover of the 
mitochondrial pool through dynamic processes such as mitophagy and biogenesis) or whether a dose of 
30mg/kg provokes adverse toxicity following repeated administrations. The present study does however 
show a correlation between observations made in vitro and in vivo and demonstrates the potential utility 
of the CRC assay, both as a potential screening aid and as an early marker of mitochondrial uncoupling. 
One difficulty in assessing uncoupling-induced effects on OCR is the bell-shaped nature of the dose 
response. A valid hypothesis for the limited effects observed in response to GSK2617971A treatment 
using the Seahorse Bioanalyser is that the concentration of the drug in the plasma was high (~270µM and 
~540µM with 30mg/kg and 60mg/kg respectively) and this high concentration is likely to be represented 
in the tissues (drug tissue concentration data not available). The peak uncoupling response in vitro (in 
terms of OCR) was observed at just 1µM and concentrations above this were toxic to the respiratory 
chain.  
 
Another feasible hypothesis is that GSK2617971A may have been washed out of the mitochondrial 
preparations during the isolation procedure and therefore has limited effects in these isolates. For this to 
be the case however, we must assume that the effects of OXPHOS uncoupling on CRC and mitochondrial 
ΔΨ are more persistent and are irreversible (or only very slowly reversible) upon removal of the drug. 
Data presented in this chapter (Fig.6.7) does however show that the effect of GSK2617971A can be 
reversed upon removal of the drug; however this experiment was performed in vitro and further work is 
required. This analysis does however raise questions about the utility of assessing direct effects on 
mitochondrial function in in vivo studies by subcellular fractionation, although this “wash out” effect 
would not apply to all compounds and other endpoints (e.g. CRC) look to be persistent. This observation 
is however pertinent when considering it amongst other compromises already associated with isolating 
mitochondria (i.e. representative of in vivo scenario, structural damage etc). Novel methods, such as using 
primary cell isolates, and in vivo biomarkers, should continue to be evaluated as better ways of assessing 
the effects of mitochondrial toxicants in vivo are sought.  
 
An increase in lactate:pyruvate ratio was observed at 4 hours post-dose with 60mg/kg GSK2617971A. 
Lactic acidosis has previously been noted following administration of uncouplers both in vitro and vivo 
[225, 226]. Lactate is known to be a biomarker of mitochondrial dysfunction in vivo as energy 
metabolism is switched to glycolysis in attempts to maintain ATP levels following perturbation of 
OXPHOS, to the detriment of increased levels of local lactate generation (also shown in chapters 3-5 
following complex III ETC inhibition). Alongside increases in lactate:pyruvate ratio, mitochondrial ultra-
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structural observations were also observed at 60mg/kg (although unfortunately data was not obtained in 
the liver). Ultra-structural observations noted in the present study were comparable to those induced in 
vivo by the classical mitochondrial uncoupler 2,4-DNP [227] and the mild uncoupler, indomethacin [228]. 
When noted in preclinical studies, these observations (mitochondrial swelling and disorganisation of 
mitochondrial networks) should in the future, alert drug safety scientists to the possibility that the 
compound may have functional effects on mitochondria and thus prompt further investigations. 
As there was no effect observed on lactate:pyruvate ratio or mitochondrial ultrastructure at 30mg/kg, it 
appears these endpoints are only affected in conjunction with the adverse outcome and not at sub-toxic 
doses (this will be further explored in chapter 7). Importantly however, as functional changes (such as 
reduction in both ΔΨ and CRC) were observed in mitochondria isolated from 30mg/kg GSK2617971A 
treated animals, we can say that increases in blood lactate and alterations in mitochondrial ultra-structure 
occur downstream in the AOP.  This may suggest that the point at which lactate is raised in whole blood 
and/or when mitochondrial ultra-structure becomes affected, might be key pathological events 
underpinning the onset of adverse clinical signs following OXPHOS uncoupling.  
 
Microarray analysis was used to identify downstream pathways or cellular functions which were 
differentially affected by GSK932121A treatment. Statistical parameters were adopted which helped to 
reduce the number of differentially expressed genes to the top 32 most significant for separating the 
experimental variables. These 32 genes were then subjected to both biological theme and IPA-Tox 
analysis. Biological theme analysis identified that a number of genes affected by GSK2617971A 
uncoupling belong to a network of transcripts involved in cell death and survival.  Kuruvilla and 
colleagues in 2003, explored the molecular events downstream of OXPHOS uncoupling in vitro and they 
observed comparable transcriptional patterns with FCCP as observed here with GSK2617971A [229]. 
They suggest that an early consequence of uncoupling is DNA damage, characterised by changes in genes 
such as Gadd153, Gadd45, p21/Waf1 and Fas, with consequences observed on cell cycle control and cell 
death at later time points. These data correspond to gene expression data / biological theme analysis in the 
present study which demonstrates transcriptional activation of genes such as Gadd45b and Jun alongside 
identification of gene networks involved in cell death (although no absolute measure of cell death was 
made). This observation opens up the possibility that the mechanisms underlying FCCP and 
GSK2617971A toxicity may be comparable. Meanwhile, IPA-Tox analysis identified specific 
toxicological events which correlated well to other functional data within the present study (e.g. 
membrane depolarisation and reduction in mitochondrial respiration). Importantly however the levels of 
confidence in these analyses are questionable when toxicological themes are generated based on alteration 
of single genes.  
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Overall, data presented in this chapter (alongside evidence reported in the literature with other tool 
mitochondrial uncouplers e.g. 2,4-DNP) enabled the assembly of a proposed AOP/MOA for OXPHOS 
uncoupling in vivo (Fig.6.11). Whilst some endpoints do not fully-fit the AOP/MOA framework outlined 
in chapter 5 (i.e. not measurable, causally related or too broad e.g. generalised mitochondrial 
insufficiency) this is a starting point for further refinement in more focussed future studies. This AOP can 
be referred to when molecules with uncoupling activity are identified in vitro, in order to aid selection of 
the most robust endpoints for in vivo assessment or to better understand the potential safety liabilities of 
this class of mitochondrial toxicant. 
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FIGURE 6.11: Proposed AOP/MOA for mitochondrial OXPHOS uncoupling in vivo.  Events which are supported by 
experimental data presented in this chapter (for GSK2617971A) and which are generally not reported (or are 
under-reported) in the literature, are shown in blue boxes. Events which are reported widely in the literature for 
OXPHOS uncouplers but which were either not observed or measured in the present study are shown in orange 
boxes. Clear boxes show endpoints which are acknowledged in the literature and were observed in the present 
study.  It is anticipated that various key events in the AOP have consequences on uncoupling-induced toxicity 
but in general it is considered that ATP depletion increased body temperature, increased substrate oxidation and 
lactic acidosis are the primary causative factors. 
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6.4. Summary 
To summarise, GSK2617971A was toxic when dosed at 60mg/kg to rats, with hyperthermia and adverse 
clinical signs observed at 4 hours post-dose. A dose of 30mg/kg was well tolerated despite functional 
changes in mitochondria being observed (reduction in ΔΨ and CRC), highlighting the utility of these 
endpoints as possible early markers of mitochondrial uncoupling at sub-toxic doses.  
 
In general, data generated in vivo correlated well with that produced by in vitro investigations suggesting 
utility of these approaches for screening of uncoupling agents. The exception was the decrease in OCR 
observed in mitochondria isolated from the kidney of rats treated with 60mg/kg GSK2617971A in vivo, 
compared with the increase in OCR observed when control isolated mitochondria were treated directly 
with GSK2617971A in vitro (although potential reasons for this discrepancy have been highlighted). At 
higher doses, mitochondrial uncoupling caused ultra-structural changes to mitochondria in the kidney, 
although analyses in other tissues are required. In addition there was an increase in blood lactate, 
reflecting attempts to maintain ATP levels via glycolysis. It is likely that these effects, together with acute 
hyperthermia are the principal causes of the acute toxicity observed downstream of OXPHOS uncoupling 
in vivo.  
 
Transcriptomics highlighted activation of gene-networks involved in cell death (although there was no 
confirmation that this was actually occurring) and lipid metabolism with IPA-Tox analysis proving a 
useful tool with regards to predicting toxicological outcomes (many of which were supported by data 
within the study) using a selection of the most statistically significant gene changes. The major limitation 
of IPA-Tox theme analysis was however, that conclusions were based around changes in just a small 
number of genes. This chapter highlights the critical importance of using a systems approach to 
understand and build AOP’s with the use of both higher (toxic) and lower (not overtly toxic) doses to aid 
determination of upstream and downstream (primary/adaptive) effects.  
 
The acute natures of the studies outlined in chapters 3-6 have however made identification of endpoints at 
sub-toxic doses challenging (i.e. measures of underlying un-attenuated DIMT). Chapter 7 below, explores 
potential underlying markers of DIMT both as biomarkers and to differentiate primary from adaptive 
toxicological events.  
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7.0. THE EFFECT OF SUB-CYTOTOXIC CONCENTRATIONS 
OF GSK932121A AND GSK2617971A IN VITRO AND 
COMPARISON WITH A BIOINFORMATICALLY 
SELECTED ‘SIMILAR’ CHEMICAL   
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7.1. Introduction 
Systems toxicology investigations presented in chapters 3-6, have identified a range of endpoints which 
are differentially affected by DIMT, specifically following respiratory chain inhibition and OXPHOS 
uncoupling in vivo and a number of common observations were made. Most notable was a metabolic 
switch to glycolysis, elevation in plasma lactate concentration, ultra-structural effects on mitochondria, 
effects on mitochondrial function and similar patterns of hepatic gene expression including alterations to 
genes involved in cell metabolism and cell stress. Taken together, these changes reflect the metabolic 
adaptation in the liver to drug-induced compromise in ATP synthesis via the ETC / OXPHOS (be this via 
inhibition of the mitochondrial complexes or uncoupling). Even with the use of well-tolerated doses of 
both GSK932121A (12.5mg/kg used in chapter 4) and GSK2617971A (30mg/kg used in chapter 6), a gap 
in the investigations completed to date is the difficulty in distinguishing primary from secondary events in 
the resulting AOP’s for both drugs. Furthermore, it remained to be determined whether the observed 
downstream effects (i.e. the metabolic switch) are specific cellular adaptations following mitochondrial 
perturbation or common stress responses. 
 
To address these questions a study was designed in vivo whereby animals would be killed at progressive 
time points in order to analyse the effect of mitochondrial perturbation at the tissue level and thus 
potentially determine the sequential order in which the key changes take place.  Due to time and practical 
constraints this wasn’t possible. As an alternative, the progression of events was explored in vitro and 
importantly at concentrations of drug which were not grossly toxic to the cells. I was especially interested 
in exploring the narrow window whereby compound-induced alterations in respiratory function were 
observable, prior to the onset of gross cellular cytotoxicity. It was hoped this analysis would help to 
determine both the order in which these fundamental events occur and the utility of in vitro systems in 
terms of replicating the in vivo effects.  
 
Furthermore, I wanted to better understand whether the transcriptional response to GSK932121A and 
GSK2617971A in the liver was similar to that of any other previously studied compound and whether any 
connected compound was a mitochondrial toxicant. It was hoped to identify other reference compounds to 
further study mitochondrial toxicity and determine whether the endpoints being studied are common to 
mitochondrial toxicants or whether they occur in response to compounds with different modes of action.  
 
Importantly the cells used in this chapter were cultured in a media supplemented with galactose rather 
than glucose. Human liver hepatocellular carcinoma cells lines (HepG2) are heavily reliant upon 
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glycolysis for energy production which has been shown to desensitise them to drug-induced 
mitochondrial perturbation (a phenomenon reported in the literature as the Crabtree effect) [106]. This 
effect can be circumvented by conditioning the HepG2 cells in galactose rather than glucose media and 
thus increasing the cells reliance on OXPHOS for ATP-production. This occurs as oxidation of galactose 
to pyruvate yields no net ATP, which forces cells to oxidize pyruvate (via OXPHOS) to survive. This 
model has shown increased sensitivity for detecting drug-induced mitochondrial perturbation in the pre-
clinical setting [230]. This approach does however have certain limitations such as the reduced growth 
rate and changes in the cellular and mitochondrial proteome. 
 
 
7.1.1. EXPERIMENTAL AIMS 
The experimental aims of the work outlined in this chapter were… 
 
1. To identify the concentration range of GSK932121A and GSK2617971A where mitochondrial 
function was compromised in the absence of gross cellular cytotoxicity. Using this narrow 
concentration window would build confidence that any observed effect was due to the 
perturbation of mitochondrial function as opposed to being secondary adaptive consequences to 
cytotoxicity.  
 
2. At the concentrations determined in (1), to assess the impact of DIMT on lactate generation, 
mitochondrial ultrastructure and on a TaqMan gene expression panel consisting of genes pertinent 
to the toxicological response of both compounds in vivo.  Furthermore, to identify the order in 
which these effects occur to be able to determine causal from consequential effects and thus 
validate early molecular events reported in the proposed GSK932121A and GSK2617971A 
AOP/MOAs.  
 
3. To perform connectivity mapping analysis on liver transcriptomics data from GSK932121A and 
GSK2617971A treated animals, and identify novel tool compounds which may mimic the 
biological action of both drugs based on the genes which are differentially altered. Any connected 
compounds would then be screened in the Seahorse analyser to assess any effect on mitochondrial 
function and using the aforementioned in vitro methods to explore mechanistic similarity to both 
GlaxoSmithKline compounds. 
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7.2. Results 
7.2.1. IDENTIFYING EFFECTUAL SUB-CYTOTOXIC CONCENTRATIONS 
The mitochondrial effects of GSK932121A and GSK2617971A were assessed in vitro. Following which, 
any concentration of drug found to affect the mitochondrial (OCR) or glycolytic (ECAR) cellular 
metabolism of HepG2 cells was assessed using a measure of cell viability. The objective was to identify 
concentrations of both compounds which caused metabolic compromise but showed no signs of gross 
cellular cytotoxicity. 
 
GSK932121A – Complex III Inhibition 
Exposure of HepG2 cells to GSK932121A in vitro (n=3) resulted in decreases in key bioenergetic 
parameters, demonstrated using a mitochondrial stress test (Fig.7.1A). The response observed was typical 
of a mid-respiratory chain inhibitor, i.e. reducing the amount of molecular oxygen consumed at 
mitochondrial complex IV via inhibition of the ETC. Statistically significant and concentration-dependent 
reductions in basal respiration and ATP-synthase linked respiration (concentrations of 7.5µM and above) 
were observed alongside a reduction in maximal respiration (concentrations of 0.75µM and above) 
following GSK932121A treatment in vitro (Fig.7.1B). OCR parameters were calculated as described in 
([231]-supplementary). Concentrations of GSK932121A were chosen to match plasma drug 
concentrations achieved in vivo (i.e. up to ~75µM).  With statistically significant effects on respiratory 
chain function noted as low as 0.75µM GSK932121A in HepG2 cells, cytotoxicity was assessed at 
concentrations of 0.75µM and above. 
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FIGURE 7.1: Analysis of HepG2 mitochondrial OCR following acute in vitro treatment with GSK932121A (measured 
using Seahorse XFe96 analyser).  HepG2 cells were treated in vitro with GSK932121A (0.075µM-75µM, 15 
technical replicates per plate) and OCR was assessed. A mitochondrial stress test was then performed in order to 
assess the effect of GSK932121A on key bioenergetic parameters (n=3). (A) A representative graph of OCR 
outputs from the XFe96 analyser of DMSO control (black line) and GSK932121A treated (various colours, 
0.075µM-75µM) and the response to oligomycin, FCCP and Antimycin A /Rotenone (A/R).  (B) Effect of 
GSK932121A on basal respiration, ATP-linked respiration and maximal respiration. OCR parameters were 
calculated as described in ([231]-supplementary). Data shown is mean ± SD (n=3), mid-point OCR. 
Significance stars depict reduction in OCR compared to DMSO control *p<0.05, **p<0.01, ***p<0.001.  
 
Cytotoxicity was assessed using a LDH assay, at an 8 hour time point (Fig.7.2.). LDH leakage and light 
microscopy analyses (not shown) were used as the measures of cytotoxicity in the present study as many 
other cytotoxicity detection assays are in fact measures of mitochondrial activity (e.g.ATP assays, MTT 
Tetrazolium assay) and as such may over-predict cytotoxicity to mitochondrial-acting compounds. This 
time point was selected as subsequent in vitro experiments (section 7.2.2-7.2.4 below) were performed up 
to a maximum of 8-hours post treatment (as I wanted to assess effects due to mitochondrial perturbation 
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using an acute experimental design as all aforementioned in vivo studies involved short periods of 
exposure).  
 
LDH was measured in spent media following an 8 hour treatment with GSK932121A or 0.1% DMSO 
control. 1% (v/v) Triton-X-100 detergent (in cell culture media) was used as a positive control (as 
described by [232]) and data were expressed as a percentage of leaked LDH compared to total LDH 
(calculated from a lysed cell sample prepared used 200µL Cell Lytic per well (Sigma Aldrich, #C2978). 
Significant effect on cell viability was observed at concentrations of 25µM, 50µM and 75µM 
GSK932121A compared to a 0.1% DMSO control (p<0.001, n=3). No effect on LDH leakage was 
observed at 0.75µM, 5µM or 10µM GSK932121A compared to the DMSO control (p>0.05). 
 
  
 
 
 
 
 
 
 
 
FIGURE 7.2: The effect of GSK932121A on HepG2 cytotoxicity using an LDH leak/lyse assay. The cytotoxicity of 
GSK932121A (at an 8 hour time point) was assessed in vitro in HepG2 cells by measurement of LDH leakage. 
Triton-X-100 was used as a positive control and the effect on media alone (MC) was also measured. Data is 
expressed as a percentage of LDH leaked compared to total LDH in the cells (i.e. lysed sample analysed 
following Cell Lytic treatment). Data is expressed as mean ± sd. ***p<0.001. 
 
Concentrations of GSK932121A selected for further analysis therefore were 1µM, 5µM and 10µM. These 
were the concentrations which were defined by experiment to be sub-cytotoxic up to an 8 hour time point 
whilst causing a significant acute effect on respiratory chain function.  
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GSK2617971A – OXPHOS Uncoupling 
The effect of GSK2617971A on HepG2 cell metabolic function was assessed using the Xfe96 analyser 
(Fig.7.3 below). A significant increase in glycolytic metabolism (represented by increase in ECAR with 
statistical significance depicted using # in Fig.7.3. below) was observed at doses of 0.1µM (p<0.05), 1µM 
(p<0.001), 5µM (p<0.001) and 10µM (p<0.01) of GSK2617971A compared to a 0.1% DMSO control, 
with a peak response observed at 5µM. The peak concentration in terms of effect on OCR was at 1µM 
with an 80.2% increase in OCR observed compared to the DMSO control. A significant reduction in OCR 
was observed following treatment with 50µM as GSK2617971A becomes toxic to the respiratory chain at 
high concentrations (typical of a mitochondrial uncoupler and as shown in Fig.5.1 following ex vivo 
treatment with GSK2617971A of control isolated liver mitochondria). As all concentrations tested had a 
significant effect on metabolic function, all were analysed in the LDH leak/lyse assay to assess where the 
onset of cytotoxicity occurs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7.3: Effect of GSK2617971A (OXPHOS uncoupling) on HepG2 cell metabolism (OCR and ECAR). The effect of 
increasing concentrations of GSK2617971A (0.1µM-50µM, + 0.1% DMSO control) on both OCR (y-axis) and 
ECAR (x-axis) is shown. Statistical significance is highlighted using stars (*) for OCR and hash tags (#) for 
ECAR. A bell shaped dose response was observed with both OCR and ECAR following GSK2617971A 
treatment. Peak response in terms of ETC function (OCR) was observed at 1µM (p<0.001, n=3) and the peak 
response relating to glycolytic activity (ECAR) was observed at 5µM GSK2617971A (p<0.001), compared to 
DMSO control. */# p<0.05, **/## p<0.01, ***/### p<0.001.    
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Following an 8 hour exposure to either GSK2617971A (0.1µM-50µM), 0.1% DMSO control, media 
alone (MC) or a 1% Triton-X-100 positive control, spent media was analysed for LDH leakage. A 
significant increase in leaked LDH (indicating compound related cytotoxicity) was observed at 10µM 
(p<0.05) and 50µM (p<0.001) GSK2617971A compared to DMSO alone (Fig.7.4). Despite no evidence 
of LDH leakage with 5µM GSK2617971A, light microscopy evaluation identified a minor degree of 
vacuolation in the HepG2 cell appearance which was absent at lower doses and in the DMSO control (not 
shown). Taking this observation into consideration it was decided that 5µM would not be used in 
subsequent investigations due to minor observations which could be considered adverse effects. Instead 
doses of 0.1µM, 1µM and 2.5µM were selected for further analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7.4: Effect of GSK2617971A on HepG2 cell cytotoxicity using an LDH leak/lyse assay. The cytotoxicity of 
GSK2617971A (at an 8 hour time point) was assessed in vitro in HepG2 cells by measurement of LDH leakage. 
Triton-X-100 was used as a positive control and the effect on media alone (MC) was also measured. Data is 
expressed as a percentage of LDH leaked compared to total LDH in the cells (i.e. lysed sample analysed 
following Cell Lytic treatment). Data is expressed as mean ± SD (n=3), p<0.05*, p<0.001*** 
 
Having identified effective sub-cytotoxic concentrations of GSK932121A and GSK2617971A, these 
concentrations were then tested in HepG2 cells for up to 8 hours to assess the effect on lactate generation, 
mitochondrial/cellular morphology and gene expression. 
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7.2.2. IN VITRO LACTATE GENERATION 
An increased level of blood lactate was observed in rats following treatment with both GSK932121A and 
GSK2617971A in vivo. Mechanistically, mitochondrial perturbation causes an increase in lactate as cells 
switch metabolism away from impaired mitochondrial OXPHOS and towards cytoplasmic glycolysis. 
Glycolysis offers cells an opportunity to produce cellular ATP, independent of mitochondrial ETC 
function via substrate level phosphorylation however the process is far less efficient and lactate 
generation is a consequence of this response.  
 
Preliminary Experiment: Prior to exploring the effect of both tool compounds on lactate generation in 
vitro, it was important to perform a preliminary experiment to determine the optimum media glucose 
concentration to ensure the cells had sufficient glycolytic substrate to optimise subsequent lactate 
generation. As proof of concept, compounds which are known to increase lactate in vitro due to 
mitochondrial inhibition were used. Oligomycin (2µg/mL) and antimycin A (1µM) were chosen with 
concentrations based on evidence in the literature showing these concentrations induced the desired 
lactate response [233]. 
 
In galactose-conditioned cell maintenance media alone, both oligomycin and antimycin A induced a 
statistically significant increase in supernatant lactate at both 1 hour and 4 hours post treatment 
(highlighted by # in Fig.7.5 below). However, the relative increase in lactate was significantly greater 
when treatment was made alongside addition of increasing concentrations of glucose (2.5mM, 5.5mM and 
11mM). The increase in lactate generation following oligomycin/antimycin A treatment in glucose 
supplemented cells was significantly higher than the relative response in galactose alone at 1 hour with 
11mM glucose (Fig.7.5A) and significantly higher than galactose alone with 2.5mM, 5.5mM and 11mM 
glucose at 4 hours (Fig.7.5B). These data suggest that supplementing the media with glucose significantly 
improves the lactate response to mitochondrial perturbation and this effect is enhanced both with time and 
glucose concentration. 
 
In order to ensure that the lactate generated was as a result of the exogenous glucose which was provided 
(i.e. lactate produced de novo by the action of glycolysis) 2-deoxyglucose (2-DG), a potent glycolytic 
inhibitor, was used. 2-DG is a competitive inhibitor of hexokinase and as such completely inhibits the 
production of glucose-6-phosphate from glucose. In the present study, 50mM 2-DG (with the same 
increasing concentrations of glucose) inhibited the lactate production which was observed following 
oligomycin and antimycin A treatment with glucose supplementation (minus 2-DG). This data confirms 
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that the lactate produced following treatment with both mitochondrial toxicants is directly linked to the 
levels of glucose supplemented to the cell maintenance media.  As 2-DG blocks glycolysis at the level of 
hexokinase (i.e. glucose conversion to glucose-6-phospate) it has no effect on galactose uptake into 
glycolysis, as galactose enters the glycolysis pathway directly at glucose-6-phosphate (via glucose-1-
phosphate). 
 
The effect of glucose treatment alone on lactate generation in galactose treated cells was also examined 
with no significant increase observed (data not shown).  
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FIGURE 7.5: Effect of glucose concentration on the generation of lactate in HepG2 cell supernatant following treatment 
with Oligomycin and Antimycin A. HepG2 cells were incubated for 1 hour (A) and 4 hours (B) with either 
oligomycin (2.5µM) or Antimycin A (1µM) in galactose conditioned media provoking a statistically significant 
increase in lactate (marked with an # and labelled as no supplements). Relative increase in lactate was however 
significantly increased with both compounds whereupon oligomycin and antimycin A were treated alongside 
increasing doses of glucose (in galactose conditioned media). 2-DG (50mM) inhibited antimycin A / 
oligomycin induced lactate generation. Data is expressed as a percentage of the response elicited to a 0.1% 
DMSO control. Data shown is mean ± sd (n=3), p<0.05*, p<0.01**, p<0.001*** 
 
Following analysis of the effect of glucose concentration on oligomycin and antimycin A induced lactate 
generation, it was decided that 11mM of glucose would be supplemented to the cell maintenance media 
upon treatment with both GSK932121A and GSK2617971A to ensure an optimal window for observing 
treatment related effects on lactate generation. It was hoped that the addition of glucose, only at the time 
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of compound-treatment, would provide the substrate required to facilitate metabolic switching (to a 
detectable level using the methods available) but not negate the effects of culturing in galactose. Further 
experimentation is however required to assess how long it takes for media supplementation (i.e. glucose 
addition) to have a significant effect on underlying metabolic activities.  
 
Assessment of lactate generation following treatment of HepG2 cells with sub-cytotoxic 
concentrations of GSK932121A and GSK2617971A: The aim of the experiment was to analyse the 
acute effect of GSK932121A/GSK2617971A on lactate generation (including speed of onset), both in 
vitro and at sub-toxic concentrations. As such three concentrations of both GSK932121A (1, 5 and 10µM) 
and GSK2617971A (0.1, 1 and 2.5µM) were tested over an 8 hour acute time-course. Supernatant 
samples were taken at 1 hour, 2 hours, 4 hours and 8 hours post-treatment for analysis of lactate (as 
described in section 2.14). Data shown is represented as a percentage of a 0.1% DMSO control (n=3).  
 
A significant increase in lactate was observed at 4 hours post-treatment with 5µM (146.2% ±14.3, 
p<0.05) and 10µM (170.6% ± 13.1, p<0.01) GSK932121A and at 8 hours post-treatment with 10µM 
(147.8% ± 18.5, p<0.05) GSK932121A alone, compared to time matched DMSO controls (Fig.7.6A). No 
effect was observed with either dose at 1 hour or 2 hours post-treatment.  No effect on lactate was 
observed at 1µM GSK932121A at any time point (p>0.05). 
 
Only a minor effect on lactate production was observed following uncoupling of OXPHOS with 
GSK2617971A in vitro (Fig.7.6B). A significant increase in lactate was only observed at 2.5µM 
GSK2617971A at the 8-hour time point (138.3% ± 5.7, p<0.05, n=3) compared to a time matched 0.1% 
DMSO control. No effect was seen at lower concentrations or earlier time points.  
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FIGURE 7.6: Effect of sub-cytotoxic concentrations of GSK932121A and GSK2617971A on HepG2 cell lactate generation 
up to 8 hours. (A) Effect of GSK932121A (1µM, 5µM and 10µM) and (B) GSK2617971A (0.1µM, 1µM and 
2.5µM) on lactate concentration in HepG2 cell media up to 8 hours post treatment. All data is expressed as a 
percentage of time matched DMSO control lactate concentration and plotted as mean ± SD (n=3). p<0.05*, 
p<0.01** 
 
These data show that lactate is increased in HepG2 cells at concentrations of both GSK932121A and 
GSK2617971A which are not grossly cytotoxic to the cells, at 4-8 hours post-treatment. To further 
investigate the early biochemical effects of complex III inhibition and OXPHOS uncoupling in vitro and 
using well tolerated concentrations, gene expression profiling was used. A gene panel was assembled 
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based on data obtained in vivo with both compounds. As the main metabolic event observed in the 
proposed AOP of both compounds was the switch towards glycolysis, the genes selected primarily 
involved cellular glycolytic function alongside genes involved in lipid metabolism, gluconeogenesis and 
cell stress responses.  
 
7.2.3. RT-PCR – METABOLIC SWITCH GENE PANEL 
The aim of this work was to identify early gene expression changes occurring as a result of subtle 
complex III inhibition and OXPHOS uncoupling in vitro (i.e. at sub-cytotoxic concentrations). The same 
experimental conditions, as described above for the lactate assay, were repeated to enable comparisons to 
be drawn between gene expression alterations and onset of lactate stimulation. Identification of genes 
responding early following exposure to these compounds may provide the opportunity to, a) better 
understand the early mechanisms of toxicity following the molecular initiating event for both drugs, and 
b), identify any potential “marker genes” which could be measured in future studies to assess potential 
underlying changes in mitochondrial function.  
 
As described above, a gene panel was assembled based on in vivo microarray data with both compounds 
in rat liver. The gene panel was selected in a supervised manner, which enabled selection of genes 
pertinent to the mechanisms under investigation. This was deemed preferable to selecting genes based on 
statistical significance (i.e. an unsupervised approach) as this method does not account for the known 
fundamental mechanisms. Table 7.1 below describes the genes selected for analysis in this experiment. 
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Gene 
symbol 
Gene name Fold change 
and stat sig 
following 
complex III 
inhibition 
(50mg/kg) 
(GSK932121A) 
Fold change 
and stat sig 
following 
OXPHOS 
uncoupling  
30mg/kg and 
60mg/kg 
(GSK2617971A) 
 
Headline summary of 
biochemical function 
Reason for inclusion 
in gene-panel 
NR4a1 Nuclear receptor 
subfamily 4, group a, 
member 1 
 
5.42x*** 
 
 
1.27x 
1.76x* 
Ligand-independent 
transcription factors which 
function as immediate or 
early response genes. Key 
transcriptional regulators of 
hepatic glucose and lipid 
homeostasis. Key review 
can be found in [234].  
Upregulated with both 
compounds in vivo 
and heavily linked to 
cell metabolism in the 
liver. NR4a2 Nuclear receptor 
subfamily 4, group a, 
member 2 
 
2.69x** 1.25x 
2.00x** 
NR4a3 Nuclear receptor 
subfamily 4, group a, 
member 3 
 
5.22x*** 1.24x 
2.26x* 
Ppargc1a 
(PGC1α) 
Peroxisome 
proliferator-activated 
receptor gamma, 
coactivator 1 alpha 
 
8.18x*** 1.05x 
3.76x*** 
Transcriptional co-activator 
and central co-ordinator of 
gluconeogenesis and 
mitochondrial biogenesis in 
the liver [235, 236]. 
Upregulated with both 
compounds in vivo 
and heavily linked to 
cell metabolism in the 
liver. 
 
 
Foxo1 Forkhead box 01 
 
 
1.56x* 1.59x* 
2.08x* 
Forkhead transcription 
factor. Plays pivotal role in 
glucose metabolism and the 
action of insulin on 
glucogenic processes [237]. 
Upregulated with both 
compounds in vivo 
and heavily linked to 
cell metabolism in the 
liver. 
Pck1 Phosphoenolpyruvate 
carboxykinase 1 
 
1.94x** 1.22x 
1.48x* 
Rate limiting step in 
gluconeogenesis – Converts 
oxaloacetate to 
phosphoenolpyruvate 
(substrate for 
gluconeogenesis) [157].  
Upregulated with both 
compounds in vivo – 
Linked to 
gluconeogenesis 
G6pd Glucose-6-phosphate 
dehydrogenase 
-1.05x -1.38x 
-1.28x 
 
Catalyses reaction between 
glucose (in the form of G6p) 
and 6-
phosphogluconolactone in 
the PPP. 
No change observed 
in vivo but key gene 
involved in 
glycolysis/PPP 
Irs2 Insulin receptor 
substrate 2 
 
4.78x*** 1.41x 
3.37x*** 
Irs2 is phosphorylated by the 
Insulin receptor during 
signal transduction and plays 
subsequent role in glucose 
metabolism in the liver 
[238]. 
Upregulated with both 
compounds in vivo 
and heavily linked to 
cell metabolism in the 
liver. 
Pdk4 Pyruvate 
dehydrogenase 
kinase isozyme 4 
 
2.22x** 1.17x 
3.76x** 
Inhibits pyruvate 
dehydrogenase complex by 
phosphorylation which 
prevents pyruvate 
conversion to acetyl-coA. 
Pyruvate instead converted 
to oxaloacetate for 
gluconeogenesis. [239] 
 
 
 
 
Upregulated with both 
compounds in vivo 
and heavily linked to 
cell metabolism in the 
liver. 
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Hmox1 Heme oxygenase 1 
 
 
2.22x** -1.04x 
3.06x*** 
An essential enzyme in 
heme catabolism, cleaves 
heme to form biliverdin, 
which is subsequently 
converted to bilirubin by 
biliverdin reductase, and 
carbon monoxide. Involved 
in cytoprotection to 
hepatocyte injury in vivo 
[240]. 
 
Upregulated with both 
compounds in vivo 
and heavily linked to 
the response to 
physiological stress. 
Lpin1  Lipin 1 
 
 
4.65x*** 1.15x 
3.30x** 
Controls the metabolism of 
FAs at different levels.  
Phosphatidate phosphatase 
enzyme which catalyses the 
conversion of phosphatidic 
acid to diacylglycerol during 
triglyceride biosynthesis. 
Acts as a nuclear 
transcriptional coactivator 
for PGC1α /Ppar-α to 
modulate lipid metabolism  
gene expression [241]. 
Upregulated with both 
compounds in vivo 
and heavily linked to 
liver cell metabolism. 
Ppar-α Peroxisome 
proliferator-activated 
receptor alpha 
 
1.01 1.27x 
1.88x** 
Among other functions, 
Ppar-α plays a role in 
regulating lipid metabolism 
via Lpin1 and PGC1α during 
periods of fasting or 
increased FA supply [242].  
Upregulated 
following 
GSK2617971A 
treatment in vivo and 
heavily involved in 
the Lpin1/PGC1α 
control of lipid 
metabolism. 
Chac1 Chac, Cation 
Transport Regulator 
Homolog 1 
 
12.72x*** -1.08x 
1.62x* 
 
Pro-apoptotic component of 
the unfolded protein 
response pathway by 
mediating the 
pro-apoptotic effects of the 
ATF4-ATF3-DDIT3/CHOP 
cascade 
 
Upregulated with both 
compounds in vivo 
and linked to cell 
stress response. 
Atf3 Activating 
transcription factor 3 
 
8.73x*** 1.28x 
5.36x*** 
Transcriptional repressor 
and induced by many stress 
signals. Plays a role in 
downstream signalling of the 
unfolded protein response 
pathway and in control of 
gluconeogenic Pck1 
expression in the liver [243] 
Also involved in EIF2 
kinase stress pathway 
following amino acid 
starvation [244].  
Upregulated with both 
compounds in vivo 
and linked to cell 
stress responses. 
 
TABLE 7.1: Genes selected for use in TaqMan gene-panel. The table describes the genes which were incorporated into a 
custom TaqMan gene-panel aimed at identifying early gene expression signatures downstream of mitochondrial 
perturbation in vitro.  Genes were selected based on observations in vivo and the effect of both GSK932121A 
and GSK2617971A on the induction of all genes is indicated (fold change, and statistical significance, p<0.05*, 
p<0.01**, p<0.001***). The proposed mechanism of action for each gene is provided alongside the main 
justification for use in this gene panel. 
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The focus of the gene panel was largely on the metabolic adaptation which occurred downstream of 
mitochondrial perturbation induced by both molecules, however a small number of genes involved in cell-
stress responses (i.e. Chac1 and Atf3) were also included.  This experiment was performed alongside the 
lactate investigation described above. As such, GSK932121A, GSK2617971A and a 0.1% DMSO control 
were introduced to a confluent monolayer of HepG2 cells in cell maintenance media supplemented with 
11mM glucose. After 1 hour, 2 hours, 4 hours and 8 hours, the cell media was removed and cells were 
lysed with RNA Lysis Buffer (Promega SV RNA Isolation Kit). Triplicate wells were pooled and the 
experiment was repeated on three separate occasions (n=3). Data was represented in a heat map format 
with statistically significant alterations in gene expression following GSK932121A (Fig.7.7) and 
GSK2617971A (Fig.7.8) treatment compared to the 0.1% DMSO control shown.   
 
GSK932121A (Complex III Inhibition) – Gene Panel Data (Fig.7.7) 
 
The NR4A Gene Family: GSK932121A (complex III inhibition) caused a significant induction of the 
nuclear receptor 4-alpha genes Nr4a1 and Nr4a3 over the time course with Nr4a1 upregulated with all 
concentrations at 4 hours and with 5µM and 10µM at 8 hours (p<0.01). Nr4a3 was significantly elevated 
at 2 hours with 5µM GSK932121A (1.7x, p<0.01) and then with 5µM and 10µM at 4 hours (1.58x and 
2.12x respectively) and finally with all concentrations at 8 hours post treatment (p<0.001). These data 
indicate that effect of GSK932121A on induction of the NR4a genes has a trend towards being more 
time-dependent than dose dependent. Despite efficient target amplification, no effect on Nr4a2 compared 
to the 0.1% DMSO control was observed throughout the study.  
 
PGC1α/Foxo1 Gene Expression: GSK932121A induced a consistent increase in gene expression of 
PGC1α and Foxo1 which are known as metabolic switch/master regulator genes. The increase in 
expression of both genes was highly significant at 1 hour post treatment with all concentrations, compared 
to the DMSO control (p<0.01). An increase in PGC1α expression (with all concentrations of 
GSK932121A) was then observed throughout the time course with the exception of with 0.1µM 
GSK932121A at a 4 hour time point (trending increase but p>0.05). At later time points (4 hour and 8 
hour), Foxo1 expression was only increased with the higher doses of 5µM and 10µM GSK932121A 
however data for both genes suggests they play a key role in the control of cell metabolism following 
complex III inhibition in vitro.  
 
PGC1α-Foxo1 Effectors: As anticipated, the downstream effector genes of PGC1α and Foxo1 were 
generally induced later in the time course than Foxo1 and PGC1α. However, a significant induction of 
Pck1 (involved in the rate limiting step of gluconeogenesis) was observed at all concentrations at 1 hour 
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post treatment compared to the DMSO control. Pdk4 was also increased at 1 hour with 5µM 
GSK932121A however a significant reduction in expression was observed with 10µM GSK932121A, 
which makes interpretation of data with Pdk4 challenging at early time points. G6pd was increased at 
1µM (p<0.01) and 10µM (p<0.05) although data with this gene appeared highly variable.  Only minor 
effects on the downstream effector genes were observed at 2 hours post-treatment with the exception of 
Pck1 which remained significantly elevated with all concentrations compared to the DMSO control. At 4 
hours post-treatment a significant increase in the expression of Irs2 was observed with all concentrations 
and with high fold-changes (2.1x with 5µM and 6.6x with 10µM GSK932121A). The activation of Irs2 
was however temporary as no effect was noted at 8 hours. GSK932121A caused only minor effects on 
Pdk4 and Hmox1 expression at 4 hours, with a slight reduction in the expression of both genes. At 8 
hours post-treatment a significant increase in the expression of Hmox1 and G6pd was observed at all 
concentrations suggesting that induction of these genes occurred later or downstream to the observed 
increase in Foxo1, PGC1α and Pck1 expression.  
 
 
Lpin1-Ppar-α and the stress response genes Atf3 and Chac1: Induction of Lpin1 (involved in 
activating FAO) was observed at 4 hours post treatment with both 5µM and 10µM GSK932121A (1.64x 
and 2.98x respectively). This increase preceded a respective increase in both Lpin1 and Ppar-α at 8 hours 
post-treatment with all concentrations of GSK932121A compared to DMSO control. This suggests that 
transcriptional activation of Lpin1/Ppar-α mediated FAO was delayed and was a later consequence of the 
action of GSK932121A although Lpin1 expression preceded that of Ppar-α. Similarly, a significant 
reduction in the expression of two genes involved in the cell stress/unfolded protein response (Chac1 and 
Atf3) was observed at 1 hour and 2 hour post-treatment with GSK932121A. Increases in the expression of 
both genes appeared however to be time dependent with all concentrations of GSK932121A inducing a 
significant increase in the expression of both genes by 8 hours.  
 
These data show that treatment with well tolerated concentrations of GSK932121A caused an early 
increase in the regulator genes PGC1α, Foxo1 and Pck1. Transcriptional effects on other genes appear to 
be time dependent rather than dose dependent and include induction of Nr4a1/3, Gdpd, Hmox1, Lpin1, 
Ppar-α, Chac1 and Atf3. 
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GSK932121A (Complex III Inhibition) – Gene Panel Data 
 
 
 
FIGURE 7.7: Heat map showing the effect in HepG2 cells of GSK932121A on a selection of pertinent genes involved in the response to DIMT. Data shown represents a 
heat map of statistically significant changes in the expression of a number of genes following GSK932121A treatment in vitro. Experiments were repeated on 
three occasions (n=3) and fold change (and statistical significance) was calculated against a 0.1% DMSO control. Any changes in gene expression where p<0.05 
are shown (in either direction). 
Key: 
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GSK2617971A (OXPHOS Uncoupling) – Gene Panel Data (Fig.7.8) 
 
Like observations made with GSK932121A, the OXOHOS uncoupling agent GSK2617971A caused a 
time dependent increase in the expression of most genes over the time course studied. At 1 hour post 
treatment 9 of the 14 genes on the panel had lower levels of expression than the corresponding 0.1% 
DMSO control. Most notably, there was a significant reduction in both of the stress response genes, 
Chac1 and Atf3, with all concentrations of GSK2617971A. Furthermore, a reduction in the expression of 
Nr4a1/3 at 0.1µM and 2.5µM GSK2617971A was observed alongside reductions in Irs2, Hmox1, G6pd, 
Lpin1 and Ppar-α, especially with the 2.5µM concentration.  However, as observed with GSK932121A, 
the expression of regulator genes PGC1α and Foxo1, alongside Pck1 (gene encoding the rate limiting 
enzyme involved in gluconeogenesis) was increased with all concentrations.  
 
At 2 hours post treatment with GSK2617971A, (with the exception of Pck1 which remained 
transcriptionally up-regulated) all downstream effector genes of the action of PGC1α / Foxo1 (Hmox1, 
Pdk4, Irs2, G6pd) were unchanged compared to control. Likewise the expression of Chac1 and Atf3 
remained reduced compared to the DMSO control. A significant increase in expression was however 
observed with Lpin1 at 1µM (p<0.01, 1.2x) and 2.5µM (p<0.01, 1.7x) and these data suggest early 
transcriptional activation of FAO genes. At 2 hours a significant increase in the expression of Nr4a1 at 
0.1µM and 1µM was observed although no effect was seen with 2.5µM. 
 
The transcriptional response to GSK2617971A remained fairly subtle at the 4 hour time point with many 
genes involved in the cell stress response, activation of FAO and glycolytic / gluconeogenic processes not 
significantly changed compared to DMSO control. However, when compared to data at 1 and 2 hours 
where many of these genes had significantly reduced expression levels compared to control, it may be 
inferred that the expression of these genes was in fact gradually increasing. Like observations noted with 
GSK932121A, the expression of Irs2 was maximally induced at 4 hours with fold changes of 5.1, 7.6 and 
13.5 observed with 0.1µM, 1µM and 2.5µM respectively (p<0.001). Despite an increase in the expression 
of Foxo1 persisting with 0.1µM and 1µM GSK2617971A, a reduction in the expression of PGC1α was 
observed with 1µM and 2.5µM GSK2617971A and it was apparent that the transcriptional activity of 
these regulator genes was starting to decline.  
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At 8 hours post-treatment with GSK2617971A (the only time-point in which an increase in lactate was 
observed), a statistically significant induction of Atf3, Lpin1, Ppar-α, Hmox, G6pd, Pck1 and Nr4a3 was 
observed with either all GSK2617971A concentrations or with 1µM and 2.5µM. This data represents a 
more similar pattern of gene expression to observations made in vivo. At 8 hours post treatment the 
expression of both PGC1α and Foxo1 was not significantly altered compared to control highlighting a 
reduction in the expression of these co-ordinators of the metabolic response. No effect on Pdk4 was 
observed throughout the study at any time points or with any concentration of compound. 
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GSK2617971A (OXPHOS uncoupling) – Gene Panel Data 
 
 
 
 
FIGURE 7.8: Heat map showing the effect in HepG2 cells of GSK2617971A on a selection of pertinent genes involved in the response to DIMT. Data shown represents a 
heat map of statistically significant changes in the expression of a number of genes following GSK2617971A treatment in vitro. Experiments were repeated on 
three occasions (n=3) and fold change (and statistical significance) was calculated against a 0.1% DMSO control. Any changes in gene expression where p<0.05 
are shown (in either direction).
Key: 
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The following conclusions can be drawn from the gene expression data with both compounds… 
 
 PGC1α, Foxo1 and Pck1 were the earliest response genes studied in this experiment and were 
induced at 1 hour post-treatment with both GSK932121A and GSK2617971A. In response to 
complex III inhibition these genes remain constitutively active over the 8 hour time course whereas 
following OXPHOS uncoupling expression of these genes gradually declines. 
 In general the expression of the majority of genes is more time-dependent than dose dependent. This 
is highlighted by the down-regulation in many genes in the panel at early time points and increases in 
expression at late time points. This is especially pertinent with regards to the effect of both 
compounds on Chac1 and Atf3, the FAO induction genes, Lpin1 and Ppar-α, as well as Hmox1 and 
G6pd. 
 The transcriptional activity of Irs2 appears to be transient with a significant elevation of expression 
observed at 4 hours post-treatment with both compounds and little effects observed at other time 
points. 
 The nuclear receptor 4-alpha genes, Nr4a1 and Nr4a3, appear to play a role in downstream adaptation 
to DIMT, also in a time dependent manner (up to 8 hours) although no effect was observed with 
Nr4a2 throughout the experiment.  
 
7.2.4. IN VITRO ELECTRON MICROSCOPY 
Another key observation noted in vivo with both compounds was the effect of DIMT on mitochondrial 
ultrastructure (both GSK932121A and GSK2617971A) and on the levels of cellular glycogen / free lipid 
in hepatocytes (GSK932121A alone). TEM investigations to date have however only been performed at 
late time points and largely in conjunction with severe clinical toxicity. The present work sought to 
investigate the effects of low concentrations of both GSK932121A (complex III inhibition) and 
GSK2617971A (OXPHOS uncoupler) on HepG2 cell ultra-structure with a particular emphasis being 
placed on mitochondrial structure and cellular glycogen / lipid levels. 
  
An important consideration of this experiment was however that TEM analysis is costly and low 
throughput. Concentrations and time-points selected for analysis were therefore based on effects seen on 
lactate generation and gene expression (sections 7.2.2 and 7.2.3 above) and as such were concentrations 
where effect on HepG2 cell structure was most likely to be observed. Taking this into account, the effect 
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of GSK932121A on HepG2 cell ultrastructure was assessed at 4 hours and 8 hours post-treatment with 
5µM and 10µM concentrations. TEM analysis was performed on GSK2617971A treated cells only at 8 
hours and with 1µM and 2.5µM concentrations. Following compound treatment (and at the defined time 
point), cells were prepared for TEM analysis as described in section 2.10.2. HepG2 cells were assessed 
for mitochondrial morphological abnormalities compared to a time-matched 0.1% DMSO control. 
Glycogen and lipid content was assessed (per 100 cells) by counting those containing glycogen clusters 
and those which contained more than 1 lipid droplet. Data is shown below in Table 7.2. 
 
Compound and 
Concentration 
Time Point (Hours 
post dose) 
% of Cells with 
Glycogen clusters 
% of Cells with Lipid 
droplets 
DMSO Control (0.1%) 4 26 16 
GSK932121A (5µM) 4 9 21 
GSK932121A (10µM) 4 10 9 
  TABLE 7.2: Effect of GSK932121A and GSK2617971A on the intracellular levels of HepG2 cell glycogen and lipid. (A) 
The percentage of cells (per 100 cells counted) containing glycogen clusters and >1 lipid droplet was assessed 
following a 4 hour treatment with 5µM or 10µM GSK932121A. (B) The same assessment was made at 8 hours 
post treatment with GSK932121A (at the same concentrations as in A) and with 1µM or 2.5µM GSK2617971A. 
 
Whilst providing an interesting insight the lack of experimental repeats makes drawing experimentally 
and statistically significant conclusions from the TEM data a challenge. The data shown in Table 7.2 
should therefore be viewed as preliminary. At 4 hours post treatment, a reduction in the percentage of 
cells containing glycogen clusters was observed following treatment with 5µM and 10µM GSK932121A. 
Inconsistent with in vivo observations however was the reduction in cells containing lipid droplets with 
10µM GSK932121A. At 8 hours post-treatment with GSK932121A, reductions in glycogen levels were 
again observed with 10µM GSK932121A. As cultured cells are more reliant on glucose for cell 
metabolism (as opposed to fatty acid), perhaps this explains the lack of lipid accumulation. 
 
A reduction in glycogen stores was also observed with 1µM GSK2617971A at 8 hours although this was 
a concentration which showed no effect on lactate generation in vitro and under the same experimental 
Compound and 
Concentration 
Time Point (Hours 
post dose) 
% of Cells with 
Glycogen clusters 
% of Cells with Lipid 
droplets 
DMSO Control (0.1%) 8 21 19 
GSK932121A (5µM) 8 25 20 
GSK932121A (10µM) 8 12 14 
GSK2617971A (1 µM) 8 12 13 
GSK2617971A (2.5 µM) 8 22 12 
A 
B 
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conditions and no effect was observed with 2.5µM. A moderate reduction in lipid levels was observed 
with GSK2617971A at both 1µM and 2.5µM however it is presently unknown whether this is a 
significant observation (although it would fit with the hypothesis of increased substrate utilization 
following OXPHOS uncoupling).  
 
Mitochondrial Morphology 
In the same survey sections, the effect of both GSK932121A and GSK2617971A on mitochondrial 
morphology was assessed.  Analysis of TEM micrographs (data not shown) supports observations made 
in vivo which suggest that mitochondrial structural changes occur only at higher exposure levels and at 
concentrations which provoke adverse effects. To confirm this (and to validate that mitochondrial ultra-
structural effects can be detected with these compounds in vitro), mitochondrial morphology would need 
to be assessed following in vitro treatment with higher concentrations of both drugs, which are grossly 
cytotoxic, however time, budget and experimental throughput constraints prevented such analysis in the 
present study.  
 
7.2.5. COMPOUND CONNECTIVITY MAPPING  
Compound connectivity mapping was performed using SScMap (statistically significant connections’ 
map) program as described in [146, 147]. It was hoped to identify other molecules with similar 
downstream transcriptomic profiles to those of GSK932121A and GSK2617971A, which therefore, may 
also modulate mitochondrial function. These could then be used as tools in order to validate observations 
made to test if changes are mechanism specific rather than compound-dependent. The 34 most 
statistically significant, differentially regulated protein coding genes following GSK932121A treatment 
and the 32 most significant genes for GSK2617971A were input into SScMap. These genes were the most 
contributory to the separation of experimental variables via principal component analysis (i.e. effect of 
drug treatment on gene expression in rat livers). The most significant genes were determined using 
Qlucore OE (as described in section 6.2.4). Only the most statistically significant gene alterations were 
selected for comparison to avoid connection with other compounds based on marginally changed genes. 
Table 7.3 below shows the genes which were submitted to compound connectivity mapping categorised 
into their reported cellular function. Common genes which were altered as a result of administration of 
both compounds are highlighted in red. 
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TABLE 7.3: Genes submitted for connectivity mapping analysis.  The most statistically significant genes in terms of 
separating VC gene expression from GSK932121A (34 genes) and GSK2617971A (32 genes) treatment are 
shown. Genes have been separated according to biological function (according to the NCBI, Entrez database – 
accessed April 2015). Genes shown in red are commonly altered genes with both GSK932121A and 
GSK2617971A. 
 
Despite the fact that GSK932121A (ETC inhibitor) and GSK2617971A (uncoupler) perturb 
mitochondrial function with differing mechanisms, they share 11 transcripts within their respective top 
significant gene lists. This opens up the possibility that, independent of mechanism, a common 
transcriptional response may exist following treatment with mitochondrially toxic agents. Connectivity 
mapping analysis was performed as described in section 2.17.6. 
 
The expression signatures for both compounds were analysed separately with connection scores and p-
values plotted as volcano diagrams (as shown in Fig.7.9). The connection score is calculated from 
comparison of query gene signatures with the reference database and therefore any closely related 
compounds appear on the far right of the x-axis. Statistically significant data points are located above a 
threshold (highlighted by the green line in Fig.7.9A) and therefore closely connected compounds which 
have a statistically significant comparison index are located as far right and as high as possible (the top 10 
Genes Submitted for Connectivity Mapping 
 
 
Cellular Function 
Gene Symbols 
 
GSK932121A GSK2617971A 
 
Cell metabolism Sds, Ppargc1a, Irs2, Sik1,  Lpin1, Nr4a1, 
Nr4a3, Coq10b 
Sds, Ppargc1a, Irs2, Sik1,  Lpin1, Got1, 
Ppp1r3b, Mir-122, Pdk4 
Cell signalling / signal 
transduction 
Jun, Gem, Trib1 Jun, Rab30, Rgs16 
Cell cycle control / 
apoptosis 
Mir-505, Insc, Zfp354a, Gdf15, Rhob, Btg2 Mir-505,  Btg2, G0s2, Klf6 
Cell stress response Atf3, Chac1, Gadd45b, Sult2a1, Sult2a2, 
Gadd45g, Il1rn, Alp1, Gstm3 
Atf3, Chac1, Hsph1, Hspb1, Upp2, Tnfaip2, 
Gadd45b, Cyp1a1 (xenobiotic metabolism) 
Transporters Slc16a6 (lactate/ pyruvate, amino acids, 
ketones) Slc38a2 (amino acid transporter), 
Atp1b1 (Na+ / K+), Slc1a4 (amino acid 
transporter) 
Slc38a2 (amino acid transporter) 
Other cell processes  Doc2a (calcium sensing), Egr1 (mitogenesis 
and differentiation), Mt2a (binds heavy 
metals), Ccrn4l (circadian rhythm) 
Igfbp1 (cell growth), Eif4ebp3 (protein 
translation), Mt1a (binds heavy metals), S1pr1 
(cell migration), Usp18 (protein deubiquination), 
P4ha1 (collagen synthesis), Midlip1 (unknown) 
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connected compounds for both GSK932121A and GSK2617971A are shown in Fig.7.9B).  Analysis of 
volcano plots for both GSK932121A and GSK2617971A identified a single “top-hit” molecule 
(azacyclonol) which was highly significant for both drugs in terms of similarity of gene expression 
signatures. 
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FIGURE 7.9: Exemplar volcano plot for GSK2617971A / GSK932121A connectivity map and top ten connected 
compounds: (A) The sscMap volcano plot generated during comparison of the most statistically significant 
genes altered following GSK932121A/GSK2617971A treatment to a reference data set. The x-axis shows 
connection score while the y-axis relates to –log10 p-value. The green horizontal line represents a pre-set 
threshold of p-value with any data points above the line considered significant. Circled is the most significant 
and highly connected compound, Azacylonol (inset).(B) Tables showing top ten connected compounds for both 
GSK932121A and GSK2617971A. Connection scores are calculated from comparison of query gene signatures 
with the reference database (higher the connection score the more significant the transcriptional similarity). 
Azacylondol was the top-hit connection for both GSK932121A and GSK2617971A. 
 
Following identification of azacyclonol as the most significantly connected compound for both 
GSK932121A and GSK2617971A, I wanted to explore whether this connection was due to effects on 
GSK932121A 
Connected 
Compounds 
Connection 
Score 
Azacyclonol 7.35 
Disulfiram 6.73 
Mometasone 6.50 
Ciclopirox 6.47 
Mefloquine 6.38 
Perphenazine 6.35 
Astemizole 6.10 
Maprotiline 6.04 
Tribenoside 6.03 
Iocetamic acid 6.02 
GSK2617971A 
Connected 
Compounds 
Connection 
Score 
Azacyclonol 6.04 
Ikarugamycin 5.64 
Helveticoside 5.42 
Lanatoside C 5.31 
Strophanthidin 5.29 
Haloperidol 5.20 
Clozapine 5.12 
Econazole 5.06 
Dosulepin 5.06 
Disulfiram 4.94 
Azacyclonol  
 
A 
B 
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mitochondrial function or whether it was due to induction of similar genes via a different mechanism. In 
order to assess whether azacyclonol provokes a high degree of similarity in gene expression to 
GSK932121A and GSK2617971A due to mitochondrial toxicity, I analysed the acute effect of 
azacyclonol (purchased from Selleck Chemicals, #S3196) on ETC function and OXPHOS efficiency 
using the Seahorse Bioanalyser. The analysis was performed in vitro (in HepG2 liver cells) and ex vivo 
(isolated liver mitochondria from a control rat). Data is shown in Fig.7.10 below. Further work is required 
to assess whether other significantly connected compounds (listed in Fig.7.9B), cause adverse effects on 
mitochondrial function.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
FIGURE 7.10: Effect of azacyclonol on mitochondrial OCR in both HepG2 cells and isolated control liver mitochondria. 
At the concentrations tested (0.1µM-100µM, n=3) azacyclonol had no significant effect on OCR in either 
HepG2 cells (A) or isolated liver mitochondria (B), p>0.05 (mean ± SD). 
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No difference was observed in OCR following treatment with azacyclonol (0.1µM-100µM, n=3) 
compared to the DMSO control in either HepG2 cell cultures (Fig.7.10A) or in naive isolated liver 
mitochondria (Fig.7.10B). This data suggests that the similarity in transcriptional response between 
azacyclonol and both GSK tool mitochondrial toxicants was not due to any effect on the respiratory chain 
(either acceleration or inhibition). 
 
To further investigate any mechanistic similarity between azacyclonol and GSK932121A/GSK2617971A 
the effect of the compound on both lactate and on intracellular glycogen / lipid stored was investigated 
(essentially as described in section 7.2.2 and 7.2.4. above). As shown in Fig.7.11 below no significant 
effect on HepG2 cell media lactate concentration was observed following treatment with azacyclonol 
(1µM, 50µM and 100µM) compared to a 0.1% DMSO control (n=3, p>0.05). Furthermore, no effect on 
the percentage of cells containing intracellular glycogen stores was observed following TEM analysis of 
azacyclonol (at 50µM and 100µM only) treated cells at 8 hours. A moderate reduction in the percentage 
of cells containing >1 lipid droplet was observed in a dose dependent manner, however further work and 
experimental repeats are required to assess whether this change is statistically significant. In addition, 
TEM micrographs of HepG2 cells treated with azacyclonol were assessed for the effect of compound 
treatment on mitochondrial morphology, however, no effect was observed compared to the DMSO 
control (data not shown). 
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FIGURE 7.11: Effect of azacyclonol on both HepG2 cell lactate generation and on the intracellular level of glycogen 
clusters and lipid droplets. (A) Effect of azacyclonol (1µM-100µM) on HepG2 cell media lactate 
concentration compared to a 0.1% DMSO control (p>0.05, n=3). Data shown is mean ± SD and expressed as a 
percentage of DMSO control. (B) The table shows the percentage of cells (per 100 cells counted) containing 
glycogen clusters and greater than 1 lipid droplet following an 8 hour treatment with 50µM + 100µM 
azacyclonol. 
 
These data indicate that azacyclonol (up to a high concentration of 100µM) has no observable effect on 
mitochondrial function and extremely limited effects on cellular metabolism (potential reduction in 
intracellular lipid stores). It was therefore decided to perform gene expression analysis, using the same 
gene panel as described in section 7.2.3, on cells following treatment with 1, 10 and 100µM azacyclonol 
(Fig.7.12). It was hoped this experiment would, (a) help to confirm the connection between azacyclonol 
and the two tool GlaxoSmithKline mitochondrial toxic compounds and, (b) help to understand whether 
changes in genes on the panel are evoked specifically by mitochondrial toxicants or whether 
mitochondrially-inactive compounds (i.e. azacyclonol) induce these genes in the present model.  
Compound and 
Concentration 
Time Point 
(Hours) 
% of Cells with 
Glycogen clusters 
% of Cells with 
Lipid droplets 
DMSO Control 
(0.1%) 
8 21 19 
Azacyclonol (50µM) 8 25 11 
Azacyclonol (100µM) 8 18 5 
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Azacyclonol – Gene Panel Data 
 
 
 
FIGURE 7.12: Heat map showing the effect in HepG2 cells of azacyclonol on a selection of pertinent genes involved in the response to DIMT. Data shown represents a heat 
map of statistically significant changes in the expression of a number of genes following azacyclonol treatment in vitro. Experiments were repeated on 3 
occasions (n=3) and fold change (and statistical significance) was calculated against a 0.1% DMSO control. Any changes in gene expression where p<0.05 are 
shown (in either direction). 
Key: 
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The gene expression data presented in Fig.7.12 lends further credence to the significant connection 
(identified using connectivity mapping analysis) between azacyclonol and GSK932121A/GSK2617971A 
in terms of the transcriptional response to drug exposure. As observed with both GlaxoSmithKline 
compounds, gene expression following azacyclonol treatment appears time dependent rather than dose 
dependent with 11 of the 14 genes down-regulated at 1 hour post-treatment compared to a 0.1% DMSO 
control and 9 of 14 up regulated by 8 hours post-treatment. In contrast to observations with GSK932121A 
and GSK2617971A, azacyclonol treatment does not cause an early (~1-2 hour) induction of the regulator 
genes Foxo1 and PGC1α, rather, these genes are induced over time in a similar manner to that of their 
downstream effectors. Pck1 is however constitutively up-regulated over the duration of the experimental 
time course and this is similar to the response shown with both GSK932121A and GSK2617971A. Unlike 
both GSK932121A and GSK2617971A, Nr4a1 and Chac1 do not appear to be effected by azacyclonol 
treatment in vitro.  
 
Despite the similarity in transcriptional responses, I have demonstrated that, unlike both GlaxoSmithKline 
tool mito-toxicants, azacyclonol has no effect on the mitochondrial ETC or OXPHOS or on lactate 
generation in vitro. There was also no change in the levels of glycogen stores in HepG2 cells although a 
slight reduction in lipid stores was noted following TEM analysis. This highlights that induction of genes 
included in the present gene-panel can be stimulated by compounds with no effect on mitochondrial 
function and therefore lacks specificity.  
 
7.3. Discussion 
7.3.1. MITOCHONDRIAL TOXICITY, CYTOTOXICITY AND LACTATE GENERATION 
A key gap of the in vivo studies performed to date is the ability to differentiate primary from adaptive 
changes due to the use of high doses and/or late time points. Essential for the detailed characterisation of 
a toxicological event these experimental studies are not designed to determine the toxicological sequence 
of events. The ideal scenario would be to perform an in vivo study with multiple time points after dosing 
of the animals in order to analyse the order in which the key changes take place. However, due to time 
and practical constraints this was not possible. As an alternative, the progression of events was explored 
in vitro and importantly at concentrations of drug which were not notably toxic. Studying endpoints 
which had proven sensitive in vivo (i.e. lactate, electron microscopy and gene expression analysis) it was 
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possible to identify essential changes which, a) are primary to the mechanism of action for the drugs and 
may be key to the downstream events within the AOP and b) could be measured in future studies to assess 
potential underlying damage to mitochondria.   
 
The effect of both GSK932121A (ETC inhibitor) and GSK2617971A (uncoupler) on both cell 
metabolism and cytotoxicity was assessed in HepG2 cells. For both drugs a concentration range was 
determined whereby drug-induced effects were observed on cell metabolism but at an exposure level 
where no obvious signs of cytotoxicity was evident. It was hypothesised that this would be a narrow 
concentration range due to the classical steep dose-response often exhibited by mitochondrial toxicants 
[245]. This hypothesis proved relatively valid in relation to GSK932121A and GSK2617971A with a 
concentration range of 1µM-10µM and 0.1µM-2.5µM selected for analysis respectively. LDH leakage 
and light microscopy analyses (not shown) were used as the measure of cytotoxicity in the present study 
as many other cytotoxicity detection assays are in fact measures of mitochondrial activity (e.g. ATP 
assays, MTT tetrazolium assay) and as such may over-predict cytotoxicity to our mitochondrial acting 
compounds [246]. Disadvantages of the LDH leak/lyse assay however includes the lack of sensitivity to 
mild cytotoxic insult and the limited half-life of LDH in culture medium. Following identification of the 
optimal concentration window for studying more subtle underlying mitochondrial effects, the 
consequence of both GSK932121A and GSK2617971A treatment on a selection of pertinent endpoints 
relating to the effects observed in vivo was assessed.  
 
Increases in blood lactate were observed in vivo following treatment with both GSK932121A and 
GSk2617971A although generally at high exposure levels. The present work sought to understand 
whether sub-toxic concentrations of mitochondrial toxicants provoke an increase in lactate at the cellular 
level. These data show that both compounds do cause an increase in media lactate although the effect was 
only observed at 4 and 8 hours with ETC inhibition and 8 hours only following uncoupling. This is in 
contrast to immediate increases in ECAR observed following OXPHOS uncoupling in vitro however, as 
described by Dranka and colleagues it is important to acknowledge that ECAR measurement is based on 
pH alteration and is therefore not a direct measure of glycolysis [247]. Lactate has been suggested as a 
potential biomarker of mitochondrial perturbation and this may be justified based on its continued 
presence downstream of mitochondrial toxicity [230]. Whilst a useful mechanistic indicator, the data 
presented here suggests that increases in lactate in systemic circulation or in cell media is not an early 
consequence of mitochondrial dysfunction, but rather its generation is a delayed consequence of the 
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metabolic disruption and a significant switch to glycolysis. This is supported by Limonciel et al [143] 
who propose that lactate is a more promising biomarker of cell stress in long term repeat dose in vitro 
toxicology testing with many of the compounds used to validate their findings modulators of 
mitochondrial function.  
 
7.3.2. GENE PANEL DISCUSSION 
A gene panel was assembled based on key genes affected by both GlaxoSmithKline tool compounds in 
vivo. Striking similarity was observed in the transcriptomic signatures in rats following treatment with 
both compounds opening up the possibility of creating a gene panel for the detection of mechanism-
independent/generalised DIMT. The main issues relating to gene panels are however that gene expression 
does not necessitate protein translation and inferring biological function from changes in gene expression 
remains extremely challenging. This is especially pertinent in the present study as the gene panel was 
comprised largely of stress-response genes and as such the induction of many genes on the panel have 
previously been reported following a diverse array of signals and for a wide range of cellular functions. 
For example the expression of PGC1α has been attributed to the control of cell metabolism [248], 
mitochondrial biogenesis [249], the anti-oxidant system [250], the determination of muscle fibre type 
[251] amongst others, and this leaves the precise nature of its induction unknown.  Furthermore, the 
expression of many of the genes on this panel have been described following administration of various 
xenobiotics with very differing MOA’s suggesting they are unsuitable as specific biomarkers of 
mitochondrial dysfunction. Despite this, it is important to acknowledge that no inferences have to date 
been made between any genes involved in the panel and DIMT. As such they all constitute novel 
mitochondrial-toxicity signature genes. 
 
GSK932121A and GSK2617971A induced the expression of PGC1α and Foxo1 in vivo and in vitro. As 
well as its role in inducing mitochondrial biogenesis, PGC1α is induced under numerous stress conditions 
such as fasting (i.e. periods of low glucose) or energy deprivation. PGC1α in turn coordinates the activity 
of several transcription factors on the promoters of genes involved in the control of cell metabolism (β-
oxidation, ketogenesis and heme-biosynthesis) within or external to the mitochondrion [252].  
Additionally PGC1α co-activates the transcription factor, Foxo1, which in turn coordinates the expression 
of genes involved in insulin-regulated gluconeogenesis [155, 253]. In the present study both PGC1α and 
Foxo1 were the earliest genes to be differentially up-regulated following treatment with GSK932121A 
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and GSK2617971A (by 1 hour post-treatment). Induction is therefore likely a primary response but 
inferring the biological function of their up regulation is a challenge. However, taking into account the 
increase in expression is observed prior to induction of numerous PGC1α-Foxo1 downstream effector 
genes (i.e. Pck1, Irs2, Pdk4, Lpin1, Hmox1 and G6pd) it can be speculated its induction is related to 
control of energy metabolism and specifically induction of gluconeogenesis.  There is however a distinct 
paucity of data in the literature which describes the effect of various drug-toxicities on the PGC1α -Foxo1 
axis and therefore, further work is required to understand their role within a toxicological response 
pathway. 
  
In the present experiment the induction of the majority of PGC1α -Foxo1-dependent effector genes occur 
at later time points following PGC1α -Foxo1 co-activation. The exception is however the Pck1 gene 
which encodes the phosphoenolpyruvate carboxykinase 1 enzyme, responsible for the first committed 
step in gluconeogenesis [254]. This gene is induced following activation of the Pck1 promoter by the 
PGC1α -Foxo1 complex however, in the present study, its expression appears to be increased alongside 
both PGC1α and Foxo1 at the 1 hour time point. Induction of Pck1 may therefore be an early biochemical 
adaptation of impaired mitochondrial function with this conclusion suggestive that cells can sense the 
requirement to generate glucose from non-carbohydrate sources very early in the AOP following 
mitochondrial perturbation. 
 
Another key effect noted in vivo was the effect of both compounds on the NR4a gene family and in the 
present study both mitochondrial toxicants induced expression of Nr4a1 and Nr4a3 in a time dependent 
manner up to 8 hours. The early-response Nr4a genes are induced by various extracellular signals and 
stressors (e.g. glucose, growth factors, inflammation and apoptotic signals) and with this diversity of 
pathways regulating Nr4a expression it is likely that the biological function of these receptors is cell-type 
specific [255]. In the liver however there is strong evidence linking NR4a expression with cellular 
regulation of hepatic glucose metabolism with activation caused by reduced glucose levels [255]. This 
data is the first known link between NR4a induction and DIMT with induction likely due to increased 
levels of glycogenolysis. Drug induced agonists which promote expression of the NR4a gene family have 
been described (e.g. 6-mercaptopurine [256] and both the benzimidazole [257]/isoxazolopyridinone [258] 
chemical classes)  but without direct association to perturbation of mitochondrial function.  
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Metabolomics data in chapter 4 identified continued efforts to drive FA β-oxidation despite respiratory 
chain compromise. This adaptation was generally under-represented in terms of the transcriptomic 
analysis with a significant increase in Lpin1 being the only sign of transcriptional regulation of FAO. In 
relation to OXPHOS uncoupling it is widely acknowledged that FA substrate utilization is a key feature 
of the resulting AOP and again Lpin1 was significantly up-regulated. Lpin1 is also activated by PGC1α 
and together they selectively activate a subset of PGC1α target pathways including FAO. Lpin1 is known 
to induce activation of Ppar-α and this was observed in the present study whereby generally Lpin1 
activation appears earlier than Ppar-α induction. Importantly Lpin1 also has a role in the cytosol as a 
Mg
2+-
dependent phosphatidate phosphatase type-1 (PAP1) involved in the synthesis of glycerolipids. 
Despite its up-regulation alongside PGC1α and Ppar-α (suggesting its role is related to its function as a 
transcriptional co-activator in the nucleus), its expression for the purposes of its cytosolic enzymatic 
function cannot be ruled out. Either way, Lpin1 upregulation was observed with both compounds in vitro 
and in vivo and as such the data suggests it plays a central role in the progression of mitochondrial 
toxicity by promoting FAO.  
 
Large increases in both Atf3 and Chac1 were noted in the liver in vivo following DIMT with both 
mitochondrial toxicants (especially GSK932121A). Chac1 specifically, is heavily implicated in the ER 
stress pathway and is pro-apoptotic with glutathione degrading activity (GSH reduction being a key event 
in the progression of GSK932121A toxicity) [259]. Meanwhile, Atf3 is a well-known stress response 
gene which is induced to a wide range of stress signals including drug toxicity [260]. Atf3 is able to both 
repress and activate gene expression and is reportedly involved in the inflammatory response [261], the 
regulation of ER stress mediated pathways, eukaryotic initiation factor kinase 2 stress response, amino 
acid starvation [244], mediation of glucose homeostasis [262, 263], tumorigenesis [264] and cell death 
[265]. Like many other genes induced in this study, the wide range of cell processes reportedly associated 
with Atf3 makes building mechanistic assessments challenging. Further data is required to better 
understand the exact role of both Chac1 and Atf3 in the cell stress response following mitochondrial 
perturbation. 
 
7.3.3. THE LINK BETWEEN AZACYCLONOL AND GSK932121A AND GSK2617971A 
The striking similarity in the transcriptional response to both GSK932121A and GSK2617971A was 
highlighted upon performing connectivity mapping analysis. Despite their very different MOA’s the 
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transcriptional response they elicit was significantly connected with one other compound within a 
database of over 1000 small molecules. The connection between the transcriptomic profile following 
azacyclonol treatment and exposure to both GSK932121A and GSK2617971A was highly statistically 
significant and opened up the possibility that azacyclonol may be toxic to mitochondria. Azacyclonol 
could rationally then be used to validate mechanistic observations with both GlaxoSmithKline 
compounds and as a new tool compound of DIMT. It is important to acknowledge however that despite 
the differing mechanisms of action of GSK932121A and GSK2617971A (i.e. complex III inhibition 
versus OXPHOS uncoupling), the resulting hepatocellular transcriptional similarity may be due to shared 
key events in the resulting AOP/MOA’s (most notably perhaps being a decline in ATP and increased 
glycolytic function). 
 
Mechanistic investigations suggest that, unlike GSK932121A or GSK2617971A azacyclonol (up to 
100µM), does not adversely affect mitochondrial function nor provoke an increase in supernatant lactate 
levels. Furthermore azacyclonol has no effect on mitochondrial morphology or on the levels of 
intracellular glycogen clusters although a moderate reduction in the levels of lipid was observed. This 
data suggests very little similarity in the biochemical response following azacyclonol treatment compared 
to both GlaxoSmithKline compounds despite a similar transcriptional response being first suggested (by 
connectivity mapping) and then confirmed (gene-panel data in the present study).  
 
Azacylonol is best known as the N-dealkylation product of terfendaine metabolism [266]. Terfenadine 
was withdrawn from development due to reports of QT-interval prolongation and cardiac arrhythmias and 
although rapidly metabolized in the liver, azacyclonol was never attributed to the terfenadine toxicity 
[267]. In fact, azacyclonol was briefly investigated as an anti-psychotic agent in schizophrenic individuals 
and although not being sufficiently efficacious, it was well tolerated in humans which, unlike both 
GlaxoSmithKline mitochondrial toxicants, sums up its minimal safety profile [268, 269]. It remains 
unknown why it induces a similar gene expression signature to two potent mitochondrial toxins. 
 
Computational analyses were performed to assess whether transcriptional similarity was caused by any 
chemical/structural similarity between azacyclonol and either/both of GSK932121A/GSK2617971A. 
Using Tanimoto coefficient, essentially as described in [270], low comparative similarity scores of 0.16 
and 0.13 were achieved in terms of comparing azacyclonol to GSK932121A and GSK2617971A 
respectively (with a score of 1 indicating high structural similarity). In addition, a ligand based target 
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prediction was performed in ChEMBL, to assess any overlap between azacyclonol and either/both of 
GSK932121A/GSK2617971A from a target-based perspective. Taking into account the top ten target 
predictions for all three compounds, no overlap was observed. These analyses (raw data not shown) 
suggests no theoretical association between azacyclonol and either GlaxoSmithKline tool compound 
based on structural similarity or target prediction. 
 
This association does however provide some important learnings for the future. Whilst the present work 
has highlighted the involvement of genes such as PGC1α, Foxo1, Irs2, Pdk4, Pck1, Lpin1, Nr4a1 and 
Atf3 in the response to mitochondrial perturbation, similar responses are observable following treatment 
with mitochondrially-inactive compounds (i.e. azacyclonol). This therefore suggests that these genes are 
unsuitable as specific biomarkers of mitochondrial toxicity. Furthermore, the present work emphasises 
that transcriptional similarity does not always correspond to mechanistic-likeness and as such, the process 
of searching for and validating highly specific single-gene or gene-panel biomarkers always requires 
additional context and validation. The implication is also that, whilst the lack of a gene change likely 
rules out involvement, existence of such a change on its own does not confirm involvement in an effect. 
Furthermore, gene changes cannot be used as strong-supporting evidence in the construction of an 
AOP/MOA. 
 
7.3.4. SUMMARY 
In summary the following conclusions can be drawn from this study. 
 
 Concentrations of 0.75µM-10µM GSK932121A (complex III inhibition) and 0.1µM-2.5µM 
GSK2617971A (OXHOS uncoupling) cause significant perturbation to mitochondrial function 
but are sub-cytotoxic in HepG2 cells at a gross cell level. 
 Sub-toxic concentrations of both GSK932121A and GSK2617971A only effect HepG2 cell 
lactate generation at 4-8 hours post-treatment and as such this may be a delayed adaptive response 
to perturbation of energy production rather than an early mechanistic event.  
 PGC1α, Foxo1 and Pck1 are early response genes following GSK932121A/GSK2617971A 
treatment which is followed by time-dependent up-regulation in the NR4a genes (NR4a1/3), the 
PGC1α -Foxo1 effector genes (Hmox1, G6pd and Irs2), the FAO activation gene (Lpin1) and the 
stress response genes (Atf3 and Chac1).  
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 Minimal effects on mitochondrial or cellular morphology were observed up to 8 hours post 
treatment with GSK932121A and GSK2617971A suggesting structural changes occur at later 
stages and at higher (potentially toxic) concentrations.  
 Compound connectivity mapping analysis identified azacyclonol as the most statistically 
significant similar compound compared with both GSK932121A and GSK2617971A in terms of 
the respective transcriptional response to drug treatment. This striking observation highlights the 
similarity in transcriptional response following complex III inhibition and OXPHOS uncoupling 
in vivo. Despite transcriptional similarity, azacyclonol did not mimic the biological action of 
either compound as no effect on mitochondrial function, lactate generation or glycogen stores was 
observed in vitro. Gene expression analysis confirmed transcriptional similarity to both 
GlaxoSmithKline compounds suggesting that the gene panel used in this study is not specific to 
DIMT. 
 This study supports the use of a systems approach as a combination of endpoints, in a multivariate 
model (e.g. genes and metabolites/ functional changes etc.), may be required for good early 
predictions. 
 
Further work should involve a timed-kill study in rats, in order to assess the effect of compound treatment 
at the tissue-level, at both early and progressive time points in vivo. Further work should also involve the 
effect of GSK932121A and GSK2617971A on PGC1α, Foxo1 and Pck1 protein concentration (i.e. using 
Western blot) as these genes constitute the earliest transcriptional markers induced following treatment 
with tolerated concentrations of mitochondrial toxicants studied to date.  Further work may also focus on 
whether any of the top 10 similar compounds for both GSK932121A and GSK2617971A effect 
mitochondrial function as only azacyclonol was explored in the present work. 
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8.0. THESIS DISCUSSION 
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Drug induced mitochondrial dysfunction is associated with some severe clinical toxicities resulting in 
adverse human suffering. Despite the progress made, defining mechanisms of DIMT even in the common 
pre-clinical test species (e.g. rat and mouse) remains difficult and the challenge is even greater when 
extrapolating to humans. The overall aim of this thesis was to use a systems approach (i.e. the use of a 
wide range of endpoints which are multi-faceted in scope) to improve current understanding of the 
mechanism and consequences of DIMT in vivo and relate these findings to in vitro observations using tool 
compounds.  
 
On personal reflection and by the very nature of the project, this was an ambitious challenge. In hindsight, 
I would have focussed more on a particular area in the field (i.e. mechanisms of DIMT specifically in 
liver injury or with a particular sub-set of mitochondrial toxicants) as this added level of focus may have 
aided more tailored investigations and as such, further progress. Despite this, the challenge provided the 
opportunity for substantial scientific advancement and project diversity. 
 
The overall aim of the thesis was broken down into a series of sub-objectives which are discussed below. 
 
8.1. Manifestation of Mitochondrial Toxicity in vitro versus in vivo 
The first sub-objective was to test the hypothesis that in vitro assessment of mitochondrial function (i.e. in 
vitro cell lines or in vitro testing of drugs on naïve isolated mitochondria) adequately reflects what occurs 
in vivo and is therefore a useful means of assessing the potential for mitochondrial toxicity in preclinical 
hazard identification. In vitro analysis of DIMT is used in the pharmaceutical industry both for screening 
activities and for making mechanistic assessments. The effect of two tool compounds, GSK932121A 
(complex III ETC inhibitor) and GSK2617971A (OXPHOS uncoupler) was assessed, to identify how 
mitochondrial toxicity manifested both in vitro and in vivo.  
 
In vitro, both GSK932121A and GSK2617971A acted as expected and in line with other respiratory chain 
inhibitors and OXPHOS uncouplers respectively. With regards to the effect of both compounds on OCR 
in vitro, the direction of change observed was as anticipated i.e. GSK932121A caused a reduction in OCR 
and GSK2617971A caused a biphasic increase in OCR. As expected, both compounds decreased the CRC 
of freshly isolated control liver mitochondria in vitro due to impairment of the mitochondrial ΔΨ. This 
suggests that in vitro studies have utility in assessing mechanisms of DIMT (i.e. by comparing the 
208 
 
response to classical tool-molecules with similar mechanisms) though on a number of occasions, the 
direction of change observed in vitro was seen to be opposite to that observed in vivo. 
 
Mitochondria isolated from the kidney of rats treated in vivo with GSK2617971A showed an unexpected 
decrease in all OCR parameters This is likely due to high levels of exposure in the kidney since the drug 
is predominantly cleared via the renal route, coupled with the fact that OXPHOS uncouplers generally 
exhibit a bell-shaped response curve (i.e. reducing OCR at high concentrations).  This is a key learning 
with regard to selecting the most sensitive endpoints to detect drug-induced OXPHOS uncoupling 
following in vivo treatment in future studies. Assays of CRC and ΔΨ in mitochondria isolated from 
treated animals provided a more sensitive indication of OXPHOS related toxicity in the present studies 
than OCR, with findings more consistent with the OXPHOS mechanism of action (i.e. dissipation of the 
ΔΨ and reduction in CRC). It is therefore advisable to use these assays, in preference to the OCR assay, 
when analysing the effect of OXPHOS uncouplers in vivo. 
 
Mitochondria isolated from rats treated in vivo with GSK932121A demonstrated unexpected yet clear 
differences with data obtained in vitro, namely an increase in basal OCR and CRC in mitochondria from 
treated animals compared to control. Whilst seemingly contradictory these observations likely represent 
an adapted state in vivo resulting from the initial insult in combination with the compensatory response of 
the animal/tissue to energy deprivation. Only the initial, unconfounded response is observable in vitro. 
Whilst acidosis and the resulting densitisation of the mPTP to calcium-induced pore triggering is 
proposed to be the cause of the increase in CRC in mitochondria from GSK932121A treated rats, the 
exact reason for the increase in OCR remains unknown. Hypotheses include washout of GSK932121A 
during the isolation procedure, increased levels of ROS-induced proton leak and stabilisation of a 
mitochondrial subpopulation in GSK932121A treated animals due to reduced mPTP triggering.  
 
Whatever the mechanisms involved, it is now evident that consideration of both the in vitro and in vivo 
data is essential; neither on its own would have been sufficient. The in vitro data informs on the likely 
molecular initiating event and initial (non-confounded) respiratory response, whist the in vivo data 
provides a view of the integrated state of the mitochondria in response to the initial insult plus the 
compensatory adaptations occurring in the tissues and organism. 
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8.2. The Use of a Systems Approach to Generate AOP’s 
The second sub-objective was to assess the utility of using a systems approach in order to highlight the 
underlying mechanisms downstream of mitochondrial perturbation in vivo. Systems toxicology 
encompasses the integration of classical toxicology (e.g. pathology, clinical chemistry) with, a) novel 
methods of evaluation, in this case functional mitochondrial changes and b) with the quantitative analysis 
of large networks of molecular changes occurring across multiple layers of biological organisation, in this 
case transcriptomic and metabolomics assessments. A systems approach is particularly useful when the 
mechanisms are either completely unknown or where only little understanding exists. To build upon 
already existing knowledge of an adverse drug reaction, targeted evaluations may be more useful. Given 
the complexity of the downstream mechanisms of DIMT relating to respiratory chain inhibition (chapters 
3-5) or OXPHOS uncoupling (chapter 6) in vivo, a systems approach seemed the most suitable.  
 
For GSK932121A, evaluations included classical toxicology (serum biochemistry and histopathology), 
novel methods of evaluating mitochondrial function, glutathione profiling, TEM, body temperature etc; 
along with the use of global “omics” approaches (transcriptomics and metabolomics). Whilst this 
provided a truly system-level view from which to build an AOP for complex III inhibition (described in 
chapter 5) determining the key events between the primary molecular initiation event (compound binding 
to the Qi site of cytochrome bc1 and inhibiting ETC) and the adverse outcome was very challenging. This 
was made harder in this case here because the progression of toxicity was so rapid (within 5 hours), 
making identification of the order of events difficult. For this reason, the study design is of paramount 
importance and generation of AOP/MOA’s should be augmented by existing literature data with other 
compounds with similar mechanistic activities. 
 
Effects of both time and dose should be investigated. The complex nature of toxicological adaptation 
makes identifying primary consequences from adaptive secondary events a major challenge. For example, 
despite extensive investigations throughout this thesis looking into lactate generation, it still remains 
unknown whether this is a primary event following DIMT or whether this occurs downstream of 
prolonged perturbation in energy production. This example highlights a key learning. Regardless of the 
number of endpoints selected for analysis, the study design is fundamentally crucial to be able to generate 
AOP’s. Time and dose responses are required in order to make informed judgements of the key events in 
an AOP and answer difficult questions such as; in the absence of any single key event does the adverse 
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outcome manifest? Are there any modifying factors, which when present, effect the progression or 
severity of the adverse outcome?  
 
For both GSK932121A and GSK2617971A further work is required in order to investigate lower doses 
and earlier time points, using data presented in this thesis as a starting point to help design the studies and 
select endpoints that will provide the best possible opportunity to clarify uncertainties remaining in both 
AOP’s. An example of such a study would be to investigate the effect of a 14-day repeat dose exposure to 
the well-tolerated 12.5mg/kg dose of GSK932121A to identify effects on liver histopathology, 
mitochondrial function and body temperature. This would bring insight from the present work into the 
repeat-dose scenario and therefore be more representative of the study designs used commonly in drug 
development with small molecules.   
 
In addition, it is important to acknowledge that observations made post-treatment with both 
GSK932121A and GSK2617971A cannot purely be attributed to their toxicological effects. For example, 
observations made following administration of GSK2617971A in vivo may be caused by the drugs action 
as a selective androgen receptor modulator as oppose to simply its effects on mitochondrial uncoupling. A 
way of delineating “on target” therapeutic effects (i.e. effects as a SARM) from “off-target” effects (i.e. 
effects as an uncoupler) would be to have included a positive control non-SARM OXPHOS uncoupler 
(e.g. 2,4-DNP) in all studies, alongside GSK2617971A and compared the differential responses (e.g. 
transcriptomic signatures) to both molecules. Although this was not feasible due to time constraints this 
work is necessary to validate the AOP/MOAs. 
 
The definitive list of AOP’s which are validated to-date are on the AOP-Wiki web-page 
[https://aopkb.org/aopwiki/index.php/Main_Page] along with guidance documentation, written by the 
Organisation for Economic Co-operation and Development (OECD), on developing and assessing AOP’s 
[271]. This was based around advancement (but importantly not replacement) of the existing, mode of 
action (MOA) approach which involved the description of a biologically plausible sequence of key events 
and processes. This document proposes a weight-of evidence based approach with a tailored set of 
Bradford Hill considerations whereby the level of confidence of all endpoints is scrutinised for biological 
plausibility, reproducibility, relationships between key events and apical endpoint, assay reliability and 
key event essentiality [272]. Table 8.1 below represents the differences between toxicity pathways, 
MOA’s, AOP’s and source to outcome pathways. 
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TABLE 8.1: Representation of the relationships between Toxicity Pathways, Mode of Action Pathways, Adverse Outcome 
Pathways, and Source to Outcome Pathways. Orange bars represent the breadth of reach common to these 
concepts. The grey boxes represent the theoretical extent of the concepts. Adapted from [271].  
 
The weight-of evidence based approach described in the OECD white-paper is  similar in many regards to 
the AOP/MOA hybrid approach taken in chapter 5 to detail the observed acute toxicity with 
GSK932121A (complex III inhibition). The approach was not taken with GSK2617971A (chapter 6) due 
to having less data available in order to distinguish key events from PKE’s and associated events.  
 
Consideration of alternative explanations for the key AOP observations is imperative as there is often 
more than one plausible pathway and as a result, the hybrid AOP/MOA framework is a useful progressive 
step in the development of a fully validated AOP. For any investigation which aims to identify a 
mechanism of toxicity, the intelligent use of a systems approach is helpful and in some cases crucial. 
Following initial identification of fundamental key events and the preparation of a draft AOP/MOA 
hybrid (such as that displayed in chapter 5), studies should then be designed for more targeted 
evaluations, with refined doses and time-points to clarify uncertainties in the AOP/MOA and progress 
towards a full AOP. The AOP-Wiki provides a validation-procedure which provides the opportunity for 
other users to comment and edit AOP proposals prior to formal review by both the OECD and Extended 
Advisory Group on Molecular Screening and Toxicogenomics (EAGMST). This level of peer-review is 
critical for the generation of reliable and informative AOP’s which have utility in future drug/chemical 
risk-assessment. 
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8.3. Markers of DIMT in the Absence of Overt Toxicity 
The third sub-objective of the thesis was to set the groundwork for identifying markers of DIMT that 
change prior to the onset of overt toxicity. Importantly, this effect can be assessed either at low (sub-
toxic) doses or at earlier time-points with a higher (toxic) dose.  
 
In the past, drugs have been withdrawn from the market due to toxicity which was subsequently identified 
to be associated with mitochondrial dysfunction that was not overtly evident throughout pre-clinical and 
clinical trials (troglitazone being a key example). This may be due to the fact that damage to mitochondria 
was not detected in preclinical trials since mitochondrial functional changes have historically not been 
assessed or because the underlying effects are asymptomatic (e.g. erosion of reserve capacity). 
Mitochondria are able to respond to a certain level of direct or indirect stress by utilisation of an innate 
reserve capacity and this mitochondrial-resilience prevents the immediate onset of toxicity early in drug 
development. In vivo markers of mitochondrial damage which change prior to the onset of overt toxicity 
would be of immense value in monitoring the potential safety of molecules with some degree of 
mitochondrial activity but which are generally well tolerated in animals. 
 
The most striking sub-toxic marker of underlying mitochondrial changes in vivo (identified in the present 
work) was measurement of CRC; for example administration of GSK2617971A to rats at a dose which 
caused no adverse clinical effects or body temperature alterations (30mg/kg) caused a significant 
depletion of CRC in isolated liver and kidney mitochondria. Mitochondrial functional measures, 
particularly CRC, may therefore be an informative marker of potential underlying DIMT in preclinical 
studies and this potential is now being investigated further in follow up studies within GlaxoSmithKline. 
Although extremely valuable in pre-clinical evaluations, CRC analysis in isolated mitochondrial fractions 
is not easily translatable to human trials due to the need for tissue. It is for this reason that more accessible 
markers of DIMT; for example, in bio-fluids or biopsy samples are being sought. Hence the plasma 
metabolite findings, described in chapter 4, are of particular value. 
 
Metabolomics analyses identified a number of potential markers of DIMT prior to the onset of clinical 
signs following GSK932121A treatment. These included changes in the fatty acyl carnitines 
palmitoylcarnitine, oleylcarnitine and stearoylcarnitine, the ketone body BHBA and amino acid 
catabolism marker AHB. Importantly, whilst these metabolomic changes can inform about the metabolic 
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adaptation due to perturbed energy generation the fact is they closely resemble other conditions such as 
metabolic syndrome and insulin resistance. Consequently any markers derived from this work need to be 
applied with this in mind until further validation work is performed. For example, they may be best used 
in scenarios where mitochondrial activity is known or suspected with a candidate molecule and used for 
monitoring purposes rather than as routine biomarkers run on every in vivo study, such as standard 
clinical pathology makers. It is however my opinion that further work is warranted due to the potential 
translatability of these measurements to humans. Without taking these findings forward and generating 
further data with other mitochondrial toxicants it is impossible to determine the potential utility of these 
endpoints in terms of DIMT.  
 
Chapter 7 focussed on identifying markers of DIMT in vitro at sub-cytotoxic concentrations of both 
GSK932121A and GSK2617971A using endpoints shown to be sensitive in vivo. Genes involved in the 
induction of gluconeogenesis, specifically the switch genes PGC1α and Foxo1 and the gene encoding the 
rate-limiting step in gluconeogenesis (Pck1) were induced early following treatment of HepG2 cells with 
sub-cytotoxic concentrations of both drugs. Like the mitochondrial functional endpoints described above, 
measurement of these genes may prove valuable in future pre-clinical assessments although, connectivity 
mapping analysis raised questions about their specificity as markers of DIMT, as the expression of many 
changed in response to a molecule with no obvious effect on mitochondrial function (azacyclonol).   
 
In addition to the potential identification of biomarkers, the work presented here has provided invaluable 
mechanistic insight. Sub-toxic markers help identify primary toxicity from adaptive cell events in the 
development of an AOP/MOA (as described above). For example, studies presented here have revealed 
that potentiation of calcium-induced mPTP does not necessarily provoke a clinical outcome and is 
therefore an early event in the AOP. Additionally it has been noted that, induction of genes involved in 
the gluconeogenic response is an early consequence and biomarker of dysfunctional mitochondrial 
ETC/OXPHOS systems.  
 
The withdrawal of a number of drugs due to toxicity which was later discovered to involve perturbation 
of mitochondrial function highlights a gap in current drug development methodologies, namely the 
apparent insensitivity of the commonly used animal models to mitochondrial perturbation. This may 
reflect the metabolic state of the animals currently used in pre-clinical studies that are generally young, 
healthy and possess a large reserve capacity allowing them to readily adapt to stress. This is at odds with 
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many patient groups whose metabolic capacities are eroded by co-morbidities, co-medication, age, 
genetics, lifestyle etc. This apparent lack of concordance between the current pre-clinical animal model 
and the patient population is illustrated by Fig.8.1 below.  
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 8.1.: Graphical representation of the relative metabolic states of potential target patient populations and the 
commonly used preclinical animal species. 
 
A potential option to address this issue is to increase the metabolic burden on the animals alongside drug 
treatment, for example increasing the exercise demand, co-administering with other molecules which alter 
metabolic demand/function or using older animals. For example, in a recent GlaxoSmithKline study (data 
not shown) a candidate drug which had been well-tolerated in 14 day oral toxicity studies (despite 
histopathological changes in cardiac tissue) was co-administered with dobutamine (a cardiac β1 receptor 
agonist used to stimulate heart contraction). This uncovered physiological changes in cardiovascular 
function which were absent in either drug alone or dobutamine alone controls. Other options are to 
explore the use of transgenic animal models in which metabolic capacity is affected, which may be more 
representative of patients in terms of underlying mitochondrial function. An example would be Sod2
+/-
 
mice which have been shown to be more sensitive to troglitazone-induced liver injury highlighting the 
increased sensitivity of this mouse model to DIMT [273].  
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What remains clear is that markers which can inform on mitochondrial perturbation prior to the onset of 
overt toxicity or the use of animals models that are more representative of patients with regard to 
metabolic status would be of immense value. This would enable improved monitoring of molecules with 
some degree of mitochondrial activity in vitro and ultimately improve drug safety for patients. 
 
8.4. Future Work 
Validation work with additional tool compounds is required to confirm that the observations made with 
GSK932121A and GSK2617971A are mechanism related and not specific to the individual compounds 
(i.e. many of the effects observed following administration of GSK2617971A for example may be due to 
its activity as a SARM as opposed to just its uncoupling effects).  Compounds such as antimycin A, and 
2,4-DNP or other terminated GlaxoSmithKline molecules with the right properties, could be considered. 
Future studies should include tissue-collection at early time-points to determine exactly when 
mitochondrial functional changes occur and to provide a time course for more in depth transcriptomic 
work.  
 
Critically, the potential markers highlighted by the in vivo studies presented (ranging from body 
temperature, through biochemical analyses to mitochondrial functional endpoints)  should be tested in 
chronic repeat-dose studies with mitochondrially-active compounds, at tolerated doses, to see if low level 
chronic reductions in mitochondrial function can be detected in the absence of overt toxicity. These 
studies should accurately represent the study designs used for standard regulatory toxicology work to test 
the utility of these markers in a standard study setting. Potential biomarkers of DIMT in plasma (i.e. 
acylcarnitines, BHBA and AHB)  should also be tested to see if they are robust and reproducible and as 
such, potentially translatable to the clinic.  
 
As described in section 8.3 above, the animal models currently used in drug safety assessment appear 
relatively insensitive to DIMT. This represents a significant gap that might be improved by the use of 
more sensitive animal models (although there is a dynamic move to reduce reliance on animal models in 
R&D and replace them with non-animal approaches where possible). Early investigations should follow 
up on existing work using the Sod2
+/-
 mouse model (increased levels of oxidative stress) or with co-
administration study designs. Ethically it will be important not to place the animals under unnecessary 
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stress. Any observed exacerbation of toxicity with known mito-toxicants compared to the effects observed 
in controls may indicate a more suitable model for the detection of underlying, asymptomatic DIMT. 
 
The corresponding protein levels of the key genes identified following DIMT (e.g. PGC1α, Foxo1 and 
Pck1) should also be explored downstream of DIMT both in vitro and in vivo, via Western blot, as gene 
expression changes are not always representative of protein translation/expression. It would also be 
interesting to modulate the expression of these genes via RNA interference (RNAi) in vitro, and analyse 
the effect of this knockdown following treatment with mitochondrial toxicants, specifically whether gene 
knockdown confers resistance or exacerbates the effect of DIMT.  
 
Further work should also focus on the intelligent mining of existing data relating to mitochondrial 
function in the pharmaceutical industry. The creation of computational tools to visualise, analyse and 
identify compounds and structures with varying degrees of mitochondrial activity (not just necessarily 
toxicity) would be invaluable both in selection of tool molecules, re-positioning of assets between 
discovery programmes (i.e. a compound which inhibits the mPTP, and thus delays cell death, may not be 
beneficial to oncology programmes but may be extremely beneficial to stress and repair groups), and to 
build structure activity relationship (SAR) paradigms. 
 
8.5. Summary 
This thesis has focused on using a systems approach to understand mechanisms of drug induced 
mitochondrial toxicity in vitro and in vivo, specifically using compounds which inhibit the mitochondrial 
ETC complex III (GSK932121A, chapters 3-5) or uncouple OXPHOS (GSK2617971A, chapter 6). This 
type of evaluation is rarely seen in the literature, particularly with novel pharmaceutical candidates (albeit 
terminated ones) and as such will be of particular interest to those who are faced with designing safety 
studies for mitochondrially active drugs and potential mito-toxicants. In vitro investigations were 
performed to assess the effect of sub-toxic concentrations of the two tool compounds on endpoints which 
had been identified as informative from in vivo studies (i.e. TEM, gene expression and lactate – chapter 
7).  
 
This project has answered some of the questions posed and in doing so has contributed to our general 
knowledge of the mechanisms of DIMT and the downstream biological consequences. It is clear that the 
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use of a systems approach can be of significant value when defining an initial mechanistic overview and 
therefore as a starting point for developing a AOP/MOA for a particular toxicity. Systems-based 
evaluations lay the groundwork for more tailored and detailed follow-up studies aimed at clarifying the 
key events to result in a final AOP (a robust resource for use in the risk assessment of other compounds 
with similar mechanistic activity). This in turn will help reduce costly compound attrition, reduce the time 
to get new drugs to market and ultimately improve the safety profile of medicines for patients by 
preventing future cases of DIMT in humans.  
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APPENDIX I – STRUCTURAL ASSESSMENT OF ISOLATED 
MITOCHONDRIAL FRACTIONS 
 
Following optimisation of mitochondrial isolation procedures for the five tissues of highest metabolic 
load (i.e. the liver, kidney, heart, skeletal muscle and brain) it was important to assess the structural 
integrity of the obtained fractions. Although the use of isolated mitochondria have proved to be a very 
powerful tool in the study of the OXPHOS system, biogenesis, substrate oxidation etc., compromises 
remain regarding their utility as tools to study DIMT. One of the primary compromises relates to the 
effect of mitochondrial isolation on the structural integrity of the obtained fraction and as a result, the 
“likeness” of the isolated mitochondria to those in the in vivo milieu.  The isolation of mitochondria from 
animal tissues is a stressful procedure, typically relying on Dounce, Potter-Elvehjem and rotor/stator 
shearing homogenisers [102]. This causes structural damage to the mitochondria, disruption of the 
heterogeneous bioenergetic network and disturbance to dynamic mitochondrial processes (e.g. fission and 
fusion). It was therefore decided to use electron microscopy and Western blots to assess the structural 
integrity of the mitochondria isolated from each tissue in an attempt to determine the suitability of these 
isolates for the study of DIMT. 
 
APPENDIX 1.1: Transmission Electron Microscopy 
 
TEM imaging was performed on isolated mitochondrial pellets (from all five tissues) as described in 
section 2.10.1. TEM images and a description of the main findings are presented in Appendix Table 1.1 
below. 
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Organ Low magnification (12000x) High magnification (30000x) Details 
 
Liver 
 
 
The mitochondria were 
generally of typical appearance 
with intact cristae and medium 
electron dense matrices.  The 
cristae showed a degree of 
swelling and the occasional pale 
swollen mitochondrion was 
seen.  A large amount of 
heterogeneous material (tubular, 
vesicular and amorphous 
material) was present between 
the mitochondria. 
Kidney 
 
 
 
 
 
Little heterogeneous material 
and no presence of other 
organelles. Large swelling of 
cristae was observed with low 
electron density matrices 
Heart 
 
 
 
The mitochondria were 
generally of normal appearance 
although a small proportion had 
swollen cristae.  They show a 
high density of tightly packed 
cristae. There was little 
heterogeneous material 
observed between the 
mitochondria with no other 
organelles present. 
 
 
 
Skeletal 
Muscle 
 
 
 
Many of the mitochondria were 
swollen or showed quite marked 
dilation of the cristae.  The 
mitochondria obtained from this 
tissue were considered to be the 
most altered. Other organelles 
were not present but fragments 
of myofibrils were seen among 
the mitochondria. 
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APPENDIX TABLE 1.1: TEM Analysis of crude mitochondrial pellets isolated from five tissues of high metabolic load. 
Isolated mitochondria from liver, kidney, heart, skeletal muscle and brain were processed for TEM as described 
in section 2.10.2. Images are shown at 12,000x and 30,000x magnification. 
 
In addition to observations made in appendix table 1.1 above, brain mitochondria were often observed 
within membrane bound vacuoles. It is believed that these vacuoles are synaptosomes which are formed 
when pre-synaptic membranes re-seal enclosing the contents of the nerve terminals (not shown). 
Furthermore a number of liver mitochondria were observed undergoing fission/fusion events although it 
remains unclear whether this is physiological (e.g. repair mechanisms, natural replication) or simply an 
idiosyncratic observation with little relevance to the population of mitochondria (not shown). 
  
Brain 
  
 
 
The mitochondria were 
generally of normal appearance 
but a proportion contained 
swollen cristae.  The 
mitochondrial membranes 
appeared densely organised.  
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APPENDIX 1.2: Western Blot 
The Western blot data presented in Fig.Appendix1 below generally supports observations from the TEM 
investigations described above. Mitochondrial protein was analysed by Western blot according to the 
method outlined in section 2.11. Mitochondria were also probed for detection of proliferating cell nuclear 
antigen (anti-PCNA) and alpha-tubulin (Anti-α-tubulin) as markers of both the nuclear and cytoplasmic 
fractions respectively. This was performed to ensure purity of the mitochondrial fractions from other 
cellular compartments. Despite observations of cellular debris in the TEM images, no PCNA or α-tubulin 
was detectable via Western blot (data not shown), suggesting that mitochondrial preparations from all 
tissues are relatively pure and lacking in contamination. 
 
The molecular weights of the structural subunit proteins are generally consistent with those suggested by 
the manufacturer (outlined in Appendix-Fig.1.1B) although a slight discrepancy is seen with the 
cyclophilin D and cytochrome c proteins. Western blot data supports the TEM observations which show 
mitochondria isolated from the heart with prominent banding and protein abundance especially in terms 
of the inner membrane respiratory complexes, the mitochondrial matrix and the IMS. The dense banding 
also suggests larger quantities of protein at all mitochondrial levels per mg of mitochondria analysed. 
Likewise mitochondria from the skeletal muscle were suggested to be the most altered in terms of 
structure following TEM analysis and this is confirmed via Western blot where banding appears faint and 
only very minor levels of the OMM porin proteins were detected. 
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APPENDIX FIGURE 1.1: Assessment of mitochondria isolated from 5 rodent tissues via Western blot.(A) Mitochondria 
isolated from the liver, kidney, heart, skeletal muscle and brain were examined via Western blot using a 
multiplexed Antibody cocktail containing proteins essential to the IMM (complex V), OMM (porin), matrix 
(cyclophilin D) and IMS (cytochrome C). (B) Image lifted from Mitosciences protocol booklet (Abcam 
#ab110414) detailing the expected molecular weights of each protein and the identification of corresponding 
bands [http://www.abcam.com/membrane-integrity-wb-antibody-cocktail-ab110414.html] – Accessed 10 July 
2015. 
 
Western blot data with liver, kidney and brain suggests that the integrity of the mitochondria isolated 
from these tissues is generally fair although all have relatively faint banding of the OMM porin protein. 
This was to be expected as it suggests that the isolation procedure affects the outer membrane structure 
more severely than the IMM, IMS and matrix. Despite general accordance with the manufacturer’s 
expected banding (see Fig.Appendix 1B) no separation of the two OMM porin isoforms was observed in 
any mitochondrial preparation. It remains unknown whether this is due to structural damage to the outer 
membrane or due to poor resolution/contrast in the Western blot images. Following analysis of both TEM 
images and Western blot data, the rank order of structural integrity following mitochondrial isolation is 
shown below. 
 
Heart  >  Liver  >  Brain  > Kidney  > Skeletal Muscle 
Liver Kidney Heart 
Skeletal 
Muscle Brain 
A B 
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The structural data presented in this appendix does however suggest that all mitochondrial isolates are 
relatively fit for purpose. The isolation protocols are all selective for the mitochondrial population (i.e. no 
obvious presence of other organelles) and all isolate mitochondria which remain structurally sound 
(although to varying degrees of success). Future work should focus on the continued improvement of 
isolation protocols and should assess the utility of methods, either not involving the manual 
homogenisation of tissue (i.e. tissue shredders [102] or nitrogen cavitation [130]), or which rely less on 
stressful homogenisation steps (i.e. the  magnetic bead capture methods [274]). 
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APPENDIX II – FUNTIONAL ASSESSMENT OF ISOLATED 
MITOCHONDRIAL FRACTIONS 
 
Following optimisation of mitochondrial isolation procedures, it was important to ensure the obtained 
fractions were functional in a number of key assays. A sustained period of time was spent optimising the 
parameters for mitochondria isolated from all five tissues in the CRC, OCR and mitochondrial ΔΨ assays. 
It does however remain inherently challenging to compare mitochondria isolated from each tissue. This is 
a result of the vastly different isolation protocols which produce fractions which vary widely with regard 
to the following… 
 
 Mitochondrial number (i.e. per mg of tissue). 
 The degree of structural damage caused by the isolation procedure, particularly the tissue 
homogenisation step. 
 The resulting buffer which the mitochondria are stored in. 
 
As a result of the above factors, the optimisation of each assay with each mitochondrial fraction required 
individual tailoring. This optimisation created a functional battery of assays with mitochondria from these 
five tissues. Key optimisation variables included the mitochondrial substrate (i.e. complex I or complex II 
driven substrates) and the concentration of mitochondria. The resulting assay kinetics therefore reflect 
artefacts of both the isolation protocol and optimisation parameters in combination with the biology and 
metabolic activity of the mitochondria from each tissue. As a result and due to the fact that the assay 
conditions of mitochondria from each tissue are so non-standardised, directly comparing the functionality 
of mitochondria from each tissue is fundamentally problematic.  
 
A functional assessment which was made however was the respiratory control ratio (RCR) of 
mitochondria from all five tissues. The RCR is calculated by dividing the respiration in state 3 (ADP-
driven respiration) by that in state 4. As a result, the RCR represents the degree of coupling between ETC 
function and OXPHOS with high RCR values implying that mitochondria have a high capacity for 
substrate utilisation and ATP turnover and a low proton leak [75]. Although there is no benchmark RCR 
to define functional/dysfunctional mitochondria (as RCR is substrate and tissue dependent), Garcia-
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Cazarin and colleagues in 2011 suggested that an RCR of above 4 is considered as evidence of a viable 
mitochondrial population [275]. This was therefore the arbitrary RCR-number which was deemed 
acceptable for mitochondria isolated from each tissue.  In order to validate the viability and functionality 
of the obtained RCR values, comparisons were drawn to others reported in the literature with 
mitochondria isolated from each tissue. RCR values obtained from isolated mitochondrial fractions are 
shown in Appendix Fig.2.1 below. These RCR values have been calculated as an average (±SD) of a 
number of control animals used in multiple studies at GlaxoSmithKline over the course of the PhD (n-
numbers stated below). 
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APPENDIX FIGURE 2.1: RCR values obtained for mitochondria isolated from liver, kidney, heart, skeletal muscle and 
brain rat tissues. Data represents RCR values (state 3/state 4) for mitochondria isolated from rat liver (n=37), 
kidney (n=8), heart (n=37), skeletal muscle (n=24) and brain (n=17). Data shown is mean ± SD. 
 
RCR values shown in appendix Fig.2.1 above correlate well with published values obtained in other 
laboratories as shown in appendix table 2.1 below. It is however important to acknowledge that 
measurement of mitochondrial respiration is performed using multiple different techniques (i.e. Seahorse 
Bioanalysers, Luxcel oxygen sensing probes, Clarke-type electrode) and, as a result, RCR values are 
likely to differ greatly making the drawing of valid comparisons challenging. The technique used to 
generate the reported RCR’s is also detailed in appendix table 2.1. 
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 APPENDIX TABLE 2.1: Non-quantitative comparison between obtained RCR values for mitochondria isolated from five 
tissues of high metabolic load and published RCR values.  
 
The obtained RCR values are comparable with those reported in the literature although, with all tissues, 
higher RCR values can be found in the literature. Any future attempts to improve isolation protocols 
should use RCR values as the gold-standard measure of mitochondrial viability and isolation protocols 
should only be changed if higher RCR values are consistently obtained. 
Tissue Origin Achieved RCR Published RCR (including method used for respiratory analyses) 
 
Liver 4.81 RCR = 4 (Hanastech Instruments, Oxygen electrode) [276]. 
 
RCR = 5.86 (Clark-type electrode)[104]. 
 
RCR = 4.45 (Gilson oxygraph) [277] 
 
RCR = 4.4 - 4.5 (Clark-type electrode) [278].   
 
Kidney  4.66 RCR = 3.6-4.1 (Oroboros oxygraph system) [102] 
 
RCR = 3 – 3.5 (Clark-type electrode) [279] 
 
RCR = ~3.2 (Seahorse XF24) [280]. 
 
RCR = 5.21 (Gilson oxygraph) [281]. 
 
Heart 4.06 RCR = 4.3 (Clark-type electrode) [282]. 
 
RCR = 2.4 – 3.5 (Clark-type electrode)[283] 
 
RCR = 5 – 12 depending on substrate utilised (Clark-type electrode) [284]. 
 
RCR = 6 – 8.5 (Clark-type electrode) [285]. 
 
Skeletal Muscle 5.82 RCR = ~2 – 6 depending on substrate utilised (Clark-type electrode) [286] 
 
RCR = 3.4 – 10 depending on substrate utilised (Clark-type electrode)[287] 
 
RCR = 6-10 (Clark-type electrode)[288] 
 
RCR = ~3.9 (Oroboros oxygraph)[289] . 
 
Brain 4.36 RCR = 3 – 3.25 (Seahorse XF24) [290]. 
 
RCR = 5.5 (Clark-type electrode) [291]. 
 
RCR = 3 – 3.5 (Clark-type electrode) [292] 
 
RCR = 6.6 (Clark-type electrode)[293] 
 
RCR = ~7 (Seahorse XF24) [294]. 
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APPENDIX III – CONCENTRATION OF GSK932121A IN 
ISOLATED LIVER MITOCHONDRIA OF RATS TREATED 
WITH A 50MG/KG DOSE (CHAPTER 3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Table 3.1: Levels of GSK932121A in the mitochondrial fraction. GSK932121A levels were assessed in the 
mitochondrial fraction to determine if GSK932121A had been washed out during the isolation procedure. An 
average concentration of 1.9µM (± 1.4µM sd) GSK932121A was detected in the mitochondrial fraction which 
is above the IC50 for mammalian cytochrome bc1 inhibition as described in reference [12], i.e.IC50 = 0.4µM 
(human Hek293 cells) and 0.6µM (rat H9C2 cells).  
 
 
 
 
 
 
 
 
 
 
 
Rat ID GSK932121A level in mitochondrial 
fraction (µg/mg) 
GSK932121A concentration (µM) 
i 1.79 4.2 
ii 1.71 4.02 
iii 0.92 2.16 
iv 0.81 1.9 
v 0.74 1.74 
vi 0.0016 0.0038 
vii 0.381 0.89 
viii 0.831 1.95 
ix 0.706 1.66 
x 0.127 0.3 
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APPENDIX IV: METABOLOMICS RAW DATA 
Liver Data 
Appendix Table 4.1: Liver metabolomics raw data: The table shown details the raw (scaled intensity) liver metabolomics data for the biochemicals reported in chapter 4. Raw 
metabolomics data is assigned to the rat ID (numbered 1-20) showing the differential effect of GSK932121A (12.5mg/kg and 50mg/kg) and vehicle control. 
 
Control 12.5mg/kg GSK932121A 50mg/kg GSK932121A 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Maltohexaose 1.196 1.026 0.675 0.974 1.100 1.306 1.056 1.652 0.889 0.165 0.165 0.165 0.228 2.576 0.165 0.165 0.165 0.535 0.165 0.165 
Maltotriose 12.954 13.252 10.160 10.838 13.005 15.368 11.461 10.745 11.877 7.635 1.531 4.209 7.905 16.607 0.459 0.057 0.091 8.940 1.000 0.345 
Maltose 3.090 3.325 2.489 2.934 3.200 3.727 2.885 2.280 3.283 2.694 1.169 1.678 2.597 3.831 0.693 0.086 0.154 2.513 0.555 0.548 
Glucose 1.393 1.485 1.176 1.543 1.152 1.427 1.259 1.116 1.484 1.411 0.806 1.098 1.328 1.250 0.696 0.247 0.306 1.199 0.499 0.615 
Glucose 6 Phosphate 0.797 0.796 0.727 1.522 0.752 0.797 0.790 0.963 0.777 1.526 1.004 1.000 1.183 1.139 1.116 1.349 0.931 1.045 1.239 1.582 
2-Phosphoglycerate 0.426 0.603 0.870 1.000 0.465 0.694 0.544 0.644 0.575 0.970 1.277 1.004 0.805 1.159 1.089 0.893 1.055 0.750 1.261 1.145 
Phosphoenolpyruvate 0.547 0.684 0.676 1.000 0.424 0.624 0.666 0.636 0.602 0.906 1.113 1.208 0.932 0.986 1.113 1.212 0.972 0.705 1.278 1.267 
Pyruvate 1.773 3.074 3.946 2.612 1.733 4.343 0.301 2.246 0.840 1.727 1.000 1.528 2.179 4.701 0.605 0.217 0.012 0.690 1.567 0.332 
Lactate 1.207 1.270 1.215 1.451 1.164 1.245 1.005 1.106 1.080 1.492 0.909 1.167 1.177 1.000 0.843 0.379 0.456 0.971 0.675 0.758 
3-hydroxybutyrate (BHBA) 0.968 0.689 0.954 0.569 0.933 0.529 1.274 0.456 1.029 0.635 1.000 1.029 1.302 0.552 1.438 1.326 1.985 1.127 1.532 1.543 
Serine 0.853 0.975 0.732 0.690 0.879 0.888 1.109 1.049 0.940 1.200 0.967 1.059 1.074 1.170 1.305 1.389 1.328 0.996 1.341 1.075 
Threonine 0.899 0.942 0.724 0.620 0.917 0.898 0.874 0.788 0.979 1.203 1.025 1.209 1.071 0.913 1.617 1.602 1.763 0.810 1.514 1.297 
Valine 0.893 0.899 0.942 0.786 0.908 1.000 0.970 0.916 1.121 1.173 0.977 0.962 1.001 0.981 1.197 0.972 1.242 0.870 1.154 1.289 
Leucine 0.871 0.947 1.020 0.776 0.980 1.097 0.970 0.967 1.170 1.179 0.920 0.874 0.961 1.037 1.147 0.889 1.187 0.871 1.069 1.252 
Isoleucine 0.934 0.989 1.006 0.850 0.948 1.086 0.989 0.935 1.186 1.181 0.970 0.887 1.000 1.053 1.205 0.934 1.223 0.889 1.169 1.311 
Sedoheptulose-7-phosphate 0.679 0.980 0.758 1.016 0.585 0.831 1.331 0.767 0.726 1.898 1.428 1.191 1.120 0.544 4.001 4.368 1.467 2.804 2.979 3.892 
Cysteine-glutathione disulfide 0.606 0.446 1.417 0.652 0.566 0.545 1.704 0.896 0.726 1.208 0.841 0.940 1.000 0.873 0.939 1.080 0.982 0.767 1.328 0.666 
Opthalmate 1.504 0.665 0.909 0.359 0.641 0.397 1.000 0.987 0.783 0.938 1.693 1.625 1.802 0.720 0.166 0.319 0.082 0.225 0.708 0.633 
Glutathione Reduced (GSH) 1.558 1.502 1.124 1.578 1.505 1.415 1.260 1.376 1.717 1.367 1.187 1.590 1.057 1.258 0.600 0.564 0.789 1.282 0.608 0.980 
Glutathione Oxidized (GSSG) 0.676 0.980 1.396 0.753 0.760 0.900 0.938 0.762 0.753 1.152 0.908 0.884 1.065 0.910 1.250 1.000 0.869 1.011 1.497 1.146 
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Plasma Data 
Animal  Time 
Dose 
(mg/kg) citrate 
α-
ketoglutarate succinate fumarate malate carnitine BHBA 
Palmitoyl 
Carnitine 
(C16) 
Oleoyl 
carnitine  
(C18) 
Stearoyl 
Carnitine 
 (C18) valine leucine isoleucine AHB AKB 
1 Predose 
VC 
0.642 0.375 0.863 0.594 0.495 1.045 0.386 0.630 0.595 0.542 0.664 0.700 0.623 0.470 0.206 
2 Predose 0.867 0.745 1.111 0.804 0.835 0.939 0.554 0.879 0.678 0.849 1.047 1.126 1.010 0.655 0.048 
3 Predose 1.162 0.956 1.100 0.953 1.151 0.961 1.000 0.712 0.745 0.978 1.088 1.095 1.019 0.671 0.268 
4 Predose 0.990 1.522 1.378 1.554 1.683 0.917 0.711 0.750 0.609 0.785 1.099 1.084 1.012 0.850 1.048 
5 Predose 1.118 0.846 0.945 0.896 0.956 0.812 0.665 0.441 0.338 0.612 1.050 1.035 0.967 0.428 0.786 
7 Predose 
12.5 
1.085 1.184 0.885 0.755 0.912 0.884 0.702 0.630 0.593 0.698 0.792 0.916 0.788 1.000 0.209 
8 Predose 1.097 0.714 0.986 0.721 0.718 0.786 0.608 0.643 0.599 0.770 1.023 1.149 0.996 0.430 0.048 
9 Predose 1.132 1.189 1.943 1.906 2.016 0.776 0.821 0.707 0.663 0.744 1.009 1.020 0.996 1.012 0.401 
10 Predose 0.914 0.821 0.992 1.044 1.233 0.998 0.587 0.873 0.712 0.901 0.922 0.959 0.859 0.822 2.163 
11 Predose 1.250 2.023 2.093 2.015 2.078 0.994 1.007 1.146 1.190 1.114 1.043 1.000 1.000 0.911 0.220 
12 Predose 1.224 1.031 1.786 1.306 1.195 1.007 0.847 1.002 1.168 1.100 0.900 0.881 0.773 0.972 0.209 
13 Predose 1.046 0.679 1.023 0.711 0.651 0.784 0.996 1.095 1.497 1.116 0.923 0.891 0.864 0.538 0.048 
14 Predose 
50 
1.110 0.581 0.855 0.753 0.740 0.831 0.529 0.835 0.760 0.999 0.932 1.023 0.921 0.833 0.332 
15 Predose 0.968 0.955 1.213 0.951 0.878 1.037 0.662 0.778 0.569 0.739 1.070 1.063 1.005 0.631 0.478 
16 Predose 0.968 0.970 1.000 0.982 1.000 0.861 1.414 1.298 1.518 1.126 1.000 0.962 0.940 1.032 1.410 
17 Predose 1.412 1.512 2.353 2.330 3.037 0.928 0.839 0.837 0.724 0.868 1.116 1.132 1.045 0.876 0.048 
18 Predose 0.940 0.779 1.046 1.035 0.929 0.977 0.878 0.631 0.514 0.718 1.137 1.174 1.087 0.508 1.066 
19 Predose 1.205 2.257 4.726 2.656 3.171 1.044 1.003 1.078 0.929 1.067 1.064 1.074 1.019 0.981 0.151 
20 Predose 1.026 1.305 2.208 1.454 1.488 0.945 0.876 0.980 0.993 0.983 0.993 1.072 0.909 0.691 0.240 
1 0.5h 
VC 
1.011 1.454 1.266 1.000 0.902 1.257 0.583 0.971 1.000 0.763 0.958 1.033 0.958 0.599 0.245 
2 0.5h 1.176 1.054 0.849 0.577 0.725 0.983 0.668 0.760 0.767 0.785 0.992 1.000 0.974 0.644 0.048 
3 0.5h 1.013 0.746 0.891 0.607 0.605 1.099 0.711 0.878 0.918 0.981 0.965 1.062 0.988 0.336 0.048 
4 0.5h 1.332 1.981 2.289 2.114 2.407 1.068 0.946 0.879 0.708 0.791 1.061 1.031 1.051 1.051 0.296 
5 0.5h 1.321 1.608 1.093 1.009 0.803 1.004 0.931 0.509 0.484 0.692 1.002 1.097 1.014 0.765 0.328 
6 0.5h 1.565 1.351 1.215 0.828 0.860 0.948 0.443 0.603 0.524 0.650 0.816 0.872 0.796 0.315 0.402 
7 0.5h 
12.5 
0.879 0.892 0.682 0.600 0.467 0.824 0.589 0.894 0.868 1.001 0.865 0.934 0.825 0.775 0.288 
9 0.5h 0.970 1.167 1.093 0.850 0.760 0.774 0.824 0.883 0.970 0.864 0.977 1.008 0.977 0.820 0.048 
10 0.5h 0.998 0.932 0.894 1.051 1.117 1.043 0.649 0.998 0.899 1.132 0.902 0.998 0.920 0.875 0.048 
11 0.5h 1.637 2.135 2.218 2.297 2.592 1.035 2.407 1.957 2.569 1.374 0.921 0.910 0.946 2.241 2.066 
12 0.5h 1.235 1.756 1.884 1.622 1.827 1.140 1.201 1.220 1.296 1.000 0.806 0.809 0.782 3.331 1.052 
13 0.5h 1.306 0.883 1.321 1.454 1.451 0.819 0.857 1.024 1.000 1.120 0.986 1.010 1.006 1.319 0.609 
14 0.5h 
50 
1.079 0.877 0.744 0.694 0.599 0.955 0.632 0.896 0.881 0.957 0.872 0.908 0.896 0.739 0.412 
15 0.5h 1.104 0.649 1.857 1.112 1.413 1.184 1.019 1.136 1.007 1.072 0.973 0.979 0.989 1.138 0.281 
16 0.5h 1.202 0.631 1.529 1.663 1.789 0.914 1.393 1.352 1.507 1.263 0.960 0.985 0.973 2.220 2.188 
249 
 
17 0.5h 1.531 0.853 1.224 1.021 1.000 1.006 1.252 1.012 1.053 0.939 1.008 1.034 0.994 0.912 0.048 
18 0.5h 1.000 1.080 1.035 1.021 1.008 1.000 1.306 0.685 0.733 0.761 0.905 0.940 0.882 0.365 0.048 
19 0.5h 1.201 0.797 2.388 1.877 1.921 1.276 1.497 1.288 1.457 1.046 0.842 0.921 0.903 2.835 1.063 
20 0.5h 0.981 1.029 1.657 1.367 1.211 0.958 1.003 1.374 1.413 1.275 0.994 1.008 0.999 2.064 1.305 
1 1h 
VC 
1.212 1.066 0.872 0.638 0.686 1.288 0.738 0.909 0.961 0.730 1.061 1.081 1.051 0.956 0.502 
2 1h 0.982 0.507 1.525 1.013 1.059 0.999 0.703 1.089 1.000 1.062 1.060 1.046 1.059 0.832 0.048 
3 1h 1.097 1.194 1.000 0.723 0.741 1.064 1.656 0.717 0.902 0.762 1.006 0.964 0.975 0.362 0.563 
4 1h 1.282 1.750 3.780 2.201 2.158 1.168 1.011 1.073 0.859 0.941 0.962 1.009 1.016 1.020 0.048 
5 1h 1.308 1.140 1.077 1.161 1.245 0.946 0.792 0.455 0.369 0.527 1.022 1.002 0.974 0.702 0.048 
6 1h 1.000 0.286 0.746 0.535 0.320 0.928 0.319 0.601 0.501 0.614 0.858 0.931 0.822 0.244 0.207 
7 1h 
12.5 
0.860 0.851 0.823 0.740 0.646 0.855 0.709 0.792 0.753 0.844 0.893 0.987 0.880 0.822 0.308 
8 1h 0.867 0.546 1.276 0.827 0.639 0.728 0.406 0.435 0.497 0.497 0.719 0.793 0.705 0.271 0.048 
9 1h 1.059 0.979 0.858 0.791 0.744 0.872 0.559 0.856 0.908 0.961 0.991 0.980 0.990 0.672 0.048 
10 1h 0.949 0.816 0.995 0.982 0.980 1.059 0.780 1.002 0.921 1.007 0.900 0.964 0.963 0.673 0.465 
11 1h 1.348 2.162 1.024 1.381 1.444 1.000 1.756 1.681 2.051 1.270 0.887 0.859 0.883 1.947 1.777 
12 1h 1.115 0.980 1.000 0.859 0.782 1.098 1.591 1.500 1.477 1.277 0.944 0.916 0.924 2.593 1.400 
13 1h 1.412 1.200 2.624 1.359 1.327 0.776 1.966 0.969 1.284 1.106 1.043 1.001 1.091 1.052 0.685 
14 1h 
50 
0.923 0.735 0.624 0.758 0.544 1.006 0.668 0.883 0.903 1.001 0.898 0.895 0.895 0.690 0.048 
15 1h 1.068 0.662 0.799 0.603 0.672 1.053 0.758 0.997 0.932 0.993 0.998 0.965 1.016 0.960 0.048 
16 1h 1.487 2.629 1.447 1.710 1.946 0.891 1.922 1.621 1.688 1.281 0.937 0.888 0.908 3.149 2.083 
17 1h 1.532 1.112 1.165 0.989 1.104 0.976 1.486 0.867 0.874 0.795 0.984 0.977 1.032 1.314 0.353 
18 1h 1.162 1.014 0.909 1.000 0.884 1.000 1.341 0.725 0.746 0.718 0.813 0.813 0.796 0.405 0.048 
19 1h 1.350 1.777 1.172 1.406 1.302 1.129 1.900 1.103 1.359 1.021 0.860 0.814 0.851 2.834 1.788 
20 1h 1.115 0.717 1.076 0.991 1.280 0.933 1.049 0.934 1.043 0.953 1.004 0.961 1.001 2.153 1.326 
1 2h 
VC 
0.974 0.293 0.657 0.431 0.657 1.234 0.970 0.888 0.876 0.780 1.147 1.125 1.143 1.000 1.470 
2 2h 0.868 0.720 0.689 0.529 0.476 1.000 0.552 0.815 0.799 0.994 1.026 1.000 0.983 0.652 0.316 
3 2h 0.965 1.046 1.129 0.792 0.778 0.937 0.914 1.032 0.988 1.137 0.861 0.873 0.862 0.481 0.302 
4 2h 1.017 0.904 1.109 1.029 0.928 0.994 0.476 0.882 0.720 0.929 0.919 0.980 0.939 0.733 0.335 
5 2h 1.081 0.971 1.156 0.870 0.848 1.002 0.800 0.628 0.496 0.694 0.902 0.897 0.863 0.734 0.048 
6 2h 0.977 1.000 1.223 0.746 0.522 0.956 0.409 0.788 0.623 0.821 0.825 0.905 0.840 0.322 0.048 
7 2h 
12.5 
0.962 0.803 0.578 0.672 0.606 0.811 1.214 0.947 0.878 0.861 0.817 0.857 0.818 0.900 0.257 
8 2h 1.432 0.992 1.518 0.970 1.136 0.813 0.756 0.710 0.808 0.890 0.957 1.019 0.958 0.365 0.188 
9 2h 0.879 0.691 1.118 0.828 0.709 0.902 0.718 0.979 1.124 1.001 0.900 0.900 0.919 0.524 0.048 
10 2h 1.148 1.492 1.171 1.218 1.446 0.980 1.394 1.078 1.106 0.975 1.019 1.014 1.127 2.372 1.306 
11 2h 1.206 0.740 0.782 0.804 0.951 0.952 2.272 2.332 2.224 1.463 0.963 0.946 1.026 2.544 3.611 
12 2h 1.295 1.049 1.393 1.000 1.183 0.959 2.868 1.767 1.985 1.244 0.903 0.908 1.000 4.946 1.846 
13 2h 1.096 0.960 0.603 0.657 0.565 0.692 2.248 1.665 2.118 1.276 0.908 0.848 0.947 2.194 2.508 
250 
 
 
Appendix Table 4.2: Plasma metabolomics raw data: The table details the raw (scaled intensity) plasma metabolomics data for the biochemicals reported in chapter 4. Raw 
metabolomics data is assigned to the rat ID (numbered 1-20) showing the differential effect of GSK932121A (12.5mg/kg and 50mg/kg) and vehicle control. Data 
is ordered according to 5 sample collection times (pre-dose, 0.5hr, 1hr, 2hr and 4hr post dose). 
 
 
 
14 2h 
50 
1.010 0.483 0.485 0.584 0.636 0.903 0.662 1.021 1.030 1.054 0.833 0.868 0.902 0.562 0.048 
15 2h 0.988 0.690 0.699 0.627 0.623 0.984 0.925 1.347 1.368 1.048 1.021 0.931 1.074 1.365 1.020 
16 2h 1.346 1.485 0.723 0.979 0.935 0.707 2.619 1.682 1.883 1.130 0.949 0.863 0.949 3.582 3.332 
17 2h 1.253 0.539 0.807 0.708 0.715 0.790 1.039 0.781 0.891 0.776 1.000 0.905 1.067 1.352 0.944 
18 2h 1.113 0.515 0.714 0.813 0.608 0.865 2.514 1.249 1.388 1.113 0.925 0.913 1.061 0.623 0.560 
19 2h 1.349 1.136 0.813 1.129 1.165 0.979 3.839 2.267 2.798 1.166 0.911 0.847 0.970 7.664 5.104 
20 2h 1.002 1.295 0.690 0.665 0.681 0.908 1.579 1.322 1.782 1.151 1.055 1.005 1.104 3.677 6.051 
1 4h 
VC 
1.066 0.800 0.658 1.911 2.498 1.139 0.911 0.989 0.803 0.817 1.309 1.273 1.352 2.288 2.475 
2 4h 0.853 0.455 0.423 0.738 0.799 0.992 0.709 0.934 0.800 0.926 1.179 1.196 1.239 1.256 1.188 
3 4h 0.965 1.239 0.490 0.880 0.862 1.031 1.196 0.898 0.783 0.929 0.954 0.907 0.938 1.000 1.252 
4 4h 0.934 1.688 0.907 1.979 1.963 1.057 0.997 0.755 0.625 0.813 0.956 1.089 1.056 1.258 0.411 
5 4h 0.968 1.134 0.597 1.443 1.530 0.981 1.035 0.605 0.598 0.538 0.883 0.862 0.913 0.941 0.710 
6 4h 0.857 0.644 0.622 1.020 1.031 0.915 0.624 0.768 0.690 0.768 1.033 1.094 1.089 0.499 0.939 
7 4h 
12.5 
1.364 1.472 0.559 1.398 1.906 0.734 1.591 1.169 1.036 1.053 0.917 0.931 0.995 3.694 2.193 
8 4h 1.118 1.115 0.674 1.359 1.450 0.744 0.739 0.721 0.826 0.816 1.008 1.078 1.166 1.156 1.246 
9 4h 0.974 0.490 0.379 0.748 0.724 0.763 1.016 0.964 1.045 0.896 1.022 1.001 1.192 0.988 0.408 
10 4h 1.031 1.034 0.581 1.211 0.939 0.867 0.997 1.181 1.020 0.893 0.979 0.920 1.095 7.376 6.091 
11 4h 1.093 1.690 1.256 3.221 3.098 0.943 1.722 2.498 2.036 1.339 1.018 0.951 1.074 4.020 3.203 
12 4h 1.053 1.457 0.605 1.871 1.760 0.942 1.768 2.003 1.738 1.406 1.143 1.074 1.250 6.856 3.618 
13 4h 1.044 1.000 0.783 1.440 1.528 0.712 4.050 2.610 2.862 1.442 1.000 0.986 1.140 6.380 8.154 
14 4h 
50 
0.954 0.774 0.509 0.916 1.025 0.840 1.591 1.248 1.287 1.047 1.166 1.191 1.366 1.691 1.933 
15 4h 1.430 1.675 1.227 5.937 8.771 0.695 1.928 1.864 1.752 1.262 1.482 1.493 1.756 8.013 2.910 
16 4h 1.269 4.528 2.627 10.358 11.156 0.682 1.801 2.134 1.925 1.464 1.356 1.470 1.527 7.429 5.848 
17 4h 2.152 4.178 4.709 15.840 22.674 0.662 3.914 2.190 2.351 1.149 1.856 1.969 2.051 10.990 3.112 
18 4h 1.030 1.487 0.735 1.948 1.737 0.850 1.737 1.279 1.330 0.884 1.196 1.168 1.358 1.193 0.833 
19 4h 1.136 2.763 1.416 4.004 4.335 0.926 1.949 2.181 2.228 1.431 1.170 1.166 1.387 13.343 5.806 
20 4h 1.156 1.775 0.602 1.481 1.527 0.746 3.120 1.883 2.312 1.248 1.108 1.008 1.237 11.351 10.924 
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APPENDIX V: METABOLON PLASMA LACTATE ANALYSIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Fig.5.1: Plasma lactate measured by Metabolon following treatment of rats with 12.5mg/kg and 50mg/kg 
GSK932121A. Data shows the effect of GSK932121A (12.5mg/kg light blue line and 50mg/kg dark blue line) 
on plasma lactate levels compared to VC (turquoise line). Plasma samples were assessed pre-dose and then 0.5, 
1, 2 and 4 hours post-dose. Data shown represents scaled intensity of the total ion counts for each metabolite 
whereby the median ion is equal to 1. A significant increase in plasma lactate was observed at 4 hours post-dose 
with 50mg/kg GSK932121A (n=7) compared to VC (n=6), p<0.01**. 
** 
